2022 ESC Guidelines on cardio-oncology
developed in collaboration with the EuropeanHematology Association (EHA), the EuropeanSociety for Therapeutic Radiology andOncology (ESTRO) and the InternationalCardio-Oncology Society (IC-OS)
Developed by the task force on cardio-oncology of the European
Society of Cardiology (ESC)
Authors/Task Force Members: Alexander R. Lyon*†(Chairperson) (United
Kingdom), Teresa López-Fernández*†(Chairperson) (Spain), Liam S. Couch (Task
Force Coordinator) (United Kingdom), Riccardo Asteggiano (Italy),Marianne C. Aznar
1(United Kingdom), Jutta Bergler-Klein (Austria),
Giuseppe Boriani (Italy), Daniela Cardinale (Italy), Raul Cordoba2(Spain),
Bernard Cosyns (Belgium), David J. Cutter (United Kingdom),Evandro de Azambuja (Belgium), Rudolf A. de Boer (Netherlands), Susan F. Dent
3
(United States of America), Dimitrios Farmakis (Cyprus), So ﬁe A. Gevaert
(Belgium), Diana A. Gorog (United Kingdom), Joerg Herrmann3(United States of
America), Daniel Lenihan3(United States of America), Javid Moslehi (United
States of America), Brenda Moura (Portugal), Sonja S. Salinger (Serbia),Richard Stephens (United Kingdom), Thomas M. Suter (Switzerland),Sebastian Szmit (Poland), Juan Tamargo (Spain), Paaladinesh Thavendiranathan
(Canada), Carlo G. Tocchetti (Italy), Peter van der Meer (Netherlands),
Helena J.H. van der Pal (Netherlands), and ESC Scienti ﬁc Document Group
*Corresponding authors: Alexander R. Lyon, National Heart and Lung Institute, Imperial College London and Cardio-Oncology Service, Royal Brompto n Hospital, London, United
Kingdom. Tel: +44 207 352 8121, E-mail: a.lyon@imperial.ac.uk.
Teresa López-Fernández, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain. Tel: +34 619 227 076, E-mail: tlfernandez8@gmail.com.
†The two chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member af ﬁliations are listed in Author information.
1Representing the European Society for Therapeutic Radiology and Oncology (ESTRO);2representing the European Hematology Association (EHA);3representing the International
Cardio-Oncology Society (IC-OS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.ESC subspecialty communities having participated in the development of this document:
Associations : Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive C ardiology (EAPC),
European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Associatio n (HFA).
Councils : Council of Cardio-Oncology, Council on Hypertension, Council on Valvular Heart Disease.
Working Groups : Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, e-Cardiology, Myocardial Function, Pulmonary Circulation and Right V entricular Function,
Thrombosis.
Patient ForumEuropean Heart Journal (2022) 43, 4229 –4361
https://doi.org/10.1093/eurheartj/ehac244ESC GUIDELINESDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Document Reviewers: Patrizio Lancellotti (CPG Review Coordinator) (Belgium), Franck Thuny (CPG Review
Coordinator) (France), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Berthe Aleman1(Netherlands),
Joachim Alexandre (France), Ana Barac3(United States of America), Michael A. Borger (Germany),
Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta Čelutkien ė(Lithuania), Maja Cikes
(Croatia), Alain Cohen-Solal (France), Kreena Dhiman (United Kingdom), Stéphane Ederhy (France),Thor Edvardsen (Norway), Laurent Fauchier (France), Michael Fradley
3(United States of America), Julia Grapsa
(United Kingdom), Sigrun Halvorsen (Norway), Michael Heuser2(Germany), Marc Humbert (France),
Tiny Jaarsma (Sweden), Thomas Kahan (Sweden), Aleksandra Konradi (Russian Federation),Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Bonnie Ky
3(United States
of America), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip
(United Kingdom), Maja-Lisa Løchen (Norway), Katarzyna Malaczynska-Rajpold (United Kingdom),Marco Metra (Italy), Richard Mindham (United Kingdom), Marie Moonen (Belgium), Tomas G. Neilan
(United States of America), Jens Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva Prescott
(Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem (France), Gianluigi Savarese (Sweden), Marta Sitges(Spain), Jurrien ten Berg (Netherlands), Rhian M. Touyz (Canada/United Kingdom), Agnieszka Tycinska
(Poland), Matthias Wilhelm (Switzerland), and Jose Luis Zamorano (Spain)
All experts involved in the development of these Guidelines have submitted declarations of interest. These have
been compiled in a report and published in a supplementary document simultaneously to the Guidelines. Thereport is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and
detailed discussion of the data that have provided the basis of the guidelines.
------------------------------------------------------------------------------------------------------------------------------- -----------------------------Keywords Guidelines Androgen deprivation therapy Anthracycline Atrial ﬁbrillation Arrhythmias Biomarkers 
Cancer Cancer survivors Carcinoid syndrome Amyloid light-chain cardiac amyloidosis Cardiac magnetic
resonance Cardiac tumour Cardio-oncology Cardiotoxicity Coronary artery disease Chemotherapy 
Echocardiography Fluoropyrimidine Heart failure Haematopoietic stem cell transplantation Hormone therapy
Hypertension Immunotherapy Ischaemic heart disease Myocarditis Pericardial disease Pulmonary
hypertension Thrombosis Risk strati ﬁcation Trastuzumab Valvular heart disease Vascular endothelial
growth factor inhibitors (VEGFi) Venous thromboembolism Pericardial disease Proteasome inhibitors QTc
prolongation Radiotherapy Strain
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is au thorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a writte n request to Oxford University
Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer : The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scienti ﬁc and medical knowledge and the evidence available at the
time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and a ny other of ﬁcial recommendations
or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Healt h professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, di agnostic or therapeutic medical strat-
egies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriat e and accurate decisions in consid-
eration of each patient ’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient ’s caregiver. Nor do the ESC Guidelines exempt health
professionals from taking into full and careful consideration the relevant of ﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to
manage each patient ’s case in light of the scienti ﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional ’s responsibility to
verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
This article has been co-published with permission in the European Heart Journal and the European Heart Journal –Cardiovascular Imaging. © The European Society of Cardiology 2022. All
rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal ’s style. Either citation can be used when citing this article. For
permissions please e-mail: journals.permissions@oup.com.4230 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Table of contents
1. Preamble ........................................................................................................ 4236
2. Introduction ................................................................................................. 4238
2.1. Cancer and cardiovascular needs of patients with cancer 4238
2.2. Role of cardio-oncology services ............................................... 4238
2.3. General principles of cardio-oncology ..................................... 4239
3. Cancer therapy-related cardiovascular toxicity de ﬁnitions ..... 4242
4. Cardiovascular toxicity risk strati ﬁcation before anticancer
therapy ................................................................................................................. 4244
4.1. General approach to cardiovascular toxicity risk in patients
with cancer ................................................................................................... 4244
4.2. History and clinical examination ................................................. 42494.3. Electrocardiogram ............................................................................. 4249
4.4. Cardiac serum biomarkers ............................................................ 4251
4.5. Cardiovascular imaging ................................................................... 42524.6. Cardiopulmonary ﬁtness assessment ....................................... 4253
4.7. Cardiovascular risk evaluation before cancer surgery ...... 4254
4.8. Genetic testing ................................................................................... 4254
5. Prevention and monitoring of cardiovascular complications
during cancer therapy ................................................................................... 4254
5.1. General principles ............................................................................. 42545.2. Primary prevention strategies ...................................................... 4256
5.2.1. Primary prevention of cancer therapy-related
cardiovascular toxicity during anthracycline
chemotherapy .................................................................................. 4256
5.2.2. Primary prevention of radiation-inducedcardiovascular toxicity .................................................................. 4256
5.3. Secondary prevention strategies ................................................ 4257
5.4. Cardiovascular surveillance during cancer therapies ......... 4257
5.4.1. Cardiac serum biomarkers ............................................. 4257
5.4.2. Cardiac imaging .................................................................... 4257
5.5. Cancer therapy-related cardiovascular toxicity monitoringprotocols ....................................................................................................... 4259
5.5.1. Anthracycline chemotherapy ......................................... 4259
5.5.2. HER2-targeted therapies ................................................. 42595.5.3. Fluoropyrimidines ............................................................... 4261
5.5.4. Vascular endothelial growth factor inhibitors ........ 4261
5.5.5. Multitargeted kinase inhibitors targeting BCR-ABL 42645.5.6. Bruton tyrosine kinase inhibitors ................................. 4267
5.5.7. Multiple myeloma therapies ........................................... 4268
5.5.8. Rapidly accelerated ﬁbrosarcoma and mitogen-
activated extracellular signal-regulated kinase inhibitor
treatment ............................................................................................ 4271
5.5.9. Immune checkpoint inhibitors ...................................... 42735.5.10. Androgen deprivation therapies for prostate
cancer ................................................................................................... 4274
5.5.11. Endocrine therapies for breast cancer ................... 42765.5.12. Cyclin-dependent kinase 4/6 inhibitors .................. 4276
5.5.13. Anaplastic lymphoma kinase inhibitors ................... 4277
5.5.14. Epidermal growth factor receptor inhibitors ...... 42775.5.15. Chimeric antigen receptor
T cell and tumour-in ﬁltrating lymphocytes therapies ..... 4278
5.5.16. Radiotherapy ...................................................................... 42795.5.17. Haematopoietic stem cell transplantation ............ 4279
5.5.18. Other cancer treatments ............................................. 4282
6. Diagnosis and management of acute and subacutecardiovascular toxicity in patients receiving anticancer treatment 42826.1. Cancer therapy-related cardiac dysfunction .......................... 4282
6.1.1. Anthracycline chemotherapy-related cardiac
dysfunction ......................................................................................... 42826.1.2. Human epidermal receptor 2-targeted therapy-
related cardiac dysfunction ......................................................... 4284
6.1.3. Immune checkpoint inhibitor-associatedmyocarditis and non-in ﬂammatory heart failure ............... 4286
6.1.4. Chimeric antigen receptor T cell and tumour-
inﬁltrating lymphocytes therapies and heart dysfunction 4290
6.1.5. Heart failure during haematopoietic stem cell
transplantation ................................................................................. 4291
6.1.6. Takotsubo syndrome and cancer ................................ 4291
6.2. Coronary artery disease ................................................................. 4291
6.2.1. Acute coronary syndromes ............................................ 4291
6.2.2. Chronic coronary syndromes ....................................... 4293
6.3. Valvular heart disease ...................................................................... 4293
6.4. Cardiac arrhythmias ......................................................................... 4294
6.4.1. Atrial ﬁbrillation ................................................................... 4294
6.4.2. Long corrected QT interval and ventricular
arrhythmias ........................................................................................ 4298
6.4.3. Bradyarrhythmias ................................................................ 4300
6.5. Arterial hypertension ....................................................................... 4300
6.6. Thrombosis and thromboembolic events .............................. 4303
6.6.1. Venous thromboembolism ............................................. 43036.6.2. Arterial thromboembolism ............................................ 4304
6.6.3. Intracardiac thrombosis ................................................... 4304
6.6.4. Anticoagulation therapy ................................................... 4305
6.7. Bleeding complications .................................................................... 4306
6.7.1. High-risk patients ................................................................ 4306
6.7.2. Antiplatelet therapy ........................................................... 43066.7.3. Management of bleeding .................................................. 4306
6.8. Peripheral artery disease ................................................................ 4307
6.9. Pulmonary hypertension ................................................................ 43076.10. Pericardial diseases ......................................................................... 4308
6.10.1. Pericarditis ........................................................................... 4308
6.10.2. Pericardial effusion ........................................................... 4308
7. End-of-cancer therapy cardiovascular risk assessment ............. 4309
7.1. Cardiovascular evaluation during the ﬁrst year after
cardiotoxic anticancer therapy ............................................................ 43097.2. Which cancer survivors require cardiovascular surveillance
in the ﬁrst year after cancer treatment? .......................................... 4309
7.3. Management of cancer therapy-related cardiac dysfunctionat the end-of-therapy assessment ...................................................... 4310
7.4. Cardiopulmonary exercise testing and
ﬁtness during the
end-of-therapy assessment .................................................................... 43107.5. The role of cardiac rehabilitation ............................................... 4310
8. Long-term follow-up and chronic cardiovascular complications
in cancer survivors .......................................................................................... 4312
8.1. Cancer survivors ................................................................................ 4312
8.1.1. Adult survivors of childhood and adolescent
cancer ................................................................................................... 43128.1.2. Adult cancer survivors ...................................................... 4313
8.2. Myocardial dysfunction and heart failure ................................ 4315
8.3. Coronary artery disease ................................................................. 43168.4. Valvular heart disease ...................................................................... 4317
8.5. Peripheral artery disease and stroke ........................................ 4317
8.6. Pericardial complications ................................................................ 43178.7. Arrhythmias and autonomic disease ......................................... 4318ESC Guidelines 4231Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus,
and hypertension ........................................................................................ 4318
8.9. Pregnancy in cancer survivors ..................................................... 43188.10. Pulmonary hypertension .............................................................. 4319
9. Special populations .................................................................................... 4319
9.1. Cardiac tumours ................................................................................ 43199.2. Pregnant patients with cancer ..................................................... 4319
9.2.1. Left ventricular dysfunction and heart failure ........ 4320
9.2.2. Venous thromboembolism and pulmonaryembolism ..................................................................................... 4320
9.3. Carcinoid valvular heart disease ................................................. 4323
9.4. Amyloid light-chain cardiac amyloidosis .................................. 43249.5. Cardiac implantable electronic devices .................................... 4326
10. Patient information, communication, and self-management 4330
11. The role of scienti ﬁc societies in the promotion and
development of cardio-oncology in modern medicine .................. 4331
12. Key messages ............................................................................................ 4331
13. Future needs .............................................................................................. 433214. Gaps in evidence ...................................................................................... 4333
15.‘What to do ’and ‘what not to do ’messages from the
Guidelines ........................................................................................................... 433316. Quality indicators for cardio-oncology .......................................... 4342
17. Supplementary data ................................................................................ 4342
18. Data availability statement ................................................................... 434219. Author information ................................................................................ 4342
20. Appendix ..................................................................................................... 4342
21. References .................................................................................................. 4343
Tables of Recommendations
Recommendation Table 1 —Recommendations for a general
approach to cardiovascular toxicity risk categorization ................. 4249Recommendation Table 2 —Recommendations for
electrocardiogram baseline assessment ................................................ 4251
Recommendation Table 3 —Recommendation for cardiac
biomarker assessment prior to potentially cardiotoxic therapies . 4252
Recommendation Table 4 —Recommendations for cardiac
imaging modalities in patients with cancer .......................................... 4253
Recommendation Table 5 —Recommendations for
primary prevention of cancer the rapy-related cardiovascular
toxicity ......................................................................................................... 4256
Recommendation Table 6 —Recommendation for secondary
prevention of cancer therapy-related cardiovascular toxicity ..... 4257Recommendation Table 7 —Recommendations for baseline risk
assessment and monitoring during anthracycline chemotherapy
and in the ﬁrst 12 months after therapy .............................................. 4259
Recommendation Table 8 —Recommendations for baseline risk
assessment and monitoring during human epidermal receptor
2-targeted therapies and in the ﬁrst 12 months after therapy ... 4260
Recommendation Table 9 —Recommendations for baseline risk
assessment and monitoring during ﬂuoropyrimidine therapy ..... 4261
Recommendation Table 10 —Recommendations for baseline
risk assessment and monitoring during vascular endothelial
growth factor inhibitors ............................................................................... 4264
Recommendation Table 11 —Recommendations for baseline
risk assessment and monitoring during second- and
third-generation breakpoint cluster region –Abelson oncogene
locus tyrosine kinase inhibitors ................................................................. 4267Recommendation Table 12 —Recommendations for baseline
risk assessment and monitoring during Bruton tyrosine kinase
inhibitor therapy .............................................................................................. 4267Recommendation Table 13 —Recommendations for baseline
risk assessment and monitoring during multiple myeloma
therapies ..................................................................................................... 4271Recommendation Table 14 —Recommendations for baseline
risk assessment and monitoring during combined rapidly
accelerated ﬁbrosarcoma and mitogen-activated extracellular
signal-regulated kinase inhibitor therapy ............................................... 4272
Recommendation Table 15 —Recommendations for baseline
risk assessment and monitoring during immunotherapy ............... 4274Recommendation Table 16 —Recommendations for baseline
risk assessment and monitoring during androgen deprivation
therapy for prostate cancer ....................................................................... 4276Recommendation Table 17 —Recommendations for baseline
risk assessment and monitoring during endocrine therapy for
breast cancer .................................................................................................... 4276Recommendation Table 18 —Recommendations for baseline
risk assessment and monitoring during cyclin-dependent kinase
4/6 inhibitor therapy ...................................................................................... 4277Recommendation Table 19 —Recommendations for baseline
risk assessment and monitoring during anaplastic lymphoma
kinase and epidermal growth factor receptor inhibitors ............... 4277Recommendation Table 20 —Recommendations for baseline
risk assessment and monitoring in patients receiving chimeric
antigen receptor T cell and tumour-in ﬁltrating lymphocytes
therapies ............................................................................................................. 4279
Recommendation Table 21
—Recommendations for baseline
risk assessment of patients before radiotherapy to a volumeincluding the heart .......................................................................................... 4279
Recommendation Table 22 —Recommendations for baseline
risk assessment in haematopoietic stem cell transplantationpatients ................................................................................................................ 4281
Recommendation Table 23 —Recommendation for the
management of cardiovascular disease and cancertherapy-related cardiovascular toxicity in patients receiving
anticancer treatment ..................................................................................... 4282
Recommendation Table 24 —Recommendations for the
management of cancer treatment-related cardiac dysfunction
during anthracycline chemotherapy ........................................................ 4284
Recommendation Table 25 —Recommendations for the
management of cancer treatment-related cardiac dysfunction
during human epidermal receptor 2-targeted therapies ............... 4286
Recommendation Table 26 —Recommendations for the
diagnosis and management of immune checkpoint
inhibitor-associated myocarditis ............................................................... 4289
Recommendation Table 27 —Recommendations for the
diagnosis and management of Takotsubo syndrome in patients
with cancer ........................................................................................................ 4291
Recommendation Table 28 —Recommendations for the
management of acute coronary syndromes in patients receiving
anticancer treatment ..................................................................................... 4292
Recommendation Table 29 —Recommendation for the
management of chronic coronary syndromes in patients receiving
anticancer treatment ..................................................................................... 4293
Recommendation Table 30 —Recommendations for the
management of valvular heart disease in patients receiving
anticancer treatment ..................................................................................... 42934232 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Recommendation Table 31 —Recommendations for the
management of atrial ﬁbrillation in patients receiving anticancer
treatment ............................................................................................................ 4297Recommendation Table 32 —Recommendations for the
management of long corrected QT interval and ventricular
arrhythmias in patients receiving anticancer treatment ................. 4300Recommendation Table 33 —Recommendations for the
management of arterial hypertension in patients receiving
anticancer treatment ..................................................................................... 4302Recommendation Table 34 —Recommendations for the
management of venous thromboembolism in patients receiving
anticancer treatment ..................................................................................... 4305Recommendation Table 35 —Recommendations for venous
thromboembolism prophylaxis during anticancer treatment ...... 4306
Recommendation Table 36 —Recommendation for management
of peripheral artery disease during anticancer treatment .................. 4307
Recommendation Table 37 —Recommendations for the
management of pulmonary hypertension during anticancertreatment ............................................................................................................ 4308
Recommendation Table 38 —Recommendations for the
management of pericardial diseases in patients receivinganticancer treatment ..................................................................................... 4309
Recommendation Table 39 —Recommendations for
end-of-cancer therapy cardiovascular risk assessment ................... 4312Recommendation Table 40 —Recommendations for
cardiovascular surveillance in asymptomatic adults who are
childhood and adolescent cancer survivors ......................................... 4313Recommendation Table 41 —Recommendations for
cardiovascular surveillance in asymp tomatic adult cancer survivors 4314
Recommendation Table 42 —Recommendations for adult
cancer survivors who develop cancer therapy-related cardiac
dysfunction late after cardiotoxic cancer therapy ............................ 4316
Recommendation Table 43 —Recommendations for adult
cancer survivors with coronary artery disease .................................. 4316
Recommendation Table 44 —Recommendations for adult
cancer survivors with valvular heart disease ....................................... 4317Recommendation Table 45 —Recommendation for adult cancer
survivors with pericardial complications ............................................... 4318
Recommendation Table 46 —Recommendations for
cardiovascular monitoring in cancer survivors during pregnancy 4319
Recommendation Table 47 —Recommendations for cardiovascular
assessment and monitoring of preg nant women with cancer ............. 4323
Recommendation Table 48 —Recommendations for carcinoid
valvular heart diseases ................................................................................... 4323
Recommendation Table 49 —Recommendations for amyloid
light-chain cardiac amyloidosis diagnosis and monitoring .............. 4326
Recommendation Table 50 —Recommendations for risk
strati ﬁcation and monitoring for patients with cardiac implantable
electronic devices undergoin g radiotherapy .................................................... 4330
List of tables
Table 1 Classes of recommendations .................................................... 4237
Table 2 Levels of evidence .......................................................................... 4237Table 3 Cancer therapy-related cardiovascular toxicity de ﬁnitions 4243
Table 4 Heart Failure Association –International Cardio-Oncology
Society baseline cardiovascular toxicity risk strati ﬁcation ............... 4246
Table 5 Anthracycline equivalence dose ............................................... 4247Table 6 Factors that could in ﬂuence peri-operative risk during
cancer surgery and preventive strategies ............................................. 4254
Table 7 Cancer treatments that predispose to acute coronarysyndromes .......................................................................................................... 4291
Table 8 Risk factors for drug-induced QT prolongation and
torsade de pointes .......................................................................................... 4298Table 9 Classi ﬁcation of corrected QT interval prolongation
induced by cancer drug therapy ............................................................... 4298
Table 10 Risk factors for future cardiovascular disease at theend-of-cancer therapy cardiovascular risk assessment ................... 4310
Table 11 Risk categories for asymptomatic adults who are
childhood and adolescent cancer survivors ......................................... 4313Table 12 Risk categories for asymptomatic adult cancer survivors 4314
Table 13 Management strategies and surgery indications for
symptomatic and asymptomatic patients with benign andmalignant cardiac tumours .......................................................................... 4321
List of ﬁgures
Figure 1 Video 1 Central Illustration: Dynamics of
cardiovascular toxicity risk of patients with cancer over their
therapy continuum .................................................................................. 4239
Figure 2 Cardio-oncology care pathways ............................................. 4240Figure 3 Baseline cardiovascular toxicity risk a ssessment checklist 4241
Figure 4 Dimensions of cancer therapy-related cardiovascular
toxicity risk and disease severity .............................................................. 4242Figure 5 Baseline cardiovascular toxicity risk assessment before
anticancer therapy .......................................................................................... 4245
Figure 6 General cardio-oncology approach after Heart FailureAssociation –International Cardio-Oncology Society
cardiovascular toxicity risk assessment ................................................ 4248
Figure 7 Baseline screening recommendations for patients withcancer treated with potentially cardiotoxic drugs ............................ 4250
Figure 8 Recommended transthoracic echocardiography and
cardiac magnetic resonance imaging parameters in the evaluation ofpatients with cancer ............................................................................................... 4252
Figure 9 Primary and secondary cancer therapy-related
cardiovascular toxicity prevention .................................................................. 4255Figure 10 Cardiovascular toxicity monitoring in patients receiving
anthracycline chemotherapy ...................................................................... 4258
Figure 11 Cardiovascular toxicity monitoring in patients receivinghuman epidermal receptor 2-targeted therapies .............................. 4260
Figure 12 Vascular endothelial growth factor inhibitors-related
cardiovascular toxicities ............................................................................... 4262Figure 13 Cardiovascular toxicity monitoring in patients receiving
vascular endothelial growth factor inhibitors ..................................... 4263
Figure 14 Breakpoint cluster region –Abelson oncogene locus
tyrosine kinase inhibitor-related cardiovascular toxicities ............ 4265
Figure 15 Second- and third-generation breakpoint cluster
region –Abelson oncogene locus tyrosine kinase inhibitors
surveillance protocol ..................................................................................... 4266
Figure 16 Multiple myeloma drug-related cardiovascular toxicities 4268Figure 17 Cardiovascular monitoring in patients with multiple
myeloma receiving proteasome inhibitors ........................................... 4269
Figure 18 Risk factors for venous thromboembolic events inpatients with multiple myeloma ............................................................... 4270
Figure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated
extracellular signal-regulated kinase inhibitor-related cardiovasculartoxicities ..................................................................................................................... ... 4272ESC Guidelines 4233Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Figure 20 Cardiovascular surveillance in patients treated with
immune checkpoint inhibitors ................................................................... 4273
Figure 21 Androgen deprivation therapy-related cardiovasculartoxicities .............................................................................................................. 4275
Figure 22 Anaplastic lymphoma kinase and epidermal growth
factor receptor inhibitor-related cardiovascular toxicities ........... 4278Figure 23 Radiotherapy mean heart dose and associated
cardiovascular toxicity risk .......................................................................... 4280
Figure 24 Risk factors and cardiovascular surveillance in patientsreferred for haematopoietic stem cell transplantation .................. 4281
Figure 25 Management of anthracycline chemotherapy-related
cardiac dysfunction ......................................................................................... 4283Figure 26 Management of human epidermal receptor 2-targeted
therapy-related cardiac dysfunction ........................................................ 4285
Figure 27 Direct and indirect immune checkpointinhibitor-related cardiovascular toxicity ................................................ 4287
Figure 28 Diagnosis and management of immune checkpoint
inhibitor-related myocarditis ...................................................................... 4288Figure 29 Diagnosis and management workup in cancer-related
Takotsubo syndrome .................................................................................... 4290
Figure 30 Pathophysiology of atrial ﬁbrillation associated with
cancer ................................................................................................................... 4295
Figure 31 Structured approach to anticoagulation for atrial
ﬁbrillation in patients with cancer ............................................................ 4296
Figure 32 Corrected QT interval monitoring before and during
treatment with corrected QT interv al-prolonging anticancer drugs 4299
Figure 33 Recommended threshold for asymptomatichypertension treatment in different clinical scenarios .................... 4301
Figure 34 Treatment of arterial hypertension in patients with
cancer ................................................................................................................... 4302Figure 35 Risk factors for venous thromboembolism in patients
with cancer ........................................................................................................ 4303
Figure 36 Structured approach to anticoagulation for venousthromboembolism in patients with active cancer ............................ 4304
Figure 37 Management of cancer therapy-related cardiac
dysfunction after cancer therapy ............................................................. 4311Figure 38 Long-term follow-up in cancer survivors ......................... 4315
Figure 39 Location of primary and secondary cardiac tumours . 4320
Figure 40 Diagnostic algorithm for cardiac masses .......................... 4321Figure 41 Cardiac monitoring protocol for pregnant women
receiving anthracycline-based chemotherapy ..................................... 4322
Figure 42 Carcinoid heart disease: clinical features and diagnostictests ....................................................................................................................... 432 4
Figure 43 Non-invasive diagnosis of amyloid light-chain cardiac
amyloidosis ......................................................................................................... 4325Figure 44 Risk strati ﬁcation in patients with a cardiac implantable
electronic device undergoing radiotherapy ......................................... 4327
Figure 45 Management of patients with a cardiac implantableelectronic device located in the radiotherapy treatment beam . 4328
Figure 46 Management of patients with a cardiac implantable
electronic device located outside the radiotherapy treatmentvolume ................................................................................................................. 4329
Figure 47 Patient information, communication, and
self-management .............................................................................................. 4330Figure 48 The role of scienti ﬁc societies in the promotion and
development of cardio-oncology ............................................................. 4331Abbreviations and acronyms
2D Two-dimensional
3D Three-dimensional5-FU 5- ﬂuorouracil
5HIAA 5-hydroxyindoleacetic acid
a
′Late diastolic velocity of mitral annulusobtained by tissue Doppler imaging
ABC Atrial ﬁbrillation Better Care
ABI Ankle –brachial index
AC Anthracycline chemotherapy
ACE-I Angiotensin-converting enzyme inhibitors
ACS Acute coronary syndromesADT Androgen deprivation therapy
ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron-MR ControlledEvaluation
AF Atrial ﬁbrillation
AI Aromatase inhibitorsAL-CA Amyloid light-chain cardiac amyloidosis
ALK Anaplastic lymphoma kinase
ANS Autonomic nervous systemARB Angiotensin receptor blockers
ARISTOTLE Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation
ASCVD AtheroSclerotic Cardiovascular Disease
ASPIRE Car ﬁlzomib, Lenalidomide, and
Dexamethasone vs. Lenalidomide andDexamethasone for the Treatment of
Patients with Relapsed Multiple Myeloma
ASTCT American Society for Transplantation and
Cellular Therapy
ATAC ‘Arimidex ’and Tamoxifen Alone or in
Combination
ATE Arterial thromboembolism
AV Atrioventricular
BB Beta-blockersBC Breast cancer
BCR-ABL Breakpoint cluster region –Abelson oncogene
locus
BIG Breast International Group
BLEED Increased bleeding risk
BMI Body mass indexBNP B-type natriuretic peptide
BP Blood pressure
BTK Bruton tyrosine kinaseC Chemotherapy cycle
CABG Coronary artery bypass graft
CAD Coronary artery diseaseCARDIOTOX CARDIOvascular TOXicity induced by
cancer-related therapies
CAR-T Chimeric antigen receptor T cellCCB Calcium channel blockers
CCS Chronic coronary syndromes
CCTA Coronary computed tomography
angiography4234 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CCU Coronary care unit
CDK Cyclin-dependent kinaseCHA
2DS2-VASc Congestive heart failure, Hypertension, Age
≥75 years (2 points), Diabetes mellitus,
Stroke (2 points) —Vascular disease, Age
65–74 years, Sex category (female)
CIED Cardiac implantable electronic device
CML Chronic myeloid leukaemiaCMR Cardiac magnetic resonance
COMPASS-CAT Prospective COmparison of Methods for
thromboembolic risk assessment with clinicalPerceptions and AwareneSS in real-life
patients —Cancer Associated Thrombosis
CPET Cardiopulmonary exercise testingCrCl Creatinine clearance
CRF Cardiorespiratory ﬁtness
CRS Cytokine release syndromeCS Cancer survivors
CT Computed tomography
CTLA-4 Cytotoxic T lymphocyte-associated
antigen-4
cTn Cardiac troponin
CTRCD Cancer therapy-related cardiac
dysfunction
CTR-CVT Cancer therapy-related cardiovascular
toxicity
CV Cardiovascular
CVD Cardiovascular disease
CVRF Cardiovascular risk factorsDAPT Dual antiplatelet therapy
DASISION DASatinib vs. Imatinib Study In
treatment-Naïve chronic myeloidleukaemia patients
DL Dyslipidaemia
DM Diabetes mellitusDNR Do not resuscitate
DVT Deep vein thrombosis
E Mitral in ﬂow early diastolic velocity
obtained by pulsed wave
e
′Early diastolic velocity of the mitral annulus
obtained by tissue Doppler imaging
EACTS European Association for Cardio-Thoracic
Surgery
EBC Early breast cancerECG Electrocardiogram
Echo Echocardiography
ECV Extracellular volume fractioneGFR Estimated glomerular ﬁltration rate
EGFR Epidermal growth factor receptor
EMA European Medicines AgencyEMB Endomyocardial biopsy
ENGAGE AF-TIMI 48 Effective Anticoagulation with Factor
Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48
ENOXACAN Enoxaparin and Cancer
EoL End of lifeERS European Respiratory Society
ESC European Society of CardiologyESC-CCO European Society of Cardiology Council of
Cardio-Oncology
ESH European Society of Hypertension
EuroSCORE European System for Cardiac Operative
Risk Evaluation
FAC Fractional area change
FDA Food and Drug Administration
FLT3 FMS-like tyrosine kinase 3FWLS Free wall longitudinal strain
GI Gastrointestinal
GLS Global longitudinal strainGnRH Gonadotropin-releasing hormone
GU Genitourinary
GVHD Graft vs. host diseaseGy Gray
HAS-BLED Hypertension, Abnormal renal and liver
function, Stroke, Bleeding Labileinternational normalized ratio, Elderly,
Drugs or alcohol
HbA1c Glycated haemoglobinHDU High-dependency unit
HER2 Human epidermal receptor 2
HF Heart failureHFA Heart Failure Association
HFmrEF Heart failure with mildly reduced ejection
fraction
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HG HyperglycaemiaHIIT High-intensity interval training
HSCT Haematopoietic stem cell transplantation
hs-cTn High-sensitivity cardiac troponinHTN Hypertension
ICD Implantable cardioverter de ﬁbrillator
ICI Immune checkpoint inhibitorsICOS International Cardio-Oncology Society
ICU Intensive care unit
IHD Ischaemic heart diseaseIMiD Immunomodulatory drugs
i.v. Intravenous
IVC Inferior vena cavaIVS Intraventricular septum
LA Left atrial
LAA Left atrial appendageLGE Late gadolinium enhancement
LIMA Left internal mammary artery
LMWH Low-molecular-weight heparinsLQTS Long QT syndrome
LS Longitudinal strain
LV Left ventricularLVD Left ventricular dysfunction
LVEDD Left ventricular end diastolic diameter
LVEF Left ventricular ejection fractionLVV Left ventricular volume
M Months
MACE Major adverse cardiovascular eventsMCS Mechanical circulatory support
MDT Multidisciplinary teamESC Guidelines 4235Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

MedDRA Medical dictionary for regulatory activities
MEK Mitogen-activated extracellular
signal-regulated kinase
MHD Mean heart dose
MI Myocardial infarctionMM Multiple myeloma
MUGA Multigated acquisition nuclear imaging
NN oNOAC Non-vitamin K antagonist oral
anticoagulants
NP Natriuretic peptidesNSTE-ACS Non-ST-segment elevation acute coronary
syndromes
NT-proBNP N-terminal pro-B-type natriuretic peptidePAD Peripheral artery disease
PAH Pulmonary arterial hypertension
PAP Pulmonary arterial pressurePCI Percutaneous coronary intervention
PD-1 Programmed death-1
PD-L1 Programmed death-ligand 1PE Pulmonary embolism
Peric-E Pericardial effusion
PET Positron emission tomographyPH Pulmonary hypertension
PI Proteasome inhibitors
Pleu-E Pleural effusionPRECISE-DAPT PREdicting bleeding Complications In
patients undergoing Stent implantation and
subsEquent Dual Anti Platelet Therapy
PRONOUNCE A Trial Comparing Cardiovascular Safety
of Degarelix Versus Leuprolide in Patients
With Advanced Prostate Cancer andCardiovascular Disease
PW Left ventricular posterior wall
QI Quality indicator↑QTc Corrected QT interval prolongation
QTc Corrected QT interval
QTcF Corrected QT interval using Fridericia
correction
RA Right atrial
RAF Rapidly accelerated ﬁbrosarcoma
RCT Randomized controlled trial
RIMA Right internal mammary artery
ROCKET AF Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation
RT Radiotherapy
RV Right ventricular
RVEF Right ventricular ejection fractionRVV Right ventricular volume
s
′Systolic velocity of tricuspid annulus
obtained by doppler tissue imaging
SBr Sinus bradycardia
SCORE2 Systematic Coronary Risk Estimation 2
SCORE2-OP Systematic Coronary Risk Estimation 2 —
Older Persons
SEER Surveillance, Epidemiology, and End ResultsSMART Second manifestations of arterial disease
sPAP Systolic pulmonary artery pressureSPEP Serum protein electrophoresis
STEMI ST-segment elevation myocardial infarction
STIR Short tau inversion recoverySTS PROM Society of Thoracic Surgeons –Predicted
Risk of Mortality
SVT Supraventricular tachycardiaSYNTAX SYNergy between percutaneous coronary
intervention with TAXus and cardiac surgery
TAPSE Tricuspid annular plane systolic excursionTAVI Transcatheter aortic valve implantation
TBIP Thromboembolic risk, Bleeding risk, drug –
drug Interactions, Patient preferences
TdP Torsade de pointes
TIL Tumour-in ﬁltrating lymphocytes
TKI Tyrosine kinase inhibitorsTRV Tricuspid regurgitation velocity
TTE Transthoracic echocardiography
TTS Takotsubo syndrometx Treatment
ULN Upper limit of normal
UPEP Urine protein electrophoresisVA Ventricular arrhythmias
VascTox Vascular toxicity
VEGF Vascular endothelial growth factorVEGFi Vascular endothelial growth factor inhibitors
VH Very high risk
VHD Valvular heart diseaseVKA Vitamin K antagonists
VTE Venous thromboembolism
Y Yes
1. Preamble
Guidelines summarize and evaluate available evidence with the aim ofassisting health professionals in proposing the best management strat-egies for an individual patient with a given condition. Guidelines and
their recommendations should facilitate decision making of health pro-
fessionals in their daily practice. However, guidelines are not a substi-tute for the patient ’s relationship with their practitioner. The ﬁnal
decisions concerning an individual patient must be made by the re-
sponsible health professional(s), based on what they consider to bethe most appropriate in the circumstances. These decisions are
made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure
that all users have access to the most recent recommendations, the
ESC makes its Guidelines freely available. The ESC warns readers
that the technical language may be misinterpreted and declines anyresponsibility in this respect.
A great number of guidelines have been issued in recent years by the
ESC. Because of their impact on clinical practice, quality criteria for thedevelopment of guideli nes have been establish ed to make all decisions
transparent to the user. The recommendations for formulating and is-
suing ESC Guidelines can be found on the ESC website (https://www.
escardio.org/Guidelines). The ESC Guidelines represent the of ﬁcial pos-
ition of the ESC on a given topic and are regularly updated.4236 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

In addition to the publication of Clinical Practice Guidelines, the ESC
carries out the EURObservational Research Programme of internation-al registries of cardiovascular dise ases and interventions, which are es-
sential to assess diagnostic/therapeutic processes, use of resources
and adherence to gu idelines. These registries aim at providing a better
understanding of medical practice in Europe and around the world,
based on high-quality data collected during routine clinical practice.
Furthermore, the ESC develops sets of quality indicators (QIs),
which are tools to evaluate the level of implementation of the guide-
lines and may be used by the ESC, hospitals, healthcare providers and
professionals to measure clinical practice, and in educational pro-grammes, alongside the key messages from the guidelines, to im-
prove quality of care and clinical outcomes.
T h eM e m b e r so ft h i sT a s kF o r c ew e r es e l e c t e db yt h eE S Ct or e -
present professionals involved with the medical care of patients with
this pathology. The selection procedure aimed to ensure that there is
a representative mix of members predominantly from across the wholeof the ESC region and from relevan t ESC Subspecialty Communities.Consideration was given to diversity and inclusion, notably with respect
to gender and country of origin. A critical evaluation of diagnostic andtherapeutic procedure s was performed, including assessment of the
risk–bene ﬁt ratio. The level of evidence and the strength of the recom-
mendation of particular managemen t options were weighed and scored
according to prede ﬁned scales, as outlined below. The Task Force fol-
lowed the ESC voting procedures. All recommendations subject to a
vote achieved at least 75% among voting members.
The experts of the writing and reviewing panels provided declar-
ation of interest forms for all relationships that might be perceived as
real or potential sources of con ﬂicts of interest. Their declarations of
interest were reviewed according to the ESC declaration of interest
rules and can be found on the ESC website (http://www.escardio.org/
Guidelines) and have been compiled in a report and published in asupplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in
the development and review processes. Any changes in declarationsof interest that arise during the writing period were noti ﬁed to theTable 1 Classes of recommendations
©ESC 2022Classes of recommendationsClass I Evidence and/or general agreement
that a given treatment or procedure is
beneficial, useful, effective.
efficacy of the given treatment or procedure.
favour of usefulness/efficacy.
Usefulness/efficacy is less well
useful/effective, and in some casesConﬂicting evidence and/or a divergence of opinion about the usefulness/ 
 Is recommended or is indicatedWording to use Deﬁnition
Class III Evidence or general agreement that the
given treatment or procedure is not
may be harmful. Is not recommended     Class IIb
established by evidence/opinion.May be considered    Class IIa Weight of evidence/opinion is in Should be consideredClass II 
Table 2 Levels of evidence
Level of
evidence A
Level of
evidence B
Level of
evidence CData derived from multiple randomized clinical trials
or meta-analyses.
Data derived from a single randomized clinical trial
or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2022ESC Guidelines 4237Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

ESC and updated. The Task Force received its entire ﬁnancial support
from the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
guidelines. The Committee is also responsible for the approval pro-
cess of these guidelines. The ESC Guidelines undergo extensive re-
view by the CPG and external experts, including a mix ofmembers from across the whole of the ESC region and from relevant
ESC Subspecialty Communities and National Cardiac Societies. After
appropriate revisions, the guidelines are signed off by all the expertsinvolved in the Task Force. The ﬁnalized document is signed off by
the CPG for publication in the European Heart Journal . The guidelines
were developed after careful consideration of the scienti ﬁc and med-
ical knowledge and the evidence available at the time of their writing.
The task of developing ESC Guidelines also includes the creation of
educational tools and implementation programmes for the recommen-
dations, including condensed pocket guideline versions, summary slides,
summary cards for non-specialists and an electronic version for digitalapplications (smartphones, etc.). These versions are abridged and thus,
for more detailed information, the user should always access the full-
text version of the guidelines, which is freely available via the ESC web-site and the European Heart Journal . The National Cardiac Societies of
the ESC are encouraged to endorse, adopt, translate and implement all
ESC Guidelines. Implementation programmes are needed because ithas been shown that the outcome of disease may be favourably in ﬂu-
enced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgement, as well
as in the determination and the implementation of preventive, diag-
nostic or therapeutic medical strategies. However, the ESCGuidelines do not override in any way whatsoever the individual re-
sponsibility of health professionals to make appropriate and accurate
decisions in consideration of each patient ’s health condition and in
consultation with that patient or the patient ’s caregiver where ap-
propriate and/or necessary. It is also the health professional ’s re-
sponsibility to verify the rules and regulations applicable in eachcountry to drugs and devices at the time of prescription and to re-
spect the ethical rules of their profession.
Off-label use of medication may be presented in this guideline if
sufﬁcient level of evidence shows that it can be considered medically
appropriate to a given condition and if patients could bene ﬁt from
the recommended therapy. However, the ﬁnal decisions concerning
an individual patient must be made by the responsible health profes-
sional giving special consideration to:
(1) the speci ﬁc situation of the patient. In this respect, it is speci ﬁed
that, unless otherwise provided for by national regulations, off-
label use of medication should be limited to situations where it
is in the patient ’s interest to do so, with regard to the quality,
safety and ef ﬁcacy of care, and only after the patient has been in-
formed and has provided consent;
(2) country-speci ﬁc health regulations, indications by governmental
drug regulatory agencies and the ethical rules to which health
professionals are subject, where applicable.
2. Introduction
This is the ﬁrst European Society of Cardiology (ESC) guideline on
cardio-oncology. The aim of this guideline is to help all the healthcare
professionals providing care to oncology patients before, during, andafter their cancer treatments with respect to their cardiovascular (CV)
health and wellness. This guideline provides guidance on the de ﬁnitions,
diagnosis, treatment, and prevention of cancer therapy-related CVtoxicity (CTR-CVT), and the management of CV disease (CVD)
caused directly or indirectly by cancer. This area of medicine has lim-
ited trials and evidence on which to base decision-making and,where evidence is limited, this guideline provides the consensus of
expert opinion to guide healthcare professionals.
This guideline includes the de ﬁnitions of CTR-CVT ( Section 3 ),
1and
provides a personalized approach to care based upon the baseline
CV toxicity risk assessment ( Section 4 ) and new protocols for CV sur-
veillance during cancer treatment ( Section 5 ). The management of acute
CTR-CVT is addressed in Section 6 , where patients with active cancer are
those receiving antican cer treatment. Throughout these sections,
decision-making depends upon the risk/bene ﬁt balance of oncology
treatment ef ﬁcacy and the severity and impact of CTR-CVT. Guidance
is provided for the ﬁrst 12 months after completion of cardiotoxic treat-
ments ( Section 7 ), when subacute CVD can emerge, and when patients
who developed CTR-CVT during cancer treatment are reviewed.
Diagnosis and management of the long-term CV complications of previ-ous oncology treatments, beyond 12 m onths after completing the cardi-
otoxic treatments, and integration into the overall survivorship strategy
for cancer survivors (CS) is presented in Section 8 with new long-term
surveillance recommendatio ns for high-risk patients.
InSection 9 , we address special populations where CVDs are dir-
ectly caused by the cancer, or where special considerations are re-quired. Section 10 provides information for patients ’involvement in
their own care. The ﬁnal section highlights the role of the ESC and
the ESC Council of Cardio-Oncology (ESC-CCO).
CTR-CVT risk is a dynamic variable, and the risk changes through-
out the pathway of care ( Figure 1 , Video 1). Absolute risk of
CTR-CVT is important to understand and balance against the abso-lute bene ﬁt of the cancer treatment before and during treatment.
However, CTR-CVT risk can be in ﬂuenced by several variables, in-
cluding implementation of primary prevention treatments, optimiza-tion of pre-existing CVD, dose, frequency, and duration of oncology
treatment, emergence of CV complications during treatment and
their severity, and in CS, the overall cumulative treatment received,the time since treatment, and the interaction with other CVDs.
2.1. Cancer and cardiovascular needs of
patients with cancer
Since the 1990s, there has been a steady decline in cancer-related
mortality mirrored by a steady increase in CS.2,3In this context,
treatment-related side effects have gained more signi ﬁcance.
Management of CTR-CVT has a tremendous impact on the type of
anticancer therapies that patients can receive as well as the long-term
morbidity and mortality outcomes of patients with cancer. Effectivemanagement of patients with both cancer and CVD requires the un-
ique interest and expertise of healthcare providers, which has led to
the formation of a new discipline: cardio-oncology.
4,5Ar e c e n t l yp u b -
lished ESC-CCO document describes appropriate criteria for the or-
ganization and implementation of cardio-oncology services.5
2.2. Role of cardio-oncology services
The overarching goal of the cardio-oncology discipline is to allow pa-tients with cancer to receive the best possible cancer treatments safely,4238 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

minimizing CTR-CVT across the entire continuum of cancer care.5
Before initiation of cancer therapies with a known CV toxicity pro ﬁle,
the cardio-oncology team should identify and treat CV risk factors
(CVRF) and pre-existing CVDs and de ﬁne an appropriate prevention
and surveillance plan for early identi ﬁcation and appropriate manage-
ment of potential CV complications ( Figure 2 ). Another important as-
pect is the participation in interdisciplinary discussions regarding thebene ﬁts and risks of certain cancer treatments and their continuation
or interruption should side effects become apparent. After cancer
treatment has been completed, the focus shifts to co-ordination oflong-term follow-up and treatment. For patients on long-term cancertherapies with CV toxicity risk, surveillance should continue until the
treatment is ﬁnished.
6–8There is also the need for re-assessment of
CV risks in patients requiring treatment for secondary malignancies.
2.3. General principles of
cardio-oncology
A guiding principle of cardio-oncology is the integration of clinical dis-
ciplines. Cardio-oncology providers must have knowledge of the
broad scope of cardiology, oncology, and haematology management.5
Recommendations are formed regarding the most permissible (from a
TimeBaseline
riskDu
Dring cardiotoxic
cancerthera
pp
p
p
yy
y
y
ppp
p
pLong-term follffow-up after
cancer treatment
Primary and
second ary
prevention
strate giesCancer treatment
surveillance
Early CTR-CVT
managemen tCancer s urvivorship programme s
Low riskHigh riskCTR-CVT CTR-CVT
riskrisk
Figure 1 Video 1 Central Illustration: Dynamics of cardiovascular toxicity ri sk of patients with cancer over thei r therapy continuum. CS, cancer
survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV , cardiovascular; CVD, cardiovascul ar disease; CVRF, cardiovascular ri sk fac-
tors; CTR-CVT risk is a dynamic variable that changes through the pathway of care, and is in ﬂuenced by several conditions including age, cancer
history, pre-existing CVRF or CVD, and previous cardiotoxic cancer th erapy. The CTR-CVT risk changes during and after treatment according
to type, dose, frequency, and duration of oncology treatment (blue solid line). Pre-existing CVRF, CVD, or previous cancer treatments may increasethe magnitude of acute and long-term CV toxicity r isk (purple solid line). CTR-CVT risk remains variable in extent during anticancer treatment and
may or may not gradually increase over time (dotted lines). Cardio-oncol ogy strategy may reduce the magnitu de of CTR-CVT by: (1) optimizing CVD
and CVRF management (green arrows); (2) considering cardioprotective strategies in high-risk patients (green arrows); (3) organizing cancer trea t-
ment surveillance; and (4) introducing early card ioprotection after the detection of subclinical CTR-CVT (purple arrows). CV risk assessment with in
theﬁrst year after completion of cardiotoxic cancer therapy identi ﬁes CS who require long-term follow-up. C ancer survivorship programmes that
include annual CV risk assessment and CVRF/CVD management are recommended to minimize long-term CV adverse events (brown arrows).ESC Guidelines 4239Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CVD perspective) and the most effective (from an oncological per-
spective) cancer treatment. Adjudication of CV events occurring in pa-
tients on active therapy is another important aspect ofcardio-oncology practice.
1,3This is in addition to recommendations
on best treatment and management practices. This includes the fullscope of CV therapies, including healthy lifestyle promotion and
pharmacological, device, and surgical treatments.4,9,10
The principle underlying the dynamic course of CTR-CVT develop-
ment in patients with cancer is that the absolute risk depends on their
baseline risk and changes with exposure to cardiotoxic therapies over
New cancer
diagnosisDuring cancer
treatmentaFirst year after
cancer treatmentbLong term
follow-upCardio-Oncology Care Pathways
Class 1 Class 1Ia Class 1IbBaseline CV
toxicity risk
assessmentcInforming, advising, and supporting patients to promote a healthy lifestyle
Management of CVRF and CVD according to ESC Guidelines
Low risk
patientsAnnual CVRF
assessmente
Reassessment if new CV
signs/symptoms Standard
surveillanceAssessment at 1 year
after completion of
cancer therapy
Moderate risk
 patientsAnnual CVRF assessmente
CV to xicity re-stratification
at 5 years
TTE every 5 yearsCardiology referraldAssessment at 1 year
after completion of
cancer therapy
High and
very high risk
patientsAnnual CVRF
assessmente
TTE at years 1, 3, 5 and 
every 5 yearsCardiology referrald
CVD preventionAssessment at 3
months and 1 year
after completion of
cancer therapy
Cardiology referrald if new CV signs/symptoms or CTR-CVT develop
Figure 2 Cardio-oncology care pathways. BP, blood pressure; CS, cancer survivors; CTR-CVT, cancer therapy-related cardiovascular toxicity;
CV, cardiovascular; CVD, cardiovascular dise a s e ;C V R F ,c a r d i o v a s c u l a rr i s kf a c t o r s ;E C G ,e lectrocardiogram; ESC, European Society of
Cardiology; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic pep-tides; RT, radiotherapy; TTE, tr ansthoracic echocardiography.
aCV surveillance according to baseline CV toxicity risk, type of cancer, cancer
stage, and cancer therapy.bCTR-CVT risk assessment is recommended during the ﬁrst year after cardiotoxic can cer treatment to establish a
long-term follow-up care plan.cThe use of HFA-ICOS risk assessment tools should be considered to assess CTR-CVT risk in patients with can-
cer scheduled to receive cardiotoxic anticancer therapy. Clinical as sessment and ECG are rec ommended at baseline in a ll patients with cancer
and echocardiography, cardiac biomarkers, or other cardiac imaging tes ts in selected patients according to baseline CV toxicity risk and cancer
treatment type (see Figure 7 ).dCardio-oncology referral is recommended when available, alternatively patients should be referred to a specia-
lized cardiologist with expertise in managing CVD in patients with cancer.eAnnual CV risk assessment (including clinical review, BP, lipid pro ﬁle,
HbA1c, ECG, and NP) and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT to avolume exposing the heart.4240 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

time ( Figure 3 ).11This has been recognized in conceptual models, with
risk strati ﬁcation tools designed to grade patients with cancer into
low, moderate, high, and very high risk of CV complications prior to
starting treatment. These have been published by the Heart FailureAssociation (HFA) of the ESC in collaboration with the International
Cardio-Oncology Society (ICOS) (see Section 4 ).
12,13Severity, dur-
ation, and type of manifestation of CTR-CVT vary by type of malig-nancy and cancer treatment. The risk itself can be understood in
two ways: (1) the likelihood of its occurrence and (2) the severity of
the complication ( Figure 4 ). For example, a patient could be very likely
to experience a CTR-CVT, but if this event is mild, oncology treat-
ment should continue. Conversely, a patient at low likelihood couldstill be at high risk according to the severity of the event, which would
lead to interruption of cancer treatment, e.g. a signi ﬁcant decline in
left ventricular (LV) ejection fraction (LVEF) to ,40% with anthracy-
cline chemotherapy. The timeline of these developments may also berather different. After the cardiotoxic cancer treatment has been
completed, a new risk assessment is recommended to establish differ-
ent long-term trajectories of CV health. These trajectories are im-pacted by the permanent CV toxic effects and cardiac or vascular
injury of some cancer therapies, patient-related CVRF, environmental
factors, and stressors (e.g. acute viral infections). The aim should be topersonalize approaches to minimize CTR-CVT and improve both
cancer and CV outcomes.Baseline CV toxicity risk assessment checklis t
Cancer tr eatment history
CV hist ory
CVRF
Physical examination
Vital si gns meas urementaBNP or NT-pTTroBNPb
cTnb
ECG
Fasting plasma glucose / HbA1c
Kidney function / eGFR
Lipid profile
TTEc
Clinical assessment
 Complementary tests
CTR-CVT
risk factorsMedical
CVRFPrevious
CVD
Lifestyle
risk factors
ECG, TTE, and
cardiac biomarkers
abnormalitiesPrevious
cardiotoxic 
therapiesAge, sex,
genetics
Figure 3 Baseline cardiovascular toxicity risk assessment checklist. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTR-CVT, cancer therapy-re lated
cardiovascular toxicity; CV, cardiovascular; CVD, CV disease; CVRF, cardiovascular risk factors; ECG, electrocardiogram; eGFR, estimated glome rular ﬁltration
rate; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-BNP; TTE, transthoracic echocardiography.aIncluding blood pressure, heart rate, height,
weight, and body mass index.bCardiac biomarkers (troponin and NP) should be measured in patients at risk of CTRCD where available and results should
be interpreted according to the patient clinical status, type of cancer treatment, and kidney function.cConsider other CV complementary tests in selected
patients: cardiac magnetic resonance, coronary computed tomography angiography, CPET (in selected patients for pre-operative [lung, colon, and r ectal can-
cers] risk strati ﬁcation). See Section 4.6 .ESC Guidelines 4241Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

3. Cancer therapy-related
cardiovascular toxicity de ﬁnitions
Several terminologies and de ﬁnitions have previously been proposed
to describe the spectrum of CTR-CVT, leading to inconsistencies indiagnosis and management. The need to harmonize these de ﬁnitions
has frequently been stated and recognized, and resulted in the recent
international de ﬁnitions of CTR-CVT
1supported by this guideline
(Table 3 ;Supplementary data, Table S1 ). This document will focus
on consensus de ﬁnitions for cardiomyopathy and heart failure(HF), myocarditis, vascular toxicities, hypertension, cardiac arrhyth-
mias, and corrected QT interval (QTc) prolongation. The de ﬁnitions
of other CTR-CVT, including pericardial and valvular heart diseases(VHDs), are the same as those used for the general cardiology popu-
lation. For cardiac injury, cardiomyopathy, and HF, the descriptive
term cancer therapy-related cardiac dysfunction (CTRCD) is recom-
mended as it captures the broad spectrum of possible presentations
and the aetiological link with the broad scope of various cancer ther-apies, including chemotherapy, targeted agents, immune therapies,
and radiation therapy.
HighIntermediateLow
Severe and
very severe
Moderate
 Mild
Likelihood of
CTR-CVTClinical severit y of CTR-CVT
Figure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity. CTR-CVT, cancer therapy-related cardiovascular tox-
icity; CV, cardiovascular. The ultimate risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse
event. The most vulnerable patient groups are those at high likelihood of experiencing a severe adverse event. The level of attention that needs to bedevoted to these patients varies accordingly. The risk and type of CTR-CVT, as well as the potential for reversibility, depends on different factors, listed in
Figure 3 , that should be considered to de ﬁne global CV and oncological prognosis and to individualize CTR-CVT surveillance. Additional factors that add to
the complexity of CTR-CVT risk assessment are the cancer type and prognosis, and type, duration, and intensity of cancer treatment.4242 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Table 3 Cancer therapy-related cardiovascular toxicity de ﬁnitions
CTRCD
Symptomatic CTRCD (HF)a,bVery severe HF requiring inotropic support, mechanical circulatory support, or
consideration of transplantation
Severe HF hospitalization
Moderate Need for outpatient intensi ﬁcation of diuretic and HF therapy
Mild Mild HF symptoms, no intensi ﬁcation of therapy required
Asymptomatic CTRCD Severe New LVEF reduction to ,40%
Moderate New LVEF reduction by ≥10 percentage points to an LVEF
of 40 –49%
OR
New LVEF reduction by ,10 percentage points to an LVEF of 40 –
49% AND either new relative decline in GLS by .15% from baseline
OR new rise in cardiac biomarkersc
Mild LVEF ≥50%
AND new relative decline in GLS by .15% from baseline
AND/OR new rise in cardiac biomarkersc
ICI myocarditis (either pathohistological diagnosis o rclinical diagnosis)
Pathohistological diagnosis (EMB) Multifocal in ﬂammatory cell in ﬁltrates with overt cardiomyocyte loss by light microscopy
Clinical diagnosisdcTn elevation (new or signi ﬁcant change from baseline)ewith 1 major criterion or 2 minor criteria,
after exclusion of ACS and acute infectious myocarditis based on clinical suspicionf
Major criterion:CMR diagnostic for acute myocarditis (modi ﬁed Lake Louise criteria)
g
Minor criteria:
Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,
shortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,syncope, muscle weakness, cardiogenic shock)
Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease
Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo
pattern
Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis
Suggestive CMR
h
Severity of myocarditis Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or
high-grade heart block, and/or signi ﬁcant ventricular arrhythmia
Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and
incidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have
reduced LVEF but no features of severe disease
Steroid refractory : non-resolving or worsening myocarditis (clinical worsening or persistent troponin
elevation after exclusion of other aetiologies) despite high-dose methylprednisolone
Recovery from myocarditis Complete recovery : Patients with complete resolution of acute symptoms, normalization of
biomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE
or elevated T1 due to ﬁbrosis, but any suggestion of acute oedema should be absent
Recovering : Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging
parameters, but not yet normalized, while on tapering doses of immunosuppression
Vascular toxicity (for general cardiology de ﬁnitions, see Supplementary data, Table S1 )
Asymptomatic vascular toxicity CAD Symptomatic vascular
toxicityStroke
PAD Transient ischaemic attackCarotid artery disease MI
Venous thrombosis ACS
Arterial thrombosis CCSPeripheral vasoreactivity PAD
ContinuedESC Guidelines 4243Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

4. Cardiovascular toxicity risk
strati ﬁcation before anticancer
therapy
The optimal time to consider CVD prevention strategies in patients
with cancer is at the time of cancer diagnosis and prior to the initi-ation of cancer treatment.
4,5This enables the oncology team to con-
sider CV risk while making cancer treatment choices, educating
patients regarding their CV risk, personalizing CV surveillance andfollow-up strategies, and making appropriate referrals of high-risk pa-
tients to cardio-oncology services. These strategies are needed to
mitigate CVD risk, and improve the adherence to effective cancertreatments and the overall survival.CVD prevention strategies require a personalized approach. Risk
assessment is a challenging task and it is vital that clinicians adopt a
systematic approach without delaying oncological treatment.
12,21,22
Figure 5 provides a comprehensive approach to risk assessment.
The choice of the cardiac tests (electrocardiogram [ECG], biomar-
kers, and imaging) should be individualized based on CV risk and
the planned cancer treatments.
4.1. General approach to cardiovascular
toxicity risk in patients with cancer
Pre-treatment CTR-CVT risk assessment should ideally be per-
formed using a recognized risk strati ﬁcation method where multiple
risk factors are incorporated to determine patient-speci ﬁc risk.23Coronary epicardial
vasoreactivityVasospastic angina
Coronary microvascular
vasoreactivityMicrovascular angina
Raynaud ’s phenomenon
Arterial hypertensionTreatment threshold for
hypertension before, during, and
after therapyIn patients with high CV risk
i:≥130 mmHg systolic and/or ≥80 mmHg diastolic
Otherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic
Cancer therapy holding threshold ≥180 mmHg systolic and/or ≥110 mmHg diastolic
Hypertensive emergency (Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,
kidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of
target organ damage
Cardiac arrhythmiasQT prolongation Prolonged: QTcF .500 ms
j
Bradycardia For general cardiology de ﬁnitions, see Supplementary data, Table S1
Supraventricular tachycardia
Ventricular arrhythmias
AF
©ESC 2022
ACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,
cardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular v olume fraction; EMB,
endomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced eje ction fraction; HFpEF, heart
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadol inium enhancement; LV, left
ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, p eripheral artery disease; QTcF,
corrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimatio n2—Older Persons.
SeeSupplementary data, Table S1 for expanded de ﬁnitions.
aWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14
bSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompan ied by signs (e.g.
elevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40%=
HFrEF; 41 –49%=HFmrEF; ≥50%=HFpEF.
ccTnI/cTnT .99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signi ﬁcant rise from baseline beyond the biological and analytical variation of the assay used.
dClinical diagnoses should be con ﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be
promptly initiated while awaiting further con ﬁrmatory testing in symptomatic patients.
eBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitan t myositis and without myocarditis.15–17
fAccording to local protocols.
gDiagnostic CMR: Based on updated Lake Louise criteria18:T 2 - b a s e dc r i t e r i o n +T1-based criterion +supportive criteria (T2-based criteria: regional or global increase of native T2, or T2 signal
intensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive crit eria: pericarditis and/or regional or global LV
systolic dysfunction).
hSuggestive CMR : meeting some but not all of the modi ﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial in ﬂammation in the
appropriate clinical scenario.
iSCORE2 ( ,70 years), SCORE2-OP ( ≥70 years) or equivalent.19CV risk strati ﬁcation:,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50 –69 years: low risk ,5%;
moderate risk 5% to ,10%; high risk ≥10%;≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.
jQTcF 480 –500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF =QT/3√RR).204244 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Only a limited number of retrospective risk scores have been pub-
lished in patients with cancer. Most of these scores have been devel-oped for speci ﬁc cancer-patient groups and cannot be readily applied
or extrapolated to other type of malignancies.
24–29While furthervalidation is needed, HFA-ICOS risk assessment tools should be con-
sidered to determine pre-treatment risk of CTR-CVT as they areeasy to use and implement in oncology and haematology services
(Table 4 ;Supplementary data, Tables S2 –S7).
12,13Other CV risk
Physical and metabolic
assessmentbECG
(Class I)Pre-existing CVD or
at risk of CTRCDc
New, untreated or
uncontrolled medical, and
lifestyle CVRFArrhythmias
Prolonged QTcF
Check and correct
precipitant factorsf
(Class I)Ref
cardiologistg
(Class I)Ref rdiologistg
(Class I)Suspected
CVDcTn and NP
increaseddTTE
(LVEF and GLS)
reducede
Aggressive management of
CVRF and pre-existing CVD
according to ESC Guidelines
Healthy lifestyle promotion
(Class I)Baseline cardiovascular toxicity risk assessment
Consider primary vs secondary preventive strategies acco rding to CV t oxicity risk,
pre-existing CV D, and cancer t reatment typeHFA-ICOS risk
assessment:
CVRFa
CVD historyCancer historyCancer treatment history
Figure 5 Baseline cardiovascular toxicity risk assessment before anticancer therapy. BNP, B-type natriuretic peptide; cTn, cardiac troponin; CTRCD,
cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ECG, electrocardiogram; ESC, EuropeanSociety of Cardiology; GLS, global longitudinal strain; HFA, Heart Failure Association; ICOS, Int ernational Cardio-Oncology Society; LVEF, left ven-
tricular ejection fraction; N P, natriuretic peptides (incl uding BNP and NT-proBNP); NT-proBNP, N-te r m i n a lp r o - B N Pp e p t i d e ;Q T c ,c o r r e c t e dQ T
interval; QTcF, corrected QT interval using Fridericia correction; TTE, transthoracic echocardiography.
aWhen assessing CVRF, include information
about unhealthy lifestyle including sedentary behaviour, smoking, and alcohol intake.bSeeFigure 3 .cAccording to cancer treatment and HFA-ICOS
risk assessment.dcTnI/T.99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL.ePatients with baseline LVEF ,50% or in the low normal
range (LVEF 50 –54%) should be referred to a specialized cardiologist or cardio-oncologist. When TTE is used, ideally three-dimensional-LVEF and GLS
should be measured. If GLS assessment is not available, other markers of longitudinal function (e.g. annular Doppler velocity) should be considered .
Cardiac magnetic resonance should be considered if echocardiography is of non-diagnostic quality.fAnaemia, infections, electrolyte abnormalities, meta-
bolic problems, other QTc-prolonging drugs.gCardio-oncology referral is recommended when available; alternatively, patients should be referred to a
specialized cardiologist with expertise in managing CVD in patients with cancer.ESC Guidelines 4245Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Table 4 Heart Failure Association –International Cardio-Oncology Society baseline cardiovascular toxicity risk
strati ﬁcation
Baseline CV toxicity
risk factorsAnthracycline
chemotherapyHER2-targeted
therapiesVEGF
inhibitorsBCR-ABL
inhibitorsMultiple
myeloma
therapiesRAF and
MEK
inhibitors
Previous CVD
HF/cardiomyopathy/
CTRCDVH VH VH H VH VH
Severe VHD H H –– – H
MI or PCI or CABG H H VH –– H
Stable angina H H VH –– H
Arterial vascular disease –– VH VH VH –
Abnormal ankle-brachial
pressure index–– – H ––
PH –– – H ––
Arterial thrombosis with TKI –– – VH ––
Venous thrombosis
(DVT/PE)–– HM 2 V H –
Arrhythmiaa– M2 M2 M2 M2 M1
QTc≥480 ms –– HH ––
450≤QTc,480 ms (men);
460≤QTc,480 ms
(women)–– M2 M2 ––
Prior PI CV toxicity –– – – VH –
Prior IMiD CV toxicity –– – – H –
Cardiac imaging
LVEF,50% H H H H H H
LVEF 50 –54% M2 M2 M2 – M2 M2
LV hypertrophy –– – – M1 –
Cardiac amyloidosis –– – – VH –
Cardiac biomarkersElevated baseline cTn
bM1 M2 M1 – M2 M2
Elevated baseline NPbM1 M2 M1 – HM 2
Age and CVRFAge≥80 years H H –– – M1
Age 65 –79 years M2 M2 –– – M1
Age≥75 years –– HH H M 1
Age 65 –74 years –– M1 M2 M1 M1
Age≥60 years –– – M1 ––
CVD 10-year risk score
.20%–– – H ––
Hypertension
cM1 M1 H M2 M1 M2
Chronic kidney diseasedM1 M1 M1 M1 M1 M1
Proteinuria –– M1 –––
DMeM1 M1 M1 M1 M1 M1
Hyperlipidaemiaf–– M1 M1 M1 –
Family history of
thrombophilia–– – M1 M1 –
Continued4246 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

calculators (e.g. SMART [Second manifestations of arterial disease]
risk score, ADVANCE [Action in Diabetes and Vascular Disease:Preterax and Diamicron-MR Controlled Evaluation] risk score,
SCORE2 [Systematic Coronary Risk Estimation 2], SCORE2-OP
[Systematic Coronary Risk Estimation 2 —Older Persons], ASCVD
[AtheroSclerotic Cardiovascular Disease] risk score, U-Prevent,
and lifetime risk calculators) may be considered at baseline for theassessment of CV risk, considering that cancer itself may increase
the likelihood of CVD.
19,23,30,31
Baseline risk assessment should be considered by the treating on-
cology or haematology team for all patients diagnosed with cancer
who are scheduled to receive a cancer treatment identi ﬁed to
have a clinically signi ﬁcant level of CRT-CVT, or by a cardiologist if
appropriate. In the case of patients scheduled to receiveCurrent cancer treatment
Dexamethasone .160 mg/
month–– – – M1 –
Includes anthracycline
before HER2-targetedtherapy– M1
g–– – –
Previous exposure to
Anthracycline H M2hH – HH
Trastuzumab – VH –– – –
RT to left chest or
mediastinumHM 2 M 1 – M1 M2
Non-anthracycline
chemotherapyM1 –– – – –
Lifestyle risk factors
Current smoker or
signiﬁcant smoking historyM1 M1 M1 H M1 M1
Obesity (BMI .30 kg/m2)M 1 M 1 M 1 M 1 M 1M1
©ESC 2022
AF, atrial ﬁbrillation; BCR-ABL, breakpoint cluster region –Abelson oncogene locus; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery
bypass graft; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DM, diabetes
mellitus; DVT, deep vein thrombosis; eGFR, estimated glomerular ﬁltration rate; H, high risk; HbA1c, glycated haemoglobin; HER2, human epidermal receptor 2; HF, heart failure; IMiD,
immunomodulatory drugs; LV, left ventricular; LVEF, left ventricular ejection fraction; M, moderate risk; MEK, mitogen-activated extracellular signal-regulated kinase; MI, myocardial
infarction; MM, multiple myeloma; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminal pro-B-type natriuretic peptide ; PCI, percutaneous coronary
intervention; PE, pulmonary embolism; PH, pulmonary hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; RAF, rapidly accelerat edﬁbrosarcoma; RT,
radiotherapy; TKI, tyrosine kinase inhibitors; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VH, very high ris k; VHD, valvular heart disease.
An expanded version of this table is provided in Supplementary data, Tables S2 –S7.
Risk level: Low risk =no risk factors OR one moderate1 risk factor; moderate risk (M) =moderate risk factors with a total of 2 –4 points (Moderate 1 [M1] =1 point; Moderate
[M2]=2 points); high risk (H) =moderate risk factors with a total of ≥5 points OR any high-risk factor; very-high risk (VH) =any very-high risk factor.
aAF, atrial ﬂutter, ventricular tachycardia, or ventricular ﬁbrillation.
bElevated above the ULN of the local laboratory reference range.
cSystolic BP .140 mmHg or diastolic BP .90 mmHg, or on treatment.
deGFR,60 mL/min/1.73 m2.
eHbA1c.7.0% or .53 mmol/mol, or on treatment.
fNon-high density lipoprotein cholesterol .3.8 mmol/L ( .145 mg/dL) or on treatment.
gHigh risk if anthracycline chemotherapy and trastuzumab delivered concurrently.
hPrevious malignancy (not current treatment protocol).
Table 5 Anthracycline equivalence dose
Doxorubicin Epirubicin Daunorubicin Mitoxantrone Idarubicina
CV toxicity dose ratio 1 0.8 0.6 10.5 5
Isoequivalent dose 100 mg/m2125 mg/m2167 mg/m29.5 mg/m2
20 mg/m2
©ESC 2022
This table refers to anthracycline equivalence dose using doxorubicin as a reference. Note that these isoequivalent doses are derived from paediatr ic CS.
CS, cancer survivors; CV, cardiovascular.
aData for idarubicin are based upon an estimated anticancer ef ﬁcacy ratio, not derived from cardiotoxicity data. The CV toxicity dose ratio provides the value that should be used to
multiply the dose of the anthracycline of interest to convert to isoequivalent doses of doxorubicin; e.g. to convert 125 mg/m2of epirubicin to doxorubicin isoequivalent, multiply the dose
by 0.8 (125 mg/m2×0.8=100 mg/m2of doxorubicin).ESC Guidelines 4247Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

anthracycline chemotherapy, the total planned cumulative anthracy-
cline dose is also relevant, and ≥250 mg/m2of doxorubicin or
equivalent should be considered higher risk ( Table 5 ).32
CV risk strati ﬁcation results should be discussed with the patient
and documented in clinical notes. This process will also enable futurevalidation of these tools.
Cardiology referral (cardio-on cology programme or cardiolo-
gist with expertise in managing CVD in patients with cancer) isrecommended for patients identi ﬁed to be at high or very high
risk for CTR-CVT at baseline ( Table 4 ) to institute strategies to miti-
gate risk.
33Patients at moderate risk can bene ﬁt from closer cardiac
monitoring, strict management of traditional CVRF, and selected
moderate-risk patients may also bene ﬁt from a cardio-oncology re-
ferral ( Figure 6 ). Low-risk patients can be followed within the oncol-
ogy programme with appropriate referral to cardio-oncology if a
CTR-CVT emerges or new or uncontrolled CVRF appear.
AND
 AND
AND
AND
AND
CV risk stratification b e
f
o
f
f
r
e anticancer t her
a
p
y
p
p
(Class I )
Com
m
unicate the CV t
o
xicity ris k assessment 
 r
esults (Class I )
Educate patients 
 r
ega
r
ding ris ks and p
r
otecti
v
e healt
h
y li
f
estyle (Class I)
f
f
Management of CVRF and CVD acc o
r
ding to ESC Guidelines (Class I)
H
F
A-ICOS baseline risk assessment
F
F
(Class IIa )
L
o
w risk
Routine onco lo
g
y
f
oll
f
f
o
w-up
Moderate ris k
Ca
r
diolo
g
y
a
r
e
f
e
f
f
r
ral if
CV t
o
xicity d
e
v
elops
(Class I )
Closer oncol o
g
y 
f
oll
f
f
o
w-up
Ca
r
diolo
g
y
a
r
e
f
e
f
f
r
ral if
CV t
o
xicity d
e
v
elops
(Class I )
Ca
r
diolo
g
y 
r
e
f
e
f
f
r
ral
a
(Class IIb )
Ca
r
diolo
g
y
a
r
e
f
e
f
f
r
ral
(Class I )
Ca
r
diop
r
otecti
v
e strate gies
(Class IIa )
Discussion of the risk /benefit
balance of ca
 r
diot
o
xic
anticancer t
 r
eatment
(Class I )
H
F
A-ICOS 
F
F
 r
esults
High/
v
e
r
y high risk
Patient wit h cancer
Figure 6 General cardio-oncology approach after Heart Failure Association –International Cardio-Oncology Society cardiovascular toxicity risk assess-
ment. CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Society of Cardiology; HFA, Heart Failure Association; ICOS,International Cardio-Oncology Society.
aCardio-oncology referral is recommended when available; alternatively, patients should be referred to a spe-
cialized cardiologist with expertise in managing CVD in patients with cancer.4248 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

4.2. History and clinical examination
A careful clinical history and physical examination is recommended as
part of the baseline risk assessment. Oncology patients can be di-
vided into two cohorts with respect to the presence or absence ofpre-existing CVD. A primary prevention strategy can be considered
in patients without previous CVD or CTR-CVT while secondaryprevention includes interventions in patients with prior or active
CVD or previous CTR-CVT.
12
Reviewing traditional risk factors for CVD is recommended.
Where present, the ef ﬁcacy of treatment and control of these modi-
ﬁable risk factors should be determined to ensure optimal control
during cancer therapy.4,34Although recent SCORE2 and
SCORE2-OP19tables are not focused on patients with cancer, risk
calculation is recommended for patients with cancer .40 years of
age (unless they are automatically categorized as being at high riskor very high risk based on documented CVD, diabetes mellitus
[DM], kidney disease, or a highly elevated single risk factor) as a ref-
erence to optimize CVRF treatment goals.
19,31,35A family history of
premature CVD should be considered because genetic abnormalities
associated with CVD may predispose patients with cancer to a high-er risk of CTR-CVT.
36–38Lifestyle factors such as smoking, alcohol
consumption, sedentary lifestyle, exposure to pollution, and frailty
are important shared risk factors for both cancer and CVD.Information on prior history of cancer, cardiotoxic cancer therapies,
and their respective doses should be collected. Patients should be
asked about typical cardiac symptoms (e.g. chest pain with activity,dyspnoea on exertion, orthopnoea, palpitations, and peripheral oe-
dema), which can guide clinical examination and investigations.
Physical examination should document vital signs and look for poten-tial indicators of undiagnosed CVD such as HF, pericardial disease,
VHD, and arrhythmias.
39–42
The second scenario is secondary prevention in patients with a
prior history of CVD. These patients with cancer are potentially at
high or very high risk of future CV events,12and require a more
comprehensive clinical evaluation of their CVD, its severity, andprior and current treatments. Depending on the type and severity
of CVD, additional investigations —including resting or stress echo-
cardiography, cardiac magnetic resonance (CMR), nuclear perfusionimaging, and coronary computed tomography angiography (CCTA)
—may be indicated to determine risk status. Identifying prior CVD
should not automatically be a reason to withhold cancer therapybut considered an opportunity to optimize CV risk prior to and dur-
ing treatment. Risk/bene ﬁt discussions should include the patient,
oncologist or haematologist, and —where available —a specialized
cardio-oncology service.
Additional factors that add to the complexity of baseline CV risk
assessment are the cancer type and prognosis, and type, duration,and intensity of cancer treatment ( Figure 1 ).
4,12,43Clinical history,
physical examination features, and treatment-related risk factors
that contribute to CTR-CVT for various cancer therapies are sum-marized in Supplementary data, Table S8 . These risk factors should
be collected and considered along with baseline ECG, cardiac serum
biomarkers, and cardiac imaging tests (summarized in Figure 7 )t o
complete baseline CTR-CVT evaluation.
4.3. Electrocardiogram
A baseline 12-lead ECG is a readily available test that can provide im-portant clues to underlying CVD. ECG evidence of chamber enlarge-ment, conduction abnormalities, arrhythmias, ischaemia, or prior
myocardial infarction (MI), and low voltages should be interpreted
in the clinical context. A baseline ECG is recommended prior tostarting a cancer treatment known to cause QTc prolongation.
44–49
Measurement of QTc using the Fridericia correction (QTcF) isRecommendation Table 1 —Recommendations for a
general approach to cardiovascular toxicity risk
categorization
Recommendations ClassaLevelb
CV toxicity risk strati ﬁcationcbefore starting
potentially cardiotoxic anticancer therapy is
recommended in all patients withcancer.
12,14,19,21,25,28,31IB
Communicating the results of the CV toxicity risk
assessment to the patient and other appropriate
healthcare professionals is recommended.IC
The use of HFA-ICOS risk assessment should be
considered to stratify CV toxicity risk in patientswith cancer scheduled to receive cardiotoxic
anticancer therapy.
12IIa C
It is recommended that patients categorized to be
at low CV toxicity risk should proceed to
anticancer therapy without delay.IC
In patients categorized at moderate CV toxicity
risk, cardiology referraldmay be considered.eIIb C
Cardiology referraldis recommended in high-risk
and very high-risk patients before anticancertherapy.
fIC
Discussion of the risk/bene ﬁt balance of
cardiotoxic anticancer treatment in high- and very
high-risk patients in a multidisciplinary approach
prior to starting treatment is recommended.IC
Cardiology referraldis recommended for patients
with cancer and pre-existing CVD or abnormalﬁndings at baseline CV toxicity risk assessment
g
who require potentially cardiotoxic anticancer
therapy.I C
©ESC 2022
CV, cardiovascular; CVD, CV disease; ECG, electrocardiogram; GLS, global longitudinal
strain; HbA1c, glycated haemoglobin; HFA, Heart Failure Association; ICOS,
International Cardio-Oncology Society; LVEF, left ventricular ejection fraction; TTE,
transthoracic echocardiography; ULN, upper limit of normal; VHD, valvular heartdisease.
aClass of recommendation.
bLevel of evidence.
cIncluding clinical history and physical examination, ECG, general blood test, HbA1c,
lipid pro ﬁle, and cardiac serum biomarkers and/or TTE (according to cancer drug
type and CV toxicity risk).
dCardio-oncology referral is recommended when available; alternatively, the patients
should be referred to a specialized cardiologist with expertise in managing CVD inpatients with cancer.
eWithout delaying cancer treatments.
fUnless there is an oncology emergency requiring immediate cancer treatment.
gModerate-to-severe pre-existing CVDs or new abnormal ﬁndings (baseline cardiac
serum biomarkers .ULN, LVEF ≤50%, GLS under normal local values, previously
undiagnosed moderate-to-severe myocardial, pericardial, or VHDs, abnormal baseline
ECG).ESC Guidelines 4249Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

HER2-tar geted ther
a
pies
c
Baseline  clinical  CV assessment
 ,
p
,
h
ysical exam and ECG a
r
e 
r
ecommended
in all cancer  patients  scheduled  
f
or ca
f
f
 r
diot
o
xic ther
a
pies
a
Previous
CVD
Previous
CVDAll other
patients
All
patientsAll
patients
All other
patients
Previous
CVD
All
patients
High and
very high riskModerat e
riskLow
riskOther
conditionsClass  IIb Class IIa Class  I
Anthrac yclines
Fluo
r
o
p
y
r
ymidine s
VEGFi
Seco nd- and thi
r
d-generation  BCR-ABL
 TKI
d
BTK inhibitors
PI
e
RAF and MEK inhibitors
ICI
Osim e
r
tinib
C
AR-T and
TIL
R
T to a 
 R
R
 v
olume including the hea
r
t
HSC TTTEbPatient risk level NP cTn
Figure 7 Baseline screening recommendations for patients with cancer treated with potentially cardiotoxic drugs. 3D, three-dimensional; ADT, andro-
gen deprivation therapy; AL-CA, amyloid light-chain cardiac amyloidosis; BC, breast cancer; BCR-ABL, breakpoint cluster region-Abelson oncogen e locus;
BNP, B-type natriuretic peptide; BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor T cell; CDK, cyclin-dependent kinase; CMR, cardiac mag-
netic resonance; cTn, cardiac troponin; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GLS, global longitudinal stra in; HER2,
human epidermal receptor 2; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; LVEF, left ventricular ejection f raction;
MEK, mitogen-activated extracellular signal-regulated kinase; NP, natriuretic peptides (including BNP and NT-proBNP); NT-proBNP, N-terminalpro-B-type natriuretic peptide; PI, proteasome inhibitors; RAF, rapidly accelerated ﬁbrosarcoma; RT, radiotherapy; TIL, tumour-in ﬁltrating lymphocytes;
TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitors.
aIncluding patients scheduled to
receive ADT for prostate cancer, CDK 4/6 inhibitors, endocrine hormone therapy for BC and anaplastic lymphoma kinase inhibitors.bTTE is recom-
mended as the ﬁrst-line modality for the assessment of cardiac function. 3D echocardiography is recommended to measure LVEF. GLS is recommended
in all patients with cancer having echocardiography, if available. CMR should be considered when echocardiography is unavailable or not diagnostic .
cBaseline cTn measurement should be considered (Class IIa, Level A) in low- and moderate-risk patients post-anthracycline chemotherapy but prior
to starting HER2-targeted therapies. Baseline NP and cTn measurement may be considered (Class IIb, Level C) in low- and moderate-risk patients.
dBaseline echocardiography is recommended in patients scheduled to receive dasatinib (Class I, Level C).eNP and cTn measurements are recommended
at baseline in patients with AL-CA (Class I, Level B).4250 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

recommended.44–48When baseline QTcF prolongation is recog-
nized, the correction of reversible causes and the identi ﬁcation of
genetic conditions that prolong QT is recommended (see Section
6.4.2 ).45
Left atrial enlargement on baseline ECG before ibrutinib has
been shown to be a predictor f or the development of atrial ﬁbril-
lation (AF) during chemotherapy.50,51The presence of atrioven-
tricular (AV) conduction delays and premature atrial complexes
are associated with the development of atrial arrhythmias in pa-tients undergoing autologous haem atopoietic stem cell transplant-
ation (HSCT).
52
4.4. Cardiac serum biomarkers
The literature on the use of biomarkers for CTR-CVT risk strati-ﬁcation before cancer therapy is limited, and recommendations
are mostly based on expert opinion.
12,43,53–55Four recent position
papers based on collaboration am ong the Cardio-Oncology Study
Group of the HFA of the ESC, the ESC-CCO, and ICOS have sug-
gested that measurement of cardiac serum biomarkers —cardiac
troponin (cTn) I or T and natriure tic peptides (NP) (e.g. B-type
natriuretic peptide [BNP] or N-terminal pro-BNP
[NT-proBNP]) —help in baseline CV risk strati ﬁcation of patients
scheduled for cancer therapies including anthracyclines, human
epidermal receptor 2 (HER2)-tar geted therapies, vascular endo-
thelial growth factor (VEGF) inhibi tors (VEGFi), proteasome inhi-
bitors (PI), immune checkpoint inhi bitors (ICI), chimeric antigen
receptor T cell (CAR-T) and tumour-in ﬁltrating lymphocytes
(TIL) therapies, allowing identi ﬁcation of those who may bene ﬁt
from cardioprotective therapy.12,43,53,54Baseline cardiac serum
biomarker measurements are required if the degree of change in
the biomarkers is to be used to ide ntify subclinical cardiac injury
during cancer treatment.A few studies of paediatric and adult patients requiring an-
thracycline chemotherapy have reported that patients with can-
c e rw i t ha ni n c r e a s e dc T nb e f o r et r e a t m e n tw e r em o r el i k e l yt odevelop CTRCD.
56–58However, most published studies have
not reported on the prognostic value of baseline cTn measure-
ments, possibly due to the low prevalence of patients with pre-vious CVD or CVRF in these studies.
55,59,60A study of 251
women receiving trastuzumab for early HER2-positive breast
cancer (BC) reported that 19% of the patients who developedcardiac dysfunction during trastuzumab therapy had positive ul-
trasensitive troponin I at baseline ( .80 ng/L).
61Furthermore,
baseline high cTnI level was a predictor of lack of recovery des-
pite optimal HF therapy.61These ﬁndings have been con ﬁrmed
in a subsequent study of 533 patients with BC who had serialhigh-sensitivity cTn (hs-cTn) I and T measurements during tras-
tuzumab therapy.
62Increased baseline cTn ( .40 ng/L and
.14 ng/L for hs-cTnI and hs-cTnT, respectively) was associated
with a four-fold risk of developing LV dysfunction (LVD).62
However, given the high propor tion of patients with previous
anthracycline exposure in both studies, these elevated cTn levelsa r en o tat r u eb a s e l i n ea st h e yr e ﬂect pre-trastuzumab but post-
anthracycline chemotherapy . It is unclear whether pre-
treatment cTn levels will be predictive of LVD in patients beforeany treatment, or for those BC pa tients treated with trastuzu-
mab without prior anthracyclines.
NP are another potential biomarker for CV risk strati ﬁcation.
Several studies have shown the role of NP measurement at baseline
or NP changes to predict future CTR-CVT.
63–65In patients with mul-
tiple myeloma (MM), pre-treatment NP may be a predictive markerfor subsequent CV adverse events. In 109 patients with relapsed MM,
BNP.100 pg/mL or NT-proBNP .125 pg/mL levels before initi-
ation of car ﬁlzomib were associated with an odds ratio of 10.8 for
subsequent CV adverse events.
66Therefore, baseline NP measure-
ment is recommended in high- and very high-risk patients and should
be considered in low- and moderate-risk patients before PItreatment.
Baseline elevated values of CV functional peptides (including
NT-proBNP) and hs-cTnT were strongly related to all-cause mortal-ity in 555 patients with different types of tumours, suggesting that
the presence of a subclinical myocardial injury might be directly
linked to disease progression.
67However, in the CARDIOTOX
(CARDIOvascular TOXicity induced by cancer-related therapies)
registry, in 855 patients treated with a range of oncological treat-
ments, including radiotherapy (RT), both NT-proBNP and cTn eleva-tion at baseline were not associated with the development of severe
CTRCD (LVEF ,40% or clinical HF).
68
There has also been interest in other novel biomarkers for
CTR-CVT risk strati ﬁcation before cancer treatment; however,
the literature is limited. Candidates include myeloperoxidase,
C-reactive protein, galectin-3, arginine –nitric oxide metabolites,
growth differentiation facto r-15, placental growth factor,
fms-like tyrosine kinase-1, micro-ribonucleic acids, and immuno-
globulin E.60,69–71Currently, there is no evidence to support
routine measurement of these no vel biomarkers and more re-
search is required.Recommendation Table 2 —Recommendations for
electrocardiogram baseline assessment
Recommendations ClassaLevelb
An ECG is recommended in all patients starting
cancer therapy as part of their baseline CV riskassessment.IC
In patients with an abnormal baseline ECG,
c
referral to a cardiologistdis recommended.I C
©ESC 2022
AF, atrial ﬁbrillation; CV, cardiovascular; ECG, electrocardiogram; LV, left ventricular;
QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction.
aClass of recommendation.
bLevel of evidence.
cAdvanced conduction disease (left bundle branch block, right bundle branch block,
second degree heart block, severe ﬁrst degree heart block with a PR interval
.300 ms); Q waves in two or more contiguous leads; LV hypertrophy; AF/atrial
ﬂutter if previously undiagnosed; QTc prolongation using Fridericia correction
formula (QTcF =QT/3√RR).450 ms for men and .460 ms for women or other
ECG abnormality raising concern.
dCardio-oncology referral is recommended when available; alternatively, the patients
should be referred to a specialized cardiologist with expertise in managing CVD in
patients with cancer.ESC Guidelines 4251Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

4.5. Cardiovascular imaging
CV imaging has an important role in identifying patients with subclin-
ical CVD, determining the degree of pre-existing cardiac comorbidity
prior to decisions regarding cancer therapy, and serves as a referencefor identi ﬁcation of changes during treatment and long-term follow-
up.
12,54,72–74Transthoracic echocardiography (TTE) is the preferred
imaging technique for baseline risk strati ﬁcation as it provides quan-
titative assessment of LV and right ventricular (RV) function, cham-ber dilation, LV hypertrophy, regional wall motion abnormalities,diastolic function, VHD, pulmonary arterial pressure (PAP), and peri-cardial disease, which may in ﬂuence the therapeutic decision.
22,72
Suggestions for the components of a baseline echocardiography
study are provided in Figure 8 .
Current de ﬁnitions of CTRCD are based on a reduction of LVEF
and/or relative changes in global longitudinal strain (GLS) ( Table 3 ).
Three-dimensional (3D) echocardiography is the preferred echocar-diography modality for the assessment of LVEF and cardiacRecommendation Table 3 —Recommendation for
cardiac biomarker assessment prior to potentially car-
diotoxic therapies
Recommendation ClassaLevelb
Baseline measurement of NPcand/or cTndis
recommended in all patients with cancer at risk of
CTRCD if these biomarkers are going to bemeasured during treatment to detect
CTRCD.
e,53,55I C
©ESC 2022
cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; NP,
natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cNPs including B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide.
dcTn includes any of troponin I, troponin T, or hs-cTnT.
eSpeci ﬁc recommendations for baseline cardiac biomarkers in patients with cancer at
low, moderate, high, and very high risk of cancer therapy-related cardiovascular
toxicity are included in Section 5 .
TTE
Left ventricle-left atriuma
TTE
LVV and LV mass
3D-LVEF (2D-LVEF if 3D not available)
Contrast echo if inadequate TTE image quality
GLS 
E/e´, LAV
RVVRVEFCMR
Right ventricle-right atriuma
RV dimensions
S´TAPSEFACRV-FWLSRA areaPeak TRV
LVV and LV mass
LVEF 
LS and circumferential strain
if available
Myocardial Characterization 
T2w (STIR), T1, T2 maps, LGECMR
Valvular and pericardial
diseases
IVC diameter, and respiratorychanges
Valvular and pericardialdiseasesOther parameters
TTE
 CMR
Figure 8 Recommended transthoracic echocardiography and cardiac magnetic resonance imaging parameters in the evaluation of patients with cancer.
2D, two-dimensional; 3D, three-dimensional; BP, blood pressure; CMR, cardiac magnetic resonance; E, mitral in ﬂow early diastolic velocity obtained by pulsed
wave; e′, early diastolic velocity of the mitral annulus obtained by tissue doppler imaging; echo, echocardiography; FAC, fractional area change; FWLS, fre ew a l l
longitudinal strain; GLS, global longitudinal strain; IVC, inferior vena cava; LAV, left atrial volume; LGE, late gadolinium enhancement; LS, long itudinal strain; LV,
left ventricular; LVEF, left ventricular ejection fraction; LVV, left ventricular volume; RA, right atrial; RV, right ventricular; RVEF, right ven tricular ejection fraction;
RVV, right ventricular volume; s′, systolic velocity of tricuspid annulus obtained by doppler tissue imaging; STIR, short tau inversion recovery; TAPSE, tricuspid
annular plane systolic excursion; TTE, transthoracic echocardiography; TRV, tricuspid regurgitation velocity.aChanges in systemic arterial BP and loading con-
ditions may in ﬂuence cardiac function measurements.4252 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

volumes.54,75–79If 3D echocardiography is not feasible (e.g. unavail-
able or poor tracking), the modi ﬁed two-dimensional (2D)
Simpson ’s biplane method is recommended.80,81In patients with in-
adequate TTE image quality, ultrasound-enhancing contrast agents
should be added to improve evaluation of LV function and volumes
if two or more LV segments are not well visualized.82Alternatively, in
subjects with poor-quality echocardiography windows, when avail-
able, CMR should be considered ( Figure 8 ).14,72,83,84If TTE and
CMR are both unavailable for the assessment of LVEF, multigated ac-quisition nuclear imaging (MUGA) can be considered as a third-line
modality. MUGA scans should be avoided whenever possible due
to radiation exposure and the inability to obtain other important in-
formation (e.g. VHD, PAP, or GLS).
Baseline LVEF and GLS are recommended in all patients evaluated
with TTE before cardiotoxic cancer treatment initiation to stratify
CTR-CVT risk and to identify signi ﬁcant changes during treat-
ment.
8,64Changes in loading conditions occur frequently during
chemotherapy (e.g. volume increase due to intravenous [i.v.] ﬂuids,
volume loss due to vomiting or diarrhoea, blood pressure [BP] and
heart rate changes with pain or stress) and may affect cardiac vo-lumes, LVEF, and GLS quanti ﬁcation. Systemic arterial BP measure-
ment is recommended with all resting TTE as it can in ﬂuence
cardiac function measurements and should be recorded on theTTE report. A baseline borderline (50 –54%) or reduced ( ,50%)
LVEF is a risk factor for future CTR-CVT from most cardiotoxic can-
cer therapies, in particular with anthracyclines or trastuzumab.
12,24,74
Increased baseline indexed LV end-diastolic volume can be a predict-
or of major CV events (symptomatic HF or cardiac death) during an-
thracycline chemotherapy in patients with preserved LVEF.85
A normal LVEF does not exclude CTRCD and deformation para-
meters can detect early systolic impairment with suf ﬁcient test reli-
ability.86–89Determination of GLS using speckle tracking is
recommended at baseline, using three apical views,90particularly
in moderate- and high-risk patients. Baseline GLS can predict
LVD89–94in patients receiving anthracyclines and/or trastuzumab.
Strain measurements may be subject to inter-vendor variability95
and serial GLS measurement for each patient is recommended tobe performed using the same machine/software. A median GLSchange of 13.6% predicted a future fall in LVEF with a 95% upper limit
of GLS reduction of 15%.
93Using the 15% cut-off improves speci ﬁ-
city and is therefore the threshold recommended when monitoringGLS during cancer therapy. Global circumferential strain
96has been
reported to identify patients at risk of CTRCD, but data are currently
insuf ﬁcient to recommend its use routinely. Baseline LV diastolic
function may be associated with a small risk of subsequent systolic
dysfunction, especially with anthracyclines and trastuzumab, al-
though the evidence is not consistent.97,98Chest computed tomog-
raphy (CT) or CMR may be helpful for identifying subclinical CVD
such as coronary calcium or intracardiac masses on readily available
routine imaging performed for cancer staging.99
In the secondary prevention setting or patients with symptoms or
signs of pre-existing CVD, a careful evaluation should begin with a
comprehensive TTE.73This is both to obtain baseline assessment
as in the primary prevention setting and to determine the severity
of the underlying CVD. In case of poor-quality or uninterpretable
TTE images, or if a speci ﬁc CVD is identi ﬁed (e.g. hypertrophiccardiomyopathy), CMR should be considered for further risk
assessment.
Functional imaging tests for myocardial ischaemia —including
stress echocardiography, perfusion CMR, or nuclear myocardial per-
fusion imaging —should be performed to assess for ischaemia in
symptomatic patients (stable angina, limiting dyspnoea) if clinical sus-picion of coronary artery disease (CAD) exists, especially prior to
use of cancer therapies associated with vascular toxicity (e.g. ﬂuoro-
pyrimidines, VEGFi, breakpoint cluster region –Abelson oncogene lo-
cus [BCR-ABL], tyrosine kinase inhibitors [TKI]). Alternatively, in
patients with low to intermediate pre-test probability of CAD,
CCTA is a robust alternate modality with high sensitivity to rule
out obstructive CAD.
100,101
4.6. Cardiopulmonary ﬁtness assessment
Maximal cardiopulmonary exercise testing (CPET) assesses the inte-
grative capacity of the CV system to transport oxygen and energysubstrate to skeletal muscle during exercise,
109described as cardio-
respiratory ﬁtness (CRF). CPET can therefore provide a more global
assessment of CV health than organ-speci ﬁc tools. CPET-derivedRecommendation Table 4 —Recommendations for
cardiac imaging modalities in patients with cancer
General ClassaLevelb
Echocardiography is recommended as the
ﬁrst-line modality for the assessment of cardiac
function in patients with cancer.4,12,54,94IC
3D echocardiography is recommended as the
preferred echocardiographic modality to measureLVEF.
77–79,89IB
GLS is recommended in all patients with cancer
having echocardiography, if
available.75,80,81,89,90,92,93,102,103IC
CMR should be considered for the assessment of
cardiac function when echocardiography is
unavailable or non-diagnostic.83,104,105IIa C
MUGA may be considered when TTE is not
diagnostic and CMR is not available.106–108IIb C
Baseline cardiac imaging prior to potentially cardiotoxic
therapiesc
Baseline comprehensive TTE is recommended in
all patients with cancer at high risk and very highrisk of CV toxicity before starting anticancer
therapy.
d,54I C
©ESC 2022
3D, three-dimensional; CMR, cardiac magnetic resonance; CTR-CVT, cancer
therapy-related CV toxicity; CV, cardiovascular; GLS, global longitudinal strain; LVEF,left ventricular ejection fraction; MUGA, multigated acquisition nuclear imaging; TTE,
transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cSpeci ﬁc recommendations for baseline CV imaging in patients with cancer at low or
moderate risk of CTR-CVT are included in Section 5 .
dExcept asymptomatic patients referred to breakpoint cluster region-Abelson oncogene
locus therapy (BCR-ABL) where base line TTE should be considered (see Figure 7
and Section 5.5.5 ).ESC Guidelines 4253Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CRF —typically measured as the peak rate of oxygen consump-
tion110,111or metabolic equivalents111,112during exercise —is one
of the most robust predictors of CV health and longevity,113,114
and improves risk classi ﬁcation.115–121Evidence for CPET pre-
treatment is limited to pre-operative risk strati ﬁcation particularly
for patients with lung,122colon,123and rectal124cancers. Whether
CPET performed prior to cardiotoxic cancer therapies is prognostic
of future CV events is unknown.
4.7. Cardiovascular risk evaluation
before cancer surgery
Cancer surgery remains the primary treatment modality for many
cancers. Cardio-oncology teams should be involved in pre-operative
CV risk strati ﬁcation to identify and provide appropriate manage-
ment and surveillance of the potential risk factors.5
In patients undergoing oncologic al surgery, peri-operative car-
diac complications are determined b y patient-related risk factors,
the tumour type, concomitant cancer therapies, and the expectedsurgical risk. To ensure safe cancer surgery, consultations should
be directed at: (1) patients with previous signi ﬁcant or symptom-
atic CVD; (2) patients at high and very high CV toxicity risk, ac-cording to baseline HFA-ICOS risk assessment tools,
12when
adjuvant (post-surgery) cancer treatment is planned; and (3) pa-
tients who have received neoadjuvant (prior to surgery) cancertherapy that is potentially cardiotoxi c. Pre-operative clinical evalu-
ation should not delay surgery. C omplementary tests required for
the patients included in groups 1 and 2 should be guided by generalESC Guidelines.
125However, in group 3 patients, the pre-
operative evaluation should be aimed at con ﬁrming that no rele-
vant events have occurred during CV monitoring ( Section 5 ).
Table 6 summarizes factors that could in ﬂuence peri-operative
risk during cancer surgery.
4.8. Genetic testing
Candidate gene and genome-wide association studies have re-sulted in the identi ﬁcation of 40 candidate genes and single nucleo-
tide polymorphisms associated wit h anthracycline-related cardiacdysfunction.
37,126 –128It should be noted that with the advent of
immunotherapies, germline genes may not be the only genetic pre-
dispositions to CTR-CVT. A study of patients with ICI-associatedmyocarditis identi ﬁed that the selective clonal T-cell populations
inﬁltrating the myocardium were id entical to those present in tu-
mours and skeletal muscle, with ribonucleic acid sequencing stud-ies revealing expression of cardiac-speci ﬁc genes in the tumour,
129
raising the intriguing possibility that somatic mutations in the tu-
mour itself could contribute to CTR-CVT. A list of genetic variantsassociated with CVD during c ancer therapy is provided
(Supplementary data, Table S9 ) and has recently been reviewed.
38
Routine use of genetic testing for the assessment of CTR-CVT risk
prior to initiation of cancer therapy is not currently recommended.
In the future, a personalized genetic approach may help de ﬁne indi-
vidual susceptibility to CVD in patients with cancer and more re-
search is required.
5. Prevention and monitoring of
cardiovascular complicationsduring cancer therapy
5.1. General principles
CTR-CVT risk may vary according t o cancer type and stage, antic-
a n c e rd r u g s ,d o s e s ,a n du n d e r l y i n g comorbidities. Certain therapy
combinations (drug –drug or drug –radiation) may have a synergis-
tically toxic effect on the heart, possibly depending on the timingof these therapies (sequential or concomitant) and previous co-
morbidities. The pathophysiology of CTR-CVT is out of the scope
of this guideline and is extensively reviewed in the
ESC
CardioMed textbook.130
CVD and cancer share common modi ﬁable and non-modi ﬁable
risk factors ( Figure 3 ).4,131,132The ﬁrst step is to optimize lifestyle
CVRF, smoking cessation, restricting alcohol consumption to a max-
imum of 100 g per week, and maintaining adequate physical activ-
ity.30Exercise prescription seems to be a promising treatment to
Table 6 Factors that could in ﬂuence peri-operative risk during cancer surgery and preventive strategies
Factors that could in ﬂuence peri-operative risk during cancer surgery Preventive strategies
Patient-related
factorsLifestyle risk factors: smoking, obesity, sedentary lifestyle
Poorly controlled CVRF: hypertension, DM
Pre-existing CVD including CTR-CVT
Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and
anticoagulants)
Historical primary malignancy
Current cancer type, stage and locationOptimal management of CVRF and
CVD ( Section 5 )
Optimize VTE and ATE preventive
strategies ( Section 6 )
Neoadjuvant cancer
therapyNeoadjuvant cardiotoxic cancer treatments (see Section 5 ; especially anthracycline
chemotherapy and/or trastuzumab, ICI, VEGFi, ﬂuoropyrimidine, and thoracic RT)
Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK
inhibitors)
Thrombocytopaenia caused by cancer treatmentEnsure optimal CV monitoring of
neoadjuvant therapy ( Section 5 )
Optimize VTE and ATE preventive
strategies ( Section 6 )
©ESC 2022
ATE, arterial thromboembolism; BTK, Bruton tyrosine kinase; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,
cardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth fac tor inhibitors; VTE, venous
thromboembolism.4254 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

counteract anticancer treatment side effects and different types of
training can be prescribed during cancer therapy according to a pa-
tient ’s individual characteristics.133A healthy lifestyle decreases the
risks of cancer, CVD, and transition from diagnosed cancer to subse-
quent CVD.134,135Poor CRF is associated with a higher prevalence of acute and
chronic CTR-CVT and exercise positively impacts CRF during
chemotherapy, although in a recent meta-analysis, the ability of exer-cise to prevent CTRCD is unclear.
136,137CVRF must be corrected
with intensive treatment of arterial hypertension,138DM,139and
Management of CVD and CVRF 
 according to ESC GuidelinesPrimary vs secondary prevention
Minimize the use of cardiotoxic drugs
ACE-I/ARB and beta-blockers
Dexrazoxane/liposomal anthracyclines
(patients treated with anthracyclines)
StatinsPrimary and secondary cancer-therapy related CV toxicity prevention strategies
In patients at high and very high
risk of CTRCD
 1°preventionBaseline CV risk
assessment
2°prevention
1st cancer requiring cardioto xic cancer therapy
2nd cancer requiring cardioto xic cancer therapy
CVD
CTR-CVT Class IIa Class I
Figure 9 Primary and secondary cancer therapy-related cardiovascular toxicity prevention. ACE-I, angiotensin-converting enzyme inhibitors; ARB, angio -
tensin receptor blockers; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; CTR-CVT, cancer therapy-related cardiovascular
toxicity; CTRCD, cancer therapy-related cardiac dysfunction; ESC, European Society of Cardiology.12Left panel represents examples of ﬁve different primary
or secondary prevention strategies de ﬁnition based on the history of pre-existing CVD and/or prior CTR-CVT. Right panel describes general strategies to
mitigate CTR-CVT risk in patients at high and very high risk of CTRCD.ESC Guidelines 4255Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

dyslipidaemia,140and underlying CVD and modi ﬁable comorbidities
should be managed according to appropriate 2021 ESC Guidelines
on CVD prevention in clinical practice ( Figure 9 ).19
Special attention should also be paid to the polypharmacy fre-
quently seen in patients with cancer, reducing the use of drugs
that may interfere with cancer therapies to the essential and ac-tively monitoring their CV side effects and drug –drug interac-
tions.
141Electrolyte imbalances such as hypokalaemia and
hypomagnesaemia should be corrected. The CV risk managementplan should be shared with the can cer specialist team, the pri-
mary care physician, and the patient to coordinate treatment
strategies.
5.2. Primary prevention strategies
Primary prevention of CTR-CVT aims to avoid or minimize the de-velopment of CV damage due to therapy in patients without
CVD
12,142and requires a multidisciplinary team (MDT) discussion
between oncologists and cardiologists for complex patients withcancer with multiple comorbidities.
4,21,22,43,143,144
5.2.1. Primary prevention of cancer
therapy-related cardiovascular toxicity duringanthracycline chemotherapy
Neurohormonal therapies during anthracycline chemotherapy (with
or without subsequent trastuzumab treatment) reduced the risk ofsigniﬁcant LVEF decline during follow-up in several small randomized
controlled trials (RCTs) ( Supplementary data, Table S10 ).
145–154
Recent meta-analyses including patients with cancer treated with an-
thracycline chemotherapy and HER2-targeted therapies reported
that renin –angiotensin –aldosterone system blockers, beta-blockers,
and mineralocorticoid receptor antagonists have a signi ﬁcant bene ﬁt
in preventing LVEF reduction, but no statistical differences in the in-
cidence of overt HF or other clinical outcomes were demonstrated
(Supplementary data, Table S11 ).155–160This may be due, in part, to
the fact that most trials included patients with a low baseline CTRCD
risk and therefore larger RCTs are needed in high-risk populations.
From the oncological perspective, some strategies that have been
investigated include managing anthracycline-related toxicity by ad-
justing the infusion time and dose intensity.161Dexrazoxane and lipo-
somal anthracyclines are currently approved in patients with high andvery high CTRCD risk or who have already received high cumulative
anthracyclines doses.
158,162–167Dexrazoxane is protective against
anthracycline-induced CTRCD. Currently, dexrazoxane is formallyapproved in adult patients with advanced or metastatic BC who
have already received a minimum cumulative anthracycline dose of
300 mg/m
2of doxorubicin or equivalent ( Table 5 ;Supplementary
data, Table S12 ).163In clinical practice, dexrazoxane infusion (dosage
ratio dexrazoxane/doxorubicin is 10/1; e.g. 500 mg/m2dexrazoxane
per 50 mg/m2doxorubicin) should be considered (at least 30 min
prior to each anthracycline cycle) in adult patients with cancer sched-
uled to receive a high total cumulative anthracycline dose for curative
treatment, and in patients with high and very high CTRCD risk (in-cluding those with pre-existing HF or low-normal or reduced
LVEF) where anthracycline chemotherapy is deemed essential.
163Pegylated and non-pegylated liposomal doxorubicin164,165,168
modify pharmacokinetics and tissue distribution without com-
promising antitumour ef ﬁcacy. Pegylated and non-pegylated liposo-
mal doxorubicin are approved for metastatic BC and pegylated
liposomal doxorubicin is also approved for advanced ovarian can-
cer, acquired immune de ﬁciency syndrome-related Kaposi sar-
coma, and MM. In a recent meta-analysis of 19 trials, in both the
adjuvant and metastatic context, liposomal doxorubicin was re-
ported to be less cardiotoxic than conventional doxorubicin.165
Liposomal daunorubicin is also available for acute leukaemia pa-
tients in place of daunorubicin when pre-existing LVD is
present.164,165
5.2.2. Primary prevention of radiation-induced
cardiovascular toxicity
Primary prevention of RT-induced damage to the CV system de-
pends on technological advances that allow improved targeting of
RT delivery, thereby maintaining or increasing oncological ef ﬁcacy
while reducing CTR-CVT.169,170Modern techniques strive to
minimize the mean heart dose (MHD), either by shaping the
dose distribution (intensity-modulated RT) or by using respira-
tory management (gating or breath-hold).171,172Proton therapy
offers the potential to further decrease exposure to surrounding
healthy organs.173However, complete cardiac avoidance is not
always possible due to the proximity of the tumour (e.g. centrallung tumours, mediastinal lymphomas, irradiation of the internal
mammary chain in BC). In patients where RT only has a consoli-
dating role and the risk of RT-induced CV injury is very high (e.g.due to baseline risk factors), a MDT is needed to consider the
risk/bene ﬁto fR T .
171,174
There are no proven medical therapies to prevent RT-induced CV
toxicity. One component of RT-induced CV toxicity is accelerating
pre-existing CAD, and therefore tight control of CVRFs is
recommended.
Recommendation Table 5 —Recommendations for
primary prevention of cancer therapy-related car-
diovascular toxicity
Recommendations ClassaLevelb
Management of CVRF according to the 2021 ESC
Guidelines on CVD prevention in clinical practice
is recommended before,cduring, and after cancer
therapy.19IC
Dexrazoxane should be considered in adult
patients with cancer at high and very high CV
toxicity risk when anthracycline chemotherapy is
indicated.d,158IIa B
Liposomal anthracyclines should be considered in
adult patients with cancer at high and very high CVtoxicity risk when anthracycline chemotherapy is
indicated.
e,164,165,168IIa B
Continued4256 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.3. Secondary prevention strategies
Secondary prevention refers to interventions in patients with pre-
existing CVD, including prior CTR-CVT, and new emerging
CTR-CVT during cancer therapy. CVD and comorbidities should re-
ceive the optimal therapy before and during cancer therapy as dis-cussed in previous sections. Regular clinical assessments, physical
examinations, and CV investigations (including 12-lead ECG, TTE,
and cardiac biomarkers) are recommended in patients receiving spe-ciﬁc cardiotoxic cancer therapies, with the frequency of surveillance
guided by baseline risk and the emergence of new
CTR-CVT.
5,12,33,53,54,187–1905.4. Cardiovascular surveillance during
cancer therapies
A careful clinical evaluation and physical examination is recom-
mended during cancer treatment to detect early signs and symptomsof CTR-CVT. ECG monitoring is required in patients at risk of car-
diac arrhythmias according to speci ﬁc drug protocols.
5.4.1. Cardiac serum biomarkers
During therapy, NP and cTn should be used for CTRCD screening
and diagnosis and they may also serve to guide therapy.55,63,191–194
The release of cTn and NP differ for different cancer treatments.
Therefore, an increase in biomarker level should be interpreted inthe patient clinical context (cancer treatment timing and
comorbidities).
It is important to consider that generally accepted cut-offs and ref-
erence values of CV biomarkers have not been established for pa-
tients with cancer or for those who receive cancer therapies. In
addition, levels of NP and cTn may differ according to local labora-tories and may be altered by many factors, including age, sex, renal
function, obesity, infections, and comorbidities such as AF and
pulmonary embolism (PE).
53,63,195–197
5.4.2. Cardiac imaging
Cardiac imaging plays a critical role in clinical decision-making during
the cancer process.72,198Imaging techniques —particularly advanced
echocardiography and CMR —facilitate early diagnosis and manage-
ment of CTR-CVT.22,54,94The frequency of cardiac imaging monitor-
ing during therapy should be adapted according to the estimatedbaseline risk
12and the expected CTR-CVT manifestation.54The car-
diac imaging technique used should be based on local expertise and
availability, and the same imaging modality (i.e. 3D-TTE, 2D-TTE,CMR) is recommended throughout the entire treatment to decrease
inter-technique variability.
94,199,200Cardiac imaging should be per-
formed at any time if patients receiving cardiotoxic therapies presentwith new cardiac symptoms.
New de ﬁnitions of CTRCD are presented in Section 3 .
1Early
recognition of asymptomatic CTR CD allows clinicians to incorp-
orate cardioprotective the rapy before there is a signi ﬁcant decline
in LVEF, which may or may not be reversible, and also decreases
the risk of interruptions in cancer therapy, which could otherwiseaffect patients ’survival.
22,43,72,94For the diagnosis and manage-
ment of asymptomatic CTRCD during cancer treatment, TTE —in-
cluding 3D-LVEF and GLS assessment —is the preferred technique
to detect and con ﬁrm cardiac dysfunction.72,83,93,102GLS evalu-
ation is particularly important in patients with low-normal LVEF
to con ﬁrm or not asymptomatic myocardial damage.201It is re-
commended to use the same vendor to analyse GLS during cancer
treatment to accurately compare values over time.73Therefore, a
relative change in GLS has been su ggested as the ideal tool to iden-
tify asymptomatic mild CTRCD.1,4,94Different thresholds have
been considered in the literature in recent years.93,202,203
Currently, a relative GLS decrease of .15% compared with base-
line is the recommended threshold as it re ﬂects the 95% upperRecommendation Table 6 —Recommendation for
secondary prevention of cancer therapy-related car-diovascular toxicity
Recommendation ClassaLevelb
Management of CVD according to applicable ESC
Guidelines is recommended before,cduring, and
after cancer therapy.I C
©ESC 2022
CVD, cardiovascular disease; ESC, European Society of Cardiology.
aClass of recommendation.
bLevel of evidence.
cWithout delaying cancer treatments.ACE-I or ARB and beta-blockers recommended
for HFfshould be considered for primary
prevention in high- and very high-risk patients
receiving anthracyclines and/or anti-HER2
therapies.145,150,155–157,159,160,175IIa B
ACE-I or ARB and beta-blockers recommended
for HFfshould be considered for primary
prevention in high- and very high-risk patients
receiving targeted cancer therapies that may cause
HF.gIIa C
Statins should be considered for primary
prevention in adult patients with cancer at highand very high CV toxicity risk.
h,149,176–185IIa B
©ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CV, cardiovascular; CVD, CV disease; CVRF, CV risk factors; ESC, European Societyof Cardiology; HER2, human epidermal receptor 2; HF, heart failure; HFA, HeartFailure Association; ICOS, International Cardio-Oncology Society; MEK,
mitogen-activated extracellular signal-regulated kinase; PI, proteasome inhibitors;
RAF, rapidly accelerated ﬁbrosarcoma; VEGFi, vascular endothelial growth factor
inhibitors.
aClass of recommendation.
bLevel of evidence.
cWithout delaying cancer treatments.
dAs per the European Medicine Agency: ≥350 mg/m2doxorubicin or equivalent; as per the
United States Food and Drug Administration: ≥300 mg/m2doxorubicin or equivalent.
eSeeSection 5.2.1 for speci ﬁc liposomal doxorubicin type and malignancies.
fCarvedilol (preferred beta-blocker for CV protection if there is no contraindication),186
bisoprolol, controlled/extended-release metoprolol succinate and nebivolol.
gVEGFi and bevacizumab, RAF inhibitor, MEK inhibitor, PI, dasatinib, ponatinib, and
osimertinib.
hAccording to HFA-ICOS risk assessment tools ( Section 4.1 ;Table 4 ).ESC Guidelines 4257Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

limit in the meta-analysis of GLS to predict future signi ﬁcant LVEF
reduction.93Using the 15% threshold will maximize speci ﬁcity and
minimize overdiagnosis of CTRCD and guide cardioprotectivetherapy.
1,4,93In patients with poor TTE image quality or when TTE is not diag-
nostic, CMR should be considered, including fast strain-encoded
CMR when available.105,204–206MUGA can be considered as a third-
line modality.
Baseline C4 C5 C63 M
post tx12 M
post txC1 C2 C3Anthracycline chemotherapy surveillance protocol
Class 1 Class 1Ia Class 1IbECG
cTnb / NPbTTEa
ECG
cTnb / NPbTTEa
ECG
cTn / NPTTEaHigh and 
very high 
riskModerate
riskLow
risk
Figure 10 Cardiovascular toxicity monitoring in patients receiving anthracycline chemotherapy. cTn, cardiac troponin; C, chemotherapy cycle;
ECG, electrocardiogram; M, months; NP, natriuretic peptides; TTE, transthoracic echocardiography; tx, treatment. Biomarker and TTE assessmentshould ideally be performed before the corresponding anthracycline cycle (C1 –C6).
aCardiac magnetic resonance should be considered for the assess-
ment of cardiac function when TTE is unavailable or not diagnostic. In moderate-risk patients, TTE should be considered after a cumulative dose of≥250 mg/m
2of doxorubicin or equivalent. In low-risk patients, TTE may be considered after a cumulative dose of ≥250 mg/m2of doxorubicin or equiva-
lent.bMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring.
cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completion may be considered in low-riskpatients (Class IIb, Level C). cTn and NP monitoring every two cycles during anthracycline chemotherapy and within 3 months after therapy completionshould be considered in moderate-risk patients and in low-risk patients receiving a cumulative dose of ≥250 mg/m
2of doxorubicin or equivalent (Class IIa,
Level C).4258 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5. Cancer therapy-related
cardiovascular toxicity monitoring
protocols
5.5.1. Anthracycline chemotherapy
Anthracycline-induced CTRCD is a dose-dependent and cumulative
process of variable onset that may present with symptomatic or
asymptomatic CTRCD.4
Figure 10 summarizes the recommended monitoring protocol
during anthracycline therapy ac cording to baseline CTRCD risk
(Table 4 ). Clinical assessment combined with cardiac biomarkers
(cTn and NP) and TTE (including 3D-LVEF and GLS when avail-
able) can identify both symptomatic and asymptomatic CTRCD
with a reasonably high negative predictive value. This topic hasbeen extensively reviewed in two recent HFA position
statements.
53,54Classifying patients based on their risk of
anthracycline-induced CV toxicit y has allowed the early implemen-
tation of personalized preventive strategies ( Section 5.2.1 ).14
Patients with pre-existing CVD should be treated with guideline-
based medical therapy.14,19,207
5.5.2. HER2-targeted therapies
HER2-targeted therapies are a crucial part of the treatment of
patients with HER2-positive inv asive BC in both early and meta-
static settings. In the neoadjuvant and/or adjuvant settings, drugscurrently approved are trastuzumab, pertuzumab, trastuzumab
emtansine, and neratinib. In the metastatic setting, trastuzumab,
pertuzumab, trastuzumab emtansine, tucatinib, and trastuzumabderuxtecan are currently approved.
214 –216Trastuzumab can
also be used in patients with HER2-overexpressing metastatic
gastric adenocarcinomas in combination with platinum-basedchemotherapy and eithe r capecitabine or 5- ﬂuorouracil (5-FU).
It is recognized that anti-HER2 therapies may lead to LVD in
up to 15 –20% of patients and to overt HF if surveillance is
missed, or in high- and very high-risk patients.
217 –220LV function
surveillance based on LVEF and GLS is recommended prior to
and every 3 months during HER2-targeted therapies treatmentsurveillance ( Figure 11 ).
22However, this single algorithm has
not been tested in low- or high-risk patients and increased fre-
quency of assessment (according t o local availability) is recom-
mended in high-risk patients.
The use of cardiac serum biomarkers to identify CTRCD is
less well-de ﬁned during anti-HER2 treatments.217Measurement
of cTn in BC patients after anthracycline-based chemotherapy
but prior to trastuzumab should be considered, as an elevated
cTn identi ﬁes patients at higher risk of trastuzumab-induced
CTRCD. Serial NP measurement was more sensitive than cTn
at predicting subsequent declines in LVEF during trastuzumab
treatment.74Recommendation Table 7 —Recommendations for
baseline risk assessment and monitoring during an-thracycline chemotherapy and in the ﬁrst 12 months
after therapy
Recommendations ClassaLevelb
TTE
Baseline echocardiographycis recommended in all
patients with cancer before anthracycline
chemotherapy.12,24,208–210IB
In all adults receiving anthracycline chemotherapy,
an echocardiogram is recommended within 12months after completing treatment.
208IB
In high- and very high-risk patients,
echocardiography is recommended every two
cycles and within 3 months after completing
treatment.24,208–210IC
In moderate-risk patients, additional
echocardiography should be considered after acumulative dose of ≥250 mg/m
2of doxorubicin
or equivalent.7IIa C
In low-risk patients, additional echocardiography
may be considered after a cumulative
dose of ≥250 mg/m2of doxorubicin or
equivalent.7IIb C
Cardiac serum biomarkers
Baseline measurement of NP and cTn is
recommended in high- and very high-risk patientsprior to anthracycline chemotherapy.
55,65,211IB
ContinuedBaseline measurement of NP and cTn should be
considered in low- and moderate-risk patientsprior to anthracycline chemotherapy.
211IIa C
cTn and NP monitoring before every cycle during
anthracycline chemotherapy and 3 and 12 months
after therapy completion is recommended in high-
and very high-risk patients.55,175,211IB
cTn and NP monitoring every two cycles during
anthracycline chemotherapy and within 3 monthsafter therapy completion should be considered in
moderate-risk patients and in low-risk patients
receiving a cumulative dose of ≥250 mg/m
2of
doxorubicin or equivalent.55,59,212,213IIa C
cTn and NP monitoring every two cycles during
anthracycline chemotherapy and within 3 months
after therapy completion may be considered inlow-risk patients.
55,59,212,213IIb C
©ESC 2022
cTn, cardiac troponin; NP, natriuretic peptides; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging
modalities recommendations (see Section 4.5 ).ESC Guidelines 4259Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

For patients requiring adjuvant chemotherapy and
anti-HER2-targeted therapy, the use of non-anthracycline chemo-
therapy should be considered by the MDT according torisk of relapse, cardiac ris ks, and in discussion with the
treating oncologist.
217When anthracycline chemotherapy in the
(neo)-adjuvant setting is necessary , sequential use ( anthracyclines
followed by taxanes and anti-H ER2 agents) has been shown
to signi ﬁcantly decrease the incidence of CTRCD in several
adjuvant trials, compared with concomitant use in earliertrials.
220 –224Recommendation Table 8 —Recommendations for
baseline risk assessment and monitoring during hu-
man epidermal receptor 2-targeted therapies and intheﬁrst 12 months after therapy
Recommendations ClassaLevelb
TTE
Baseline echocardiographycis recommended
before HER2-targeted therapies in all patients.225IB
Continued
9 M 12 M 3 M 6 MHER2-targeted therapy surveillance protocol
High and 
very high 
riskbLow and
moderate
riskaBaseline
eECG
cTnd / NPdTTEc
ECG
cTn / NPTTE
c
Class 1 Class 1Ia Class 1Ib3 M
post tx12 M
post tx
Figure 11 Cardiovascular toxicity monitoring in patients receiving human epidermal receptor 2-targeted therapies. cTn, cardiac troponin; CV,
cardiovascular; EBC, early breast cancer; ECG, electrocardiogram; HER2, human epidermal receptor 2; M, months; NP, natriuretic peptides; TTE, tra ns-
thoracic echocardiography; tx, treatment. This protocol refers to CV toxicity monitoring in patients receiving neoadjuvant or adjuvant anti-HER2 tar-
geted therapies for non-metastatic disease or ﬁrst year in metastatic disease. Biomarker assessment should ideally be performed before the
corresponding trastuzumab cycle. TTE should be performed in week 2 or 3 of a 3-weekly trastuzumab cycle.aIn low-risk HER2 +EBC patients who
are asymptomatic and with a normal assessment after 3 months, reducing TTE monitoring to every 4 months may be considered (Class IIb, Level C).In low- and moderate-risk metastatic HER2 +disease, TTE surveillance can be reduced to every 6 months after the ﬁrst year in asymptomatic patients
with normal TTE assessment (Class I, Level C).
bIn high- and very high-risk metastatic HER2 +disease, TTE monitoring every 2 –3 cycles may be considered
depending on the absolute risk and local availability.cCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE
is unavailable or not diagnostic.dMeasurement of NP and/or cTn is recommended in all patients with cancer if these biomarkers are going to be used
during treatment monitoring.eBaseline cTn measurement should be considered in low- and moderate-risk patients after anthracycline chemotherapy
but prior to starting anti-HER2 targeted therapies for CV toxicity risk prediction.4260 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.3. Fluoropyrimidines
Fluoropyrimidines such as 5-FU and its oral prodrug capecitabine
are mainly used for gastrointestinal (GI) malignancies and advanced
BC. The most common CTR-CVTs are angina pectoris,ischaemia-related ECG abnormalities, hypertension, Takotsubo syn-
drome (TTS), and MI (even in patients with normal coronary arter-
ies),
1,4,10,43,229,230with rarer CTR-CVT including myocarditis,
arrhythmias, and peripheral arterial toxicity (Raynaud ’s phenomenon
and ischaemic stroke).231The incidence of myocardial ischaemia var-
ies according to the dose, scheduling, and route of administration andis up to 10%.232Among the several mechanisms responsible for
5-FU-induced myocardial ischaemia are coronary vasospasm and
endothelial injury.233Chest pain and ischaemic ECG changes usually
occur at rest (less typically during exercise) within days of drug ad-
ministration and sometimes persist even after treatment cessation.
CTR-CVT risk markedly increases in patients with cancer with pre-existing CAD. Aggressive control of modi ﬁable CVRFs, according to
the 2021 ESC Guidelines on CVD prevention in clinical practice,
19is
recommended during and after treatment. A baseline TTE isrecommended in patients with a history of symptomatic CV to
conﬁrm the presence of pre-existing regional wall motion
abnormalities or LVD. Screening for CAD may be considered in
selected high- and very high-risk patients before the administration
of these drugs and according to local protocols and currentrecommendations.
12,234,235
5.5.4. Vascular endothelial growth factor inhibitors
Aberrant activation of kinases plays a critical role in both the devel-
opment of numerous cancer types and in CV and metabolic homeo-stasis. Inhibition of the VEGF signalling pathway is achieved with
either monoclonal antibodies (administered i.v.) against circulating
VEGF or with small-molecule TKI (taken orally) targeting VEGF re-ceptors.
236VEGFi are used for the treatment of numerous cancer
types, including renal, thyroid, and hepatocellular carcinomas.
However, their use is associated with a wide array of CV complica-tions including hypertension, HF, QTc prolongation, and acute vascu-
lar events ( Figure 12 ).
131,237–240It can be challenging to assess the
prognosis of patients experiencing severe CV side effects becauseIn patients receiving neoadjuvant or adjuvant
HER2-targeted therapies, echocardiography isrecommended every 3 months and within 12
months after completing treatment.
225,226IB
In low-risk HER2 +EBC patientsdwho are
asymptomatic and with a normal assessment after
3 months, reducing monitoring to every 4 monthsmay be considered.IIb C
In high- and very high-risk HER2 +EBC patients,
d
more frequent echocardiography monitoringe
should be considered during treatment.IIa C
In metastatic HER2 +disease, echocardiography is
recommended every 3 months during the ﬁrst
year; if the patient remains asymptomatic without
CV toxicity, then surveillance can be reduced to
every 6 months during future treatment.fIC
In metastatic HER2 +disease patients at high- and
very high-risk, more frequent echocardiographymonitoring
emay be considered.IIb C
Cardiac biomarkers
Baseline NP and cTn measurement are
recommended in high- and very high-risk patientsprior to anti-HER2-targeted therapies.
227,228IC
NP and cTn monitoring every 2 –3 cycles during
therapy and 3 and 12 months after the end of
therapy should be considered in high- and very
high-risk HER2 +EBC patients.d,55IIa C
Baseline cTn measurement should be considered
in low- and moderate-risk patientspost-anthracycline chemotherapy but prior to
starting anti-HER2-targeted therapies.
55,62IIa A
NP and cTn monitoring at baseline, every 3
months, and 12 months after therapy may be
considered in low- and moderate-risk HER2 +
EBC patients.d,55IIb C
©ESC 2022
BC, breast cancer; cTn, cardiac troponin; CV, cardiovascular; EBC, early breast cancer;
HER2, human epidermal receptor 2; NP, natriuretic peptides; TTE, transthoracicechocardiography.
aClass of recommendation.
bLevel of evidence.
cIf echocardiography is unavailable or non-diagnostic, follow general cardiac imaging
modalities recommendations (see Section 4.5 ).
dThese recommendations are also applicable for HER2 +non-BC patients.
eEvery 2 –3 cycles depending on the absolute risk and local availability.
fPatients at low and moderate risk.Recommendation Table 9 —Recommendations for
baseline risk assessment and monitoring during ﬂuor-
opyrimidine therapy
Recommendations ClassaLevelb
Baseline CV risk assessment and evaluation
including BP measurement, ECG, lipid pro ﬁle,
HbA1c measurement, and SCORE2/
SCORE2-OPcor equivalent is recommended19
before starting ﬂuoropyrimidines.IC
A baseline echocardiogram is recommended in
patients with a history of symptomatic CVD
before starting ﬂuoropyrimidines.IC
Screening for CADdmay be considered in patients
at high and very high risk of CADcbefore
ﬂuoropyrimidines.IIb C
©ESC 2022
BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVD,
cardiovascular disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary
Risk Estimation 2 —Older Persons.
aClass of recommendation.
bLevel of evidence.
cSCORE2 ( ,70 years) or SCORE2-OP ( ≥70 years) CV risk strati ﬁcation:,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50 –69 years: low risk
,5%; moderate risk 5% to ,10%; high risk ≥10%;≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.
dAccording to pre-existing CVD and local protocols.234ESC Guidelines 4261Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

these drugs are often used in patients with advanced cancer. The goal
must be to continue VEGFi treatment for as long as possible with ini-
tiation or optimization of CV treatment if indicated.
Hypertension is a class effect and is the most reported adverse
event under VEGFi treatment. It occurs within hours or days, is dose-
dependent, and is usually reversed by VEGFi discontinu-
ation.131,239,241–243The risk is higher in patients with pre-existing
hypertension or CVD, previous anthracycline treatment, advanced
age, history of smoking, hyperlipidaemia, and/or obesity ( Table 4 ).4,244LVD and HF occur in a minority of patients in RCTs,245but are re-
ported more frequently in routine practice246and are often revers-
ible.247Acute arterial events (aortic dissection, stroke, arterial
thrombosis, acute coronary events, vasospasm) and venousthromboembolism (VTE) can also complicate treatment with
VEGFi.
248QTc prolongation has been described with sunitinib, sor-
afenib, and vandetanib,249but it is rarely related to severe arrhythmic
events, except with vandetanib.250Some small-molecule TKI (e.g.
sorafenib and sunitinib) can cause AF251and HF.43,129,247
AfliberceptMonoclonal antibodies
VEGF TKIBevacizumaba
Ramucirumaba
Axitinib
CabozantinibLenvatinib
PazopanibRegorafenibSorafenib
SunitinibVandetanibHTN HF VTE ATE MIVEGFi-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to < 1% incidence
Rare: <0.1% incidenceQTc
Figure 12 Vascular endothelial growth factor inhibitors-related cardiovascular toxicities. ATE, arterial thromboembolism; EMA, European Medicines
Agency; FDA, Food and Drug Administration; HF, heart failure; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocar dial
infarction; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor; VEGFi, vascular endothe-
lial growth factor inhibitors; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use a re listed
by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.
aBevacizumab: hypertension frequency 5 –42% (EMA); 60 –77% of the patients who received bevacizumab in combination with erlotinib. Pre-existing
hypertension should be adequately controlled before starting treatment. Ramucirumab: hypertension frequency 16 –26% (EMA/FDA); in combination
with erlotinib, the incidence of hypertension was 24 –45%. Patients with uncontrolled hypertension were excluded from the trials. Figure developed
from EMA prescribing information,252FDA prescribing information.2534262 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

A baseline CV risk assessment includes clinical examination, BP
measurement, and an ECG with baseline QTcF measurement (see
Section 4 ).20Especially in patients with known hypertension, BP
should be controlled before VEGFi therapy. A baseline TTE isrecommended for high- and very high-risk patients.14Patients with
impaired LV function and/or patients at high or very high risk of de-
veloping HF should be referred to the cardiologist before startingVEGFi therapy.
14
ECGa
ECGaTTEb6 M 8 M 9 M 12 MEvery
6–12 M3 M 4 M
NPc,dECGaNPcTTEbVEGFi surveillance protocol
High and 
very high 
riskModerate
riskLow
risk
TTEb,dBaseline
Class 1 Class 1Ia Class 1Ib
Figure 13 Cardiovascular toxicity monitoring in patients receiving vascular endothelial growth factor inhibitors. ECG, electrocardiogram; M, months;
NP, natriuretic peptides; QTc, corrected QT interval; TTE, transthoracic echocardiography; VEGFi, vascular endothelial growth factor inhibitor s.aIn pa-
tients treated with VEGFi at moderate or high risk of QTc prolongation, ECG is recommended (Class I, Level C) monthly during the ﬁrst 3 months and
every 3 –6 months thereafter ( Section 6.4 ). Consider an ECG 2 weeks after starting treatment in high-risk patients and new monitoring in the case of any
dose increase (see Section 6.4.2 ).bCardiac magnetic resonance should be considered for the assessment of cardiac function when TTE is unavailable or not
diagnostic.cMeasurement of NP is recommended in all patients with cancer if these biomarkers are going to be used during treatment monitoring.dTTE
and NP should be considered at 4 weeks after starting treatment in very high-risk patients.ESC Guidelines 4263Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Monitoring during and after treatment is indicated for all patients
treated with a VEGFi and is based on close clinical follow-up using
serial ECGs, biomarkers, and echocardiography. Early recognitionand treatment of hypertension are essential to prevent other CV
complications, especially HF. Home BP monitoring is recommended
daily during the ﬁrst cycle, after each increase of anticancer therapy
dose, and every 2 –3 weeks thereafter.
138,254,255When treatment
with a VEGFi is stopped, a drop in BP must be anticipated and
BP-lowering therapy must be reduced and/or interrupted according-ly (Section 6 ).
In patients at risk of QTc prolongation, regular monitoring of the
QTc interval is recommended after a dose increase, whenever other
QT-prolonging agents are added, or if electrolyte imbalances occur
(Section 6 ).
Patients treated with a VEGFi must also be screened regu-
larly for symptoms and clinical signs of HF. Regular NP meas-
urement and echocardiogr aphy can be useful for the
detection of CTRCD, although evidence is weak
(Figure 13 ).
138,254,255
5.5.5. Multitargeted kinase inhibitors targeting
BCR-ABL
Chronic myeloid leukaemia (CM L) results from aberrant acti-
vation of ABL1 kinase due to a chromosomal translocation.Small-molecule TKIs targeting BCR-ABL —including imatinib,
bosutinib, dasatinib, nilotinib, and ponatinib —have proven ef-
fective in the treatment of CML. The toxicities associatedwith these TKIs are unique and due to ‘off-target ’effects of
each drug. Dasatinib is associ ated with group 1 pulmonary
hypertension (PH), HF, and pleur al and pericardial effusion,
whereas nilotinib and ponatinib are generally associated
with vascular events ( Figure 14 ).
131,256 –259Second-
generation BCR-ABL TKI may induce a QTc prolongation(see Section 6.4.2 ). CV toxicity risk is higher in patients
aged.65 years (relative risk 1.8) and in those with under-
lying DM (relative risk 2.5), hypertension (relative risk 3.2) orpre-existing CAD (relative risk 2.6).
256 –258,260Before
BCR-ABL TKI therapy, it is critical to de ﬁne baseline CV tox-
icity risk with special attention to BP, glucose, and lipids.Recommendation Table 10 —Recommendations for
baseline risk assessment and monitoring during vascu-lar endothelial growth factor inhibitors
Recommendations ClassaLevelb
BP monitoring
BP measurement is recommended for patients
treated with VEGFi, bevacizumab, or
ramucirumab at every clinical visit.IC
Daily home monitoring of BP for patients treated
with VEGFi during the ﬁrst cycle, after each
increase of VEGFi dose, and every 2 –3 weeks
thereafter is recommended.IC
ECG monitoring
In patients treated with VEGFi at moderate or
high risk of QTc prolongation, QTccmonitoring is
recommended monthly during the ﬁrst 3 months
and every 3 –6 months thereafter.dIC
Echocardiography
Baseline echocardiography is recommended in
high- and very high-risk patients treated with
VEGFi or bevacizumab.IC
Baseline echocardiography should be considered
in low- and moderate-risk patients treated with a
VEGFi or bevacizumab.IIa C
ContinuedEchocardiography may be considered every 4
months during the ﬁrst year in moderate-risk
patients receiving VEGFi or bevacizumab.IIb C
Echocardiography should be considered every 3
months during the ﬁrst year in high- and very
high-risk patients receiving a VEGFi or
bevacizumab.eIIa C
Echocardiography every 6 –12 months should be
considered in moderate- and high-risk patients
with cancer who require long-term treatment
with a VEGFi.IIa C
Cardiac biomarker
NP may be considered at baseline and then every
4 months during the ﬁrst year in moderate-risk
patients receiving a VEGFi.IIb C
NP should be considered at baseline, 4 weeks
after starting treatment, and them every 3 months
during the ﬁrst year in high- and very high-risk
patients receiving a VEGFi.IIa C
©ESC 2022
BP, blood pressure; ECG, electrocardiogram; NP, natriuretic peptides; QTc, corrected
QT interval; QTcF, corrected QT interval using Fridericia correction; VEGFi, vascular
endothelial growth factor inhibitors.
aClass of recommendation.
bLevel of evidence.
cQTc interval using Fridericia correction (QTcF =QT/3√RR) is the preferred method.
dConsider an ECG 2 weeks after starting treatment in high-risk patients and new
monitoring in the case of any dose increase (see Section 6.4.2 ).
eAn additional echocardiography 4 weeks after starting treatment should be considered
in selected high- and very high-risk patients according to local availability, especially if
cardiac biomarker surveillance is not available.4264 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Imatinib1st generation
BCR-ABL TKI
2nd generation
BCR-ABL TKI
3rd generation
BCR-ABL TKINilotinib
DasatinibBosutinib
PonatinibHTN HF HG AF DL Peric-E Pleu-E PH VascToxBCR-ABL TKI-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to < 1% incidence
Rare: <0.1% incidenceQTc
Figure 14 Breakpoint cluster region –Abelson oncogene locus tyrosine kinase inhibitor-related cardiovascular toxicities. AF, atrial ﬁbrillation; BCR-ABL,
breakpoint cluster region –Abelson oncogene locus; DL, dyslipidaemia; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart
failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; PAD, peripher al artery
disease; Peric-E, pericardial effusion; PH, pulmonary hypertension; Pleu-E, pleural effusion; ↑QTc, corrected QT interval prolongation; TKI, tyrosine kinase
inhibitors; VascTox, vascular toxicity (stroke, MI, PAD). Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by
system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.261
Figure developed from EMA prescribing information,252FDA prescribing information.253ESC Guidelines 4265Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Baseline
 3 M
 6 M
 9 M
 12 M
Every
6–12 M
BP
HbA1c
ECG
ABI
TTEPhysical 
examinationa
Bosutinib
Dasatinib
Nilotinib
Ponatinib
Nilotinib
PonatinibNilotinib
Ponatinib
Dasatinib
Nilotinib
Ponatinib
High and very high risk patients
treated with dasatinib or ponatinibSecond and third generation/nobreakspaceBCR-ABL TKI surveillance protocol
Class 1
 Class 1Ia
 Class 1Ib
Bosutinib
Dasatinib
Nilotinib
Ponatinib
Nilotinib
Ponatinib
Dasatinib
PonatinibBosutinib
Nilotinib
PonatinibLipid profile/
Figure 15 Second- and third-generation breakpoint cluster region –Abelson oncogene locus tyrosine kinase inhibitors surveillance protocol. ABI, ankle –
brachial index; BCR-ABL, breakpoint cluster region-Abelson oncogene locus; BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA 1c,
glycated haemoglobin; M, months; TKI, tyrosine kinase inhibitors; TTE, transthoracic echocardiography.aCoronary artery calcium scoring can reclassify
CV risk upwards and downwards in addition to conventional risk factors, and may be considered in men and women with calculated CV risk arounddecision thresholds.
194266 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Baseline ECG is recommended in all patients and QTc mon-
itoring in patients treated with second-generation BCR-ABL
TKI. Depending on the type of therapy used, speci ﬁcC Va s -
sessments should be performed after drug initiation
(Figure 15 ).256
5.5.6. Bruton tyrosine kinase inhibitors
Bruton tyrosine kinase (BTK) inhibitors are increasingly used to
treat lymphoid malignancies. Ibrutinib, a ﬁrst-in-class irreversibleoral inhibitor of BTK, has proven highly effective in chronic
lymphocytic leukaemia and related B-cell malignancies including
mantle cell lymphoma, Waldenström macroglobulinemia, and mar-ginal zone lymphomas.
262These disorders are usually diagnosed in
e l d e r l yp a t i e n t si nw h o mf r e q u e n tc o m o r b i d i t i e sc o e x i s ta td i a g n o -
sis that increase the risk of CTR-CVT.263,264Ibrutinib has been as-
sociated with bleeding diathesis, infections, and an increased risk of
hypertension, AF, and HF.265–267Ibrutinib may also cause ventricular
arrhythmias without prolonging QT.267,268Acalabrutinib is a second-
generation BTK inhibitor with greater BTK selectivity. In a recent
phase III, randomized, multicentre, open-label, non-inferiority study,
acalabrutinib demonstrated a non-inferior progression-free survival
compared to ibrutinib in patients with previously treated chronic
lymphocytic leukaemia with a lower incidence of symptomatic CVevents.
269However, grade ≥3 AF (symptomatic AF where urgent
intervention is indicated)270and AF in patients ≥75 years old or with
previous AF history were comparable between groups, as was therisk of CV events in patients with pre-existing CVRFs or CVD.
271
Therefore, we currently do not have enough data to establish differentmonitoring strategies in patients treated with these drugs.
Due to the lack of evidence-based recommendations, the manage-
ment of these CV events is challenging.
264Antihypertensive initiation
has been associated with a lower risk of a major adverse CV events(MACE).
264Opportunistic screening for AF by pulse-taking or ECG
rhythm strip is recommended at every clinical visit during BTK inhibi-
tor therapy.272
Due to a higher bleeding risk, ibrutinib should be temporarily
interrupted in patients requiring dual antiplatelet therapy (DAPT)
and 3 –7 days before invasive procedures. In case of emergency inter-
ventions, platelet transfusion should be considered to minimize
bleeding risks.262Recommendation Table 11 —Recommendations for
baseline risk assessment and monitoring during
second- and third-generation breakpoint cluster re-
gion –Abelson oncogene locus tyrosine kinase
inhibitors
Recommendations ClassaLevelb
Baseline CV risk assessmentcis recommended in
patients who require second- or third-generation
BCR-ABL TKI.256,261IC
In patients treated with nilotinib or ponatinib, CV
risk assessmentcis recommended every 3 months
during the ﬁrst year and every 6 –12 months
thereafter.256,261IC
QTcdmeasurement should be considered at
baseline, at 2 and 4 weeks after starting nilotinib,and 2 weeks after any dose increase.
259IIa C
Baseline echocardiography should be considered
in all patients before starting second- and
third-generation BCR-ABL TKI.IIa C
Baseline echocardiography is recommended in
patients scheduled to receive dasatinib.IC
Echocardiography should be considered every 3
months during the ﬁrst year in high- and very
high-risk patients receiving dasatinib or ponatinib.IIa C
Echocardiography may be considered every 6 –12
months in patients who require long-term ( .12
months) ponatinib or dasatinib.IIb C
Serial assessment of ankle brachial index may be
considered to detect subclinical peripheral
vascular disease.IIb C
©ESC 2022
BCR-ABL, breakpoint cluster region –Abelson oncogene locus; BP, blood pressure; CV,
cardiovascular; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HFA, HeartFailure Association; ICOS, International Cardio-Oncology Society; QTc, corrected
QT interval; QTcF, corrected QT interval using Fridericia correction; TKI, tyrosine
kinase inhibitors.
aClass of recommendation.
bLevel of evidence.
cPhysical examination, BP measurement, ECG, lipid pro ﬁle, and HbA1c measurement.
Coronary artery calcium scoring can reclassify CV disease risk upwards and downwardsin addition to conventional risk factors, and may be considered at baseline in low- andmoderate-risk patients as per HFA-ICOS risk assessment tools.
19
dQTc interval using Fridericia correction (QTcF =QT/3√RR) is the preferred
method.Recommendation Table 12 —Recommendations for
baseline risk assessment and monitoring duringBruton tyrosine kinase inhibitor therapy
Recommendations ClassaLevelb
BP monitoring and management
BP measurement is recommended for patients
treated with BTK inhibitors at every clinical
visit.264IB
Weekly home monitoring of BP during the ﬁrst 3
months and every month thereafter should be
considered for patients treated with BTK
inhibitors.IIa C
Echocardiography
Baseline echocardiography is recommended in
high-risk patientscscheduled to receive BTK
inhibitors.267,268IC
TTE is recommended in all patients who develop
AF during BTK inhibitor therapy.IC
ContinuedESC Guidelines 4267Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.7. Multiple myeloma therapies
There are many classes of pharmacotherapy that are approved for
the treatment of MM using a range of combinations. These include
immunomodulatory drugs (IMiD), dexamethasone, PI, and monoclo-
nal antibodies (e.g. daratumumab). PI —including bortezomib, car ﬁl-
zomib, and ixazomib —have become a mainstay of therapy for
newly diagnosed MM as well as relapsed disease.276,277Several large
studies using combination therapy for MM have demonstrated an in-creased risk of serious CV adverse events.
278–281MM patients being
treated with PI have a high incidence of coexistent CV comorbiditiesAF
Opportunistic screening for AF by pulse-taking or
ECG rhythm strip is recommended at everyclinical visit during BTK inhibitor therapy.
273I C
©ESC 2022
AF, atrial ﬁbrillation; BP, blood pressure; BTK, Bruton tyrosine kinase; DM, diabetes
mellitus; ECG, electrocardiogram; HF, heart failure; QTc, corrected QT interval; TTE,
transthoracic echocardiography; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cMale, age ≥65 years, previous history of hypertension, DM, QTc ≥480 ms, AF, HF,
cardiomyopathy, or severe VHD.263,274,275
Cyclophosphamide
Melphalan
Lenalidomide
PomalidomideAlkylating agents
Bortezomib
CarfilzomibProteasome inhibitorsaImmunomodulatory drugs
Thalidomide
Daratumumab
ElotuzumabMonoclonal antibodies
Isatu ximabHTN HF AF HG/DM MI VTE PH ATEMultiple myeloma drugs-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to < 1% incidence
Rare: <0.1% incidence
Figure 16 Multiple myeloma drug-related cardiovascular toxicities. AF, atrial ﬁbrillation; ATE, arterial thromboembolism; DM, diabetes mellitus; EMA,
European Medicines Agency; FDA, Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictiona ry
for regulatory activities; MI, myocardial infarction; PH, pulmonary hypertension; VTE, venous thromboembolism. Adverse reactions reported in mu ltiple clinical
trials or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the
available data, a blank space has been left.aIxazomib produces peripheral oedema in up to 18% of patients and hyperglycaemia in combination with lenalidomide
or pomalidomide and dexamethasone. Figure developed from EMA prescribing information,252FDA prescribing information.2534268 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

and increased baseline CV risk.282,283PI have been associated with a
variety of CV toxicities including hypertension, HF,284acute coron-
ary syndromes (ACS),66arrhythmias,285PH,286and VTE
(Figure 16 ).287,288During therapy, cardiac biomarkers and TTE are
important diagnostic and prognostic tools that can inform clinicaldecision-making ( Figure 17 ).
66
HF—especially HF with preserved ejection fraction (HFpEF) —is a
frequent manifestation of cardiac amyloidosis, but it is also an im-portant adverse effect of PI therapy, especially under car ﬁlzomib.In a safety analysis of patients with MM being treated with car ﬁlzo-
mib, 7.2% of patients were found to have new HF.
284In another
study, 23% of patients with MM treated with car ﬁlzomib developed
clinical HF and/or LVD.289The mechanism is not well understood
but is possibly related to PI-induced oxidative stress within myocytes,inhibition of the proteasome, or transient endothelial dysfunc-
tion.
281,283Although no studies have yet addressed the optimal
follow-up scheme in patients with MM treated with PI, a commonscheme consists of 3 –6-monthly visits with ECG, complete blood
Clinical assessment Clinical assessment
BP and ECG
TTE TTE every 3 cycles under carfilzomibBaseline During therapy
NPProteasome inhibitors surveillance protocol
Low-
moderate
risk
High and 
very high 
risk
Cardiac
amyloidosisClinical assessment
BP and ECG
TTE TTE every 3 cycles under carfilzomibNPNP every cycle during the first 6 cycles
under carfilzomib or bortezomiba
Clinical assessment
BP and ECG
TTE and CMR TTE every 3 cyclesNP and cTn NP and cTn every 3-6 monthsBP at every
clinical visitBP home
monitoring
Class 1 Class 1Ia Class 1IbBP at every
clinical visitBP home
monitoringClinical assessment
BP at every
clinical visitBP home
monitoringClinical assessmentNP every cycle during the first 6 cycles
under carfilzomib or bortezomiba
Figure 17 Cardiovascular monitoring in patients with multiple myeloma receiving proteasome inhibitors. BP, blood pressure; CMR, cardiac magnetic
resonance; cTn, cardiac troponin; ECG, electrocardiogram; NP, natriuretic peptides; TTE, transthoracic echocardiography.aEvery 2 months for patients
treated with ixazomib.ESC Guidelines 4269Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

tests (including NP and cTn) and echocardiography surveillance dur-
ing PI therapy.290A recent prospective study of patients with re-
lapsed MM con ﬁrmed the utility of NP to assist in risk strati ﬁcation
as well as management of CV morbidity during treatment.66
Hypertension, another adverse effect of PI, may also contribute to
the development of HFpEF.
Patients with MM are at elevated risk of thrombosis due to both
patient- and myeloma-related factors, particularly the combin-ation of PI and IMiD ( Figure 18 ).
279,287,291 –297In the ASPIRE
(Car ﬁlzomib, Lenalidomide, and Dexamethasone vs.
Lenalidomide and Dexamethasone for the Treatment ofPatients with Relapsed Multiple Myeloma) study, patients treatedwith a combination of car ﬁlzomib, lenalidomide, and dexametha-
sone had higher rates of VTE compared with those treated withlenalidomide and dexamethasone (6.6% vs. 3.9%).
279
Oncological guidelines recommend the use of aspirin or prophy-lactic doses of low-molecular-weight heparins (LMWH) in low-risk patients receiving thalidomide- or lenalidomide-based regi-
mens.
298In patients at high risk of VTE, therapeutic doses of
LMWH are recommended.299The role of non-vitamin K antagon-
ist oral anticoagulants (NOAC) in MM patients needs further val-
idation in larger trials, but recent small studies have con ﬁrmed the
efﬁcacy and safety of low doses of apixaban and rivaroxaban for
VTE prevention.300 –302
Risk factors for venous thromboembolic events in patients with multiple myeloma
Patient-related risk factors
Previous VTE
Acute infections
Autoimmune diseaseCentral venous catheterChronic renal diseaseCigarette smokingCVDDMGeneral surgeryHistory of inherited thrombophiliaImmobilization, surgery, traumaObesity (BMI >30 kg/m
2)
Myeloma-related risk factors
Advanced disease statusErythropoietin-stimulating agentsHigh dexamethasone dosesHyper-viscosity state
Thalidomide/lenalidomide/ponalidomide
Figure 18 Risk factors for venous thromboembolic events in patients with multiple myeloma. BMI, body mass index; CVD, cardiovascular disease; DM,
diabetes mellitus; VTE, venous thromboembolism.4270 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.8. Rapidly accelerated ﬁbrosarcoma and
mitogen-activated extracellular signal-regulated
kinase inhibitor treatment
The rapidly accelerated ﬁbrosarcoma (RAF) inhibitors —vemurafenib,
dabrafenib, and encorafenib —are approved for the treatment of
metastatic melanoma with a BRAF V600 mutation. The mitogen-
activated extracellular signal-re gulated kinase (MEK) inhibitors —
trametinib, cobimetinib, binimetinib, and selumetinib —have also
shown signi ﬁcant clinical activity in me lanoma patients whose tu-
mour contains a BRAF V600 mutation, and are now largely used
in combination with RAF inhibitors. The main CV effects to be con-
sidered are hypertension, PE, and CTRCD, which are associated
with all combinations of RAF and MEK inhibitors, and QTc pro-longation, associated solely with the coadministration of cobimeti-
nib and vemurafenib ( Figure 19 ).
12,308,309RAF inhibitor treatment
alone or in combination with a MEK inhibitor is associated with anincreased risk of MI and AF.
308
Patients with cancer with pre-existing CVD have an increased
frequency of CV adverse events during treatment with MEKand RAF inhibitors, and therefore baseline risk strati ﬁcation is
recommended.
12Most cardiac complicat ions induced by admin-
istration of MEK and RAF inhibitors seem to be attributable tothe MEK inhibitor, with the RAF inhibitor enhancing the toxic
effects of the MEK inhibitor.
310 –313Hypertension and LVD
were twice as frequent when MEK and RAF inhibitors werecoadministered compared with single therapy with RAF inhibitor
alone.
314
CTRCD can manifest any time from the ﬁrst month of ther-
apy to 2 years after the end of the oncological treatment.315
Baseline TTE is recommended in patients at moderate to high
risk of CTR-CVT. During treatment, it is necessary to monitorBP at each visit and promote week ly outpatient monitoring dur-
ing the ﬁrst 3 months and monthly thereaf ter. In patients treated
with cobimetinib/vemurafenib, an ECG is recommended at 2and 4 weeks after initiation of treatment and every 3 months
thereafter. In high-risk patients, periodic monitoring of ven-
tricular function with echocardiography should be consideredevery 6 –12 months.
CV protective medications (such as angiotensin-converting
enzyme inhibitors [ACE-I], angiotensin receptor blockers [ARB],Recommendation Table 13 —Recommendations for
baseline risk assessment and monitoring during mul-
tiple myeloma therapies
Recommendations ClassaLevelb
BP monitoring
BP measurement is recommended for patients
treated with PI at every clinical visit.IC
Home monitoring of BP weekly during the ﬁrst 3
months and monthly thereafter should be
considered for patients treated with PI.IIa C
Cardiac serum biomarkers
Measurement of NP is recommended prior to PI
in high- and very high-risk patients.66,303IC
Measurement of NP should be considered prior
to PI in low- and moderate-risk patients.66IIa C
In patients receiving car ﬁlzomib or bortezomib,
measurement of NP should be considered at
baseline and every cycle during the ﬁrst 6
cycles.c,66IIa B
NP and cTn measurements are recommended at
baseline and every 3 –6 months in patients with
AL-CA.d,290IB
TTE
Baseline echocardiography, including assessment
for AL-CA, is recommended in all patients with
MM scheduled to receive PI.IC
Echocardiography surveillance every 3 cycles
should be considered in high- and very high-risk
patients receiving car ﬁlzomib.280IIa B
Echocardiography surveillance every 3 cycles may
be considered in low- and moderate-risk patientsreceiving car ﬁlzomib.IIb C
Echocardiography surveillance should be
considered every 3 –6 months in patients with
AL-CA treated with PI.
d,290IIa C
VTE prophylaxis
Therapeutic doses of LMWH are recommended
in patients with MM with previousVTE.
296,298,302,304,305IB
Prophylactic doses of LMWH are recommended
in patients with MM with VTE-related risk factorse
(excluding previous VTE) at least during the ﬁrst 6
months of therapy.296,304,305IA
Aspirin should be considered as an alternative to
LMWH in patients with MM with no risk factors
or one VTE-related risk factore(excluding
previous VTE) at least during the ﬁrst 6 months of
therapy.296,304–307IIa B
ContinuedLow doses of apixaban or rivaroxabanfmay be
considered as an alternative to LMWH or aspirin
in patients with MM with VTE-related risk factorse
(excluding previous VTE) at least during the ﬁrst 6
months of therapy.300–302IIb C
©ESC 2022
AL-CA, amyloid light-chain cardiac amyloidosis; BP, blood pressure; cTn, cardiac
troponin; HF, heart failure; LMWH, low-molecular-weight heparins; MM, multiple
myeloma; NP, natriuretic peptides; PI, proteasome inhibitors; TTE, transthoracic
echocardiography; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cEvery 2 months for patients treated with oral ixazomib.
dDepending on HF severity and treatment.
eSeeFigure 18 .295,296,299
fLow doses of apixaban (2.5 mg twice a day) or rivaroxaban (10 mg once a day).ESC Guidelines 4271Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

and beta-blockers) have not been evaluated in patients treated
with MEK and RAF inhibitors but, from a mechanistic perspective,
beta-blockers might prevent CTRCD induced by MEK inhibitors.
The MEK/ERK pathway has a cardiac protective effect, regulatedby beta-adrenergic signalling, which also controls the p38 mito-
gen-activated protein kinases pathway, associated with cardiotoxic
effects. Beta-blockers might exert their cardioprotective effects
by reducing p38 signalling.315
Dabrafenib
EncorafenibRAF inhibitors
Vemurafenibb
Binimetinib
CobimetinibMEK inhibitors
TrametinibbHTN SVT/SBraHG/DM HF BLEED VTE/PE
RAF inhibitor- and MEK inhibitor-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to < 1% incidence
Rare: <0.1% incidenceQTc
Figure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor-related cardiovascular toxicities. AF, atrial
ﬁbrillation; BLEED, increased bleeding risk; DM, diabetes mellitus; EMA, European Medicines Agency; FDA, Food and Drug Administration; HF, heart fa ilure;
HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities; MEK, mitogen-activated extracellular signal-reg ulated kinase;
PE, pulmonary embolism; ↑QTc, corrected QT interval prolongation; RAF, rapidly accelerated ﬁbrosarcoma; SBr, sinus bradycardia; SVT, supraventricular
tachycardia; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical trials or during post-marketing use are listed by syste mo r g a nc l a s s
(in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.aDabrafenib is related with
SBr. Encorafenib is related with SVT. Vemurafenib rarely causes AF. Trametinib is related with bradycardia in some post-marketing reports.bPeripheral oe-
dema is very common. Figure developed from EMA prescribing information,252FDA prescribing information.253
Recommendation Table 14 —Recommendations for baseline risk assessment and monitoring during combined rap-
idly accelerated ﬁbrosarcoma and mitogen-activated extracellular signal-regulated kinase inhibitor therapy
Recommendations ClassaLevelb
BP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is
recommended.IC
In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3
months thereafter.cIC
Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK
inhibitors.IC
Baseline echocardiography may be considered in low- and moderate-risk patients scheduled to receive combined RAF and MEK
inhibitors.IIb C
Echocardiography should be considered every 4 months during the ﬁrst year in high- and very high-risk patients receiving combined RAF
and MEK inhibitors.IIa C
©ESC 2022
BP, blood pressure; ECG, electrocardiogram; MEK, mitogen-activated extracellular signal-regulated kinase; RAF, rapidly accelerated ﬁbrosarcoma.
aClass of recommendation.
bLevel of evidence.
cConsider an ECG and new monitoring in the case of any dose increase (see Section 6.4.2 ).4272 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.9. Immune checkpoint inhibitors
Immunotherapies, which harness the immune system to des-
troy cancer cells, come in diffe rent forms but the most widely
used are ICI.316The immune checkpoints are proteins ex-
pressed in the T cells that inhibit their activation when theycontact a body cell. ICI include monoclonal antibodies that
block the immune brakes or regulators, cytotoxic T
lymphocyte-associated antigen-4 (CTLA-4) (ipilimumab,tremelimumab), programmed death-1 (PD-1) (nivolumab, ce-
miplimab, pembrolizumab), and programmed death-ligand 1
(PD-L1) (atezolizumab, avelumab, durvalumab) expressed inthe cancer cells, with the consequent cytotoxic immune re-
sponse. By blocking these checkpoints from binding with their
partner proteins, ICI inhibit the ‘off’signal, activating T cells
and promoting killing of cancer cells. Although their patho-
physiology is not clearly de ﬁned, ICI may also trigger an
Low 
risk
cTn
Class 1
 Class 1Ia
 Class 1IbECG
TTE
CV assessmenta
NP
cTn
ECG
TTE
CV assessmenta
NP
High 
riskb
C4
Every
3Cc
Every
6 M–
12 Md
C2
 C3 BaselineImmune checkpoint inhibitors surveillance protocol
Figure 20 Cardiovascular surveillance in patients treated with immune checkpoint inhibitors. BNP, B-type natriuretic peptide; BP, blood pressure; C,
chemotherapy cycle; cTn, cardiac troponin; CV, cardiovascular; CVD, card iovascular disease; CTRCD, cancer therapy-related cardiac dysfunction ;
ECG, electrocardiogram; HbA1c, glycated haemoglobin; ICI, immune checkpoint inhibitors; M, months; NP, natriuretic peptides (including BNP andNT-proBNP); NT-proBNP, N-terminal p ro-B-type natriuretic peptide; TTE, t ransthoracic echocardiography.
aIncluding physical examination, BP,
lipid pro ﬁle, and HbA1c.bDual ICI, combination ICI-cardiotoxic therapy, ICI-related non-CV events, prior CTRCD or CVD.cEvery three cycles until
completion of therapy to detect sub clinical ICI-related CV toxicity.dIn patients who require long-term ( .12 months) ICI treatment.ESC Guidelines 4273Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

overactivation of T cells against n on-cancerous tissues, leading
to immune-related adverse events.317Immune-related CV side
effects may lead to life-threatening CV complications such asfulminant myocarditis, myopericarditis, cardiac dysfunction, ar-
rhythmias, or MI, which often results in the discontinuation of
ICI.
318,319
The largest case series of 122 patients with ICI-associated
myocarditis had early onset of symptoms (median of 30 days
after initial exposure to ICI), and up to 50% died.320Late CV
events ( .90 days) are less well charac terized but generally ex-
hibit a higher risk of non-in ﬂammatory HF, progressive athero-
sclerosis, hypertension, and mortality rates.321Other CV
toxicities described during ICI therapy are MI, AV block, supra-
ventricular and ventricular arrhythmias, sudden death,Takotsubo-like syndrome, non-in ﬂammatory HF, hypercholes-
terolaemia, pericarditis, perica rdial effusion, ischaemic stroke,
and VTE.
322A meta-analysis including 32 518 patients receiving
ICI treatment reported an increased risk of myocarditis, peri-
cardial diseases, HF, dyslipidaemia, MI, and cerebral arterial is-
chaemia.323Conditions related with high baseline ICI-related
CV toxicity risk include dual ICI therapy (e.g. ipilimumab and ni-
volumab), combination ICI thera py with other cardiotoxic ther-
apies, and patients with ICI-related non-CV events or priorCTRCD or CVD ( Figure 20 ).
324,325All patients on ICI treat-
ment should have an ECG and troponin assay at baseline
(Figure 20 ).326 –329High-risk patients should additionally have a
TTE evaluation at baseline. Due to the lack of evidence-based
recommendations, the monitoring of ICI therapy is challenging.
Once started on therapy, ECG, cTn, and NP should bechecked.
330 –332In the JAVELIN trial, which assessed avelumab
plus axitinib vs. sunitinib, no clinical value was observed for on-
treatment routine TTE monitoring in asymptomatic patients.333
However, in high-risk patients, and in those with high baseline
cTn levels, TTE monitoring may be considered. In patients
who develop ECG abnormalities, new biomarker changes, ornew cardiac symptoms at any time, prompt cardio-oncology
evaluation is strongly recommended, including TTE for the
evaluation of LVEF and GLS, and CMR when myocarditis is sus-pected ( Table 3 ).
3345.5.10. Androgen deprivation therapies for
prostate cancer
Androgen deprivation therapy (ADT) is prescribed in 40% of men
with prostate cancer as neoadjuvant and/or adjuvant therapy toRT or for biochemical relapse following prostate cancer surgery.
Gonadotropin-releasing hormone (GnRH) agonists are the most fre-
quently prescribed ADT. However, GnRH agonists are associatedwith an increased CV risk and mortality, particularly in patients
with prostate cancer aged .60 years.
337,338Baseline risk strati ﬁca-
tion in patients requiring GnRH agonists depends on vascular diseaserisk ( Figure 21 ).
339,340No dedicated CV toxicity risk calculators have
been developed for patients receiving ADT. It was the consensus of
the authors to recommend SCORE2 or SCORE2-OP to stratify CVrisk in patients receiving ADT without previous CVD.
19
The use of GnRH antagonists represents an alternative in the
treatment of prostate cancer, and preclinical and clinical (HEROtrial)
341data suggest that GnRH antagonist use is associated with sig-
niﬁcantly lower overall mortality and CV events compared with ago-
nists.342However, more research is needed in this ﬁeld. In the
PRONOUNCE trial, no difference in MACE at 1 year was observed
between degarelix (a GnRH antagonist) and leuprolide (a GnRH
agonist), although the trial was stopped early.343Lower CV event
rates were detected compared with previous studies and all patients
were reviewed by a cardiologist at enrolment (leading to optimal
CVRF management).343
The main CV effects to be considere d are hypertension, DM, ischae-
mic heart disease (IHD) and CTRCD.339,344ADT is uncommonly asso-
ciated with QTc prolongation and rarely causes torsade de pointes(TdP) through blockade of testosterone effects on ventricular repolar-
ization.
345,346ECG monitoring and correction of QT prolongation pre-
cipitant factors (see Section 6.4.2 ;Table 9 ;Supplementary data,
Table S13 ) is recommended340,347,348during prostate cancer treatment
if the baseline QTc interval is prolonged.49,339,340,347,349,350Recommendation Table 15 —Recommendations for
baseline risk assessment and monitoring during
immunotherapy
Recommendations ClassaLevelb
ECG, NP, and cTn measurements are
recommended in all patients before starting ICItherapy.
333IB
Baseline echocardiography is recommended in
high-risk patientscbefore starting ICI therapy.333IB
Baseline echocardiography may be considered in
all patients before starting ICI therapy.IIb C
ContinuedSerial ECG and cTn measurements should be
considered before ICI doses 2, 3, and 4, and ifnormal, reduce to every three doses until
completion of therapy to detect subclinical
ICI-related CV toxicity.
333IIa B
CV assessmentdis recommended every 6 –12
months in high-risk patientscwho require
long-term ( .12 months) ICI treatment.321–
323,335,336IC
CV assessmentdmay be considered every 6 –12
months in all patients who require long-term
(.12 months) ICI treatment.IIb C
©ESC 2022
BNP, B-type natriuretic peptide; BP, blood pressure; cTn, cardiac troponin; CTRCD,
cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular
disease; ECG, electrocardiogram; HbA1c, glycated haemoglobin; ICI, immunecheckpoint inhibitors; NP, natriuretic peptides; NT-proBNP, N-terminal pro-B-typenatriuretic peptide.
aClass of recommendation.
bLevel of evidence.
cDual ICI, combination ICI-cardiotoxic therapy; ICI-related non-CV events, prior
CTRCD, or CVD.
dPhysical examination, BP, NP (BNP or NT-proBNP), lipid pro ﬁle, HbA1c, and ECG.4274 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

GoserelinGnRH agonist
GnRH antagonistHistrelin
Degareli x
Relugoli xLeuprorelin
Bicalutamide
Flutamide
Nilutamide
Apalutamide
AbirateronebDarolutamide
EnzalutamideTriptorelinHTN HG/DM HF IHD/MI AFAndrogen deprivation therapy-related cardiovascular toxicities
1st generation antiandrogens
2nd generation
androgen deprivation therapy
Androgen metabolism inhibitor
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to < 1% incidence
Rare: <0.1% incidenceQTca
Figure 21 Androgen deprivation therapy-related cardiovascular toxicities. ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; DM, diabetes mel-
litus; EMA, European Medicines Agency; FDA, Food and Drug Administration; GnRH, gonadotropin-releasing hormone; HF, heart failure; HG, hypergly-caemia; HTN, hypertension; IHD, ischaemic heart disease; MedDRA, medical dictionary for regulatory activities; MI, myocardial infarction; ↑QTc,
corrected QT interval prolongation; TdP, torsade de pointes. Adverse reactions reported in multiple clinical trials or during post-marketing use a re listed
by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from the available data, a blank space has been left.
aADT may prolong the QTc interval. In patients with a history of risk factors for QT prolongation and in patients receiving concomitant medicinal pro-
ducts that might prolong the QT interval, physicians should assess the bene ﬁt/risk ratio including the potential for TdP prior to initiating the treatment.
bIncreased risk of QTc prolongation in combination with ADT.49,339,340,349,350Figure developed from EMA prescribing information,252FDA prescribing
information.253ESC Guidelines 4275Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.11. Endocrine therapies for breast cancer
Endocrine therapy is a common treatment as 65 –70% of all early
and metastatic BC patients develop hormone receptor-positive
disease.22Selective oestrogen receptor modulators (tamoxifen,
toremifene) or aromatase inhibito rs (AI) (letrozole, anastrozole,
or exemestane) are recommended in early BC (EBC) according
to menopausal status, comorbiditi es, and the risk of disease relapse.
The use of AI in combination with cyclin-dependent kinase (CDK)
4/6 inhibitors is recommended as ﬁrst- or second-line therapy
in patient with hormone receptor -positive/HER2-negative meta-
static BC.
The use of AI increases the risk of dyslipidaemia, metabolic syn-
drome, hypertension, HF, and MI.339In the ATAC ( ‘Arimidex ’and
Tamoxifen Alone or in Combination) trial, anastrozole-treated pa-
tients with pre-existing CAD experienced more CV events (17%
vs. 10%) and cholesterol level elevation (9% vs. 5%) than those trea-ted with tamoxifen.
351,352Similarly, HF was signi ﬁcantly more com-
mon with letrozole compared with tamoxifen in the BIG (Breast
International Group) 1 –98 trial.353Longer AI treatment duration
was associated with increased odds of developing CVD in two large
meta-analyses.354,355Signiﬁcantly increased VTE risk has been con-
sistently demonstrated with tamoxifen351,353and it is not recom-
mended in patients with thrombotic risks. Toremifene andhigh-dose tamoxifen were found to prolong QTc interval339,340;
however, no risk data have been published in patients treated with
the standard tamoxifen dose used in BC (20 mg/day).
The risks of VTE, hypercholesterolaemia, and CVD should be dis-
cussed with patients, while recognizing that the absolute bene ﬁts of
preventing BC recurrence usually outweigh the CV risks.339In pa-
tients,70 years old without clinical manifestations of atherosclerot-
ic disease, estimation of 10-year fatal and non-fatal CVD risk with
SCORE2 (if ≥70 years, SCORE2-OP) is recommended.19
Cholesterol levels and BP should be monitored regularly in patients
receiving AI.356Physical activity and healthy diet are also advised to
reduce weight and cholesterol levels. Smoking cessation is strongly
recommended to reduce CV risk (e.g. CAD during AI therapy and
VTE during tamoxifen therapy).
5.5.12. Cyclin-dependent kinase 4/6 inhibitors
The use of CDK 4/6 inhibitors (palbociclib, ribociclib, and abemaci-clib) in combination with endocrine therapy is approved for the
treatment of patients with hormone receptor-positive/
HER2-negative metastatic BC. This combination has resulted in im-provements in progression-free survival and, in some trials, overall
survival.
357–359CDK 4/6 inhibitors have demonstrated a potential
for QT prolongation,339,360particularly with ribociclib. The phase
III trials of ribociclib incorporated routine ECG monitoring.361–368Recommendation Table 16 —Recommendations for
baseline risk assessment and monitoring during an-
drogen deprivation therapy for prostate cancer
Recommendations ClassaLevelb
Baseline CV risk assessmentcand estimation of
10-year fatal and non-fatal CVD risk with
SCORE2 or SCORE2-OPdis recommended in
patients treated with ADT without pre-existing
CVD.19,341,342IB
Baseline and serial ECGs are recommended in
patients at risk of QTc prolongation during ADTtherapy.
e,339–342IB
A GnRH antagonist should be considered in
patients with pre-existing symptomatic CADf
who require ADT.341,342IIa B
Annual CV risk assessmentcis recommended
during ADT.19,339,341,342I B
©ESC 2022
ACS, acute coronary syndromes; ADT, androgen deprivation therapy; BP, blood
pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CV,cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; GnRH,gonadotropin-releasing hormone; HbA1c, glycated haemoglobin; QTc, corrected QT
interval; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic
Coronary Risk Estimation 2 —Older Persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG, and patient education on healthy lifestyle and
lifestyle risk factor control is recommended.
dSCORE2 ( ,70 years) or SCORE2-OP ( ≥70 years) CV risk strati ﬁcation:,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50 –69 years: low
risk,5%; moderate risk 5% to ,10%; high risk ≥10%;≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.
eSeeTable 9 .
fCCS and ACS.Recommendation Table 17 —Recommendations for
baseline risk assessment and monitoring during endo-
crine therapy for breast cancer
Recommendations ClassaLevelb
Baseline CV risk assessmentcand estimation of
10-year fatal and non-fatal CVD risk with
SCORE2 or SCORE2-OPd,eis recommended in
BC patients receiving endocrine therapies withoutpre-existing CVD.
19IC
Annual CV risk assessmentcis recommended
during endocrine therapy in BC patients with high
10-year risk of (fatal and non-fatal) CV events
according to SCORE2/SCORE2-OP.d,eIC
CV risk assessmentcshould be considered every 5
years in BC patients with low or moderate10-year risk of (fatal and non-fatal) CV events
according to SCORE2/SCORE2-OP.
d,eIIa C
©ESC 2022
BC, breast cancer; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease;
ECG, electrocardiogram; HbA1c, glycated haemoglobin; SCORE2, SystematicCoronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2 —
Older persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG and patient education on healthy lifestyle and
lifestyle risk factor control.
dOr other validated CV risk scores.
eSCORE2 ( ,70 years) or SCORE2-OP ( ≥70 years) CV risk strati ﬁcation:,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50 –69 years: low
risk,5%; moderate risk 5% to ,10%; high risk ≥10%;≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.194276 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Baseline ECG is recommended and ECGs should be repeated at day
14 of the ﬁrst cycle, before the second cycle, with any dose increase
and as clinically indicated.357
In patients who already have, or are at signi ﬁcant risk of develop-
ing, QT prolongation ( Section 6.4.2 ), the risks/bene ﬁts for ribociclib
should be discussed by a MDT. Importantly, the use of ribociclibshould be avoided in combination with drugs known to prolong
QT interval and/or strong CYP3A inhibitors.
357
The prescribing information does not recommend ribociclib in
combination with tamoxifen due to a higher risk of QTc
prolongation.252,367
5.5.13. Anaplastic lymphoma kinase inhibitors
Patients with cancer treated with anaplastic lymphoma kinase
(ALK) inhibitors may develop adverse CV events including sinusbradycardia, AV block, QTc prolongation, hypertension, hypergly-
caemia, and dyslipidaemia.
370,371ACS and HF have rarely been de-
scribed under crizotinib.372A baseline ECG is recommended in
patients prior to starting an ALK inhibitor, especially crizotinib,
and patients may have an ECG 4 weeks after the start of treatment
and every 3 –6 months thereafter, particularly if the baseline ECG is
abnormal. Home BP monitoring should be considered in patients
treated with brigatinib or lorlatinib. Patients receiving lorlatinib orcrizotinib treatment should have cholesterol levels checked every
3–6 months and treated if elevated.
5.5.14. Epidermal growth factor receptor inhibitors
Osimertinib is an oral irreversible, epidermal growth factor receptor
(EGFR)-TKI approved for patients with non-small cell lung cancer ex-
pressing EGFR mutations. Recent data have shown that osimertinib is
associated with an increased risk of QTc prolongation, AF, VTE, LVD,and HF ( Figure 22 ).
373,374A study of 123 patients with EGFR -mutant
non-small cell lung cancer treated with osimertinib reported a 4.9%
incidence of HF or MI and a signi ﬁcant decrease in LVEF ,53% in
11% of patients with TTE surveillance.375Pre-existing hypertension
and older age are risk factors for LVD and HF (3.9% and 2.6% inci-
dence, respectively).376LVD and HF were more common during
theﬁrst year of therapy.376
Baseline CV risk strati ﬁcation, ECG and TTE prior to starting osi-
mertinib is recommended. Three-monthly echocardiographic sur-veillance for new LVD during osimertinib treatment should be
considered. Close monitoring of magnesium levels is also recom-
mended to minimize the risk of osimertinib-induced hypomagnes-aemia and QTc prolongation.Recommendation Table 18 —Recommendations for
baseline risk assessment and monitoring during cyclin-
dependent kinase 4/6 inhibitor therapy
Recommendations ClassaLevelb
QTcc,dmonitoring is recommended at baseline
and 14 and 28 days in all patients with cancer
receiving ribociclib.361,365,367,368IA
QTcc,dmonitoring is recommended in patients
treated with ribociclib with any doseincrease.
361,365,367,368IB
QTccmonitoring should be considered in patients
treated with palbociclib or abemaciclib who have a
baseline QTc above the normal rangecor other
conditions that may prolong the QTc interval.eIIa C
©ESC 2022
QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction.
aClass of recommendation.
bLevel of evidence.
cQT interval using Fridericia correction (QTcF =QT/3√RR) is the preferred method in
patients with cancer. Upper 99% limit of normal for QTc values in the generalpopulation are 450 ms for men and 460 ms for women.
369
dAccording to the European Medicines Agency: (1) ribociclib should be interrupted
when QTcF .480 ms; (2) if QTcF prolongation resolves to ,481 ms, resume
treatment at the same dose level; (3) if QTcF ≥481 ms recurs, interrupt dose until
QTcF resolves to ,481 ms and then resume ribociclib at next lower dose level.
eSeeSection 6.4.2 andTable 8 .Recommendation Table 19 —Recommendations for
baseline risk assessment and monitoring during ana-
plastic lymphoma kinase and epidermal growth factor
receptor inhibitors
Recommendations ClassaLevelb
Baseline CV risk assessmentcis recommended in
patients before ALK inhibitors and EGFR
inhibitors.IC
Baseline echocardiography is recommended in all
patients with cancer before starting osimertinib.376IB
Home BP monitoring should be considered for
patients treated with brigatinib, crizotinib, orlorlatinib.IIa C
Cholesterol pro ﬁle assessment every 3 –6 months
should be considered for patients on crizotinib
and lorlatinib.IIa C
Echocardiography should be considered every 3
months in patients during osimertinib therapy.
376IIa B
ECG should be considered 4 weeks after starting
therapy and every 3 –6 months in patients during
ALK inhibitor therapy.IIa C
©ESC 2022
ALK, anaplastic lymphoma kinase; BP, blood pressure; CV, cardiovascular; ECG,
electrocardiogram; EGFR, epidermal growth factor receptor; HbA1c, glycated
haemoglobin.
aClass of recommendation.
bLevel of evidence.
cPhysical examination, BP measurement, ECG, lipid pro ﬁle, and HbA1c measurement.ESC Guidelines 4277Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.15. Chimeric antigen receptor
T cell and tumour-in ﬁltrating lymphocytes
therapies
CAR-T therapy is used for the treatment of acute lymphocytic leu-
kaemia and aggressive B-cell lymphomas.377Although the reported
incidence is variable, there is a growing recognition of the associationbetween CAR-T therapy and CTR-CVT, including LVD, HF, cardiac
arrhythmias, pericardial effusion, TTS, and cardiac arrest.
378–383The
majority of the described CV toxicities have been shown to be asso-ciated with the occurrence of cytokine release syndrome
(CRS).
377,384Baseline CV evaluation including ECG, NP, and cTn is
recommended in all patients. Baseline TTE should also be consid-ered, especially in patients with pre-existing CVRF and CVD. After
receiving CAR-T therapy, patients may develop systemic in ﬂamma-
tory syndromes.
385CRS should be suspected when a patient devel-
ops fever, with or without tachypnoea, tachycardia, hypotension,
hypoxia, and/or other end-organ dysfunction hours to days after
treatment.385A high index of suspicion is necessary to diagnoseCRS and to distinguish it from other conditions that occur in these
settings (infections, HF, drug reactions, and PE).378,386Among adults,
there was a relationship between CRS and CV events. An elevation incTn is commonly seen in patients with CRS and is associated with an
increased risk for subsequent CV events.
378In a recent retrospective
pharmacovigilance study, CAR-T was associated with tachyarrhyth-mias (AF the most common, followed by ventricular arrhythmias),
cardiomyopathy, and pleural and pericardial diseases.
379Globally,
the fatality rate of CV and pulmonary adverse events was30.9%.
378,379,387Early cardiac evaluation in patients with cTn increase
should include NP, ECG, and echocardiography (see Section 6.1.4 for
management).388
Adoptive cellular therapy with TIL has emerged as an effective
treatment option for unresectable stage III/IV metastatic melanoma.
With TILs, the CV toxicity appears to be related to direct myocardialand vascular toxicity.
380Baseline assessment and CV surveillance in
patients before TIL therapies is the same pathway recommended
for CAR-T therapies.
Alectinib
BrigantinibCeritinib
Crizotinib
Lorlatinib
Osimertinib
aALK inhibitors
EGFR inhibitorsHTN HF SBr DL HG/DM AF VTEALK inhibitor- and EGFR inhibitor-related cardiovascular toxicities
Very common: ≥10% incidence
Common: 1% to <10% incidenceUncommon: 0.1% to <1% incidence
Rare: <0.1% incidenceQTc
Figure 22 Anaplastic lymphoma kinase and epidermal growth factor receptor inhibitor-related cardiovascular toxicities. AF, atrial ﬁbrillation; ALK, ana-
plastic lymphoma kinase; DL, dyslipidaemia; DM, diabetes mellitus; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA,Food and Drug Administration; HF, heart failure; HG, hyperglycaemia; HTN, hypertension; MedDRA, medical dictionary for regulatory activities;↑QTc, corrected QT interval prolongation; SBr, sinus bradycardia; VTE, venous thromboembolism. Adverse reactions reported in multiple clinical tr ials
or during post-marketing use are listed by system organ class (in MedDRA) and frequency. If the frequency is unknown or cannot be estimated from theavailable data, a blank space has been left.
aOsimertinib increases the risk of hypomagnesaemia. Figure developed from EMA prescribing information,252
FDA prescribing information.2534278 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.16. Radiotherapy
RT increases the risk of developing subsequent CVD and periph-
eral artery disease (PAD).173,389 –394There is ongoing debate re-
garding the safest radiation dose, which cardiac substructures
are most sensitive to RT-induced injury, and the most appropriate
strategies to minimize RT-related CVD.395,396The heart is consid-
ered a radiosensitive ‘organ at risk ’during RT and radiation expos-
ure to the heart should be kept as low as reasonably achievable
because there is no ‘safe’dose ( Figure 23 ).389,390RT-induced CV
toxicity risk categorization based on MHD389,397is recommended
over categorization based on pre scribed dose, which may not ac-
curately re ﬂect cardiac radiation exposure (e.g. 35 Gray [Gy] pre-
scribed dose to approximately 70% of the heart is equivalent to
approximately 25 Gy MHD, whereas 35 Gy prescribed dose to ap-
proximately 40% of the heart is equivalent to approximately 15 GyMHD). However, MHD is not a perfect metric, and in some pa-
tients, a very small portion of the heart might be irradiated to a
very high dose, still conveying a substantial risk despite a lowMHD.
398Therefore, depending on dos e distribution and exposure
of speci ﬁc cardiac substructures and CVRFs, the cancer treatment
team may judge the patient to belong to a higher-risk cat-egory.
397,399 –401
Strategies to prevent and attenuate CV complications of RT
have focused on reducing radiation exposure of the heart andCV substructures during cancer treatment and include the
following.(1) Modi ﬁcation of cancer management to omit RT. This emphasizes
the importance of integrating a personalized cardio-oncology
evaluation.
402–404
(2) Modi ﬁcation of the dose and volume of RT treatments where
possible. RT protocols should target the minimum volume re-
quired to the minimum dose needed to obtain the desired clin-ical bene ﬁt.
(3) Modi ﬁcation of delivery techniques to reduce cardiac radiation
exposure should lead to a considerable reduction in risk.Modern heart-sparing RT strategies include: the optimal use of
modern intensity-modulated photon RT technologies; the use
of deep inspiration breath-hold or respiratory-gated techniques
in BC,
405lymphoma,406and lung cancer407; or the use of image-
guided RT to ensure accuracy of delivery and proton beamtherapy.
408
The incidence of cardiac events following RT may vary according
to patient risk factors and synergistic effects of radiation with othercardiotoxic cancer treatments.
12,173
There are no known RT-speci ﬁc secondary preventative mea-
sures (e.g. drug treatments) to reduce the risk of CV events fol-lowing RT. However, given the known importance of
conventional CVRF on the incidence of RT-related events, opti-
mization of modi ﬁable CVRF is recommended in all patients
before and after RT.
5.5.17. Haematopoietic stem cell transplantation
HSCT constitutes a potentially curative therapeutic option for manyhaematological malignancies. Improvements in HSCT techniques andsupportive strategies have markedly decreased treatment-related
mortality ( Supplementary data, Table S14 ).
409,410There is a growing
recognition of HSCT-related CV toxicities and HSCT survivors con-stitute a population at high future CV risk. Several factors contribute
to de ﬁne the risk of HSCT-related CV toxicities, including the HSCTRecommendation Table 20 —Recommendations for
baseline risk assessment and monitoring in patients
receiving chimeric antigen receptor T cell and tumour-
inﬁltrating lymphocytes therapies
Recommendations ClassaLevelb
Baseline ECG, NP, and cTn are recommended in
all patients with cancer before starting CAR-T and
TIL therapies.388IC
A baseline echocardiography is recommended in
patients with pre-existing CVD before starting
CAR-T and TIL therapies.388IC
A baseline echocardiography should be
considered before starting CAR-T and TIL
therapies.388IIa C
Measurement of NP, cTn, and echocardiography
are recommended in patients who develop CRS
of ASTCT ≥2.c,378,388I C
©ESC 2022
ASTCT, American Society for Transplantation and Cellular Therapy; CAR-T, chimeric
antigen receptor T cell; CRS, cytokine release syndrome; cTn, cardiac troponin; CVD,
cardiovascular disease; ECG, electrocardiogram; NP, natriuretic peptides; TIL,
tumour-in ﬁltrating lymphocytes.
aClass of recommendation.
bLevel of evidence.
cDetermine CRS grade according to ASTCT grading: Grade 1: fever; Grade 2: fever
AND hypotension not requiring vasopressors AND/OR hypoxia requiring low- ﬂow
nasal oxygen; Grade 3: fever AND hypotension requiring one vasopressor +
vasopressin AND/OR hypoxia requiring high- ﬂow nasal cannula or facemask or
non-rebreather mask or Venturi mask; Grade 4: fever AND hypotension requiring
multiple vasopressors, not including vasopressin AND/OR hypoxia requiring positiveairway pressure.Recommendation Table 21 —Recommendations for
baseline risk assessment of patients before radiother-
apy to a volume including the heart
Recommendations ClassaLevelb
Baseline CV risk assessmentcand estimation of
10-year fatal and non-fatal CVD risk withSCORE2 or SCORE2-OP
dis recommended.19,389IB
Baseline echocardiography should be considered
in patients with previous CVD before RT to a
volume including the heart.IIa C
©ESC 2022
BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; ECG,
electrocardiogram; HbA1c, glycated haemoglobin; RT, radiotherapy; SCORE2,Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary RiskEstimation 2 —Older Persons.
aClass of recommendation.
bLevel of evidence.
cBP, lipids, fasting glucose, HbA1c, ECG and patient education on healthy lifestyle and
lifestyle risk factor control.
dSCORE2 ( ,70 years) or SCORE2-OP ( ≥70 years) CV risk strati ﬁcation:,50 years:
low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50 –69 years: low
risk,5%; moderate risk 5% to ,10%; high risk ≥10%;≥70 years: low risk ,7.5%,
moderate risk 7.5% to ,15%, high risk ≥15%.19ESC Guidelines 4279Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

type (higher risk after allogeneic HSCT), multiple uncontrolled
CVRF, pre-existing CV conditions (AF or atrial ﬂutter, sick sinus syn-
drome, ventricular arrhythmias, CAD, MI, moderate-to-severe VHD,
and HF or LVEF ,50%),411direct cardiotoxic effects of anticancer
therapies received prior to and during HSCT (anthracycline-
combined induction regimen, mediastinal RT, total body irradiation,
or cyclophosphamide-based conditioning regimen) ( Supplementarydata, Table S14 ) and the development of graft vs. host disease
(GVHD), thrombotic microangiopathy, or sepsis.410,412In the early
phase following HSCT ( ,100 days), the most frequent CV event
is AF, although some patients may experience HF, hypertension,hypotension, pericardial effusion, or VTE.
413,414Late toxicities in-
clude DM, dyslipidaemia, metabolic syndrome, hypertension, HF,
CAD, conductions disorders, and pericardial effusion.410Acute
>25 Gy MHDb
>15 Gy MHDb +
cumulative do xorubicinc
≥100 mg/m2Very high risk
>15 to 25 Gy MHDb
5 to 15 Gy MHDd/nobreakspace+
cumulative do xorubicinc 
≥100 mg/m2
5 to 15 Gy MHDd
<5 Gy MHDe +
cumulative do xorubicinc 
≥100 mg/m2<5 Gy MHDeHigh risk
Moderate risk Low riskRT doses CVa
toxicity risk
Low risk
Figure 23 Radiotherapy mean heart dose and associated cardiovascular toxicity risk. CV, cardiovascular; Gy, Gray; MHD, mean heart dose; RT, radio-
therapy.aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately re ﬂect cardiac
radiation exposure. Depending on dose distribution and exposure of speci ﬁc cardiac substructures (as well as clinical risk factors) the treatment team may
judge the patient to belong to a higher risk category. In addition, a patient may be judged to belong to a lower risk category if only a small part of the hea rt
was exposed to a relatively low prescribed dose.397,399–401 bOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note that
in this case, the limited information about cardiac exposure does not allow one to distinguish between high- and very high-risk categories.cOr equivalent.
dOr prescribed RT 15 –34 Gy to a volume exposing the heart if MHD is not available.eOr prescribed RT ,15 Gy to a volume exposing the heart if MHD
is not available.4280 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

GVHD is associated with thrombosis and in ﬂammatory myocardial
damage (myocarditis, HF, conduction abnormalities, arrhythmias,
and pericardial effusions), and chronic GVHD has been linked with
increasing risk of hypertension, DM, and dyslipidaemia.415,416
A comprehensive CV evaluation, including NP assessment, ECG,
and TTE, has become a core component of the pre-HSCT assess-
ment409,410to detect undiagnosed CVD, stratify CTR-CVT risk,
and optimize pre-existing CV conditions.411,417 –420In early surveil-
lance, TTE monitoring is recommended in high-risk HSCT recipients
at 3 and 12 months as LVEF and GLS can decrease after transplant(see Section 7 ). Independent factors associated with long-term CVD
in HSCT survivors are allogenic HSCT, pre-existing CVD or multiple
uncontrolled CVRF, cancer treatment history (mediastinal or man-tleﬁeld radiation, alkylating agents, .250 mg/m
2doxorubicin or
equivalent), high-risk conditioning schemes (total body irradiation,
alkylating agents), and GVHD.410Figure 24 summarizes strategies
for the prevention and attenuation of CV complications in patients
undergoing HSCT.
Cardiovascular surveillance in patients referred for haematopoietic
stem cell transplantation
If new cardiac symptoms
occur at any time
If new cardiac symptoms
occur at any time
In selected
patients
In selected
patientsLow risk
Class 1 Class 1Ia Class 1IbECG
TTECV assessmenta
NP
NPECG
TTECV assessmenta
CPET3 M
after
HSCT12 M
after
HSCT>12 M
(yearly)Before
HSCT
High risk
Allogenic HSCT
Pre-e xisting CVD 
Multiple uncontrolled CVRFCancer treatment history
b
Conditioning schemesc
GVHD
Figure 24 Risk factors and cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation. BNP, B-type natriuretic pep-
tide; BP, blood pressure; CPET, cardiopulmonary exercise testing; CV, cardiovascular; CVD, CV disease; CVRF, cardiovascular risk factors; ECG, el ec-
trocardiogram; GVHD, graft vs. host disease; HbA1c, glycated haemoglobin; HSCT, haematopoietic stem cell transplantation; M, months; NP,natriuretic peptides (including BNP or NT-proBNP); NT-proBNP, N-terminal pro-BNP; TTE, transthoracic echocardiography.
aIncluding physical exam-
ination, BP, lipid pro ﬁle, and HbA1c.bMediastinal or mantle ﬁeld radiation, alkylating agents, .250 mg/m2doxorubicin or equivalent.cTotal body irradi-
ation, alkylating agents.
Recommendation Table 22 —Recommendations for
baseline risk assessment in haematopoietic stem celltransplantation patients
Recommendations ClassaLevelb
Baseline and serial CV risk assessment (3 and 12
months, then yearly) including BP measurement,ECG, lipid measurement, and HbA1c is
recommended in HSCT patients.IC
Echocardiography is recommended in all patients
before HSCT.IC
Baseline NP measurement should be considered
before HSCT.
417,418IIa C
©ESC 2022
BP, blood pressure; CV, cardiovascular; ECG, electrocardiogram; HbA1c, glycated
haemoglobin; HSCT, haematopoietic stem cell transplantation; NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.ESC Guidelines 4281Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

5.5.18. Other cancer treatments
Several other cancer therapies may also induce clinically relevant CV
events. Cyclophosphamide, cisplatin, ifosfamide, and taxanes (pacli-
taxel and docetaxel) can induce myocardial dysfunction and HF.4
Cyclophosphamide CV toxicity is primarily seen in patients receiving
high doses ( .140 mg/kg) before HSCT and typically occurs within
days of drug administration.410
Platinum-containing chemotherapy (cisplatin, carboplatin, oxali-
platin) may cause vascular disease (vasospasm, MI, and venous and
arterial thrombosis). These may occur during treatment and also
contribute to increased long-term risk of CAD in survivors.Patients with testicular cancer treated with cisplatin have a higher
risk for vascular disease at long-term follow-up.
421The risk of the in-
dividual patient is still hard to predict, but lifestyle interventions, ahigh degree of clinical suspicion in patients who experience chest
pain, and close CVRF monitoring is recommended during and after
therapy.
422Cisplatin422infrequently causes HF; however, because
it requires the administration of a high i.v. volume to avoid renal tox-
icity, patients with pre-existing CVD may develop symptomatic HF.
Arsenic trioxide is used to treat some leukaemias and myelomas.
Arsenic trioxide frequently prolongs the QT interval (26 –93% of pa-
tients), and life-threatening ventricular tachyarrhythmias have been
reported.45,259QTc prolongation was observed 1 –5 weeks after ar-
senic trioxide infusion and then returned towards baseline by the end
of 8 weeks. Patients receiving treatment with arsenic trioxide should
be monitored weekly with ECG during the ﬁrst 8 weeks of therapy.
Electrolyte monitoring is also required as arsenic trioxide may induce
hypokalaemia, hypomagnesaemia, and renal dysfunction. Risk factors
for QT prolongation should be controlled before, during, and aftercancer treatment ( Section 6.4.2 ).
Several FMS-like tyrosine kinase 3 (FLT3) inhibitors ( ﬁrst-generation:
midostaurin; second-generation: gilteritinib) have been tested for thetreatment of acute myeloid leukaemias. Gilterinib-induced differenti-
ation syndrome (fever, dyspnoea, pleuropericardial effusion, pulmon-
ary oedema, peripheral oedema, hypotension, renal dysfunction, andrash) requires early corticosteroid therapy and haemodynamic moni-
toring until resolution of symptoms. Midostaurin and gilterinib may
prolong QTc interval and close electrolyte surveillance and minimizingdrug –drug interactions are required (see Section 6.4.2 ;Table 9 ;
Supplementary data, Tables S15 and S16 ).
423
6. Diagnosis and management of
acute and subacute cardiovascular
toxicity in patients receivinganticancer treatment
A coordinated MDT is recommended to discuss patients with cancer
who develop acute CV complications of their cancer treatment.5
Referral to a specialized cardio-oncology service is recommendedfor patients with cancer who present with new CTR-CVT duringand after cancer treatment.
12The prevention and management of
CVD in patients with cancer should generally follow published ESC
Guidelines for speci ﬁc CVD. This chapter provides guidance on
the management of CTR-CVT that occur during cancer treatment,
and highlights where management differs for patients with cancer
compared with those without. The decision to initiate CV treatment(medication, devices) needs to include consideration of a range of
factors including both cancer and CV symptom burden, cancer prog-
nosis, ongoing cancer treatment requirements including alternativeoptions, possible adverse drug reactions, drug –drug interactions,
and patient preferences. An extensive list of drug –drug interactions
is provided in Supplementary data, Tables S15 –S17.
6.1. Cancer therapy-related cardiac
dysfunction
6.1.1. Anthracycline chemotherapy-related cardiac
dysfunction
CTRCD during anthracycline chemotherapy may present clinically or
be detected in asymptomatic patients during surveillance ( Figure 10 ;
Table 3 ).4The diagnosis of anthracycline chemotherapy-related car-
diac dysfunction includes new CV symptoms, new abnormalities in
cardiac function on CV imaging, and/or new increases in cardiac bio-markers ( Table 3 ). A MDT discussion is recommended to consider
the risk/bene ﬁt ratio of continuing anthracycline chemotherapy in
patients who develop new CTRCD.
Discontinuation of anthracycline chemotherapy is recommended
in patients with cancer who develop severe symptomatic CTRCD.
22
There are rare exceptions where rechallenge with further anthracy-
cline chemotherapy may be considered after a MDT discussion, using
prevention strategies described below and under close monitoring
with each cycle of anthracycline chemotherapy. Temporary interrup-tion of anthracycline chemotherapy is recommended in patients who
develop moderate symptomatic CTRCD, and in patients who de-
velop moderate or severe asymptomatic CTRCD. A MDT approachregarding interruption vs. continuation of anthracycline chemother-
apy is recommended in patients who develop mild symptomatic
CTRCD.
Guideline-based HF therapy is recommended in patients who de-
velop symptomatic CTRCD or asymptomatic moderate or severe
CTRCD during anthracycline chemotherapy. The use of an ACE-I/ARB or angiotensin receptor –neprilysin inhibitor, a beta-blocker, a
sodium –glucose co-transporter 2 inhibitor, and a mineralocorticoid re-
ceptor antagonist is recommended unless the drugs are contraindi-cated or not tolerated. Up-titration to target doses as described in
the 2021 ESC Guidelines for the diagnosis and treatment of acute
and chronic HF is recommended.
14ACE-I, ARB, and/or beta-blockersRecommendation Table 23 —Recommendation for
the management of cardiovascular disease and cancer
therapy-related cardiovascular toxicity in patients re-ceiving anticancer treatment
Recommendation ClassaLevelb
A specialist CV assessmentcis recommended for
optimal diagnostic workup and management ofpatients with cancer who present with new CV
toxicity during and after cancer treatment.
5I C
©ESC 2022
CV, cardiovascular; CVD, cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
cCardio-oncology referral is recommended when available; alternatively, patients should
be referred to a specialized cardiologist with expertise in managing CVD in patients with
cancer.4282 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

should be considered in mild asymptomatic CTRCD while anthracy-
cline chemotherapy continues uninterrupted ( Figure 25 ).1,14,102,424
The bene ﬁcial effects of aerobic exercise before and during anthracy-
cline chemotherapy have been demonstrated and is recommended
for patients with cancer who develop CTRCD.11
A MDT is recommended to discuss restarting anthracycline
chemotherapy in patients who developed mild or moderatesymptomatic CTRCD, or moderate or severe asymptomatic
CTRCD, after recovery of LV function under HF treatment. If there
is a compelling reason to continue anthracycline chemotherapy,three other strategies exist in addition to continuing ACE-I/ARB
and beta-blockers at target doses for HF.
14First, minimizing the
dose of anthracycline chemotherapy administered. Second, switch-ing to liposomal anthracycline preparations. Third, pre-treatment
Disconti
n
ue
A
C
(Class I )
Inte
r
rupt
A
C
(Class I )
MDT
 a
pp
r
oach
r
ega
r
ding inte
r
ruption
vs
.
 conti
.
 n
uation
of
A
C
(Class I )
Inte
r
rupt
A
C
(Class I )
Conti
n
ue
A
C
with CV monitorin g
(Class I )
Symptomatic CTRCD
a
V
e
V
V
r
y s
e
v
e
r
e/s
e
v
e
r
e
Oncological
strategy
CV
strategy
Moderate
MDT
b
Mild
 S
e
v
e
r
e/moderat e
 Mild
GLS dec
r
ease >1 5%
orcTn inc
r
ease
A
CE-I/ARB
and/or BB
(Class IIb )
A
CE-I/ARB
and/or BB
(Class IIa )
HF ther
a
p
y
p
p
(Class I )
NP in c
r
ease
Asymptomatic CTRC D
a
Management of patients wit h
A
C-
r
elated ca
r
diac d ysfunctio n
AND
MDT
c
AND
MDT
c
AND
Figure 25 Management of anthracycline chemotherapy-related cardiac dysfunction. AC, anthracycline chemotherapy; ACE-I, angiotensin-converting
enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunc tion;
CV, cardiovascular; GLS, global longitudinal strain; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, mult idisciplinary
team; NP, natriuretic peptides.aSeeTable 3 (Section 3 ) for complete de ﬁnition (symptomatic CTRCD: symptomatic con ﬁrmed HF syndrome; asymptom-
atic severe CTRCD: LVEF ,40%; asymptomatic moderate CTRCD: LVEF 40 –49%; asymptomatic mild CTRCD: LVEF .50%).bIn rare exceptions, an-
thracycline chemotherapy may be restarted after recovery of LV function with optimal HF therapy.cA MDT discussion is recommended before restarting
anthracycline chemotherapy after recovery of LV function.ESC Guidelines 4283Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

with dexrazoxane before each further cycle of anthracycline chemo-
therapy ( Section 5.2.1 ).
Close cardiac monitoring every 1 –2 cycles is recommended in pa-
tients who restart anthracycline chemotherapy following an episode
of CTRCD and in patients with mild asymptomatic CTRCD while
they continue anthracycline chemotherapy.
6.1.2. Human epidermal receptor 2-targeted
therapy-related cardiac dysfunction
The diagnosis of HER2-targeted therapy-related CTRCD can be
made using the combination of new CV symptoms, imaging, andbiomarkers. Patients may present with symptomatic CTRCD or
may be asymptomatic.
426Early treatment of symptomatic and
asymptomatic severe CTRCD (LVEF ,40%), according to the
2021 ESC Guidelines for the diagnosis and treatment of acute
and chronic HF,14is recommended to prevent worsening HF,425
particularly when targeted cancer therapy is continued.427In pa-
tients who develop CTRCD, a MDT is recommended to guide
clinical decisions. Temporar y interruption is recommended
in patients who develop mode rate or severe symptomatic
CTRCD or severe asymptomatic CTRCD (LVEF ,40%) during
HER2-targeted therapy. In pat ients with mild symptomatic
CTRCD, a MDT approach is recommended to continue vs. inter-rupt HER2-targeted therapy. In p atients with asymptomatic mod-
erate CTRCD (LVEF 40 –49%), HER2-targeted treatment should
be continued, and cardioprotective therapy (ACE-I/ARB and beta-blockers) is recommended with frequent cardiac monitor-
ing.
22,33,189In patients with asymptomatic mild CTRCD (LVEF ≥
50% with a signi ﬁcant new GLS reduction and/or cardiac biomark-
er increase), continuing HER2-t argeted treatment is recom-
mended and cardioprotective therapy (ACE-I/ARB and/or
beta-blockers) should be considered.22,211,428,429
Frequent cardiac surveillance with cardiac imaging and cardiac
serum biomarkers is recommended in all patients with CTRCDRecommendation Table 24 —Recommendations for
the management of cancer treatment-related cardiac
dysfunction during anthracycline chemotherapy
Recommendations ClassaLevelb
Anthracycline chemotherapy-induced symptomatic CTRCD
HF therapy is recommended for patients who
develop symptomatic CTRCD duringanthracycline chemotherapy.
c,208,425IB
Discontinuation of anthracycline chemotherapy is
recommended in patients who develop
symptomatic severe CTRCD.cIC
Temporary interruption of anthracycline
chemotherapy is recommended in patients who
develop symptomatic moderate CTRCDcand a
multidisciplinary approach regarding the decision
to restart is recommended.IC
A multidisciplinary approach regarding
interruption vs. continuation of anthracyclinechemotherapy is recommended in patients who
develop mild symptomatic CTRCD.
cIC
Anthracycline chemotherapy-induced asymptomatic
CTRCD
Temporary interruption of anthracycline
chemotherapy and initiation of HF therapy is
recommended in patients who developasymptomatic moderate or severe CTRCD.
c,22IC
A multidisciplinary approach regarding the
decision when to restart is recommended in all
patients with moderate or severe asymptomatic
CTRCD.c,22IC
Continuation of anthracycline chemotherapy is
recommended in asymptomatic patients whohave LVEF ≥50% and who have developed a
signiﬁcant fall in GLS
cor a troponin or a NP
elevation .ULN.IC
Asymptomatic patients who have LVEF ≥50%
and who have developed a signi ﬁcant fall in GLSc
should be considered for ACE-I/ARB and/or
beta-blockers.d,75,93,102IIa B
Asymptomatic patients who have LVEF ≥50%
and who have developed a troponin elevation
.ULN should be considered for ACE-I/ARB and/
or beta-blockers.d,147,211IIa B
ContinuedAsymptomatic patients who have LVEF ≥50%
and who have developed NP .ULN may be
considered for ACE-I/ARB and/or
beta-blockers.d,211IIb C
Strategies for restarting anthracycline chemotherapy in
patients with CTRCD
Liposomal anthracyclineemay be considered in
patients with moderate or severe symptomatic orasymptomatic CTRCD
cwho require further
anthracycline chemotherapy to reduce the risk of
further CV toxicity.IIb C
Dexrazoxanefmay be considered in patients with
moderate or severe symptomatic orasymptomatic CTRCD
cwho require further
anthracycline chemotherapy to reduce the risk of
further CV toxicity.IIb C
©ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; GLS, global
longitudinal strain; HF, heart failure; LVEF, left ventricular ejection fraction; NP,
natriuretic peptides; ULN, upper limit of normal.
aClass of recommendation.
bLevel of evidence.
cSeeTable 3 . Signi ﬁcant fall in GLS =relative reduction .15%.
dAvoid hypotension.
eSee text for speci ﬁc liposomal doxorubicin type and malignancies ( Section 5.2 ).
fAs per the European Medicines Agency: ≥350 mg/m2doxorubicin or equivalent; as
per the United States Food and Drug Administration: ≥300 mg/m2doxorubicin or
equivalent.4284 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

who continue HER2-targeted cancer therapies and in those who
restart after an interruption following resolution of HF signs andsymptoms and recovery of LVEF ≥40% (and ideally recovery to
LVEF≥50%) ( Figure 26 ).
22,33,189Echocardiography and cardiacserum biomarker measurement every two cycles for the ﬁrst
four cycles after restarting HER2-targeted therapy is recom-mended, and then the frequency can be reduced if cardiac function
and biomarker levels remain stable.
Anti-HER2
inte
r
ruption
(Class I )
Anti-HER2
inte
r
ruption
(Class I )
MDT 
a
pp
r
oach
r
ega
r
ding
inte
r
ruptio n
vs
.
 conti
.
 n
uation of
anti-HER2
(Class I )
c
Conti
n
ue anti-HER2
under CV monitorin g
(Class I )
Conti
n
ue anti-HER2
under CV monitoring
(Class IIa )
Symptomatic CTRCD
a
Modera
 t
a
a
e 
t
o 
v
e
r
y s
e
v
e
r
e
Oncological
strategy
CV
strategy
Mild
MDT
b
,c
S
e
v
e
r
e
 Moderate
 Mild
A
CE-I/ARB
and/or BB
(Class IIa )
HF ther
a
p
y
p
p
(Class I )
Asymptomatic CTRC D
a
Mana gement of patients with HER2-tar geted the r
a
pies 
r
elated ca
r
diac dysfunctio n
AND
MDT
b
,c
AND
GLS dec
r
ease >1 5%
cT
n
 a
n
d NP 
i
nc
r
eas
e
Figure 26 Management of human epidermal receptor 2-targeted therapy-related cardiac dysfunction. ACE-I, angiotensin-converting enzyme inhibitors;
ARB, angiotensin receptor blockers; BB, beta-blockers; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovas cular;
GLS, global longitudinal strain; HER2, human epidermal receptor 2; HF, heart failure; LVEF, left ventricular ejection fraction; MDT, multidiscipl inary team;
NP, natriuretic peptides.aSeeTable 3 (Section 3 ) (symptomatic CTRCD: symptomatic con ﬁrmed HF syndrome; asymptomatic severe CTRCD: LVEF ,
40%; asymptomatic moderate CTRCD: LVEF 40 –49%; asymptomatic mild CTRCD: LVEF .50%).bFor patients in whom HER2-targeted therapy has
been interrupted, whose signs and symptoms of HF do not resolve and/or LVEF remains ,40%, resumption of HER2-targeted therapy may be considered
if no alternative therapeutic option exists. In advanced cancer that only responds well to trastuzumab, the risk/bene ﬁt ratio may warrant continued ther-
apy if other options remain limited.22cFor patients where HER2-targeted therapy has been interrupted and who have recovered LVEF ≥40% and are
now asymptomatic, resumption of HER2-targeted therapy should be considered, supported by HF therapy, and echocardiography and cardiac biomarker
assessment every two cycles for the ﬁrst four cycles after restarting and then the frequency can be reduced.22ESC Guidelines 4285Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.1.3. Immune checkpoint inhibitor-associated
myocarditis and non-in ﬂammatory heart failure
Myocarditis is a severe complication of ICI with a high fatality
rate that most frequently develops during the ﬁrst 12 weeks of
treatment, although late cases (after week 20) may occur.386
Other ICI-related CV toxicities in clude dyslipidaemia, ACS, vascu-
litis, AV block, supraventricular and ventricular arrhythmias, sud-
den death, TTS, non-in ﬂammatory LVD, pericarditis, pericardial
effusion, and ischaemic stroke, with higher risks for myocarditis
(odds ratio 4.42) and dyslipidaemia (odds ratio 3.68)
(Figure 27 ).323,325
The diagnosis of ICI-associated myocarditis is initially based on the
presence of symptoms, a new increase in troponin (associated with
either CV symptoms or non-CV immuno-related adverse events),and new ECG abnormalities (AV or intraventricular conduction dis-
orders, bradycardia, tachyarrhythmias) (see Section 3 ;
Table 3 ).
17,434,435Any abnormal ﬁnding should prompt urgent CV im-
aging and other causes of myocardial injury (e.g. ACS, acute infec-
tious myocarditis) should be excluded. Treatment with high-dose
methylprednisolone should be promptly initiated in haemodynamic-ally unstable patients (including those with ventricular arrhythmias
[VA] or complete AV block) while awaiting further con ﬁrmatory
testing.
436TTE and CMR are recommended in all patients with sus-
pected ICI-associated myocarditis. Currently, speci ﬁc CMR features
for ICI-induced myocarditis are not well described and modi ﬁed Lake
Louise criteria are recommended ( Table 3 ).18Cardiac ﬂuorodeoxy-
glucose positron emission tomography (PET) may be consid-
ered437,438if CMR is not available or contraindicated, although PET
sensitivity is low and requires a strict 18-h carbohydrate-freefast.
439Endomyocardial biopsy (EMB) should be considered in cases
where the diagnosis is suspected but not con ﬁrmed non-invasively
(e.g. con ﬂicting results of cardiac imaging and biomarkers or clinically
unstable patients).440All cases of ICI-associated myocarditis should
be classi ﬁed according to the severity of the myocarditis (fulminantRecommendation Table 25 —Recommendations for
the management of cancer treatment-related cardiac
dysfunction during human epidermal receptor 2-tar-
geted therapies
Recommendations ClassaLevelb
HER2-targeted therapy-induced symptomatic CTRCD
HF therapy is recommended for patients who
develop symptomatic moderate-to-severe
CTRCD with LVEF ,50%cduring HER2-targeted
treatment.14,61,430,431IB
Temporary interruption of HER2-targeted
treatment is recommended in patients whodevelop moderate or severe symptomatic
CTRCD
cand the decision to restart should be
based on a multidisciplinary approach afterimprovement of LV function and symptoms
resolved.
dIC
In patients who develop mild symptomatic
CTRCD,cHF therapy and a multidisciplinary
approach regarding the decision to continue vs.interrupt HER2-targeted therapy are
recommended.
d,431,432IC
HER2-targeted therapy-induced asymptomatic CTRCD
Temporary interruption of HER2-targeted
therapy and initiation of HF therapy is
recommended in patients who develop
asymptomatic severe CTRCD.cIC
A multidisciplinary approach regarding the
decision to restart HER2-targeted treatment isrecommended in patients with severe
asymptomatic CTRCD.
cIC
Continuation of HER2-targeted therapy should be
considered in patients who develop asymptomaticmoderate (LVEF 40 –49%) CTRCD
cwith more
frequent cardiac monitoring.33,189,428,433IIa B
Continuation of HER2-targeted therapy is
recommended in patients who develop
asymptomatic mild (LVEF ≥50%) CTRCDcwith
more frequent cardiac monitoring.428IC
ACE-I/ARB and beta-blockers are recommended
in patients who develop asymptomatic moderate
(LVEF 40 –49%) CTRCDcduring HER2-targeted
treatment.e,189IC
ACE-I/ARB and/or beta-blockers should be
considered in asymptomatic patients receivingHER2-targeted therapies who have LVEF ≥50%
but develop a signi ﬁcant fall in GLS
cwhile
continuing HER2-targeted therapy.e,22,428IIa B
ContinuedACE-I/ARB and/or beta-blockers should be
considered in asymptomatic patients receivingHER2-targeted therapies who have LVEF ≥50%
but develop a new troponin or NP rise while
continuing HER2-targeted therapy.
e,22,211,428IIa B
©ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CTRCD, cancer therapy-related cardiac dysfunction; GLS, global longitudinal strain;
HER2, human epidermal receptor 2; HF, heart failure; LV, left ventricular; LVEF, LV
ejection fraction; NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cSeeTable 3 .
dFor patients where HER2-targeted therapy has been interrupted and who have
recovered LVEF ≥40% and are now asymptomatic, resumption of HER2-targeted
therapy should be considered supported by HF therapy and echocardiography and
cardiac biomarkers assessment every two cycles for the ﬁrst four cycles after
restarting and then frequency can be reduced.
eAvoid hypotension.4286 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

or non-fulminant, including symptomatic but haemodynamically and
electrically stable patients and incidental cases diagnosed at the sametime as other immune-related adverse events) to guide the manage-
ment pathway ( Figure 28 ).
331
Interruption of ICI treatment is recommended in all cases of
suspected ICI-associated myocarditis (any patient developing
new cardiac symptoms, new cardiac arrhythmias, new heart
blocks, or new troponin increase who has received an ICI therapyin the past 12 weeks) while investigations are performed. Once
the abnormal ﬁndings have resolved, a MDT discussion is recom-
mended to determine the risk/bene ﬁt to permanent stopping vs.
resuming ICI treatment in patients with suspected but not con-
ﬁrmed myocarditis.Cessation of ICI treatment is recommended in patients with can-
cer with fulminant or non-fulminant ICI-associated myocarditis andthe patient should be admitted to hospital and a level 2 or 3 bed
with continuous ECG monitoring is required. CV complications
should be treated as per speci ﬁc ESC Guidelines (HF,
14tachyarrhyth-
mias,441,442AV block,443or pericardial effusion444).
Treatment of both non-fulminant and fulminant ICI-associated
myocarditis with methylprednisolone 500 –1000 mg i.v. bolus once
daily for the ﬁrst 3 –5 days should be started as soon as possible,
once the diagnosis is considered likely, to reduce MACE including
mortality.386,436If clinical improvement is observed (cTn reduced
by.50% from peak level within 24 –72 h and any LVD, AV block,
and arrhythmias resolved), switching to oral prednisolone is
Direct CV Toxicity
ArrhythmiasArrhythmias Myocarditis Non-inflammatory HF
Takotsubo syndrome Pericarditis Vascular
Indirect CV Toxicity
Thyroid Adrenal Pituitary
Pancreas Embolism
Figure 27 Direct and indirect immune checkpoint inhibitor-related cardiovascular toxicity. CV, cardiovascular; HF, heart failure.ESC Guidelines 4287Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

recommended starting at 1 mg/kg up to 80 mg/day. Although the
most appropriate weaning off protocol is not con ﬁrmed, a weekly
reduction of oral prednisolone (most commonly by 10 mg per
week) under clinical, ECG, and cTn surveillance should be consid-
ered ( Figure 28 ). A reassessment of LV function and cTn should be
considered when the prednisolone dose is reduced to 20 mg/day
and then continue weaning the prednisolone by 5 mg per week to5m g / d a y ,a n da ﬁnal reduction from 5 mg/day in 1-mg per week
steps.
If the troponin does not reduce signi ﬁcantly (.50% reduction
from peak) and/or AV block, ventricular arrhythmias, or LVD persist
despite 3 days of i.v. methylprednisolone plus cardiac treatments,then steroid-resistant ICI-associated myocarditis is con ﬁrmed and
second-line immunosuppression should be considered.
22,445,446
Complete 
 r
ec
o
v
e
r
y
Rec
o
v
ering
b
Ste
r
oid
r
efracto
r
y
Haemo dynamica l
l
y unsta ble
fulminant 
m
y
oca
r
ditis
Switchin g to
oral p
r
ednisolone (1 mg/kg/ d
a
y)
a
a
(Class IIa )
Second-line i m
m
unosupp
r
ession
(Class IIa )
Met
h
ylp
r
ednisolone 500–1000 m g i.
v
.
v
v
 bolus once dai
.
 l
y (mini
m
um 3 d
a
ys)
a
a
(Class I )
Disconti
n
ue ICI
;
 hospital admission
;
 ;
 ECG monitoring
;
(Class I)
S
e
v
erity (fulminant v s
.
 non-fulminant)
.
a
Admission to ICU (l
e
v
el 3)
(Class I )
Optimal CV t
 r
eatment
includin g MCS
(Class I )
W
eaning p
W
W
 r
otoco l
b
y 10 m g/
w
eek
with t
r
oponin monitorin g
(Class IIa )
Mana gement of patients with a definit i
v
e diagnosis of ICI -
r
elated 
m
y
oca
r
ditis
AND AND
Second-line i m
m
unosupp
r
ession
(Class I )AND
Figure 28 Diagnosis and management of immune checkpoint inhibitor-related myocarditis. CMR, cardiac magnetic resonance; CV, cardiovascular;
ECG, electrocardiogram; HF, heart failure; ICI, immune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; LGE, late gadolinium en hancement;
LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support.aFulminant : haemodynamic instability, HF requiring non-invasive or inva-
sive ventilation, complete or high-grade heart block, and/or signi ﬁcant ventricular arrhythmia. Non-fulminant : including symptomatic but haemo-
dynamically and electrically stable patients and incidental cases diagnosed at the same time as other immuno-related adverse events. Patients mayhave reduced LVEF but no features of severe disease.
bRecovering : ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging
parameters, but not yet normalized, while on tapering doses of immunosuppression. Complete recovery : patients with complete resolution of acute
symptoms, normalization of biomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE or elevated T1 duetoﬁbrosis, but any suggestion of acute oedema should be absent.4288 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

There is a lack of data to recommend a speci ﬁc second-line immunosup-
pression regimen and MDT discussion is recommended. Several agents
are currently being investigated with promising results from case series
including i.v. mycophenolate mofetil, anti-thymocyte globulin (anti-CD3
antibody), i.v. immunoglobulin, plasma exchange, tocilizumab, abatacept
(CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and tofacitinib.Caution is advised against the use of in ﬂiximab for steroid-refractory
myocarditis and HF.
447,448Patients with fulminant ICI-associated myo-
carditis, complicated by haemodynamic and/or electrical instability, re-quire admission to the intensive care unit (ICU) and cardiogenic
shock should be managed according to the 2021 ESC Guidelines for
the diagnosis and treatment of acute and chronic HF.
14As i n g l ed o s e
of i.v. methylprednisolone should be considered in clinically unstable pa-
tients with cancer where ICI-induced m y o c a r d i t i si ss u s p e c t e da tp r e s -
entation but before de ﬁnitive diagnosis can be con ﬁrmed.
Following recovery from ICI-associated myocarditis and weaning
of oral steroid therapy, MDT discussion is recommended to reviewthe decision on whether to restart ICI treatment. This depends on
various factors including the severity of the ICI-associated myocardi-
tis (fulminant vs. non-fulminant vs. asymptomatic), alternative oncol-ogy treatment options, metastatic vs. adjuvant/neoadjuvant
indication, and reducing from dual ICI to single ICI treatment if trig-
gered by combination ICI treatment.
449
Non-in ﬂammatory HF syndromes have also been observed in pa-
tients treated with ICI. These include TTS, non-in ﬂammatory HF or
LVD,450and post-MI HF.451,452Non-in ﬂammatory HF is generally a
late event and the diagnostic work ﬂow should be based on de ﬁning
the HF phenotype and excluding myocarditis, TTS, and ACS.14There
is also evidence that vasculitis and CAD can occur after ICI treat-ment.
335HF treatment as per the 2021 ESC Guidelines for the diagno-
sis and treatment of acute and chronic HF is indicated,14but there is no
indication for immunosuppression if myocarditis has been excluded.Interruption vs. continuing ICI therapy depends on the severity of
the HF syndrome and each case should be reviewed by a MDT.
Arrhythmias, such as AF, can be seen in patients with ICI therapy with-out myocarditis (e.g. ICI-associate d thyroiditis with thyrotoxicosis,
ICI-associated pericarditis, or ICI-associated severe systemic in ﬂamma-
tory syndromes). ICI treatment can be continued after excludingmyocarditis.
Recommendation Table 26 —Recommendations for
the diagnosis and management of immune checkpoint
inhibitor-associated myocarditis
Recommendations ClassaLevelb
cTn, ECG, and CV imaging (echocardiography and
CMR) are recommended to diagnoseICI-associated myocarditis.
320,434,435,453IB
In patients with suspected ICI-associated
myocarditis, temporary interruption of ICItreatment is recommended until the diagnosis isconﬁrmed or refuted.IC
ContinuedEMB should be considered to con ﬁrm the
diagnosis of ICI-associated myocarditis if thediagnosis is suspected but not con ﬁrmed after
cardiac imaging and biomarkers.
cIIa C
Interruption of ICI treatment is recommended in
patients with con ﬁrmed ICI-associated
myocarditis.IC
Continuous ECG monitoring to assess for new
AV block and tachyarrhythmias during the acutephase is recommended for all patients withsymptomatic ICI-associated myocarditis.IC
Early high-dose corticosteroids
dare
recommended in patients with cancer andconﬁrmed ICI-associated myocarditis.
22,436,454IC
Continuation of high-dose corticosteroids is
recommended for the treatment of ICI-associatedmyocarditis until resolution of symptoms, LVsystolic dysfunction, conduction abnormalities,and signi ﬁcant cTn reduction.
eIC
Switching from i.v. to oral prednisolone should be
considered after clinical improvement (resolutionof: symptoms, LV systolic dysfunction, conductionabnormalities, and signi ﬁcant cTn reduction
e).fIIa C
Second-line immunosuppression treatment
should be considered in patients withsteroid-refractory ICI-associated myocarditis.
gIIa C
Admission to ICU (level 3), treatment with i.v.
methylprednisolone, and optimal CV treatmentincluding mechanical support (when indicated) isrecommended for patients with ICI-associatedfulminant myocarditis.
14IC
A single dose of i.v. methylprednisolonedshould
be considered in unstablehpatients with cancer
where ICI-induced myocarditis is suspected.IIa C
A multidisciplinary discussion is recommended
before restarting ICI treatment in selectedpatients with previous uncomplicatedICI-associated myocarditis.I C
©ESC 2022
AV, atrioventricular; CMR, cardiac magnetic resonance; cTn, cardiac troponin;
CV, cardiovascular; ECG, electrocardiogram; EMB, endomyocardial biopsy; HF, heartfailure; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous;
LGE, late gadolinium enhancement; LV, left ventricular; LVD, LV dysfunction; LVEF,
LV ejection fraction.
aClass of recommendation.
bLevel of evidence.
cSeeTable 3 for ICI-related myocarditis de ﬁnition. EMB should be considered in unstable
patients or when CMR is contraindicated.
dEarly:≤24 h; high-dose corticosteroids (methylprednisolone 500 –1000 mg/day).
eReduction of cTn by .50% from peak level.
fComplete recovery: Patients with complete resolution of acute symptoms,
normalization of biomarkers, or reduction of cTn by .50% from peak level and
recovery of LVEF after discontinuation of immunosuppression are considered tohave achieved complete recovery. CMR may still show LGE or elevated T1 due to
ﬁbrosis but any suggestion of acute oedema should be absent. Incomplete
recovery: (1) an increase in symptoms or biomarkers of myocarditis or an inability
to taper immunosuppression without a clinical or biomarker ﬂare; (2) patients with
persistent LVD despite resolution of acute symptoms with immunosuppression.
gSteroid refractory: non-resolving or worsening myocarditis (clinical worsening or
persistent troponin elevation after exclusion of other aetiologies) despite high-dosemethylprednisolone ( Table 3 ;Supplementary data, Table S1 ).
hUnstable: patients with symptomatic HF, ventricular arrhythmias, new complete
heart block.ESC Guidelines 4289Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.1.4. Chimeric antigen receptor T cell and
tumour-in ﬁltrating lymphocytes therapies and
heart dysfunction
Although no large-scale studies on the multiple CV complications
among adults treated with CAR-T therapies exist, small studiesand case reports have shown that CV complications represent
around 20% of adverse events.
378CV complications are associated
with high mortality rates, and are secondary to CRS and immune ef-fector cell-associated neurotoxicity syndrome. The most common
CV complications in patients receiving CAR-T therapies are arrhyth-
mias (77.6%), including QTc prolongation, ventricular arrhythmias,and AF; HF (14.3%); and MI and VTE (0.5%).
455When suspected, aresting 12-lead ECG, continuous ECG monitoring, TTE, and cTn
and NP are recommended. Admission to ICU (level 3) is recom-
mended in severe cases due to the risk of malignant cardiac arrhyth-mias, circulatory collapse, and multiorgan system failure. In general,
the degree of elevation of cytokines correlates with the severity of
CRS. C-reactive protein is not speci ﬁc for CRS and changes in
C-reactive protein may lag behind clinical changes by ≥12 h. A dra-
matic elevation of interleukin-6 is a supportive ﬁnding for the diagno-
sis of CRS. Management of the speci ﬁc CV complication should
follow ESC Guidelines, with additional management of the CRS
(e.g. the anti-interleukin-6 receptor antibody, tocilizumab, and
dexamethasone).
381
Rec
o
v
e
r
y of functio n
MDT
(Class I )N
Diagnosis an d mana gement 
 w
orkup in patients wit h cance
 r
-
r
r
r
elated
  T
a
T
T
k
otsubo synd
k
k
 r
ome
AND
Co
r
ona
r
y angiogr
a
p
h
y
(i
n
vasi
v
e orCC
T
A)
T
T
to exclude
 A
CS
(Class I )
CMR
to exclude 
m
y
oca
r
ditis and
m
y
oca
r
dial infa
r
ction
(Class I )
AND
Y
Clinical 
 e
valuat ion
ECG
TTE
Ca
r
diac serum biomar
k
ers
k
k
AND
Inte
r
ruption o f the
culprit cancer drug
(Class I )
A
v
A
A
oid Q
T
-p
T
T
r
olongin g
drugs
(Class III )
Consider 
 r
esuming cancer
t
r
eatment under close
monitoring
(Class I )
MDT
a
pp
r
oach 
r
ega
r
ding
inte
r
ruption vs 
 r
esuming
the culprit cancer drug
F
or ICI-
r
elated
TTS:
met
h
ylp
r
ednisolone 
(1000 mg i.
 v
.)
v
v
AND
CCU/ HDU/ICU admissio n
ECG monitoring
Figure 29 Diagnosis and management workup in cancer-related Takotsubo syndrome. ACS, acute coronary syndromes; CCTA, coronary computed
tomography angiography; CCU, coronary care unit; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HDU, high-dependency unit; ICI, im-mune checkpoint inhibitor; ICU, intensive care unit; i.v., intravenous; MDT, multidisciplinary team; N, no TTE, transthoracic echocardiography; TTS,
Takotsubo syndrome; Y, yes.4290 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Although CV complications are common with TIL therapies, sur-
vival does not appear to be signi ﬁcantly affected. The most frequent
CV events are hypotension that may require treatment with i.v. ﬂuids
and pressors, AF, and to a lesser extent, cTn elevation suggestive of
myocardial damage.380Further research is needed to de ﬁne mechan-
isms and potential prevention strategies to help clinicians with themanagement of these CV events.
6.1.5. Heart failure during haematopoietic stem cell
transplantation
CV complications during HSCT, including congestive HF,456arterial
events, tamponade, and rhythm disturbances (AF, atrial ﬂutter, and
supraventricular tachycardia),457are uncommon but clinically rele-
vant, and should be treated as per speci ﬁc ESC Guidelines (HF,14ta-
chyarrhythmias,273,441pericardial effusion,444or acute coronary
syndrome458). Studies of treatments during HSCT to prevent both
acute and late CV toxicity are limited.145ACE-I and beta-blockers
may be effective, but this requires further con ﬁrmation.
Outpatient and home-based exercise and education programmes in-
stituted after HSCT can improve exercise capacity and quality oflife,
459and the role of exercise pre-habilitation prior to HSCT is
being investigated.460,461
6.1.6. Takotsubo syndrome and cancer
The prevalence of malignant diseases is high in patients with TTS
and is a risk factor for worse outcomes. Malignancy itself, somecancer treatments (5-FU, ICI, VE GFi), and the stress associated
with the diagnosis, investigations, and treatment are recognized
triggers or predisposing factors for TTS.
462 –466Diagnosis using
general TTS criteria is recommended.467,468Investigations in a pa-
tient with cancer with suspected TTS should include clinical exam-
ination, ECG, TTE, cardiac biomarkers (cTn and NP), and CMR(Figure 29 ).
468,469Most patients require invasive coronary angiog-
raphy to exclude acute MI. In patie nts with advanced malignancy or
signiﬁcant thrombocytopaenia where invasive coronary angiog-
raphy is contraindicated, a CCTA is recommended. Cardiac im-
aging studies should be perform ed as early as possible when the
diagnosis is suspected as LVD can be transient, and if signi ﬁcant
LVD is detected then repeat imaging to con ﬁrm recovery is
recommended.
Interruption of the culprit cancer drug in patients with TTS is re-
commended. QT-prolonging drugs should be avoided.467In cases of
ICI-associated TTS, the role of immunosuppression is unknown and
if myocardial in ﬂammation is present in a TTS pattern on CMR then
i.v. methylprednisolone is recommended given the overlap between
ICI-induced TTS and ICI-induced myocarditis. Limited information
exists regarding the feasibility of ICI rechallenge following TTS andafter recovery of LV function.
A MDT discussion is recommended after recovery from the
acute phase of TTS and, if restarting the culprit cancer drug is re-quired from an oncology perspective, regular cardiac biomarker
monitoring is recommended (e.g . cTn and NP measured before
every ICI cycle, and TTE if a new ri se in cardiac biomarkers occurs)
(Figure 29 ).6.2. Coronary artery disease
6.2.1. Acute coronary syndromes
Patients with cancer are at increased risk of CAD because of shared
CVRFs34and CV toxicity of cancer therapy12compounded by a
cancer-induced pro-in ﬂammatory and prothrombotic state
(Table 7 ).467,468,470–473
Current knowledge on ACS in patients with cancer is based on
observational data and registries demonstrating that, especially
when diagnosed within 1 year, they are at increased risk for major
CV events, bleeding, and cardiac and non-cardiac mortality.474–480
The proportion of ACS patients with a diagnosis of cancer is rising
and constitutes about 3% of large series.475
Diagnosis of ACS is based on the same principles as in patients
without cancer, including symptoms, an early 12-lead ECG, and serial
measurements of hs-cTn for patients presenting with possible
non-ST-segment elevation ACS (NSTE-ACS).458Clinical presenta-
tion can be atypical481or masked by cancer or therapy-related
side effects; therefore, diagnostic suspicion should be increased in pa-
tients at high CV risk or treated with vascular cardiotoxic therapiesRecommendation Table 27 —Recommendations for
the diagnosis and management of Takotsubo syn-
drome in patients with cancer
Recommendations ClassaLevelb
Coronary angiography (invasive or CCTA) is
recommended to exclude ACS.IC
CMR is recommended to exclude myocarditis and
MI.458IB
QT-prolonging drugs are not recommended
during the acute TTS phase.cIII C
©ESC 2022
ACS, acute coronary syndromes; CMR, cardiac magnetic resonance; CCTA, coronary
computed tomography angiography; LV, left ventricular; MI, myocardial infarction;
QTc, corrected QT interval; TTS, Takotsubo syndrome.
aClass of recommendation.
bLevel of evidence.
cUntil full recovery and normalization of LV function and QTc.
Table 7 Cancer treatments that predispose to acute
coronary syndromes
Accelerated atherosclerosis
and plaque ruptureADT (GnRH agonists), ICI, nilotinib,
ponatinib, radiation therapy, VEGFi
Vasospasm Bleomycin, ﬂuoropyrimidines, taxanes,
VEGFi, vinca alkaloids
Coronary thrombosisAlkylating agents (cisplatin,
cyclophosphamide), erlotinib, ICI, IMiD
(lenalidomide, thalidomide), monoclonal
antibodies (VEGFi, anti-CD20), nilotinib,platinum chemotherapy, PI, ponatinib,
VEGFi.
©ESC 2022
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone; ICI,
immune checkpoint inhibitors; IMiD, immunomodulatory drugs; PI, proteasomeinhibitors; VEGFi, vascular endothelial growth factor inhibitors.ESC Guidelines 4291Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

(Table 7 ). Echocardiography improves the diagnostic precision in pa-
tients with atypical symptoms and assesses for other cardiac causes
of chest pain.
Management of ACS in patients with cancer can be challenging be-
cause of frailty, increased bleeding risk, thrombocytopaenia, increased
thrombotic risk, and the possible need for future surgery/interven-tions.
482Cancer treatment should be temporarily interrupted, and
an urgent multidisciplinary approach5is indicated to plan an individua-
lized guideline-based management, taking into account cancer status,prognosis, and the patient ’s preferences regarding invasive manage-
ment. As in patients without cancer, admission to a monitored unit
and initiation of appropriate anti-ischaemic and antithrombotic treat-
ment are indicated, in the absence of contraindications.
A large retrospective propens ity score-matching analysis
found that percutaneous coronar y intervention (PCI), despite
its lower use, was strongly associated with lower adjusted
MACE and all-cause mortality in patients with cancer(Hodgkin and non-Hodgkin lymphomas and breast, lung, colon,
and prostate cancers).
483Therefore, immediate coronary angi-
ography and PCI are recommended in patients with cancerand ACS if cancer prognosis is ≥6 months or if they have acute
complications of ACS (cardioge nic shock, pulmonary oedema,
ventricular tachyarrhythmias) , where PCI offers palliation of
symptoms.
483When stenting is indicated, third-generation
drug-eluting stents are preferred because of the lower risk of
in-stent thrombosis. Balloon angioplasty is associated withworse outcome
474and should only be used in case of severe
thrombocytopaenia or need for u rgent surgery. Fractional
ﬂow reserve or instantaneous f ree wave ratio are advised by
experts484to avoid unnecessary interventions while intravascu-
lar ultrasound and optical coherence tomography can be used
to ensure optimal stent apposition and expansion, to avoidthrombotic complications.
485
Retrospective data have demonstrated a lower use of invasive
management in patients with cancer with ST-segment elevation MI(STEMI), with a better outcome for invasively treated pa-
tients.
475,480,483PCI has not demonstrated a mortality bene ﬁt in pa-
tients with advanced cancer and NSTE-ACS compared with optimalmedical therapy.
479Therefore, a non-invasive approach can be at-
tempted in low-risk (without signs or symptoms of ongoing ischae-
mia or haemodynamic instability) NSTE-ACS patients with poorcancer prognosis ( ,6 months).
Due to a potentially higher bleeding risk (especially in patients with
active GI cancer),
477the preferred antithrombotic strategy after
drug-eluting stent consists of DAPT with aspirin and clopidogrel in-
stead of newer P2Y12 antagonists. The duration of DAPT should be
kept as short as possible (1 –3 months).458In patients with need for
therapeutic anticoagulation and antiplatelet therapy, a NOAC and
single oral antiplatelet (preferably clopidogrel) is the default strategy
after a short period of triple antithrombotic therapy (up to 1 week inhospital).
458Coronary artery bypass graft (CABG) surgery can be
considered in patients with extensive CAD who are not amenable
with PCI, after MDT discussion and where cancer prognosis is.12 months.Thrombocytopaenia (platelet count ,100 000/µL) is present in
about 10% of patients with cancer and may complicate ACS manage-
ment. Based on a small series, coronary angiography can be safely per-formed in these patients when preventative measures to avoid
bleeding are taken: platelet transfusion before catheterization (for
platelets ,20 000/µL), radial access, careful haemostasis, and
the use of a lower heparin dose (30 –50 U/kg).
486Antiplatelets should
not be withheld unless platelet count is ,10 000/µL for aspirin or
,30 000/µL for clopidogrel. For PCI and CABG, experts advise min-
imum platelet counts of 30 000/µL and 50 000/µL, respectively.484
In case of MI with non-obstructive coronary arteries, CMR may be
considered to detect other causes of myocardial injury, especially
myocarditis and TTS.
When acute ischaemia is provoked by cancer therapy, alternative
cancer therapies should be considered after a MDT discussion. In the
case of coronary vasospasm secondary to ﬂuoropyrimidines, and in
the absence of an alternative therapy, a rechallenge, although contro-versial, can be considered in a monitored unit after exclusion of se-
vere CAD (CT or coronary angiography) and after initiation of
prophylactic therapy with long-acting nitrates and calcium channelblockers (CCB).
487–489
Following ACS, a review of the cancer medications is recom-
mended, and any cancer drug associated with thrombosis and MIshould be stopped. Restarting cancer drugs associated with acute
thrombosis and MI after ACS ( Table 7 ) should occur only after a
MDT to explore other cancer therapies, with appropriate patienteducation and consent. Cancer therapies not associated with MI
can be restarted once revascularization, where indicated, has been
completed and the patient is stabilized on ACS medical therapy with-out complications.
Recommendation Table 28 —Recommendations for
the management of acute coronary syndromes in pa-
tients receiving anticancer treatment
Recommendations ClassaLevelb
An invasive strategy is recommended in patients
with cancer presenting with STEMI or high-risk
NSTE-ACS with life expectancy ≥6
months.475,479,483IB
A conservative non-invasive strategy should be
considered in patients with poor cancer
prognosisc(with life expectancy ,6 months) and/
or very high bleeding risk presenting with STEMIor NSTE-ACS.
479IIa C
A temporary interruption of cancer therapy is
recommended in patients where the cancer
therapy is suspected as a contributing
cause.d,10,490IC
A short DAPT strategy should be considered in
patients with cancer with very high bleeding risktreated with PCI for an ACS.
eIIa C
Continued4292 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.2.2. Chronic coronary syndromes
Several cancer treatments are associated with an increased risk of
stable angina and chronic coronary syndromes (CCS).4915-FU and
capecitabine can precipitate effort angina in some cases.4,482,492
Platinum-containing chemotherapy-induced ischaemia usually occurs
after one of the ﬁrst three cycles and in patients with underlying
CAD.493The incidence of cardiac ischaemia is 1 –5% with antimicro-
tubule agents, 2 –3% with small-molecule VEGF-TKI, and 0.6 –1.5%
with VEGFi monoclonal antibody therapies.492Nilotinib, ponati-
nib,494and ICI335also accelerate atherosclerosis, which can lead to
stable angina.
Patients receiving cancer therapy who present with new stable an-
gina should have careful clinical evaluation, with aggressive CVRFmodi ﬁcation and an initial medical management of their symp-
toms.
484The diagnosis and management of CAD should follow the
2019 ESC Guidelines for the diagnosis and management of chroniccoronary syndromes.
100
The management of CCS is similar in patients with and with-
out cancer, in accordance with guideline recommendations.100
However, in the setting of CCS, decisions regarding coronary
revascularization should be undertaken by a MDT that includes
cardio-oncology, interventi on, and oncology specialists.5PCI in
patients with cancer is associated with an increased risk of
bleeding, 90-day readmissions for acute MI, in-hospital and long-
term mortality, and the need for repeat revascularization, with
the magnitude of risk depending on both cancer type and
stage.495,496The excess bleeding risk should be mitigated by
keeping the duration of DAPT as short as possible.497,498The
risk is higher in patients with a cancer diagnosis within the pre-
ceding year.4776.3. Valvular heart disease
New or worsening VHD in patients with cancer may be relatedto coexisting conditions, including CTRCD, ACS, PH, endocarditis,cardiac tumours, and mechanical prosthetic valve thrombosis.
499,500
Pre-existing severe VHD is associated with an increased risk of
CTRCD,12,501–503and may also pose a risk for cancer surgery out-
comes. In patients with mechanical prosthetic valves, the risk of
thrombosis vs. bleeding should be carefully balanced during chemo-
therapy treatment. In patients with severe VHD diagnosed at base-line assessment, a MDT is required before cancer therapy to
decide the best treatment option. Cardiac surgery is frequently chal-
lenging in patients with cancer because of comorbidities, frailty, me-diastinal ﬁbrosis due to prior RT, impaired wound healing, and the
need for urgent oncology treatment (surgery, chemotherapy, tar-
geted cancer therapies that effect wound healing). Transcatheteraortic valve implantation (TAVI) may be a viable option for patients
with cancer with severe aortic stenosis to limit recovery time and de-
lays in starting cancer treatment.
504–506
Patients with cancer suspected of new or worsening VHD, such as
dyspnoea or a new cardiac murmur, or those with fever and positive
blood cultures, should be screened for endocarditis and managed ac-cording to the recommendations from the 2021 ESC/European
Association for Cardio-Thoracic Surgery (EACTS) Guidelines for
the management of VHD,
507while considering the cancer-related
prognosis. If valve surgery or percutaneous valve treatment is indi-
cated in a patient receiving cancer treatment, then a MDT is recom-
mended regarding type of valve treatment and periproceduralmanagement of cancer treatments.In patients with cancer, thrombocytopaenia,
and ACS, aspirin is not recommended if platelets,10 000/µL.III C
In patients with cancer, thrombocytopaenia, and
ACS, clopidogrel is not recommended if platelets
,30 000/µL and prasugrel or ticagrelor are not
recommended if platelets ,50 000/µL.III C
Ticagrelor or prasugrel may be considered in
patients with cancer with low bleeding risk andexcessive thrombotic risk who are treated with
PCI for ACS.IIb C
©ESC 2022
ACS, acute coronary syndromes; CrCl, creatinine clearance; CV, cardiovascular; DAPT,
dual antiplatelet therapy; GI, gastrointestinal; GU, genitourinary; NSTE-ACS,non-ST-segment elevation acute coronary syndromes; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial infarction; ULN, upper limit of
normal.
aClass of recommendation.
bLevel of evidence.
cRelated to advanced cancer stage and/or severe irreversible non-CV comorbidities.
dAnticancer therapies associated with high risk of ACS (very common [ .10%]):
capecitabine, paclitaxel, cisplatin, car ﬁlzomib, bevacizumab, ramucirumab, a ﬂibercept,
axitinib, sorafenib, pazopanib, cabozantinib, lenvatinib, ponatinib, erlotinib.
eHigh risk of GI or GU bleeding, signi ﬁcant drug –drug interactions, severe renal
dysfunction (CrCl ,30 mL/min), signi ﬁcant liver disease (alanine aminotransferase/
aspartate aminotransferase .2×ULN), or signi ﬁcant thrombocytopaenia (platelet
count,50 000/µL).Recommendation Table 29 —Recommendation for
the management of chronic coronary syndromes in
patients receiving anticancer treatment
Recommendation ClassaLevelb
Individualized duration of DAPT is recommended
in patients with cancer with CCS, following
revascularization, based upon thrombotic/ischaemic and bleeding risk, type and stage of
cancer, and current cancer treatment.
100,498I C
©ESC 2022
CCS, chronic coronary syndromes; DAPT, dual antiplatelet therapy.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 30 —Recommendations for
the management of valvular heart disease in patients
receiving anticancer treatment
Recommendations ClassaLevelb
In patients with cancer and pre-existing severe
VHD, management according to the 2021 ESC/EACTS Guidelines for the management of VHD is
recommended, taking into consideration cancer
prognosis and patient preferences.
507IC
ContinuedESC Guidelines 4293Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.4. Cardiac arrhythmias
6.4.1. Atrial ﬁbrillation
AF may occur in patients with cancer in different settings: it may be a
marker of cancer type or occult cancer, or it may develop in patientsundergoing surgery, chemotherapy, or RT.
508,509All types of cancer
show an increased risk of AF compared with the control group, but
the risk of AF depends on the cancer type and stage.510,511AF during
a cancer treatment may be caused by a speci ﬁc therapy or interaction
with a pre-existing substrate in older patients with cancer.
During cancer therapy AF may occur with a frequency ranging
from 2% to 16%, according to a variety of factors,4,490,508,512–514
and may present either as ﬁrst-diagnosed AF or as recurrence of par-
oxysmal AF. The risk of developing AF is greater in patients olderthan 65 years and/or with pre-existing CVD.
4,509,512,515Cancer sur-
gery is associated with a variable rate of AF occurrence, with the
highest incidence reported for lung surgery, ranging from 6% to32%, but with occurrence also in cases of non-thoracic surgery
(e.g. 4 –5% after colectomy).
509
Many anticancer drugs have been associated with an increased risk
of AF both in terms of incident and recurrent AF ( Supplementary
data, Table S18 ).251AF may occur shortly after treatment516or
weeks or months after starting treatment.517,518The pathophysi-
ology of AF associated with cancer is complex and has been exten-
sively reviewed elsewhere ( Figure 30 ).509
In patients with cancer, the occurrence of AF is associated with a
two-fold higher risk of systemic thromboembolism/stroke and a six-
fold increase in the risk of HF.4,509,512The coexistence of cancer in-
creases the risk of all-cause mortality, major bleeding, and intracranialhaemorrhage in patients with AF. The association between cancer
and ischaemic stroke differs between cancer types, and in some
types, the risk of bleeding seems to exceed the thromboembolicrisk.
519The management of AF in patients with cancer should follow
the 2020 ESC Guidelines for the diagnosis and management of atrial
ﬁbrillation273and the ‘ABC pathway ’(Atrial ﬁbrillation Better Care)
approach should be applied (A: Anticoagulation to avoid stroke/sys-
temic embolism, B: Better symptom control with rate- and/or
rhythm-control drugs and interventions, and C: Comorbidities andCVRF management, including lifestyle changes).
273,520
The acute management of AF in patients with cancer should con-
sider electrical cardioversion in cases of haemodynamic instability,521
while in others, the alternative between rate and rhythm control has
several important considerations speci ﬁc to patients with cancer.
Drugs for rhythm control may lead to QT-interval prolongation,369
frequently have drug –drug interactions with cancer therapies, ormay have a limited ef ﬁcacy if a cancer therapy is the speci ﬁc cause
of the AF.508Among rate-control drugs, beta-blockers are preferred,
especially if the cancer therapies have potential CTRCD risk, where-as diltiazem and verapamil should be avoided where possible due to
their drug –drug interactions and negative inotropic effects.
508The
possibility of AF ablation should be discussed in selected patientswith HF/LVD and/or uncontrolled symptoms, taking into consider-
ation cancer status and prognosis in the context of a MDT
approach.
522
A complex issue in patients with cancer with new AF is risk strati-
ﬁcation for stroke/systemic embolism, which according to guidelines,
should be based on the CHA 2DS2-VASc score (Congestive heart fail-
ure, Hypertension, Age ≥75 years [2 points], Diabetes mellitus,
Stroke [2 points] —Vascular disease, Age 65 –74 years, Sex category
[female]).273,523,524The CHA 2DS2-VASc score has not been exten-
sively validated in patients with cancer.525In a large cohort of patients
with AF, the predictive value of the CHA 2DS2-VASc score was lower
in patients with cancer than in those without, but a progressive in-
crease in the risk of ischaemic stroke according to the
CHA 2DS2-VASc score was also found in AF patients with cancer
(from 0.9% per year to 8.9% per year).519However, the scope of
this score is not to identify high-risk patients, but rather to identify
low-risk individuals in whom anticoagulation can be avoided. A studybased on the Danish healthcare system data set found that
CHA
2DS2-VASc scores of 0 and 1 in patients with recent cancer
were linked with higher risk of stroke/thromboembolism at 2 yearsthan in patients without recent cancer.
526This concept should be
considered in de ﬁning the risk/bene ﬁt ratio of anticoagulation in indi-
vidual patients with cancer. Therefore, the decision for anticoagula-tion in patients with an active malignancy should take into account
the enhanced thrombotic and/or bleeding risk and other risk predic-
tion scores used for general AF populations.
509For bleeding risk as-
sessment, the HAS-BLED (Hypertension, Abnormal renal and liver
function, Stroke, Bleeding Labile international normalized ratio,
Elderly, Drugs or alcohol) score may be considered. A proposed ap-proach to anticoagulation therapy in cancer, based on the acronym T
(thrombotic risk), B (bleeding risk), I (interactions among drugs), P
(patient access and preferences), is outlined in Figure 31 .
519,527
Long-term anticoagulation is recommended in adult patients with
CHA 2DS2-VASc score ≥2 in men or ≥3 in women and must be con-
sidered also when the score is 1 in men and 2 in women.273The clin-
ical pattern of AF (i.e. ﬁrst detected, paroxysmal, persistent,
long-standing persistent, permanent, post-operative) should not in-
ﬂuence the indication of thromboprophylaxis.273The same approach
can be proposed for patients with cancer and AF, also considering
that the CHA 2DS2-VASc score likely underestimates their thrombo-
embolic risk.530In the speci ﬁc setting of cancer, decision-making on
long-term oral anticoagulation should also consider the cancer-
related type, stage, prognosis and the potentially changing thrombo-
embolic or bleeding risk.508,509The use of vitamin K antagonists
(VKA) in cancer is limited by their drawbacks in this setting; however,
they remain the only indicated anticoagulants in patients with mod-
erate to severe mitral stenosis or a mechanical prosthetic valve.LMWH constitute a viable short-term anticoagulation option, par-
ticularly in hospitalized patients with a recent cancer diagnosis, ad-
vanced cancer disease, or during some cancer treatments (e.g.In patients with cancer developing new VHD
during cancer therapy, management according tothe 2021 ESC/EACTS Guidelines for the
management of VHD
507is recommended, taking
into consideration cancer prognosis and patientcomorbidities.I C
©ESC 2022
EACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of
Cardiology; VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.4294 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

patients receiving myelosuppressive chemotherapy or with recent
active bleeding). However, LMWH ef ﬁcacy for stroke or systemic
embolism prevention in AF has not been established and theiruse is only based on their proven ef ﬁcacy and safety in VTE. The
use of a NOAC for AF has not been evaluated in a dedicated
RCT in patients with cancer. However, secondary analyses of sem-inal NOAC trials using direct factor Xa inhibitors (ROCKET AF
[Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention ofStroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE
[Apixaban for Reduction in Stroke and Other ThromboembolicEvents in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation –Thrombolysis in Myocardial Infarction 48]) and obser-
vational data suggest better safety and at least similar effectiveness
of the NOAC when compared with VKA in patients with AF and
active cancer.
531 –538NOAC use in cancer is limited by drug –drug
interactions,508severe renal dysfunction, increased risk of bleeding
in patients with unoperated or residual GI or genitourinary (GU)
malignancies, or impaired GI absorption.
Left atrial appendage (LAA) occluder devices are used in very se-
lected patients with cancer in clinical practice. The potential
Pathophysiology ofAF assoc iated with cancer
AF
in cancerAgeing
CV and metabolic
comorbiditiesbAnticancer
treatmentsa
Cancer
invasionCancer
surgeryInflammation
Hypo xia
ANS imbalanceParaneoplasticmanifestations
Figure 30 Pathophysiology of atrial ﬁbrillation associated with cancer. AF, atrial ﬁbrillation; ANS, autonomic nervous system; CV, cardiovascular; DM,
diabetes mellitus; HF, heart failure; IHD, ischaemic heart disease; VHD, valvular heart disease.aSupplementary data, Table S18 .bObesity, hypertension,
DM, CVDs (HF, VHD, IHD, cardiomyopathies, cardiac amyloidosis), thyroid diseases, obstructive sleep apnoea, chronic obstructive pulmonary disea se,
chronic kidney disease, autonomic dysfunction, alcohol consumption, genetic predisposition.ESC Guidelines 4295Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Thrombocytopaenia
GI/GU  cancer,  GI comorbidities,  or GI toxicity
Recent  or evolving  intracranial  lesions
Active  bleeding  or recent  major bleeding
Severe  renal dysfunction  (eGFR  <30 mL/min/1. 73 m2)
Bleeding  risk scores  (e.g., HAS-BLED)Assess  Bleeding  risk:
Cancer-related  risk (cancer  type and stage,  cancer  treatment)
CHA2DS2-VASc  score  for risk stratiﬁcation  (Class  IIa)aAssess  Thromboembolic  risk:
Anticancer  agents
Supportive  therapiesAssess  drug-drug  Interactions  (P-glycoprotein,  CYP3A 4):
Assess  Patient  preferences  and drug availability
T
B
I
P
Thromboembolic  and
bleeding  risk reassessment
(Class  I)Very high bleeding  riskb
Type of anticoagulant
treatment
LAA oclusionc
(Class  IIb)
LMWH
(Class  IIa)Moderate/severe  mitral  stenosis
or mechanical  prosthetic  valve
Patients  suitable
for NOACdN
NStructured  approach  to anticoagulation  for AF in patients  with cancer
No anticoagulation Y
VKA
(Class  IIa)Y
NOAC
(Class  IIa)YLong-term anticoagulation
according to CHA2DS2-VASc score
≥2 (men)  or ≥3 (women)  (Class  I)
1 (men)  or 2 (women)  (Class  IIa)
 0 (men)  or 1 (women)  (Class  IIb)
N
Figure 31 Structured approach to anticoagulation for atrial ﬁbrillation in patients with cancer. AF, atrial ﬁbrillation; CHA 2DS2-VASc, Congestive heart
failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, Stroke (2 points) —Vascular disease, Age 65 –74 years, Sex category (female); CrCl,
creatinine clearance; eGFR, estimated glomerular ﬁltration rate; GI, gastrointestinal; GU, genitourinary; HAS-BLED, Hypertension, Abnormal renal and
liver function, Stroke, Bleeding Labile international normalized ratio, Elderly, Drugs or alcohol; LA, left atrial; LAA, left atrial appendage; LM WH,
low-molecular-weight heparins; N, no; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonists; Y, yes.aIn selected patients, car-
diac imaging parameters related to increased thromboembolic risk should be considered (LAA thrombus, severely dilated left atrium, severely impai red
LA strain528).bVery high bleeding risk : active or recent major bleeding ( ,1 month previously); recent/evolving intracranial lesions; platelet count ,25
000/µL. According to the International Society on Thrombosis and Haemostasis,529major bleeding is de ﬁned as a fall in haemoglobin level ≥2 g/dL and/or
transfusion of ≥2 units of red blood cells and/or fatal bleeding and/or bleeding in a critical area (intracranial, intraspinal, intraocular, pericardial,
intra-articular, intramuscular with compartment syndrome, or retroperitoneal).cPercutaneous left appendage closure may be considered in pa-
tients with a life expectancy of .1 year who are at high thromboembolic and bleeding risk and in whom anticoagulation is contraindicated.dConditions
favouring LMWH : unoperated GI/GU cancer; GI comorbidities or toxicity; severe renal dysfunction (CrCl ,15 mL/min); NOAC major drug –drug
interactions, platelet count ,50 000/µL.4296 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

complications related to the implant —including device-related throm-
bosis —and the lack of prospective data in the setting of patients with
cancer have to be taken into consideration for this option. In a recentretrospective analysis of patients referred to LAA occlusion the risk of
in-hospital ischaemic stroke/transient ischaemic attack was higher in
patients with active cancer than in those with no cancer or prior his-tory of cancer. The rate of in-hospital composite outcome (in-hospital
death, ischaemic stroke/transient ischaemic attack, systemic embolism,
bleeding requiring blood transfusion, pericardial effusion/cardiac tam-ponade treated with pericardiocentesis or surgically, and removal of
embolized device) and 30-day/180-day readmission outcomes were
not signi ﬁcantly different between the groups.
539
The onset of AF may be related to transient factors, such as the
peri-operative period or the effect of drugs known to facilitate AFonset. The traditional assumption that in these cases, AF may occur
as an isolated event without recurrence may not be valid as the oc-
currence of AF may often be related to a pre-existing atrial substratewith vulnerability to AF.
540Post-operative AF has been associated
with a four- to ﬁve-fold risk of AF recurrence in the following 5 years,
along with a comparable long-term thromboembolic risk with AF notrelated to surgery.
273,540,541Anticoagulation therapy yielded a simi-
larly lower risk of thromboembolic events and all-cause death in
both groups.541In the absence of direct evidence, anticoagulation
to prevent thromboembolic events should be considered in patients
at risk for stroke with AF after cancer surgery considering the antici-
pated net clinical bene ﬁt and informed patient preferences.273
Similarly, in patients with AF apparently related to transient factors
—such as chemotherapy, other drugs, or electrolyte disturbances
—a careful clinical assessment of the propensity to further develop
AF is recommended, with need to revisit the risk/bene ﬁt ratio of
long-term prescription of anticoagulation after a period of 3 months.
In patients with cancer and newly detected or recurrence of AF, de-
cision making on anticancer treatment requires a cardio-oncology MDT
management,5taking into account that neither the presence nor the risk
of AF constitutes contraindications to anticancer treatment.508,517
Recommendation Table 31 —Recommendations for
the management of atrial ﬁbrillation in patients re-
ceiving anticancer treatment
Recommendations ClassaLevelb
CHA 2DS2-VASc score should be considered for
risk strati ﬁcation for stroke/systemic
thromboembolism taking into account that it may
underestimate the actual thromboembolic
risk.519,526IIa C
Long-term anticoagulation is recommended for
stroke/systemic thromboembolism prevention inpatients with cancer with AF and a
CHA
2DS2-VASc score ≥2 (men) or ≥3 (women)
as per the 2020 ESC Guidelines for the diagnosis
and management of atrial ﬁbrillation.273IC
ContinuedLong-term anticoagulation should be considered
for stroke/systemic thromboembolism
prevention in patients with cancer with AF and a
CHA 2DS2-VASc score =1 (men) or =2
(women) as per the 2020 ESC Guidelines for the
diagnosis and management of atrial ﬁbrillation.273IIa C
Patients with cancer,cAF, and CHA 2DS2-VASc
score 0 (men) or 1 (women) may have a higher
thrombotic risk than patients without cancer and
may be considered for therapeutic anticoagulation
after consideration of the bleeding risk.526IIb C
Thromboembolic and bleeding risk reassessment
is recommended during follow-up in patients withcancer with AF.
d,273IC
NOAC should be considered for stroke
prevention in preference to LMWH and VKA
(excluding patients with mechanical heart valves
or moderate-to-severe mitral stenosis) in patients
without a high bleeding risk, signi ﬁcant drug –drug
interactions, or severe renal dysfunction.531–537IIa B
LMWH should be considered in patients with
active cancereand AF who are not suitable for
NOACf.525IIa C
LAA occlusion may be considered for stroke
prevention in patients with cancer with AF and
contraindications for long-term anticoagulationwith a life expectancy .12 months.
273,539IIb C
Antiplatelet therapy or prophylactic LMWH are
not recommended for stroke or systemic
thromboembolism prevention in AF with
cancer.273III C
Heart rate control strategy, preferably with
beta-blockers, should be considered in patientswho develop well-tolerated AF while they are
receiving active cancer treatment
g.IIa C
©ESC 2022
5-FU, 5- ﬂuorouracil; AF, atrial ﬁbrillation; BMI, body mass index; CHA 2DS2-VASc,
Congestive heart failure, Hypertension, Age .75 years (2 points), Diabetes mellitus,
Stroke (2 points) —Vascular disease, Age 65 –74 years, Sex category (female); CrCl,
creatinine clearance; eGFR, estimated glomerular ﬁltration rate; EGFR, epidermal
growth factor receptor; ESC, European Society of Cardiology; HF, heart failure; LAA,
left atrial appendage; LMWH, low-molecular-weight heparins; LV, left ventricular;
MM, multiple myeloma; NOAC, non-vitamin K antagonist oral anticoagulants; VKA,vitamin K antagonists.
aClass of recommendation.
bLevel of evidence.
cFactors that may increase thromboembolic risk in patients with cancer including
comorbidities (proteinuria .150 mg/24 h, eGFR ,45 mL/min/1.73 m2,B M I≥30 kg/m2,
thrombophilia), cancer type (pancreatic, gastric, ovarian, brain, lung, MM), cancer stage
(metastatic disease) anticancer therapies: alkylating agents, a ﬂibercept, bevacizumab,
anthracyclines, capecitabine, 5-FU, gemcitabine, methotrexate, EGFR inhibitors,bleomycin, axitinib, lenvatinib, pazopanib, sorafenib, sunitinib, car ﬁlzomib, irinotecan,
taxanes, tasonermin, tretinoin.
dStroke and bleeding risk may change during both cancer treatment and the course of the
underlying disease; reassessment is important to inform treatment decisions and addresspotentially modi ﬁable bleeding risk factors.
ePatients receiving cancer treatment, patients diagnosed with cancer in the past 6 months,
and patients with progressive or advanced disease.
fHigh bleeding risk, severe renal dysfunction (CrCl ,15 mL/min); NOAC major drug –drug
interactions.
gAsymptomatic or mild symptomatic patients without HF signs or symptoms or
deterioration of LV function. The optimal heart rate target in AF patients is unclear. A
resting heart rate ,110 bpm (i.e. lenient rate control) should be considered as the
initial heart rate target for rate control therapy. A review of rate vs. rhythm strategyshould be made at the end of cancer treatment.
273ESC Guidelines 4297Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.4.2. Long corrected QT interval and ventricular
arrhythmias
VA are not common during cancer, although their incidence in-
creases in patients with advanced cancer and CV comorbid-
ities.49,259,516,542Mechanisms proposed to explain cancer
therapy-induced VA include: (1) direct effects of cancer drugs on
the activity/expression of ionic channels that regulate the ventricular
action potential,4,369,442,516,542,543and (2) a permanent arrhythmo-
genic substrate created by cancer and systemic in ﬂammation caused
by cancer, pre-existing CV comorbidities, and/or a new
CTR-CVT.4,9,259,369,442,516,542,543
Treatment of cancer therapy-induced VA should follow general
clinical guidelines.22,442,544In patients with asymptomatic self-
terminating VA, drug discontinuation is not required unless theyhave additional CVRF or persistent ECG abnormalities.
270
Symptomatic VA require cancer drug dose reduction or discontinu-ation and patients should be referred to the cardiologist for evalu-ation and treatment.
4,442
Recurrent symptomatic life-threatening VA require urgent inter-
vention.4,270,442,544The administration of class IA, IC, and III anti-
arrhythmic drugs is limited by the risk of drug –drug interactions
and QTc prolongation. Beta-blockers and class IB drugs are less likely
to cause drug interactions or QTc prolongation. Beta-blockers arethe preferred choice if the cancer drug is also associated with
CTRCD. Amiodarone is the antiarrhythmic drug of choice in patients
with structural heart disease and haemodynamic instability.
Table 8 Risk factors for drug-induced QT prolonga-
tion and torsade de pointes
Correctable Non-correctable
QT-prolonging drugsa
Antiarrhythmics
Antibiotics
Antidepressants
Antifungals
Antiemetics
Antihistamines
Antipsychotics
Loop diuretics
Opioids (methadone)
BradyarrhythmiaElectrolyte imbalance/
abnormalities
Hypokalaemia ( ≤3.5 mEq/L)
Hypomagnesaemia
(≤1.6 mEq/L)
Hypocalcaemia ( ≤8.5 mEq/L)
Inadequate dose adjustment of
renal or hepatic cleared
QT-prolonging drugsAcute myocardial ischaemia
Age.65 years
Baseline QTc interval
prolongation
b
Family history of sudden death
(congenital LQTS or genetic
polymorphism)
Female sexImpaired renal function (for
renally excreted drugs)
Liver disease (for hepaticallyexcreted drugs)
Personal history of syncope or
drug-induced TdPPre-existing CVD (CAD, HF, LV
hypertrophy)
©ESC 2022
CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; LQTS,
long QT syndrome; LV, left ventricular; QTc, corrected QT interval; TdP, torsade de
pointes.
aSee https://www.crediblemeds.org.
bQTc using Fridericia correction (QTcF =QT/3√RR) is recommended in patients with
cancer.Table 9 Classi ﬁcation of corrected QT interval pro-
longation induced by cancer drug therapy
Classi ﬁcation Drugs
High risk : QTcF prolongation ≥10 ms and risk
of TdPAclarubicin
Arsenic trioxide
Glasdegib
Nilotinib
Oxaliplatin
Pazopanib
Ribociclib
Sunitinib
Toremifene
Vandetanib
Moderate risk : QTcF prolongation ≥10 ms
and low or no risk of TdP (or uncertain)Abarelix
Belinostat
Brigantinib
Carbozantinib
Ceritinib
Crizotinib
Dovitinib
Entrectinib
Eribulin
Gilteritinib
Ivosidenib
Lapatinib
Lenvatinib
Osimertinib
Panobinostat
Rucaparib
Selpercatinib
Sorafenib
Tipiracil/
triﬂuridine
Vemurafenib
Low risk : QTcF prolongation ,10 msa
ADT
Afatinib
Axitinib
Binimetinib
Bortezomib
Bosutinib
Carﬁlzomib
Dabrafenib
Dasatinib
Encorafenib
Midostaurin
Pertuzumab
Ponatinib
Romidepsin
Quizartinib
Tamoxifen
Vorinostat
©ESC 2022
ADT, androgen deprivation therapy; QTcF, corrected QT interval using Fridericia
correction; TdP, torsade de pointes.
aADT may prolong the QTc interval (GnRH agonist, GnRH antagonist, bicalutamide,
ﬂutamide, apalutamide, darolutamide, enzalutamide, and abiraterone) (see Figure 21 ).
Developed from EMA prescribing information,252FDA prescribing information,253
and AZCERT.5474298 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Decisions on the use of antiarrhythmic drugs or device therapy (car-
dioverter de ﬁbrillators, catheter ablation) should consider life ex-
pectancy, quality of life, and complication risks.349
Most cancer therapy-induced VA are related to a prolongation of
QTc leading to the development of TdP.259,516,542Risk factors for
QTc prolongation and TdP are summarized in Table 8 .4,22,45,48,516,543
The upper 99% limits of normal for QTc values in the general
population are 450 ms for men and 460 ms for women.545
Although there is no threshold of QTc prolongation at which TdP
can occur, a QTc ≥500 ms is associated with a two- to three-fold
higher risk for TdP, while TdP rarely occurs when QTc is,500 ms.442Although the incidence of QTc prolongation
≥500 ms and TdP is low during cancer therapy, QTc prolongation
to levels that require closer monitoring (QTc ≥480 ms) is more
common ( Table 9 ).4,9,22,45,48,49,259,369,516,543,546Changes in the QT
interval of .60 ms from baseline should not routinely affect treat-
ment decisions if the QTc remains ,500 ms.1Cardiology consult-
ation is advised in patients with an abnormal baseline QTc interval,
patients treated with drugs that prolong the QT interval, those
who develop new cardiac symptoms (syncope or pre-syncope, rapidpalpitations or QTc prolongation with new-onset bradycardia, high
degree of heart block), and/or those with known inherited arrhythmia
QTcF value
QTcF value
QTcF valueQTcF monitoring
according to drug-
specific protocol
ECG after any
dose increase of QTc-
prolonging drug
(class I)
If QTcF <500 ms
Continue treatment at same or
reduced dose according to
drug-specific protocol
(Class I)Consider
alternative
treatmentAlternative
treatment
(Class I) (Class I) (Class I)QTcF value
Resume treatment at the same
or reduced dose according
to drug-specific protocol
Consider restarting treatment
at reduced dose
(Class IIb)
MDT to discuss alternative
cancer treatments
(Class I)≤480 ms
≤480 ms≤480 ms >480 ms
>480 ms and
<500 ms
>480 ms and
<500 ms>480 ms and
<500 ms≥500 ms
≥500 ms≥500 msTdP or
sustainedVACorrect baseline risk factors for QTc prolongationb
Avoid/stop concomitant QTc prolonging drugsb
Ensure K+ >4.0 mmol/L, Mg2+ >2.0 mg/dL (>1.10 mmol/L) and normal values of corrected Ca2+Baseline 12-lead ECG: QTcF
Start therapy
ECG monitoringcCardio-oncology evaluation
Correct reversible causesb
Correct
reversible
causesb
Weekly ECGmonitoringDrug
interruption
Correct
reversible
causesbDrug
withhold
Correct
reversible
causesbQTc monitoring before and during/nobreakspacetreatment with/nobreakspaceQTc prolonging/nobreakspaceanticancer/nobreakspacedrugsa
Figure 32 Corrected QT interval monitoring before and during treatment with corrected QT interval-pro longing anticancer drugs. Ca2+,c a l c i u m ;E C G ,
electrocardiogram; K+,p o t a s s i u m ;M D T ,m u l t i d i s c i p l i n a r yt e a m ;M g2+,m a g n e s i u m ;Q T c ,c o r r e c t e dQ Ti n t e r v a l ;Q T c F ,c o r r e c t e dQ Ti n t e r v a lu s i n g
Fridericia correction; TdP, Torsade de po intes; VA, ventricular arrhythmias. QT interval using Fridericia correction (QTcF =QT/3√RR) is recommended in
patients with cancer. Upper 99% limits of normal for QTc values i n the general population are 450 ms for men and 460 ms for women.369 aTable 9 .
bTable 8 and https://www.crediblemeds.org.cECG monitoring at baseline, once steady-state anticancer drug levels have been achieved, after each dose modi-
ﬁcation, or any treatment interruption .2 weeks; monthly for the ﬁrst 3 months, and then periodically during treatment depending on patient-speci ﬁcr i s k
factors and cancer treatment.ESC Guidelines 4299Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

disorders.4,45,48,442,544The challenges for the cardio-oncology teams
are to identify patients more susceptible to developing VA, determine
whether a VA is directly due to CTR-CVT, individualize the treatmentstrategy, and optimize clinical monitoring during treatment.
Figure 32 shows the algorithm for the management of QTc pro-
longation during cancer therapy. In patients with cancer, theFridericia formula is recommended and has demonstrated less error
than other correction methods such as Bazzett at both high and low
heart rates.
44In patients treated with QTc-prolonging drugs, serum
electrolytes and other risk factors should be closely monitored and
corrected, and concomitant QT-prolonging drugs avoided if pos-
sible.4,22,45,369,543For selected cancer drugs, there are speci ﬁc manu-
facturer recommendations for ECG monitoring during treatment,
dosage adjustments, or discontinuation of therapy in case of QTcprolongation.
548
Although there are no recommendations, patients with cancer
with QTc prolongation associated with severe bradycardia or sinuspauses may bene ﬁt from isoprenaline infusion or temporary pa-
cing. Despite present restrictions, the improved prognosis for
many malignancies is increasing the number of patients with cancerwho are candidates for an implantable cardioverter de ﬁbrillator
(ICD), particularly when life expectancy is .1 year (including pa-
tients who experienced resuscitated sudden cardiac death or se-vere VA from a QTc-prolonging drug with no alternative
treatment available).6.4.3. Bradyarrhythmias
AV conduction disease can be caused by ICI in the presence or ab-sence of myocarditis. If the PR interval increases (new ﬁrst-degree
heart block) in patients treated with ICI, serial ECG monitoring is re-commended, and if PR prolongation to .300 ms develops, the pa-
tient should be hospitalized under close ECG monitoring and i.v.
methylprednisolone is recommended.
550
IMiD (thalidomide, pomalidomide)285and ALK inhibitors (crizoti-
nib, alectinib, brigatinib, or ceritinib)551are associated with sinus
bradycardia. Holter ECG monitoring is recommended to excludesigniﬁcant sinus pauses in symptomatic patients. In asymptomatic pa-
tients with normal LV function, sinus bradycardia is usually well tol-
erated and treatment can continue. If patients are symptomatic(syncope, pre-syncope of reduced exercise tolerance from chrono-
tropic incompetence) then a trial of cancer drug withdrawal to con-
ﬁrm causation with the symptoms is recommended. A MDT
discussion is needed to analyse risks/bene ﬁts of alternative cancer
therapies vs. restarting the culprit cancer therapy at a lower dose
with heart rate monitoring. In selected cases, when no cancer treat-ment alternative is available, pacing is indicated.
6.5. Arterial hypertension
Arterial hypertension in patients with cancer may be caused by their
cancer treatments (e.g. VEGFi, second- and third-generation
BCR-ABL TKI, brigatinib, ibrutinib, ﬂuoropyrimidines, cisplatin, abir-
aterone, bicalutamide, enzalutamide), non-cancer drugs (e.g. corti-
costeroids, non-steroidal anti-in ﬂammatory drugs), and other
factors including stress, pain, excessive alcohol consumption, renalimpairment, untreated sleep apnoea, obesity, and reduced exer-
cise.
552In all patients with cancer with new hypertension assessment,
correction of these other factors is important before consideringinterruption of a cancer treatment.
Untreated hypertension
344is a con ﬁrmed risk factor of HF during
treatment with anthracyclines,553ibrutinib,264and VEGFi.554Given
that many of the cancer therapies that cause hypertension also causeRecommendation Table 32 —Recommendations for
the management of long corrected QT interval and
ventricular arrhythmias in patients receiving antican-cer treatment
Recommendations ClassaLevelb
How to manage QTc prolongation in patients with cancer
Discontinuation of QTc-prolonging cancer
therapy is recommended in patients who develop
TdP or sustained ventricular tachyarrhythmiasduring treatment.
549IC
Temporary interruption of QTc-prolonging
cancer therapy is recommended in patients who
develop asymptomatic QTcF ≥500 ms and an
ECG should be repeated every 24 h untilresolution of the QTcF prolongation.
549IC
Immediate withdrawal of any offending drug and
correction of electrolyte abnormalities and other
risk factorscis recommended in patients with
cancer who develop QTcF ≥500 ms.349,442,546IC
Weekly ECG monitoring is recommended in
asymptomatic patients with cancer with QTcF
480–500 ms who are treated with a
QTc-prolonging cancer therapy.349,442,546IC
A 12-lead ECG is recommended after any dose
increase of QTc-prolonging cancertherapy.
270,442,544IC
ContinuedRestarting QTc-prolonging cancer therapy
A multidisciplinary discussion is recommended
before restarting QTc-prolonging drugs inpatients who have developed signi ﬁcant QTcF
prolongation, to discuss alternative cancer
treatments.
4,22,259,349,442,546IC
In patients who experienced signi ﬁcant QTcF
prolongation, restarting the culpritQTc-prolonging cancer treatment may be
considered, ideally at a reduced dose according to
each drug recommendation.
45,259,349,442,546,549IIb C
Weekly ECG monitoring during the ﬁrst 4 –6
weeks and then monthly thereafter isrecommended in patients with cancer after
restarting QTc-prolonging cancer therapy.
549I C
©ESC 2022
ECG, electrocardiogram; QTc, corrected QT interval; QTcF, corrected QT interval
using Fridericia correction; TdP, torsade de pointes.
aClass of recommendation.
bLevel of evidence.
cSee https://www.crediblemeds.org and Table 8 .4300 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CTRCD, treatment of hypertension with ACE-I or ARB as ﬁrst-line
therapy is recommended to reduce the risk of CTRCD.
Combination therapy with an ACE-I or ARB and a dihydropyridineCCB is recommended in patients with cancer with systolic BP ≥
160 mmHg and diastolic BP ≥100 mmHg due to the more rapid on-
set of BP control with the combination compared with ACE-I/ARBmonotherapy ( Figures 33 and34).
If severe hypertension is diagnosed (systolic BP ≥180 mmHg or
diastolic BP ≥110 mmHg), the competing cancer and CV risks
should be evaluated by a MDT, and any cancer therapy associated
with hypertension should be deferred or temporarily withheld until
the BP is controlled to values ,160 mmHg (systolic BP) and
,100 mmHg (diastolic BP). Culprit cancer therapy can be restarted
once BP is controlled, with consideration for dose reduction.In patients with resistant cancer therapy-related hypertension,
spironolactone, oral or transdermal nitrates, and/or hydralazine
should be considered. In patients with cancer with evidence ofhigh sympathetic tone, stress, and/or pain, beta-blockers including
carvedilol or nebivolol should be considered. Diuretics, preferably
spironolactone, may be considered in patients with cancer withhypertension and evidence of increased ﬂuid retention, with moni-
toring of BP, electrolytes, and renal function.
The decisions to initiate BP treatment and BP targets during the
management of cancer-drug induced hypertension depend upon
the context of the cancer and prognosis ( Figure 34 ). CS should be
treated according to the 2018 ESC/European Society of
Hypertension (ESH) Guidelines for the management of arterial
hypertension.
138
Recommended threshold for asymptomatic hypertension treatment
in different/nobreakspaceclinical/nobreakspacescenarios
CS Home
BP mmHgCurable cancer
during treatmentMetastatic cancer
Prognosis >3 yearsMetastatic cancer
Prognosis 1–3 yearsMetastatic cancer
Prognosis <1 year
160+ Treat Treat Treat Treat Treat
140–159 Treat Treat TreatConsider
treatmentMay treat
135–139 Treat May treatConsider
treatmentMay treat None
130–134 May treat None None None None
<130 None None None None None
Class 1 Class 1Ia Class 1Ib
Figure 33 Recommended threshold for asymptomatic hypertension treatment in different clinical scenarios. BP, blood pressure; CS, cancer survivors.ESC Guidelines 4301Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

BP target durin g cancer ther
 a
p
y
p
 Systolic BP
 ≥
160 mmH g and diastolic BP
 ≥
100 mmH g
Hype
r
tension caused
 b
y cancer ther
 a
p
y
p
A
CE-I or
 ARB
(Class I )
A
CE-I or
 ARB
(Class I )
Di
h
yd
r
o
p
yridine CCB
p
p
as second-lin e ther
a
p
y
p
p
in patients wit h
uncont
r
olled BP
(Class I )
Di
h
yd
r
o
p
yridine CCB
p
p
(Class I )
BP tar get <1 40 mmH g systolic an d
<90 mmHg diastolic
(Class I )
BP target <130 mmH g systolic and <80 mmH g
diastolic i f 
w
ell tolerate d
(Class IIb )
Beta-bloc
k
ers
k
k
b
Spi
r
onolactone
Oral or transdermal nitrates and/o r 
h
ydralazine
(Class IIa )
If
r
esistant h ypertension
a
:
 In selected asymptomatic patients wit h
metastatic cancer s ystolic BP 1 40–160 mmH g,
and diastolic BP 90–100 mmH g 
(Class IIb )N
T
r
T
T
eatment of a
r
terial 
h
ype
r
tension in patients wit h cancer
Y
OR
AND
OR
Figure 34 Treatment of arterial hypertension in patients with cancer. AF, atrial ﬁbrillation; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angio-
tensin receptor blockers; BP, blood pressure; CCB, calcium channel blockers; HF, heart failure; MI, myocardial infarction; N, no; VEGFi, vascular e ndothelial
growth factor inhibitors; Y, yes.aResistant hypertension is de ﬁned as BP being uncontrolled despite treatment with optimal or best-tolerated doses of three
or more drugs including a diuretic, and con ﬁrmed by ambulatory and home BP monitoring.bConsider beta-blockers (nebivolol or carvedilol are preferred in
patients on VEGFi) at any treatment step, when there is a speci ﬁc indication for their use, e.g. HF, angina, post-MI, or AF.
Recommendation Table 33 —Recommendations for
the management of arterial hypertension in patients
receiving anticancer treatment
Recommendations ClassaLevelb
General
Effective treatment of cancer therapy-induced
arterial hypertension to prevent cancer treatment
interruption and CV complications is
recommended.IC
A BP target ,140 mmHg systolic and ,90 mmHg
diastolic is recommended during cancer therapy.IC
A BP target ,130 mmHg systolic and ,80 mmHg
diastolic may be considered during cancer therapy
provided that the treatment is well tolerated.IIb C
In selected asymptomatic patients with metastatic
cancer, a systolic BP 140 –160 mmHg and diastolic
BP 90 –100 mmHg treatment threshold may be
considered provided there i s ongoing BP monitoring.IIb C
The competing cancer and CV risk evaluation is
recommended if the systolic BP is ≥180 mmHg or
diastolic BP ≥110 mmHg, and any cancer therapy
associated with hypertension should be deferredor temporarily withheld until the BP is controlled
to values ,160 mmHg (systolic) and
,100 mmHg (diastolic).IC
ContinuedCancer therapy-induced arterial hypertension treatment
ACE-I or ARB are the ﬁrst-line antihypertensive
drugscrecommended for BP management in
patients with cancer.555–557IB
Dihydropyridine CCB are recommended as
second-line antihypertensive drugs for patientswith cancer with uncontrolled BP.IC
Combination therapy with ACE-I or ARB and
dihydropyridine CCB is recommended in patients
with cancer with systolic BP ≥160 mmHg and
diastolic BP ≥100 mmHg.IC
Diltiazem and verapamil are not recommended to
treat arterial hypertension in patients with cancerdue to their drug –drug interactions.
dIII C
©ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
BP, blood pressure; CCB, calcium channel blockers; CV, cardiovascular.
aClass of recommendation.
bLevel of evidence.
cUnless contraindicated.
dIn selected patients with cancer, who are intolerant to multiple other antihypertensive
drugs, diltiazem and verapamil may be considered with close monitoring of drug –drug
interactions.4302 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.6. Thrombosis and thromboembolic
events
Thromboembolic events that develop during cancer and its treat-
ment encompass both VTE and arterial thromboembolism (ATE)and are collectively referred to as cancer-associated thrombosis.
Cancer-associated thrombosis is determined by the prothrombotic
milieu induced by cancer, the prothrombotic properties of certainanticancer and adjunctive therapies, and patient-related risk
factors, including demographics, genetic predisposition, and
comorbidities.
513
6.6.1. Venous thromboembolism
VTE, including deep vein thrombosis (DVT) and PE, is thesecond-leading cause of death in patients with malignancies.
558Cancer confers a ﬁve-fold higher risk of VTE and cancer-associated
VTE represents 30% of all VTE cases.559,560The risk of VTE varies
in the course of cancer, with the highest risk occurring in the periodfollowing cancer diagnosis, during hospitalization and chemotherapy,
and upon development of metastatic disease.
561,562Unprovoked
VTE may be the ﬁrst clinical sign of a malignancy, followed by a 5%
incidence of cancer diagnosis during the subsequent 12 months.563
The risk factors for VTE in cancer are summarized in
Figure 35 .564,565Patients with symptoms or signs suggestive of
VTE, such as unilateral lower limb oedema or unexplained dyspnoea,
should be screened with lower-extremity venous ultrasonography
or contrast-enhanced CT for DVT and CT pulmonary angiography
for PE, according to the 2019 ESC Guidelines for the diagnosis and
management of acute pulmonary embolism recommendations566
Risk factors for VTE in patients with cancer
Patient-related factors
Ageing
Comorbiditiesa
Sex (female)Hereditary coagulation defects
b 
Performance status Prior VTE history
Treatment-related factors
Cancer therapyc 
Central venous cathetersHospitalization Major surgeryCancer-related factors
Cancer typeGenetic characteristics (JAK2 or K-ras mutations)Histology (adenocarcinoma)Initial period after diagnosis 
Primary site (pancreas, stomach, ovaries,
brain, lung, myeloma)Stage (advanced, metastatic)
Figure 35 Risk factors for venous thromboembolism in patients with cancer. ATE, arterial thromboembolism; BMI, body mass index; CrCl, creatinine
clearance; IMiD, immunomodulatory drugs; PI, proteasome inhibitors; VTE, venous thromboembolism.aAcute infection, chronic kidney disease (CrCl ,
45 mL/min), pulmonary disease, obesity (BMI ≥30 kg/m2), ATE.bFactor V Leiden, prothrombin gene mutation.cChemotherapy (carboplatin, cyclophos-
phamide, anthracyclines, antimetabolites, irinotecan, taxanes, tasonermin), anti-angiogenic agents (bevacizumab, axitinib, lenvatinib, paz opanib, sorafenib,
sunitinib), IMiD (thalidomide, lenalidomide), PI (car ﬁlzomib), hormonal therapy, erythropoiesis-stimulating agents.ESC Guidelines 4303Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

and the second consensus document on diagnosis and management
of acute deep vein thrombosis.567
6.6.2. Arterial thromboembolism
Cancer carries a two-fold higher risk of ATE, including MI and ischae-mic stroke.
568ATE risk is higher in men, with advanced age, and in
patients with lung or kidney cancer. Pathologies related to ATE incancer include ischaemic stroke induced by AF or RT-induced ca-
rotid artery disease, embolization by tumour cells or non-bacterial
thrombotic endocarditis, disseminated intravascular coagulation-related peripheral microcirculatory thromboembolism, paradoxical
cerebral embolism in the course of VTE, and cerebral sinus
thrombosis.
5696.6.3. Intracardiac thrombosis
Intracardiac thrombus in patients with malignancies may result fromthe prothrombotic properties of cancer and its treatment and the
use of central venous catheters. Thrombus is the most common in-
tracardiac mass and it can occur within any cardiac chamber. Rightatrial thrombi are often related to a venous catheter where the
line has inappropriately advanced into the right atrium.
Intraventricular thrombi usually occur in the setting of CTRCD.LAA thrombi are most commonly associated with AF, which may
also be related to cancer or its therapy.
Patients with systemic embolization should be screened for car-
diac origin of thrombus initially with TTE and/or transoesophageal
echocardiography.
528CMR is more sensitive and speci ﬁc than TTE
Thrombocytopaenia
GI/GU cancer, GI comorbidities, or GI to xicity
Recent or evolving intracranial lesionsActive bleeding or recent ma jor bleeding
Severe renal dysfunction (eGFR <30 mL/min/1. 73 m
2)Assess Bleeding risk:Patient-related factors
Cancer-related factorsTreatment-related factorsAssess Thromboembolic risk:
Anticancer agents
Supportive therapiesAssess drug-drug Interactions (P-glycoprotein, CYP3A 4):
Assess Patient preferences
T
B
I
PThromboembolic and
bleeding risk reassessment
(Class I)
Very high bleeding riska
Conditions favouring
LMWH over NOACb
NOAC or LMWH 
(Class I)LMWH
(Class I)No anticoagulation
Patient’s preferenceN
NStructured approach to anticoagulation forVTE in patients with cancer
Y
Y
Figure 36 Structured approach to anticoagulation for venous thromboembolism in patients with active cancer. CrCl, creatinine clearance; eGFR, es-
timated glomerular ﬁltration rate; GI, gastrointestinal; GU, genitourinary; LMWH, low-molecular-weight heparins; N, no; NOAC, non-vitamin K antag-
onist oral anticoagulants; VTE, venous thromboembolism; Y, yes.aVery high bleeding risk : active or recent major bleeding ( ,1 month); recent/
evolving intracranial lesions; platelet count ,25 000/µL. According to the International Society on Thrombosis and Haemostasis,529major bleeding is
deﬁned as: fall in haemoglobin level ≥2 g/dL, transfusion of ≥2 units of red blood cells, fatal bleeding, or bleeding in a critical area (intracranial, intraspinal,
intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal).bConditions favouring LMWH :u n o p e r -
ated GI/GU cancer; GI comorbidities or tox icity; severe renal dysfunction (CrCl ,15 mL/min); NOAC major drug –drug interactions, platelet
count,50 000/µL.4304 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

for detecting intracardiac thrombi and late gadolinium enhancement
(LGE) CMR with the long inversion time technique is currently con-
sidered the gold standard.570,571
6.6.4. Anticoagulation therapy
Patients with cancer frequently have both an increased thrombotic risk
and an increased bleeding risk associated with certain cancer locations
(e.g. GI, intracranial), thrombocytopaenia, and other coagulation de-
fects (secondary to bone marrow invasion, cancer therapies, or canceritself) and associated comorbidities (e.g. renal or hepatic dysfunction,
GI toxicities). Several anticancer agents are further characterized by
drug –drug interactions with anticoagulants. All these factors may ren-
der anticoagulation in cancer quite challenging. A proposed approach
to anticoagulation therapy in cancer-associated venous thrombosis,
based on the TBIP acronym (Thromboembolic risk, Bleeding risk,drug –drug Interactions, Patient preferences), is outlined in Figure 36 .
527
6.6.4.1. Treatment and secondary prevention of venous
thromboembolism
Several large RCTs and meta-analyses have shown that LMWH de-
crease the risk of recurrent VTE by 40% compared to VKA, with asimilar risk of major bleeding.
572–576However, VKA are character-
ized by an unpredictable anticoagulation effect and low time in thera-
peutic range in patients with malignancies due to multiple drug –drug
interactions, GI toxicity, malnutrition, and liver dysfunction.577
NOAC have been assessed as potential alternatives to LMWH for
cancer-associated VTE, based on RCTs that compared edoxaban, rivar-oxaban or apixaban to dalteparin.
578–583The totality of evidence de-
rived by these trials and s ubsequent meta-analyses584–586shows that
NOAC are non-inferior to dalteparin in reducing the risk of VTE recur-rence. The risk of major bleeding was similar, although NOAC were as-
sociated with an increased risk of clini cally relevant non-major bleeding,
particularly in patients with luminal GI and GU malignancies.
586As a re-
sult, edoxaban, rivaroxaban, and apixaban are recommended for the
treatment of VTE (DVT and PE) in patients with cancer without any
of the following bleeding risk factors: unoperated GI or GU malignan-cies, history of recent bleeding or within 7 days of major surgery, signi ﬁ-
cant thrombocytopaenia (platelet count ,50 000/µL), severe renal
dysfunction (creatinine clearance (CrCl ,15 mL/min), or GI comorbid-
ities.
582,586In addition, drug –drug interactions between NOAC, cancer
therapies, and other concomitant treatments should be checked.587
There are also concerns about NOAC in patients with GI toxicity
such as vomiting or those having undergone gastrectomy or extensive
intestine resection, as well as those with severely impaired renal func-
tion. Shared decision-making considering informed patient preferencesshould guide the choice of anticoagulation.
Incidentally encountered proximal DVT or PE should be treated in
the same manner as symptomatic VTE as they bear similar rates ofrecurrence and mortality.
588
The minimal duration of anticoagulation is 6 months and extended
anticoagulation is suggested in the presence of active malignancy,metastatic disease, or chemotherapy use. Cohort studies have
shown that extended LMWH therapy beyond 6 and up to 12 months
is safe in cancer-associated VTE.
589,590However, patients with can-
cer are also at high risk of bleeding during anticoagulant treatment
and a periodic assessment of the risk/bene ﬁt ratio should performed.In VTE relapse under anticoagulation, the patient should be investi-
gated for treatment adherence, cancer progression or relapse, while a
different anticoagulation strategy should be endorsed (e.g. replacementof NOAC with LMWH). The management of patients with VTE and a
platelet count ,25 000/µL should be individualized by a MDT.
299
The duration of anticoagulation in patients with catheter-
associated thrombosis depends upon whether the catheter is re-
moved or remains in situ . If removed, then anticoagulation should
continue for a minimum of 3 months and until follow-up cardiac im-aging con ﬁrms resolution of the thrombus. If the catheter remains in
situ, then long-term therapeutic anticoagulation should continue.
6.6.4.2. Primary prevention of venous thromboembolism
Patients undergoing surgery and those who are hospitalized or in
prolonged bed rest require thromboprophylaxis with low-dose an-ticoagulation.
298,299,592–594The ENOXACAN (Enoxaparin andRecommendation Table 34 —Recommendations for
the management of venous thromboembolism in pa-
tients receiving anticancer treatment
Recommendations ClassaLevelb
Apixaban, edoxaban, or rivaroxabancare
recommended for the treatment of symptomatic
or incidental VTE in patients with cancer without
contraindications.d,578–581,584,585IA
LMWH are recommended for the treatment of
symptomatic or incidental VTE in patients withcancer with platelet count .50 000/µL.
298,299,578–
581,584,585IA
In patients with cancer with platelet counts of
25 000 –50 000/µL, anticoagulation with half-dose
LMWH may be considered after amultidisciplinary discussion.
591IIb C
Prolongation of anticoagulation therapy beyond 6
months should be considered in selected patients
with active cancereincluding metastatic
disease.589,590IIa A
Catheter-associated VTE
Duration of anticoagulation in patients with
cancer with a catheter-associated VTE isrecommended for a minimum of 3 months and
continuing longer if the catheter remains in situ .I C
©ESC 2022
CrCl, creatinine clearance; GI, gastrointestinal; GU, genitourinary; LMWH,
low-molecular-weight heparins; ULN, upper limit of normal; VTE, venousthromboembolism.
aClass of recommendation.
bLevel of evidence.
cDrugs are listed in alphabetical order
dHigh risk of GI or GU bleeding, GI absorption concerns, signi ﬁcant drug –drug
interactions, severe renal dysfunction (CrCl ,15 mL/min), signi ﬁcant liver disease
(alanine aminotransferase/aspartate aminotransferase .2×ULN), or signi ﬁcant
thrombocytopaenia (platelet count ,50 000/µL). In addition, patients with primary
brain tumours or brain metastases and acute leukaemia were excluded from the
seminal apixaban trial.580
ePatients receiving cancer treatment, patients diagnosed with cancer in the past 6
months, and patients with progressive or advanced disease.ESC Guidelines 4305Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Cancer) II study showed favourable outcomes with LMWH as pri-
mary thromboprophylaxis for 4 weeks after major abdominal or pel-
vic cancer surgery.595For ambulatory patients, VTE risk should be
individually determined and proposed scores such as the Khorana
or the COMPASS-CAT (prospective COmparison of Methods for
thromboembolic risk assessment with clinical Perceptions andAwareneSS in real-life patients —Cancer Associated Thrombosis)
score may be useful.
596,597Further trials and a meta-analysis have
shown that LMWH signi ﬁcantly reduced the incidence of symptomatic
VTE in ambulatory patients with cancer receiving chemotherapy with
acceptable safety.598–600Two randomized, placebo-controlled,
double-blind clinical trials have assessed the role of NOAC in primary
prevention of VTE in high-risk ambulatory patients receiving systemic
cancer therapy (Khorana score ≥2).601,602Over a follow-up period of
180 days, apixaban (2.5 mg twice a day)601therapy resulted in a signi ﬁ-
cantly lower rate of VTE, although the rate of major bleeding episodes
was higher than with placebo. Rivaroxaban (10 mg once a day)602
treatment resulted in a non-signi ﬁcantly lower incidence of VTE or
death due to VTE with low bleeding risk (no signi ﬁcant differences
with placebo). Further data on the use of NOAC in this setting arewarranted. Consideration of such therapy should be accompanied
by a discussion with the patient about the relative bene ﬁts and harms,
cancer prognosis, drug cost, and duration of prophylaxis.6.7. Bleeding complications
Bleeding complications are more common in patients with cancer
than in patients without cancer. This may be directly related to the
tumour itself, or indirectly related to chemotherapy- orRT-induced weakening of mucosal barriers.
530
6.7.1. High-risk patients
GI and GU cancers are associated with a signi ﬁcant excess bleeding
risk compared with other solid tumours.603Thrombocytopaenia
and platelet dysfunction due to haematological malignancies or
bone marrow suppression can exacerbate bleeding. Other bleed-
ing risk factors include advanci ng age, renal or hepatic impair-
ment, metastatic disease, low body mass index, and treatment
with ibrutinib, VEGFi, cetuximab, or bevacizumab.578,603 –605
Gastric protection with routine proton pump inhibitor use
should be considered in all patients with cancer on DAPT606,607
or anticoagulation.530
6.7.2. Antiplatelet therapy
Antiplatelet therapy, in particular DAPT, increases the risk of bleed-
ing in patients with cancer.477Following ACS and/or PCI, the risk of
bleeding is approximately 1.6-fold greater in patients with cancer
than in those without.477,605The risk is greatest in those diagnosed
with cancer in the preceding year, whereas more remote cancers
carry lower excess risk.477The PRECISE-DAPT (PREdicting bleeding
Complications In patients undergoing Stent implantation andsubsEquent Dual Anti Platelet Therapy) score appears not to per-
form well for predicting bleeding in patients with cancer.
477In order
to reduce bleeding risk, the duration and intensity of DAPT should beminimized
477,607and triple therapy avoided whenever possible. At
the same time, DAPT —if indicated —should not be withheld without
good reason. A recent expert consensus statement suggests reducedplatelet count thresholds for CV therapies, recommending aspirin
initiation for platelet counts .10 000/µL and DAPT initiation (with
aspirin and clopidogrel) for platelet counts .30 000/µL.
608In pa-
tients with platelet counts ,50 000/µL, clopidogrel is preferred
over prasugrel or ticagrelor, and glycoprotein IIb/IIIa inhibitors
should be avoided.608To reduce peri-procedural bleeding, PCI
should preferably be undertaken via the radial approach484and
prophylactic platelet transfusion may be considered for patients
with platelet count ,20 000/µL.609
6.7.3. Management of bleeding
Basic principles of bleeding management should be followed with
control of the bleeding source whenever possible. Platelet transfu-
sions for signi ﬁcant thrombocytopaenia and withholding and reversal
of anticoagulation for life-threatening bleeding may be needed as in
the general population.530,610Antiﬁbrinolytic agents, such as tranex-
amic acid or e-aminocaproic acid, can be considered. Non-speci ﬁc
support of haemostasis using coagulation factor concentrates and
speci ﬁc reversal agents may be needed for patients on a NOAC
with life-threatening bleeding.530Recombinant activated factor VII
or activated prothrombin complex concentrates should be avoided
in patients with recent thrombosis.Recommendation Table 35 —Recommendations for
venous thromboembolism prophylaxis during antican-
cer treatment
Recommendation ClassaLevelb
Extended prophylaxis with LMWH for 4 weeks
post-operatively is recommended for patients
with cancer undergoing major open orlaparoscopic abdominal or pelvic surgery with low
bleeding risk and high VTE risk.
c,298,299,595IB
Prophylactic LMWH for the primary prevention
of VTE is indicated in hospitalized patients with
cancer or those with prolonged bedrest orreduced mobility in the absence of bleeding or
other contraindications.
298,299,592,594IB
For ambulatory patients with cancer at high risk of
thrombosis receiving systemic therapy,dprimary
thromboprophylaxis with a NOAC (apixaban orrivaroxaban) or LMWH may be considered,
provided there are no signi ﬁcant
contraindications.
e,298,593,594,601,602IIb B
A discussion with the patient about the relative
bene ﬁts and harms, cancer prognosis, drug cost,
and duration of treatment is recommended prior
to prophylactic anticoagulation for the primary
prevention of VTE.I C
©ESC 2022
LMWH, low-molecular-weight heparins; NOAC, non-vitamin K antagonist oral
anticoagulants; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.
cReduced mobility, obesity, VTE history.
dLocally advanced or metastatic pancreas or lung cancer or Khorana score ≥2.
eRisk factors for bleeding, signi ﬁcant drug –drug interactions, or severe renal dysfunction.4306 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

6.8. Peripheral artery disease
There is growing evidence that cancer therapy affects the vascula-
ture. A recent meta-analysis showed a signi ﬁcantly increased arterial
stiffness after anthracycline and non-anthracycline treatment.611
Paraneoplastic acral vascular syndrome was described after initiation
of nivolumab, with ﬁrst symptoms 3 weeks after initiation of ther-
apy.612Raynaud phenomenon has been associated with the use of
bleomycin, cyclophosphamide, platinum compounds, vinca alkaloids,
and ﬂuoropyrimidines.491Usual treatment of Raynaud ’s includes
non-pharmacological measures to help prevent an episode (avoid-ance of provoking factors such as cold temperature, vasoconstricting
drugs) and a long-acting dihydropyridine CCB (amlodipine,
modi ﬁed-release nifedipine).
Treatment with nilotinib or ponatinib may be associated with an
increased risk of vascular adverse events, including arterial stiffness
and PAD development.
494In a subgroup of patients, these events
are severe or even life-threatening.613Although the exact mechan-
isms remain unknown, we recommend screening for pre-existing
PAD and for vascular risk factors such as DM in all patients beforeand during nilotinib or ponatinib therapy. Pooled data from three
clinical trials showed arterial occlusive disease to be related to
dose intensity in ponatinib-treated patients,
614but PAD was not ad-
dressed separately. If rapidly progressive PAD occurs with second-
generation TKI, it may be advisable to switch to an alternative lower-
risk TKI (e.g. imatinib). Platelet aggregation inhibitors or anticoagula-tion and statins should be considered. Despite lack of evidence, all
risk factors should be corrected.
615
6.9. Pulmonary hypertension
Allﬁve groups of the PH classi ﬁcation can be observed in patients
with cancer. Several cancer drugs can cause group 1 PH (pulmonary
arterial hypertension [PAH]), including car ﬁlzomib, bosutinib, dasati-
nib,616ponatinib, interferon alpha, and alkylating agents (e.g. mitomy-
cin C and cyclophosphamide, which mostly cause pulmonary
veno-occlusive disease).617PH associated with left heart disease
(group 2) is related to drugs causing HF (e.g. anthracyclines). PH as-sociated with lung disease (group 3) is related to drugs and therapies
causing pulmonary ﬁbrosis (e.g. bleomycin, thoracic radiation). The
most common pulmonary vascular disease complicating cancer isVTE, which can cause chronic thromboembolic PH (group 4). Of
note, central venous catheters are important causes of group 4 PHcomplicating cancer management. Other group 4 PH due to pulmon-
ary artery obstructions includes angiosarcoma and other malignant
tumours (e.g. renal carcinoma, uterine carcinoma, germ cell tumoursof the testis).
618
PH with unclear and/or multifactorial mechanisms (group 5) in-
cludes several conditions that may be complicated by complex andsometimes overlapping pulmonary vascular involvement. Tumoral
PH includes pulmonary tumour micro-embolism and pulmonary tu-
mour thrombotic microangiopathy.
619Multiple causes of PH have
been described in patients with chronic myeloproliferative disorders.
In chronic myelogenous leukaemia, spleen enlargement and anaemia
can give rise to hyperkinetic syndrome. In polycythaemia vera and es-
sential thrombocythemia, there is an increased risk of VTE and
chronic thromboembolic PH. Moreover, formation of a blood clotwithin the hepatic veins can lead to Budd –Chiari syndrome and sub-
sequent porto-PH. Pulmonary extramedullary haematopoiesis com-
plicating idiopathic or secondary myelo ﬁbrosis may also contribute
to dyspnoea and PH.
620
Symptoms of PH are non-speci ﬁc, such as shortness of breath and
fatigue. In later stages, symptoms of right-sided HF may develop. AnECG should be performed and examined for RV hypertrophy, but a
normal ECG does not exclude PH. Echocardiography is the ﬁrst
choice for assessing PH probability in patients who develop symp-toms and/or signs suggestive of PH during cancer treatment.
When peak tricuspid regurgitation velocity (TRV) is ≤2.8 m/s
(equating to an estimated systolic PAP [sPAP] of ≤35 mmHg)
and no other signs of PH are present, then the probability of PH
is low. In the absence of a tricuspid regurgitant jet, other echocar-
diography signs may increase suspicion of PH (e.g. RV/LV basaldiameter ratio .1, RV out ﬂow tract acceleration time ,105 ms,
inferior vena cava diameter .21 mm with decreased inspiratory col-
lapse).
620Baseline TTE should be considered in patients receiving
cancer drugs that can cause PH; ho wever, a right-heart catheter-
ization is required for de ﬁnitive diagnosis of PH and to support
PAH treatment decisions. In the DASISION (DASatinib vs. ImatinibStudy In treatment-Naïve chronic myeloid leukemia patients) trial,
5% of patients randomized to da satinib were diagnosed with
PH, compared with 0.4% of those randomized to imatinib.
621In
patients who develop PH, dasatin ib treatment should be inter-
rupted and an alternative TKI should be used.616
Overall management of PH in oncology patients should be based
on the 2022 ESC/European Respiratory Society (ERS) Guidelines for
the diagnosis and treatment of pulmonary hypertension.620Referral
to a PH centre is recommended for multidisciplinary managementwith the oncology team. In patients with CML treated with drugs
causing PH-induced PAH, discontinuation of the potential culprit
therapy is recommended if there is a high probability of new PH(peak TRV .3.4 m/s, equating to an estimated sPAP of
≥50 mmHg) until the diagnosis is con ﬁrmed or ruled out by a right-
heart catheterization. In CML patients on dasatinib, an alternativeBCR-ABL TKI is recommended if they develop symptomatic PAH
or an asymptomatic increase in peak TRV .3.4 m/s. Dasatinib
dose reduction and close monitoring of peak TRV with TTE every4 weeks should be considered in CML patients who develop new
asymptomatic peak TRV ranging from 2.9 to 3.4 m/s.
620If peak
TRV remains normal or mildly elevated on serial monitoring, then da-satinib can continue, with reduced TTE monitoring to every 3Recommendation Table 36 —Recommendation for
management of peripheral artery disease during antic-
ancer treatment
Recommendation ClassaLevelb
In patients who develop new symptomatic PAD, a
multidisciplinary approach regarding the decision
to continue vs. interrupt culprit cancer therapycis
recommended.I C
©ESC 2022
PAD, peripheral artery disease; VEGFi, vascular endothelial growth factor inhibitors.
aClass of recommendation.
bLevel of evidence.
cVEGFi, nilotinib, ponatinib, platins, etc.ESC Guidelines 4307Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

months. If peak TRV continues to rise, then right-heart catheteriza-
tion should be performed, dasatinib treatment should be stopped,
and PAH drugs should be considered if PAH is con ﬁrmed.
6.10. Pericardial diseases
Pericarditis and pericardial effusion can be related to a wide range of
cancer treatments including chest radiation, cytotoxic therapies (an-
thracyclines, bleomycin, cyclophosphamide, cytarabine), targeted
therapies (all- trans retinoic acid, arsenic trioxide, dasatinib), and
immune-based therapies (interleukin-2, interferon- αICI). A combin-
ation of therapies may have a synergistic effect on the pericardium.
These therapy-induced complications must be differentiated fromprogressive cancer (local invasion, metastatic involvement, or medias-
tinal lymphatic drainage obstruction) and non-cancer-related causes
such as infection, especially in immune-compromised patients.
622A
careful history and clinical examination are of help to determine the
cause. TTE plays a central role in diagnosis and management. CT
and CMR can provide additional information on pericardial in ﬂamma-
tion and constrictive physiology. The principles for the diagnosis and
management should follow the 2015 ESC Guidelines for the diagnosis
and management of pericardial diseases,444but there are some speci ﬁc
issues to consider in patients with cancer.482
6.10.1. Pericarditis
The diagnosis of pericarditis in patients with cancer follows the same
principles as in those without, but symptoms can be atypical.444
Acute pericarditis caused by radiation has become rare due to lower
doses and improved radiation techniques. It occurs within days to
weeks after treatment and is usually self-limiting, but can evolve to-
wards constrictive pericarditis many years later ( Section 8.6 ).
Pericarditis caused by conventional cancer therapies often resolveswith standard therapy or after discontinuation of the treatment.444
Cancer treatment interruption should be discussed with the
cardio-oncology team. Treatment with anti-in ﬂammatory drugs
(e.g. ibuprofen) and colchicine, in the absence of contraindications,
is recommended as it reduces the rate of recurrence requiring re-
peat intervention.623Low-to-moderate doses of steroids are only in-
dicated for resistant cases except ICI-related pericarditis.444
ICI-associated pericarditis has a median time of onset of 30 days in
retrospective surveillance studies and is associated with a poor prog-nosis, especially in case of concomitant myocarditis.
444,624
In patients with severe ICI-associated pericarditis with moderate or
severe effusion, ICI discontinuation and high-dose steroids (methylpred-
nisolone 1 mg/kg/day) with or without colchicine are recommended, as
well as pericardiocentesis in case of cardiac tamponade.624,625In case of
refractory pericarditis, immunosupp ressive drugs should be considered.
For uncomplicated ICI-related pericarditis, the ICI might be continued
and colchicine or non-steroidal anti-in ﬂammatory drugs could be con-
sidered.326,444For patients requiring ICI discontinuation, restarting ICI
can be considered in a MDT discussion after resolution of pericardial
disease and under close monitoring.
6.10.2. Pericardial effusion
Pericardial effusions are often observed as an incidental ﬁnding in pa-
tients with cancer. Cancer therapy is the cause of a pericardial effu-
sion in,30% of cases, although this may increase with the expanding
use of ICI in cancer. Malignancy-related pericardial effusions caused
by direct (lung, oesophageal, breast) or metastatic invasion (haem-
atological malignancies, ovarian, melanoma) or by lymph node ob-struction are generally associated with poor prognosis.
Clinical presentation depends on the size of the effusion and the
speed of its growth.
444Malignancy-related pericardial effusions
make up .30% of patients presenting with cardiac tamponade626
and usually develop slowly, resulting in larger pericardial effusions
at the time of diagnosis compared with non-malignant pericardial ef-fusions. Management consists of determination of the cause and
evaluation of the haemodynamic impact. Small-to-medium-sized ef-
fusions ( .4 and,20 mm) can be monitored with a reassessment
7–14 days after initial diagnosis and at further 4 –6-weekly inter-
vals.
444,627In unstable patients with signs of tamponade, immediate
echocardiographic-guided percutaneous pericardiocentesis is pre-ferred over surgical pericardiotomy to minimize potential complica-
tions.
628In patients with cardiac tamponade due to malignant
pericardial effusions, colchicine may be useful to improve clinical out-comes and reduce the rate of repeat intervention.
623Drainage of a
pericardial effusion related to ICI is rarely required629and corticos-
teroids should be considered.630Intrapericardial instillation of
cytostatic/sclerosing agents, colchicine,623and radiation for
radiation-sensitive tumours can reduce recurrence after drainage.
The creation of a pleuropericardial or pleuroperitoneal windowwith balloon pericardiotomy or surgery should be considered in
case of recurrent malignant pericardial effusions after emergency
pericardiocentesis.
444
A surgical pericardial window should be considered if the percu-
taneous approach is not feasible and in stable patients with large
(≥20 mm) or rapidly expanding malignant pericardial effusions prior
to the development of cardiac tamponade.Recommendation Table 37 —Recommendations for
the management of pulmonary hypertension during
anticancer treatment
Recommendations ClassaLevelb
Right-heart catheterization and discontinuation of
dasatinib is recommended in patients whodevelop symptomatic or asymptomatic increase in
peak TRV .3.4 m/s.IC
Dasatinib dose reduction and close monitoring of
peak TRV with echocardiography should be
considered in patients who develop newasymptomatic peak TRV ranging from 2.9 to
3.4 m/s.IIa C
In patients with con ﬁrmed dasatinib-induced
PAH
cor new asymptomatic peak TRV .3.4 m/s,
an alternative BCR-ABL inhibitor is recommendedafter peak TRV recovery to ,2.8 m/s.I C
©ESC 2022
BCL-ABL, breakpoint cluster region –Abelson oncogene locus; PAH, pulmonary arterial
hypertension; TRV, tricuspid regurgitation velocity.
aClass of recommendation.
bLevel of evidence.
cDeﬁnite diagnosis of PAH requires a right-heart catheterization.4308 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

7. End-of-cancer therapy
cardiovascular risk assessment
7.1. Cardiovascular evaluation during the
ﬁrst year after cardiotoxic anticancer
therapy
End-of-cancer therapy CV risk assessment covers the ﬁrst 12
months after the last cardiotoxic cancer treatment. These recom-mendations are where cardiotoxic cancer therapy has been success-
fully completed with good long-term prognosis. These
recommendations are not indicated when cancer therapies are dis-continued due to cancer progression and prognosis is poor, or
where end-of-life care is indicated. Selected patients with cancercontinue on long-term oncology therapies, e.g. women with oestro-
gen receptor-positive early invasive BC. In this example, the
end-of-therapy risk assessment refers to the timepoint from thelast anthracycline or trastuzumab dose.
High-risk patients can be identi ﬁed at completion of their cardio-
toxic cancer therapies by their clinical characteristics, history ofCTR-CVT during treatment, and by elevated cardiac biomarkers
and/or abnormal CV imaging at follow up.
53,54,92Cardiac serum bio-
markers (NP and cTn) are useful given their high negative predictivevalue for future CV events.
197,631In a prospective study of 2625 adult
patients with cancer that assessed LVEF after anthracycline-based
chemotherapy, the overall incidence of CTRCD was 9%; 98% of
cases could be detected within 12 months after chemotherapy and
the median time from chemotherapy to CTRCD detection was3.5 months (interquartile range 3 –6 months).
208The response to
ACE-I treatment declined when the interval between the end of
chemotherapy and CTRCD detection lengthened; complete LVEFrecovery was not observed in patients where treatment was delayed
by.6 months.
425
Measurement of cTn after completion of anthracycline chemo-
therapy during the end-of-treatment assessment should be consid-
ered. Rises in cTnI after anthracycline chemotherapy identify
patients at risk of future cardiac dysfunction who then bene ﬁt
from CV protection.4Educating patients with cancer of their poten-
tial increased CVD risk and supporting them to make appropriate
healthy lifestyle choices is recommended. CS should also be advisedto promptly report early signs and symptoms of possible CVD and
inform medical teams of their previous cardiotoxic cancer therapies.
CVRF including hypertension, DM, and dyslipidaemia correlate withthe probability of future CV events in CS and should be well con-
trolled after completion of cancer therapy.
31,632,633
7.2. Which cancer survivors require
cardiovascular surveillance in the ﬁrst
year after cancer treatment?
The end-of-treatment risk assessment ideally identi ﬁes those high-risk
CS, who require long-term CV surveillance, based on the following
criteria ( Table 10 ):
(1) Baseline high or very high risk based on HFA-ICOS risk assess-
ment tools12(Section 4 ).
(2) Cardiotoxic cancer therapy with a high risk of long-term CV
complications7,21(Section 8 ).
(3) Moderate or severe CTR-CVT diagnosed during cancer treat-
ment ( Table 3 ).68
(4) New abnormalities in cardiac function detected by echocardiog-
raphy, new elevated cardiac serum biomarkers, or newly CV
symptoms detected at the end-of-therapy assessment (3 or 12
months after treatment).68,208
The timing of the ﬁrst CV assessment after cardiotoxic cancer
treatment depends on the risk de ﬁned by baseline CV assessment,
the type of cancer therapy, and whether CTR-CVT was diagnosed
during treatment.
In asymptomatic high-risk patients ( Table 10 ), echocardiography
and cardiac serum biomarkers are recommended at 3 and 12 months
after completion of cancer therapy.53,54,59,61,68,148,208,425InRecommendation Table 38 —Recommendations for
the management of pericardial diseases in patients re-
ceiving anticancer treatment
Recommendations ClassaLevelb
General
Diagnosis and management of acute pericarditis in
patients with cancer based on the 2015 ESC
Guidelines for the diagnosis and management ofpericardial diseases is recommended and a
multidisciplinary discussion is needed before
interrupting cancer therapy.
444IC
A surgical pericardial window should be
considered if the percutaneous approach is notfeasible or in cases of recurrent malignant
pericardial effusions.IIa C
Intrapericardial instillation of cytostatic or
sclerosing agents may be considered for
prevention of recurrence.IIb C
Diagnosis and management of ICI-associated pericarditis
Multimodality CV imaging (echocardiography,
CMR+CT), ECG and measurement of cardiac
biomarkers are recommended to con ﬁrm the
diagnosis, assess the haemodynamic
consequences of pericardial disease, and rule out
associated myocarditis.IC
Prednisolone and colchicine are recommended
for patients with ICI-associated
pericarditis.
326,624,625,630IC
Interruption of ICI treatment in patients with
conﬁrmed ICI-associated pericarditis with
moderate-to-severe pericardial effusion isrecommended.IC
A multidisciplinary discussion is recommended
before restarting ICI treatment.I C
©ESC 2022
CMR, cardiac magnetic resonance; CT, computed tomography; CV, cardiovascular;
ECG, electrocardiogram; ESC, European Society of Cardiology; ICI, immune
checkpoint inhibitors.
aClass of recommendation.
bLevel of evidence.ESC Guidelines 4309Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

asymptomatic moderate-risk patients (according to CV toxicity
baseline risk strati ﬁcation), echocardiography and cardiac serum bio-
markers should be considered within 12 months after completion of
cancer therapy.53,54,59,61,68,148,208In asymptomatic low-risk patients
(according to CV toxicity baseline risk strati ﬁcation), echocardiog-
raphy and cardiac serum biomarkers may be considered within 12
months after completion of cancer therapy.634
All patients started on CV therapies (ACE-I/ARB/angiotensin
receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid re-
ceptor antagonists, sodium-glucose co-transporter 2 inhibitors, anti-hypertensive medications, antiarrhythmic medications, antiplatelet
therapies, statins) for any CTR-CVT (especially CTRCD) should
have a clinical assessment, ECG, echocardiography, and cardiac ser-um biomarkers (if LV systolic dysfunction/HF is a potential risk) at 3,
6, and 12 months after completing cancer treatment. A MDT-based
approach to palliative and end-of-life care for patients with cancerwith HF or other CTR-CVT should be focused on symptom relief
according to general ESC Guidelines.7.3. Management of cancer
therapy-related cardiac dysfunction at
the end-of-therapy assessment
During this end-of-treatment assessment, a review of cardioprotec-
tive medications initiated during cancer therapy to treat CTRCD is
recommended ( Figure 37 ). In selected patients with asymptomatic
mild or moderate CTRCD who have fully recovered with normalTTE and cardiac serum biomarkers, a trial of weaning off CV
medication should be considered after MDT discussion. This is
most common after asymptomatic mild or moderate CTRCD sec-ondary to trastuzumab, particularly in younger otherwise healthy
HER2+BC survivors with no exposure to anthracycline chemother-
apy. Further assessment of cardiac function with TTE and cardiacserum biomarkers is recommended following withdrawal of CV
medication in patients with previous CTRCD to ensure cardiac func-
tion remains normal.
Continuing long-term CV medication is generally recommended
in patients with moderate and severe symptomatic or severe asymp-
tomatic CTRCD due to the high rate of recurrent HF. Long-termtreatment is also recommended in CS with mild or moderate
CTRCD who fail to recover normal LV function at their
end-of-therapy assessment ( Figure 37 ).
7.4. Cardiopulmonary exercise testing
andﬁtness during the end-of-therapy
assessment
CRF impairment is a strong predictor of patient outcome following
cancer treatment and an intervention target in CS. Low CRF is asso-
ciated with poor quality of life, increased morbidity, reduced exercisecardiac function and worse CVD risk pro ﬁle, and is a robust inde-
pendent predictor of all-cause, cancer-related, and CVD-related
mortality in CS.
119,120Recent evidence suggests the risk of
CVD-related mortality in CS decreases by 14% per 1 metabolic
equivalent (3.5 mL O 2/kg/min) increase in CRF.120
CPET may be considered for CS with exertional limitation, who
may have substantial bene ﬁt from cardiac rehabilitation. Eligible pa-
tients include those treated with higher doses of anthracycline
chemotherapy and/or RT to a volume including the heart, high CVtoxicity risk at baseline, patients who developed CTRCD during can-
cer therapy, and those identi ﬁed with new abnormalities in LV func-
tion at their end-of-therapy assessment.
11CPET can be an objective
tool in the diagnosis of decreased physical capacity and identify CV vs.
non-CV causes.635
7.5. The role of cardiac rehabilitation
Exercise is a potent multitarg eted therapy that prevents and
treats multiple competing mechanisms of CTR-CVT in CS, includ-ing CRF impairment,
636CV injury, and pre-existing and new
CVRF.137Prescribing exercise facilitates the delivery of therapeut-
ic exercise that is individualized to a person ’sﬁtness level and sys-
tematically progressed to optimize physiological adaptation.637
Current evidence demonstrates that supervised exercise therapy(including high-intensity interval training [HIIT]) is safe and welltolerated,
638attenuates CTR-CVT risk, and improves CRF.
Furthermore, HIIT reduces CVRF460and CV risk639in patientsTable 10 Risk factors for future cardiovascular dis-
ease at the end-of-cancer therapy cardiovascular risk
assessment
High-risk conditions
High- and very-high baseline CV toxicity risk based on HFA-ICOS
assessment
Speci ﬁc anticancer treatment proven to have a high risk of long-term CV
complicationsa
Doxorubicinb≥250 mg/m2
RT.15 Gy MHDc
Both doxorubicinb≥100 mg/m2and RT 5 –15 Gy MHDd
High-risk HSCT patientse
Moderate or severe CTR-CVT during cancer treatment (especially
CTRCD), ICI-related myocarditis, cardiac arrhythmias, or severe vascular
toxicities (ACS, stroke, PVD)
New CV symptoms or new asymptomatic abnormalities in
echocardiography and/or cardiac serum biomarkers at the end of therapy
assessment
©ESC 2022
ACS, acute coronary syndromes; CTRCD, cancer therapy-related cardiac dysfunction;
CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD,
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host
disease; Gy, Gray; HFA, Heart Failure Association; HSCT, haematopoietic stem celltransplantation; ICI, immune checkpoint inhibitors; ICOS, InternationalCardio-Oncology Society; MHD, mean heart dose; PVD, peripheral vascular disease;
RT, radiotherapy.
aRT risk categorization based on MHD is recommended over categorization based on
prescribed dose, which may not accurately re ﬂect cardiac radiation exposure.
Depending on dose distribution and exposure of speci ﬁc cardiac substructures (as
well as clinical risk factors), the treatment team may judge the patient to belong to a
higher risk category. In addition, a patient may be judged to belong to a lower riskcategory if only a small part of the heart is exposed to a relatively high prescribeddose (i.e. RT to left breast or left chest wall only).
bOr doxorubicin equivalent.
cOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available.
dOr prescribed RT 15 –34 Gy to a volume exposing the heart if MHD is not available.
eHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled
CVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating
agents, .250 mg/m2doxorubicin or equivalent); conditioning schemes (total body
irradiation, alkylating agents); development of GVHD.4310 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

with cancer in the pre-, active-, and post-treatment settings.
HIIT-related bene ﬁts on CRF, physical activity behaviour, fatigue,
and quality of life persist months post-intervention.640,641HIITmay not be feasible in elderly and frail patients.642Dedicated
cardio-oncology rehabilitation programmes are currently underdevelopment.
11
CTRCD
Mild or moderate
Pa
r
tial or non e
a
Full
b
High risk
d
k
k
 L
o
w risk
e
k
k
MDT to conside r
w
eaning HF ther
 a
p
y
p
p
c
Rec
o
v
e
r
y
Patient risk
S
e
v
e
r
e and
v
e
r
y s
e
v
e
r
e
N
Patients who d
e
v
elop CTRCD durin g cancer t
 r
eatment and a
r
e bein g sta
r
ted on HF ther
a
p
y
p
p
Y
Conti
n
ue HF the r
a
p
y
p
p
(Class I )
Conti
n
ue
HF ther
a
p
y
p
p
(Class I )
Consider 
 w
eaning
HF ther
a
p
y
p
p
(Class IIa )
Figure 37 Management of cancer therapy-related cardiac dysfunction after cancer therapy. CTRCD, cancer therapy-related cardiac dysfunction; CV,
cardiovascular; GLS, global longitudinal strain; HF, heart failure; HFA, Heart Failure Association; ICOS, International Cardio-Oncology Societ y; LV, left
ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; N, no; Y, yes.aPartial or no recovery : patients who do not
meet all of the criteria for full recovery.bFull recovery : no signs or symptoms of HF +LVEF.50%+GLS within normal range or similar to baseline
measurements +cardiac serum biomarkers within the normal range or similar to baseline measurementscTheCTRCD trajectory of each patient is
unique and dynamic and withdrawal of HF therapy requires a MDT to consider several key points that help to stratify patients into low- or high-riskcategories. Key points to consider during a MDT discussion are : HFA-ICOS baseline CV toxicity risk assessment, pre-existing indications for
CV medication, class of cancer treatment causing CTRCD (generally reversible vs. generally irreversible), magnitude and duration of CTRCD before r e-
covery, intensity of HF therapy needed to recover LV function, family history of cardiomyopathy or known cardiomyopathy gene carrier (see Section 4.8 ).
dSeeTable 10 .eLow-risk patient characteristics : low to moderate baseline CV toxicity risk (HFA-ICOS risk assessment), no pre-existing indications
for CV medication, cancer treatment generally associated with reversible myocardial damage, asymptomatic mild CTRCD, early cardiac function reco very
(3–6 months) under HF therapy, no family history of cardiomyopathy.ESC Guidelines 4311Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

8. Long-term follow-up and
chronic cardiovascularcomplications in cancer survivors
8.1. Cancer survivors
8.1.1. Adult survivors of childhood and adolescent
cancer
The survival of children and adolescents with cancer has increased
considerably in recent decades, with 5-year survival rates currentlyexceeding 80%.
647However, the long-term health effects in the
growing population of childhood and adolescent CS are a major con-
cern.648CTR-CVT, as a consequence of treatment with anthracy-
clines, mitoxantrone, and/or chest-directed RT can manifest as
CTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunc-
tion, pericardial disease, and premature CV mortality, dependingon the type of cardiotoxic treatment.
643,649
CTRCD is one of the most frequent late effects in childhood CS
who received cardiotoxic cancer treatment and contributes to sig-niﬁcant morbidity and non-cancer-related mortality later in life.
650
The cumulative incidence of CTRCD varies depending on the diag-
nostic criteria applied and the population studied and ranges from4.8% to 10.6% at 40 –45 years of age.
651RT to a ﬁeld involving the
heart increases the risk of CTRCD and valvular and vascular
complications.652
Follow-up of paediatric CS according to the International Late
Effects of Childhood Cancer Guideline Harmonization Group is re-
commended.653This includes risk strati ﬁcation based upon the total
cumulative dose of anthracycline chemotherapy and MHD delivered
(Table 11 ). Annual review of CVRF and education to promote a
healthy lifestyle is recommended. The frequency of CV reviewwith TTE depends upon risk. A CV review should be considered
every 5 years for moderate-risk childhood and adolescent adult CS
and every 2 years for high-risk childhood and adolescent adult CS.A recent retrospective analysis has shown that quanti ﬁcation of
LVEF.5 years after cancer diagnosis improves long-term childhoodRecommendation Table 39 —Recommendations for
end-of-cancer therapy cardiovascular risk assessment
Recommendations ClassaLevelb
Educating and supporting patients with cancer to
make appropriate healthy lifestyle choices is
recommended.cIC
Education is recommended for patients with
cancer regarding recognition for early signs and
symptoms of CVD.IC
CVRF assessment is recommended during the
ﬁrst year after cancer therapyc,12,22,31,632,643and
thereafter according to the 2021 ESC Guidelines
on CVD prevention in clinical practice.19IB
In asymptomatic high-risk patients,d
echocardiography and cardiac serum biomarkers
are recommended at 3 and 12 months aftercompletion of cancer
therapy.
53,54,59,61,68,148,208,425IB
In asymptomatic moderate-risk patients,e
echocardiography and cardiac serum biomarkers
should be considered within 12 months aftercompletion of cancer therapy.
53,54,59,61,68,148,208IIa B
In asymptomatic low-risk patients,e
echocardiography and cardiac serum biomarkers
may be considered within 12 months after
completion of cancer therapy.634IIb C
Cardiology referralfis recommended in patients
with cancer with new cardiac symptoms or newasymptomatic abnormalities in echocardiography
and/or cardiac serum biomarkers at the end of
therapy assessment.
11IC
In selected patients with exercise intolerance
persisting at 12 months after cancer treatmentand with normal resting echocardiogram and
cardiac biomarkers, exercise stress
echocardiography and/or CPET may beconsidered.IIb C
Targeted cardiac rehabilitation should be
considered in CS with high CV risk.
638–640IIa B
Long-term continuation of cardiac medication is
recommended in patients who develop severe
CTRCD during cancer therapy.IC
CV follow-up and treatment optimization is
recommended in patients who developedTKI-mediated hypertension during cancer
therapy.
644,645IC
CV follow-up and treatment optimization is
recommended in patients who developed vascular
toxicities during cancer therapy.10,237IC
ContinuedECG follow-up is recommended in patients who
developed QT lengthening or LQTS during cancer
therapy.646I C
©ESC 2022
CPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer
therapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease;
CVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;
ESC, European Society of Cardiology; LQTS, long QT syndrome; TKI, tyrosine kinaseinhibitors.
aClass of recommendation.
bLevel of evidence.
cIncluding regulation of hypertension, DM, dyslipidaemia, smoking cessation, weight loss
in case of obesity, and an adequate amount of exercise.
dHigh-risk patients: see Table 10 .
eModerate- or low-risk patients: according to CV toxicity baseline risk strati ﬁcation.
fCardio-oncology referral is recommended when available; alternatively, the patient
should be referred to a cardiologist with expertise in managing CVD in patients withcancer.4312 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CS risk strati ﬁcation. A LVEF of 40 –49% is associated with an almost
eight-fold increased risk for LVEF ,40% at 10-year follow-up com-
pared with patients with a preserved LVEF ( ≥50%).654Lifelong sur-
veillance for high-risk survivors is recommended.78.1.2. Adult cancer survivors
Long-term cancer survivorship care is an advancing ﬁeld of research.
Many survivors will experience several cancer- and treatment-relatedlate effects throughout their lives, including CTR-CVT. Besides affect-
ing their physical and psychosocial health status, these might reduce
life expectancy and quality of life. This is relevant in some cancer types,when CVD risk —especially CTRCD risk —exceeds cancer mortal-
ity.
658,659The risk of fatal heart disease is increased more than two-
fold in survivors of several solid cancers and lymphoma comparedwith the general population.
660–662
CV risk assessment at the end of therapy ( Section 7 ) identi ﬁes CS
who require long-term cardiology follow-up beyond the ﬁrst 12
months after completing their cancer treatment. Asymptomatic
CS with new or persisting abnormalities at their end-of-therapy as-
sessment will be identi ﬁed as at high risk for future CV events and
require long-term surveillance.
Speci ﬁc cancer treatments carry the highest risk of long-term CV
toxicity including anthracycline chemotherapy and RT where theheart is within the RT treatment volume. Progressive RT-related
CV toxicity typically develops 5 –10 years after the initial treatment,
and may cause CAD and HF at an incidence up to six-fold higher thanin the general population. An increased CV mortality compared with
the general population has been attributed to radiation-associated
heart disease in Hodgkin lymphoma, non-Hodgkin lymphoma, BC,and patients with lung cancer.
663–665The incidence and progression
of the radiation-related CV complications depends on the dose to
the CV tissue and on concomitant cancer therapies and patient char-acteristics, such as pre-existing CVD, CVRF, and age.
389,400
Late CV complications are also observed in CS who required HSCT.
The incidence of HF increases up to 14.5% in women 15 years afterHSCT. Risk factors for CVD following HSCT include age, anthracycline
dose, chest radiation exposure, hypertension, DM, and smoking.
666
Long-term follow-up surveillance, based on CV toxicity risks
(Table 12 ), includes patient education and CVRF optimization. An an-
nual clinical CV risk assessment is recommended for all adult CS to
optimize CVRF control, promote a healthy lifestyle, and symptom re-view. This can be done in collaboration with primary care or aTable 11 Risk categories for asymptomatic adults who are childhood and adolescent cancer survivors
Risk category RT dosea(Gy MHD) Total cumulative doxorubicinb
dose (mg/m2)Combination therapy
RT dosea(Gy MHD) Total cumulative doxorubicinb
dose (mg/m2)
Very high risk .25c≥400 .15c≥100
High risk .15 to 25c250–399 5 –15d≥100
Moderate risk 5 –15d100–249 ,5e≥100
Low risk ,5e,100–
©ESC 2022
Gy, Gray; MHD, mean heart dose; RT, radiotherapy.
aRT risk categorization based on MHD is recommended over categorization based on prescribed dose, which may not accurately re ﬂect cardiac radiation exposure. Depending on dose
distribution and exposure of speci ﬁc cardiac substructures (as well as clinical risk factors), the treatment team may judge the patient to belong to a higher risk category. In addition, a
patient may be judged to belong to a lower risk category if only a small part of the heart is exposed to a relatively high prescribed dose.
bOr doxorubicin equivalent.
cOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note that in this case, the limited information about cardiac exposure does not allow one to d istinguish
between high- and very high-risk categories.
dOr prescribed RT 15 –34 Gy to a volume exposing the heart if MHD is not available.
eOr prescribed RT ,15 Gy to a volume exposing the heart if MHD is not available.
Recommendation Table 40 —Recommendations for
cardiovascular surveillance in asymptomatic adults
who are childhood and adolescent cancer survivors
Recommendations ClassaLevelb
Education of adults who are childhood and
adolescent CS treated with anthracyclines,
mitoxantrone, and/or RT to a volume includingthe heart and their healthcare providers regarding
their increased CV risk is recommended.
655–657IB
Annual screening for modi ﬁable CVRFcis
recommended in adults who are childhood and
adolescent CS treated with anthracyclines,mitoxantrone, and/or RT to a volume including
the heart.IC
CV assessment
dis recommended in female
childhood and adolescent CS prior to pregnancy
or in the ﬁrst trimester.IC
Echocardiography surveillance should be
considered every 2 years in adults who arehigh-risk childhood and adolescent
eCS.7IIa B
Echocardiography surveillance should be
considered every 5 years in adults who are
moderate-risk childhood and adolescenteCS.7,654IIa B
©ESC 2022
BP, blood pressure; CS, cancer survivors; CV, cardiovascular; CVRF, cardiovascular risk
factors; DM, diabetes mellitus; ECG, electrocardiogram; HbA1c, glycated haemoglobin;RT, radiotherapy; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cObesity, sedentary lifestyle, cigarette smoking, alcohol intake, unhealthy diet,
dyslipidaemia, hypertension, DM.
dBP, lipids, fasting glucose, HbA1c, ECG, and TTE.
eSeeTable 11 .ESC Guidelines 4313Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

specialist in CV medicine with expertise in CVRF management. CS at
high or very high risk of future CVD can be divided into those at high
early risk (within 5 years of completing cancer therapy) and those athigh late risk ( .30 years from completing treatment). The timing and
frequency of other complementary tests depends upon the risk for
CTR-CVT ( Figure 38 ).
CS with a high or very high baseline risk and patients with abnormal
LV function at the end-of-therapy assessment have a high or very highearly risk, particularly in the ﬁrst 2 years.
61,667,668Annual CV assess-
ment with clinical examination, ECG, and NP measurement is recom-
mended in CS. TTE should be considered at years 1, 3, and 5 aftercompletion of cardiotoxic cancer therapy and every 5 years thereafter
in asymptomatic very high- and early high-risk adult CS.
In adult CS with late high CTR-CVT risk (e.g. young adults with
Hodgkin lymphoma or sarcomas who received a high total cumula-
tive anthracycline dose or patients treated with high-dose radiation
to a ﬁeld involving the heart, e.g. Mantle RT) there is a progressive
risk of CTRCD.
661,669Annual CV assessment with clinical examin-
ation, ECG, and NP measurement is recommended, starting 5 years
after the end of treatment, provided the end-of-therapy assessment
at 12 months is normal. TTE should also be considered every 5 years,
as well as non-invasive screening for CAD ( Section 8.3 ) and carotid
disease ( Section 8.5 ) according to local protocols.670
The long-term effects of CTRCD caused by trastuzumab and
other targeted cancer therapies (e.g. TKI) beyond 10 years are un-known. Currently, there is no recommendation for lifelong surveil-
lance in these CS unless they have another indication.
CV assessment with clinical examination, ECG, echocardiography,
and NP measurement every 5 years should be considered in asymp-
tomatic adult CS at moderate risk of future CTR-CVT and a normal
end-of-therapy CV assessment.Table 12 Risk categories for asymptomatic adult can-
cer survivors
Risk categoryaPatient characteristics
Very high risk Very high baseline CV toxicity risk
pre-treatment
Doxorubicinb≥400 mg/m2
RT.25 Gy MHDc
RT.15–25 Gy MHDc+doxorubicinb
≥100 mg/m2
Early high risk
(,5 years after
therapy)High baseline CV toxicity risk
Symptomatic or asymptomatic
moderate-to-severe CTRCD duringtreatment
Doxorubicin
b250–399 mg/m2
High-risk HSCTd
Late high risk RT.15–25 Gy MHDc
RT 5 –15 Gy MHDe+doxorubicinb
≥100 mg/m2
Poorly controlled CVRF
Moderate risk Moderate baseline CV toxicity risk
Doxorubicinb100–249 mg/m2
RT 5 –15 Gy MHDe
RT,5 Gy MHDf+doxorubicinb≥100 mg/
m2
Low riskLow baseline CV toxicity risk and normal
end-of-therapy cardiac assessment
Mild CTRCD during therapy but recovered by
the end of cancer therapy
RT,5 Gy MHDf
Doxorubicinb,100 mg/m2
©ESC 2022
CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; CVD,
cardiovascular disease; CVRF, cardiovascular risk factors; GVHD, graft vs. host
disease; Gy, Gray; HSCT, haematopoietic stell cell transplantation; MHD, mean heartdose; RT, radiotherapy. References:
397,399,400,673,674
aRT risk categorization based on MHD is recommended over categorization based on
prescribed dose, which may not accurately re ﬂect cardiac radiation exposure.
Depending on dose distribution and exposure of speci ﬁc cardiac substructures (as well
as clinical risk factors), the treatment team may judge the patient to belong to a higherrisk category. In addition, a patient may be judged to belong to a lower risk category in
case only a small part of the heart is exposed to a relatively high prescribed dose.
bOr equivalent.
cOr prescribed RT ≥35 Gy to a volume exposing the heart if MHD is not available. Note
that in this case, the limited information about cardiac exposure does not allow one to
distinguish between high- and very high-risk categories.
dHigh-risk HSCT patients: allogenic HSCT; pre-existing CVD or multiple uncontrolled
CVRF; cancer treatment history (mediastinal or mantle ﬁeld radiation, alkylating agents,
.250 mg/m2doxorubicin or equivalent); conditioning schemes (total body irradiation,
alkylating agents); development of GVHD.
eOr prescribed RT 15 –34 Gy to a volume exposing the heart if MHD is not available.
fOr prescribed RT ,15 Gy to a volume exposing the heart if MHD is not available.Recommendation Table 41 —Recommendations for
cardiovascular surveillanc e in asymptomatic adult can-
cer survivors
Recommendations ClassaLevelb
Annual CV risk assessment,cincluding ECG and
NP, and CVRF management is recommended in
CS who were treated with a potentiallycardiotoxic cancer drug or RT.
d,631–633,671,672IB
CV toxicity risk restrati ﬁcationeis recommended
5 years after therapy to organize long-term
follow-up.IC
Echocardiography at years 1, 3, and 5 after
completion of cardiotoxic cancer therapy and
every 5 years thereafter should be considered inasymptomatic very high- and early high-risk adult
CS.
fIIa C
Echocardiography should be considered in
asymptomatic late high-risk adult CSfstarting at 5
years after radiation to a volume including theheart and then every 5 years.IIa C
Echocardiography may be considered every 5
years in asymptomatic moderate-risk adult CS.
fIIb C
Non-invasive screening for CADgshould be
considered every 5 –10 years in asymptomatic
patients who received .15 Gy MHD,dstarting at
5 years after radiation.IIa C
Carotid ultrasound imaging should be considered
every 5 years in asymptomatic patients with ahistory of head/neck RT, starting at 5 years after
radiation and every 5 –10 years thereafter.IIa C
Continued4314 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

8.2. Myocardial dysfunction and heart
failure
HF treatment in CS should follow the current 2021 ESC Guidelines
for the diagnosis and treatment of acute and chronic HF.14
Treatment with ACE-I/ARB and/or beta-blockers is recommended
for both symptomatic and asymptomatic CS who have LVEF ,
50% detected on CV assessment.14,61,208,675In CS with mild asymp-
tomatic CTRCD detected on CV assessment (LVEF .50% but new
fall in GLS and/or cardiac serum biomarker increase), treatment with
ACE-I/ARB and/or beta-blockers may be considered.Renal artery ultrasound should be considered in
patients with a history of abdominal and pelvicradiation who present with worsening renal
function and/or systemic hypertension.IIa C
©ESC 2022
BP, blood pressure; CAD, coronary artery disease; CMR, cardiac magnetic resonance;
CS, cancer survivors; CT, computed tomography; CTR-CVT, cancer therapy-relatedcardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,
cardiovascular risk factors; ECG, electrocardiogram; HbA1c, glycated haemoglobin;
MHD, mean heart dose; NP, natriuretic peptides; RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.
cClinical review, BP, lipid pro ﬁle, HbA1c.
dRT risk categorization based on MHD is recommended over categorization based on
prescribed dose ( ≥35 Gy to a volume exposing the heart if MHD is not available).
eRestrati ﬁcation includes evaluation of new or pre-existing CVRF and CVD (including
CTR-CVT).
fSeeTable 12 .
gStress echocardiography, cardiac CT, stress CMR, single-photon emission CT stress
test, according to local protocol.234
Long-term surveillance in asymptomatic CS
High and 
very high 
riskModerate
riskLow
risk
Class 1
 Class 1Ia
 Class 1Ib
TTE every 2 years in
adults who are childhood
and adolescent CS
TTE at years 1, 3, and 5 after
cardioto xic cancer therapy and
every 5 years thereafter in adult CSAnnual CV risk 
assessmenta
CV to xicity risk 
re-stratificationc
at 5 years 
Patient education and
CVRF optimizationCardiology referralb
if new CV
symptoms develop
TTE every 5 years in
adults who are childhood
and adolescent CS
TTE every 5 years in
adult CS
Figure 38 Long-term follow-up in cancer survivors. BP, blood pressure; CAD, coronary artery disease; CS, cancer survivors; CTR-CVT, cancer
therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; ECG, electrocar diogram;
HbA1c, glycated haemoglobin; NP, natriuretic peptides; TTE, transthoracic echocardiography.aClinical review, BP, lipid pro ﬁle, HbA1c, ECG, NP. In
selected patients, non-invasive screening for CAD and carotid or renal diseases every 5 –10 years, starting at 5 years after radiation may be considered.
bCardio-oncology referral is recommended when available; alternatively, the patient should be referred to a specialized cardiologist with experti se in
managing CVD in patients with cancer.cRestrati ﬁcation includes evaluation of new or pre-existing CVRF and CVD (including CTR-CVT).ESC Guidelines 4315Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

8.3. Coronary artery disease
Any vascular location within the RT treatment volume is at increased
risk for both accelerated atherosclerosis and RT-related vasculopa-
thy.173,392RT to the chest (e.g. treatment of Hodgkin lymphoma,
early-stage BC, lung and oesophageal cancer, and for some patients
receiving infradiaphragmatic irradiation if the apex of the heart is
within the treatment volume) increases the risk of CAD. The latencybetween RT and the appearance of CAD varies from a few years to
several decades, depending upon the presence or absence of pre-
existing atherosclerosis and the age of the patient at the time ofRT. This is a serious complication for young CS with a good progno-
sis and long-life expectancy (e.g. BC and Hodgkin lymphoma).
389,390
Patients treated for mediastinal Hodgkin lymphoma have shown an
increased risk of CAD as a ﬁrst cardiac event.400RT-induced CAD
depends on the location of the RT treatment volume and most com-
monly affects either the proximal left anterior descending or theright coronary arteries. RT-related vasculopathy is progressive and
typically manifests in severe, diffuse, long, smooth and concentric
angiographic lesions.
679,680
The risk and severity of CAD increases with radiation dose, larger
volume exposed, younger age at time of treatment ( ,25 years),390
time from treatment, smoking,400the presence of other typical
CVRF, type of radiation source, and concurrent metabolic risk
factors.493RT accelerates pre-existing atherosclerosis leading to in-
creased ACS risk within 10 years of treatment.681
Patients with RT-induced CAD undergoing PCI with bare-metal
stent or balloon angioplasty have an increased risk of all-cause and
CV mortality.682Conversely, after PCI with a drug-eluting stent,
there is no difference in target lesion revascularization or cardiac
mortality between patients with and without prior chest RT.683
Surgical revascularization in patients with prior RT may be compli-
cated by poor tissue healing (skin and sternum), RT-induced injury to
the left and right internal mammary arteries (LIMA and RIMA, re-
spectively), inadequate target coronary vessels, and increasedsternotomy-related pain.
684Pre-operative assessment of internalmammary artery viability, venous access, and sternal wound healing
is recommended in CS with RT-induced CAD where CABG is con-
sidered. PCI with drug-eluting stents may be considered over CABGin CS with RT-induced severe left main or three-vessel disease, with a
high SYNTAX (SYNergy between percutaneous coronary interven-
tion with TAXus and cardiac surgery) score ( .22), in whom the
planned PCI is technically feasible given the increased complications
associated with CABG after mediastinal RT.
Screening for CAD should be considered in high-risk patients who
have received chest RT to a treatment volume including the heart.
Screening should take the form of functional imaging and/or CCTA be-
ginning at 5 years post-RT.
234,484The natural history of RT-related vas-
culopathy is different to atherosclerosis and may accelerate rapidly.173
Functional cardiac imaging should be considered in asymptomatic CS
with pre-existing CAD or when new signi ﬁcant CAD is detected on
anatomical imaging. In asymptomatic patients with inducible ischaemia
secondary to RT-induced CAD, a MDT is recommended to discuss re-vascularization needs according to the location of the RT-induced CAD,
the ischaemia burden, LV function, arrhythmia burden, time since treat-
ment, time since previous normal review (if available), concomitantvalvular disease, risks of surgical o r percutaneous revascularization,
medical options, and patient preference.
173
Platinum-based chemotherapies are now recognized to cause
CAD in CS. Cisplatin-based chemotherapy for testicular cancer is
associated with a 1.5 –7-fold increased risk of developing
CAD.421,493,685Testicular CS who received platinum-based chemo-
therapy should have their CVRF tightly controlled and be educated
to report any new chest pain or cardiac symptoms to their doctor
promptly. The role of screening for CAD in patients who receivedplatinum-based chemotherapy is unknown.
Aggressive risk-factor modi ﬁcation and CV diagnostic work-up
strongly enhance survival.
5,672Medical therapy with aspirin and sta-
tins for primary/secondary prevention, and beta-blockers and ni-
trates for symptom control, are recommended in CS.686,687Recommendation Table 42 —Recommendations for
adult cancer survivors who develop cancer
therapy-related cardiac dysfunction late after cardio-
toxic cancer therapy
Recommendations ClassaLevelb
ACE-I/ARB and/or beta-blockers are
recommended in adult CS with moderate
asymptomatic CTRCD.c,208,425,675–678IC
ACE-I/ARB and/or beta-blockers may be
considered in adult CS with mild asymptomatic
CTRCD.dIIb C
©ESC 2022
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; GLS,
global longitudinal strain; LVEF, left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cNew LVEF reduction by ≥10 percentage points to an LVEF of 40 –49% OR new LVEF
reduction by ,10 percentage points to an LVEF of 40 –49% AND either new relative
decline in GLS by .15% from baseline OR new rise in cardiac biomarkers.
dLVEF≥50% and new relative decline in GLS by .15% from baseline AND/OR new
rise in cardiac biomarkers.
Recommendation Table 43 —Recommendations for
adult cancer survivors with coronary artery disease
Recommendations ClassaLevelb
Asymptomatic radiation-induced CAD detected during
surveillance
Non-invasive stress testingcis recommended in
asymptomatic CS with new moderate or severe
radiation-induced CAD detected on CCTA to
guide ischaemia-directed management.635,688IC
A MDT discussion is recommended for clinical
decision-making in patients with radiation-inducedCAD and inducible ischaemia or severe left main
CAD.IC
Symptomatic CAD
Pre-operative assessment of LIMA and RIMA
viability, venous access, and sternal wound healing
is recommended in CS with radiation-induced
CAD where CABG is considered.IC
Continued4316 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

8.4. Valvular heart disease
VHD can appear in CS at any point in time but typically occurs
10 or more years after cancer treatment.691Chest RT is the
main risk factor in CS, in particular at higher dose ranges, which
can cause either stenosis or regurgitation, or both.391
The reported incidences of val vular regurgitation are up to
40% of CS survivors who received high-dose chest RT to a vol-
ume involving the heart, with ,10% presenting with clinically
signi ﬁcant VHD.670
Prognosis and management depend on the extent and severity of
VHD, as it does in patients without cancer.692TAVI should be con-
sidered for patients with symptomatic RT-induced severe aorticstenosis at intermediate surgical risk.
504,506,693,694Similar strategies
with percutaneous mitral valve repair or replacement can be consid-
ered.695Importantly, commonly used calculators such STS PROM
(Society of Thoracic Surgeons –Predicted Risk of Mortality) or
EuroSCORE (European System for Cardiac Operative Risk
Evaluation) II507may underestimate the surgery-related risk in CS,
and especially those who develop RT-induced VHD, due to addition-
al RT-related risk factors such as pericardial calci ﬁcation, aortic calci-
ﬁcation, increased bleeding risk, impaired skin healing, and RT-related
pulmonary ﬁbrosis. A Heart Team with cardiac surgeons, interven-
tional cardiologists, and cardio-oncology specialists should review
each case to guide appropriate treatment. The Heart Team recom-mendation should be discussed with the patient, who can then make
an informed treatment choice.8.5. Peripheral artery disease and stroke
Peripheral arterial and cerebrovascular disease in CS can be due tothe continuum of vascular disease pre-existing before, or developing
during or after cancer therapy. Cancer therapies such as cisplatin,BCR-ABL inhibitors, and RT can have a direct long-lasting effect on
the vasculature. Approximately 30% of CML patients on nilotinib
may develop PAD, which is clinically recognized 2 –4 years after
the start of therapy.
698The disease process may progress even after
discontinuation of nilotinib. Long-term vascular effects, generally as-
sociated with vascular reactivity, can also be seen in patients treatedwith ponatinib, cisplatin, and bleomycin.
699,700Accelerated vascular
aging, in ﬂammation, ﬁbrosis, and atherosclerosis are characteristic
consequences of RT.701Up to 30% of patients may develop signi ﬁ-
cant carotid artery stenoses ( .70%) after head/neck radiation.702,703
Vascular disease can also be an indirect consequence of cancer and
its therapy, e.g. via reduction in physical activity, hyperlipidaemia, DM,obesity, hypothyroidism, and/or kidney disease. These CVRF-related
effects are mostly additive to the direct treatment-related effects.
Promoting vascular health and preventing vascular disease in CS is re-commended.
672This should be in line with the 2021 ESC Guidelines
on CVD prevention in clinical practice.19
8.6. Pericardial complications
The risk of long-term pericardial complications after cancer
drug-induced acute pericarditis, caused by anthracyclines, cyclophos-
phamide, cytarabine, and bleomycin, is unknown but generally con-
sidered low. Long-term dasatinib treatment may lead to pericardialeffusion and pericarditis. The incidence of long-term ICI-associated
pericardial complications is low.
10
RT-induced chronic pericardial diseases can appear months to
decades after the initial RT and constrictive pericarditis is the most
serious.173,392Incidence is dif ﬁcult to determine, and many cases
are initially asymptomatic.704Five-yearly echocardiographic surveil-
lance for pericardial constriction in CS following RT-induced acute
pericarditis may be considered. The absolute risk is considerably re-
duced with modern radiation protocols,704but a high rate of pericar-
dial effusion has still been reported in patients with lung (grade ≥2,
.40%705) and oesophageal cancer ( .25%706) treated with RT.
Pericardial disease has been less investigated than other
RT-induced CVD, and clear protocols for post-therapy surveillance
are lacking.707,708In CS with chronic pericardial effusions following
RT, cardiac imaging can assess for evidence of in ﬂammation,PCI may be considered in CS with
radiation-induced CAD with severe left main orthree-vessel disease with a high SYNTAX score
(.22) in whom the procedure is technically
feasible.
682,689,690IIb B
©ESC 2022
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCTA, coronary
computed tomography angiography; CS, cancer survivors; LIMA, left internal
mammary artery; MDT, multidisciplinary team; PCI, percutaneous coronary
intervention; RIMA, right internal mammary artery; SYNTAX, SYNergy betweenpercutaneous coronary intervention with TAXus and cardiac surgery.
aClass of recommendation.
bLevel of evidence.
cAccording to local protocols and Non-invasive imaging in coronary syndromes:
recommendations of the European Association of Cardiovascular Imaging and theAmerican Society of Echocardiography, in collaboration with the American Society of
Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society
for Cardiovascular Magnetic Resonance recommendations.
234
Recommendation Table 44 —Recommendations for
adult cancer survivors with valvular heart disease
Recommendations ClassaLevelb
A MDT approach is recommended to discuss and
deﬁne the surgical riskcin CS with severe VHD.IC
ContinuedTAVI should be considered for patients with
symptomatic severe aortic stenosis caused by
radiation at intermediate surgicalrisk.
504,506,693,694,696,697IIa B
©ESC 2022
CS, cancer survivors; EuroSCORE, European System for Cardiac Operative Risk
Evaluation; MDT, multidisciplinary team; STS PROM, Society of Thoracic Surgeons –
Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation; VHD,valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cSurgical risks include: vascular access, sternal and skin wound healing, concomitant
cardiac disease, radiation-induced lung and thoracic vessels disease, aorticcalciﬁcation, STS PROM/EuroSCORE II.ESC Guidelines 4317Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

constriction, or tamponade.709Percutaneous balloon pericardiot-
omy or pericardial window creation should be used in selected cases
for large or growing chronic effusions if haemodynamic compromisedevelops. Management of these conditions should follow general
guideline recommendations.
14,444
8.7. Arrhythmias and autonomic disease
Arrhythmias, conduction disease, and autonomic disease are com-
mon complications in CS. Conduction disease after thoracic RT is
typically associated with other CTR-CVT.710It may include AV
block, bundle branch block, and s ick sinus syndrome that should
be monitored and treated according to the 2021 ESC Guidelines
on cardiac pacing and cardiac resynchronization therapy.443
Patients who require valve replacement after thoracic RT have a
high risk of post-operative AV block requiring permanent pace-
maker therapy.711Supraventricular and ventricular arrhythmias
are more common in patients after thoracic RT,712possibly due
to RT-induced myocardial ﬁbrosis. A common long-term complica-
tion after HSCT is supraventricular arrhythmia including AF and at-rialﬂutter,
457particularly in CS treated with anthracyclines or with
new CVRF or CV toxicity.
Autonomic dysfunction is an emerging but poorly understood
complication observed in CS, and is most frequently observed as a
late complication after thoracic RT. Orthostatic hypotension, pos-
tural orthostatic tachycardia syndrome, inappropriate sinus tachy-cardia, and loss of circadian heart rate variability can occur.
713,714
Physicians caring for these patients should consider referral for auto-
nomic evaluation. In addition, the perception of angina pain may beimpaired,
714making the diagnosis of post-radiation CAD challenging.
Evidence-based pharmacological treatment strategies are based on
studies of patients with other autonomic dysfunction aetiologies(e.g. DM or in ﬁltrative diseases) and the reported effectiveness is
generally poor.
714
8.8. Metabolic syndrome, lipid
abnormalities, diabetes mellitus, andhypertension
There is a growing understanding about shared CVRF that may be
responsible for cancer development or progression and premature
CV morbi-mortality.34Modi ﬁable CVRF continue to be underdiag-
nosed and undertreated in CS, especially hypertension,715obesity,
DM, metabolic syndrome,716and dyslipidaemia. Early diagnosis viastandardized risk-based screening and management of these condi-
tions according to general ESC Guidelines is recommended19to im-
prove long-term outcomes in CS.672
Increasing numbers of patients with cancer are already overweight
or obese at cancer diagnosis,717and additional weight gain is a fre-
quent complication of anticancer treatments.718Obesity is asso-
ciated with metabolic syndrome, worsening CVRF, and cancer.
Increasing evidence indicates that being overweight increases the
risk of cancer recurrence and reduces the likelihood of disease-freesurvival and overall survival among those diagnosed with cancer.
719–
724There is also growing evidence to support intentional weight loss
post-treatment in CS, which may result in improved prognosis and
survival.719Dietary patterns characterized by a high intake of vegeta-
bles/fruits and whole grains has been shown to be associated with re-duced mortality and cancer recurrence when compared with a high
intake of re ﬁned grains, processed and red meats, and high-fat dairy
products.
725–727
The identi ﬁcation and treatment of hyperlipidaemia in CS is asso-
ciated with a profound impact on outcomes.182,183There is a bene ﬁt
for CS from an all-cause mortality perspective as well as for decreas-ing cancer recurrence.
728–730
Several studies have demonstrated the therapeutic bene ﬁts of ex-
ercise during primary anticancer treatment,731,732and exercise is re-
commended during and after anticancer treatment.11,733For CS,734
aerobic exercise results in improved survival.735Based on current
guidelines, patients undergoing anticancer therapy and long-termCS should be encouraged to exercise for at least 150 min per
week.
736
8.9. Pregnancy in cancer survivors
Improvements in the treatment of cancer have led to an increasingnumber of female paediatric and adolescent CS who experience
pregnancy many years after their oncological treatments.Approximately 60% of them will have been previously exposed to
anthracycline chemotherapy or chest RT and they have a 15-fold in-
crease in their lifetime risk of developing HF.
737As young CS enter
their reproductive years and contemplate pregnancy, it is important
to understand the impact of cancer and its treatment on fertility,
pregnancy outcomes, and CV health. There are limited data availableregarding CV risk in pregnancy following cancer treatments. The
overall incidence of LVD or HF associated with pregnancy in female
adult CS varies according to the studied population. In a single insti-tution report including 337 female CS treated with cardiotoxic ther-
apies, 58 (17%) had a subsequent pregnancy.
738Cardiac events,
deﬁned as LVEF ,50% on two TTE or new CAD, were identi ﬁed
in 17 patients.738Patients with cardiac events were likely to be
younger at cancer diagnosis, received a higher cumulative dose of an-
thracycline, and had a longer delay (in years) from cancer treatmenttoﬁrst pregnancy compared with pregnant women with no cardiac
event.
738In a recent meta-analysis of six studies, the weighted risk of
pregnancy-associated LVD or HF in CS treated with anthracyclineswas 1.7% with no reported maternal cardiac deaths.
739Major risk
factors for CV events during pregnancy in CS include CTRCD (inci-
dence 28%; 47.4-fold higher odds),739younger age at cancer diagno-
sis,738,740longer time from cancer treatment to ﬁrst pregnancy, and
cumulative anthracycline dose.738Recommendation Table 45 —Recommendation for
adult cancer survivors with pericardial complications
Recommendation ClassaLevelb
Patients with acute pericarditis during RT to a
volume including the heart are at higher risk of
developing chronic constrictive pericarditis, henceechocardiography surveillance every 5 years may
be considered.IIb C
©ESC 2022
RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.4318 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Management by an expert MDT (the pregnancy heart team) is re-
commended for all CS with CTRCD who are considering preg-
nancy.739,741,742The risk of HF in CS without CTRCD is low,
although vigilance remains important for potential maternal cardiac
complications.
8.10. Pulmonary hypertension
Long-term clinical evaluation may be considered in patients who de-velop PH during therapy ( Section 6 ). In patients with new exertional
dyspnoea, fatigue, or angina, a TTE is recommended to assess theprobability of PH. As TTE alone is not enough to con ﬁrm the diagnosis
of PH, CS diagnosed with high PH probability require a right-heart
catheterization to con ﬁrm the diagnosis. PH should be treated accord-
ing to general guidelines with referral to a specialist PH service.
620
9. Special populations
9.1. Cardiac tumours
Cardiac tumours are classi ﬁed as either benign or malignant.743Over
90% of primary cardiac tumours are benign (myxomas arepredominant in adults, rhabdomyomas in children).744Malignant pri-
mary tumours most commonly consist of sarcomas (approximately
65%) or lymphomas (approximately 25%).745Cardiac metastases
(from melanoma, lymphoma, leukaemia, breast, lung, and oesopha-
geal cancers) are much more common than primary cardiac tumours
(Figure 39 ).746Presenting symptoms are paraneoplastic (fever, weak-
ness, fatigue), thromboembolic, haemodynamic (due to compression
or obstruction from the tumour) or arrhythmic.747,748
The diagnostic pathway should be based on knowledge about
tumour type epidemiology, imaging features, and usually the
requirement for a histopathological diagnosis. This topic has been
extensively reviewed in ESC CardioMed,749and here we
summarize the main recommendations for differential diagnosis
and management. Differential diagnosis should exclude cardiacthrombi or the presence of chemotherapy catheters. Imaging must
assess the possibilities of cardiac surgery, and may include: (1) echo-
cardiography (initial approach using TTE or transoesophagealechocardiography)
748,750; (2) CMR (for cardiac tumour tissue char-
acterization)751,752; and (3) CT and PET (to distinguish malignant
from benign lesions and assess for non-cardiac metastatic diseaseor primary cancers) ( Figure 40 ).
753,754
Myxomas are primarily treated with surgery with a good progno-
sis. Malignant tumours are associated with a poor prognosis and evi-dence of the best treatment is lacking. Complete surgical resection is
often impossible and adjuvant RT, systemic chemotherapy, and/or
debulking palliative surgery are needed.
755Cardiac aggressive B-cell
lymphomas require histopathological diagnosis (often obtained via
analysis of pericardial effusion, EMB, or direct surgical biopsy) and
are treated with chemotherapy, possibly followed by RT(Table 13 ).
756
9.2. Pregnant patients with cancer
The diagnosis of cancer during pregnancy is uncommon (1 in every
1000 pregnant women is diagnosed with cancer), with BC, melan-oma, and cervical cancer being the most frequent diagnoses.
757
Chemotherapy is generally not applied during the ﬁrst trimester
due to the high risk of foetal congenital abnormalities (up to 20%)and cytotoxic chemotherapies have different risk pro ﬁles during
the second or third trimesters.
758,759Furthermore, chemotherapy
administration is usually not given beyond week 34 of gestation toprovide a 3-week window between the last cycle and delivery.
757
Supplementary data, Table S19 summarizes the chemotherapies
for pregnant patients with cancer.760,761
Cardiac assessment prior to chemotherapy in pregnant women
with cancer should consist of clinical history, physical examination,
ECG, cardiac biomarker assessment and TTE ( Figure 41 ).741
Baseline and follow-up TTE should be interpreted in the context
of physiological haemodynamic alterations during pregnancy. In nor-
mal pregnancy, increase in stroke volume, heart rate, and pre-loadblood volume, and decrease in systemic vascular resistance, lead to
an increase in cardiac output from the ﬁrst trimester to 80 –85%
above baseline by the third trimester.
762–764An increase in LV
mass and LV and RV volumes is observed in the third trimester.
During normal pregnancy, LVEF is usually unchanged and can be
used for CTRCD monitoring. Although NP and cTn may be slightlyelevated during normal pregnancy (NT-proBNP ,300 ng/L, BNP ,
100 pg/mL,
14and hs-cTnT765,766), serial evaluation may be useful forRecommendation Table 46 —Recommendations for
cardiovascular monitoring in cancer survivors during
pregnancy
Recommendations ClassaLevelb
In high-risk female CS, pre-pregnancy counselling
and management during pregnancy and around
delivery by a multidisciplinary pregnancy heartteam is recommended.IC
A baseline CV evaluation including history,
physical examination, ECG, NP, and
echocardiography is recommended in female CS
with a history of CTRCD who are consideringpregnancy.IC
A baseline CV evaluation including history,
physical examination, ECG, and echocardiography
should be considered in all female CS who
received potentially cardiotoxic cancer therapyand are considering pregnancy.IIa C
A CV evaluation including echocardiography is
recommended at 12 weeks of pregnancy in female
CS who are either high-risk or who received
potentially cardiotoxic cancer therapy and did nothave a baseline CV assessment.IC
A second CV evaluation including
echocardiography should be considered at 20
weeks of pregnancy in high-risk female CS
cwho
received potentially cardiotoxic cancer therapy.IIa C
©ESC 2022
CS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,
cardiovascular; ECG, electrocardiogram, NP, natriuretic peptides.
aClass of recommendation.
bLevel of evidence.
cSeeTables 11 and12.ESC Guidelines 4319Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

close CTRCD monitoring during cancer treatment with the higher
cut-off NP levels for pregnancy.
The topic of CVD during pregnancy has been extensively re-
viewed in the 2018 ESC Guidelines for the management of CVD
during pregnancy.741Here we focus on speci ﬁc recommendations
in pregnant women with cancer receiving anthracyclinechemotherapy.
9.2.1. Left ventricular dysfunction and heart failure
Medical history evaluating signs and symptoms of HF should be per-formed at every clinical visit of pregnant women with cancer receiv-
ing anthracycline chemotherapy. More frequent CV evaluations withTTE during treatments with potential CTRCD risk should be advised
(e.g. every 4 –8 weeks or every two cycles for a 3-weekly anthracycline
chemotherapy cycle). The management of clinical HF or asymptomaticLVD during pregnancy is fully described in the 2018 ESC Guidelines for
the management of CVD during pregnancy.
741
9.2.2. Venous thromboembolism and pulmonary
embolism
Pregnant patients with cancer have an increased risk of
developing VTE, especially when hospitalized.767 –769
Identi ﬁed risks for VTE in pregnant patients include having a
history of BC or previous chemotherapy in the past 6 months.
Lipoma
MetastasisMyxomaSarcomaLeft atrium
Lung tumoursSarcomaPulmonary veins
FibroelastomaMetastasisValves
Left ventricle
FibromaLipomaLymphomaMetastasisRhabdomyomaSarcoma
LeiomyomaRenal tumourInferior cava vein
Right atrium
LipomaLymphomaMetastasisMyxomaSarcoma
Right ventricle
FibromaLipomaLymphomaMetastasisRhabdomyoma
Pericardium
Lipo-sarcomaLipomaLymphomaMesotheliomaMetastasis
SarcomaPulmonary artery
Figure 39 Location of primary and secondary cardiac tumours.4320 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CTbEchocardiographyaPETdCMRc
Secondary tumour
(metastasis)f
Benign primary
tumour
Malignant primary
tumour
Diagnostic algorithm for cardiac masses
Non-invasive assessment of single or multiple cardiac masses
T umour
TypeThrombus, vegetation, structuralConsider cardiac mass biopsy if malignant primary
tumour suspected or diagnosis uncertain on imaginge
LymphomaSarcoma Angioma, lipoma, papillaryfibroelastomaMyxoma Leukaemias 
LymphomasMelanomas
Solid tumours: breast, lung,
and oesophageal cancers
Figure 40 Diagnostic algorithm for cardiac masses. CMR, cardiac magnetic resonance; CT, computed tomography; PET, positron emission tomog-
raphy; TTE, transthoracic echocardiography.aTTE/transoesophageal echocardiography: location, size, and haemodynamic disturbances. Contrast echo-
cardiography to assess vascularization.bIdentify primary extra-cardiac malignancy. Reveal extra-cardiac changes. Staging of malignant lesions.cTissue
characterization (fat in ﬁltration, necrosis, haemorrhage, calci ﬁcation, and vascularization). Exclude thrombus.dDistinguish malignant vs. benign lesions.
Staging of malignant lesions.eMass biopsy of suspected primary malignant cardiac tumours and/or biopsy of extracardiac masses if detected and safer
to biopsy.f20–30 times more likely than primary tumours.
Table 13 Management strategies and surgery indications for symptomatic and asymptomatic patients with benign
and malignant cardiac tumours
Classi ﬁcation Management strategies Surgery indications
Benign
tumoursAsymptomatic MDT discussion is required considering: tumour type,
location, size, growth rate, and likelihood of embolism.
Anticoagulation should be considered for left-sidedtumours or right-sided tumours associated with an
intracardiac shunt, according to the individual ’s embolic and
bleeding riskIf left-sided and endocardial: even if small and incidental, a
MDT is needed to consider the indication for surgical
removal due to the embolic risk
Symptomatic Non-surgical management for:
Rhabdomyomas (possible spontaneous regression)
Intramural haemangioma (possible response to
corticosteroids)
Unresectable cases: if antiarrhythmic therapy is suf ﬁcientSurgical resection is indicated in all other cases.
For large, benign, unresectable, symptomatic cardiactumours (obstruction, severe HF, or malignant
arrhythmias), heart transplantation may be indicated in
some cases
Malignant
tumoursAsymptomatic Histopathological diagnosis is required If primary cardiac sarcoma, a complete surgical resection
may increase survival
Symptomatic Chemotherapy and/or RT are the only therapeutic options
for secondary cardiac tumours.
If primary cardiac lymphoma: chemotherapySecondary cardiac tumours may also be treated with
palliative cardiac surgery
©ESC 2022
HF, heart failure; MDT, multidisciplinary team; RT, radiotherapy.ESC Guidelines 4321Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Recommendations for the diagnosis and treatment of PE during preg-
nancy are the same as in the general 2018 ESC Guidelines for the man-agement of CVD during pregnancy
741and 2019 ESC Guidelines for the
diagnosis and management of acute pulmonary embolism.566
Determination of VTE risk score and the use of thrombo-
prophylaxis protocols may be useful to prevent maternalmorbidity and/or mortality due to VTE.770LMWH have be-
come the drug of choice for the prophylaxis and treatmentof VTE in pregnant patients.
741The recommendation for
thromboprophylaxis should be individualized, weighing the
risks of bleeding vs. thromboembolism in pregnant patientswith cancer.1st trimester Follow-up Anthracycline chemotherapy
 1st trimester
 Anthrac ycline chemothera py
 Follow-up
ECG
TTE
Physical examination
Baseline
Week
12
Week
20
Every visit
Every
4–8 W
Week
34
Delivery
 12 MCardiac monitoring protocol for pregnant women receiving
anthracycline-based chemotherapy
ECG
cTn/NP
Class 1
 Class 1Ia
 Class 1Ib
Figure 41 Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy. cTn, cardiac troponin; ECG, electrocardio-
gram; M, months; NP, natriuretic peptides; TTE, transoesophageal echocardiography; W, week.4322 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

9.3. Carcinoid valvular heart disease
Carcinoid tumours represent rare neuroendocrine malignancies ori-
ginating from the enterochromaf ﬁn cells ( Figure 42 ).771Carcinoid
syndrome is a rare cause of acquired VHD including mainly right-
sided valvular lesions, but also left-sided involvement, pericardial ef-
fusion, and myocardial metastases.772Coronary artery vasospasm
and paroxysmal atrial or ventricular tachycardias may rarely occur
due to sympathetic stimulation. Cardiac metastases are reported
with an incidence of 3.8% on the ventricles, con ﬁrmed by PET-CT
scans.773,774Data from the SEER (Surveillance, Epidemiology, and
End Results) registry identi ﬁed that approximately 20% of patients
with neuroendocrine malignancies develop carcinoid syndrome(7.6–32.4%), which is associated with shorter survival (4.7 years
compared with 7.1 years in patients without carcinoid syndrome)
and poor quality of life.
775It is estimated that 20 –50% of these pa-
tients present cardiac involvement, especially of the right-sided car-
diac valves.771In the presence of a patent foramen ovale, interatrial
shunt, primary bronchial neuroendocrine tumour, or extensive livermetastases, humoral substances directly enter the systemic circula-
tion, causing left-sided valvular involvement in up to one-third of
cases.
776
NP should be considered for screening and surveillance of patients
at risk of carcinoid cardiac involvement and TTE is recommended in
patients with NT-proBNP .260 pg/mL or clinical signs or symp-
toms.777–780In asymptomatic patients with NT-proBNP ,260 pg/
mL, repeat clinical and NP assessment should be considered every
6 months.
Survival has improved in carcinoid tumours, with the use of som-
atostatin analogues and surgical techniques in liver metastasis.
However, right HF still represents a major cause of death.781,782
Many patients with severe tricuspid regurgitation due to carcinoidsyndrome require both tricuspid and pulmonary valve surgery.783
Administration of i.v. somatostatin analogues (e.g. octreotide) is re-
commended to avoid a peri-operative carcinoid crisis. The infusionshould be started on the morning of the procedure (up to 12 h pre-
operatively), continued throughout the procedure (surgery, pre-
operative coronary angiography, pacemaker implantation), and post-operatively for at least 48 h following valve surgery or until stable if a
carcinoid crisis is triggered post-operatively.
772
The optimal choice of valve prosthesis is still a matter of debate
due to the balance of risk of both accelerated bioprosthetic valve de-
generation vs. bleeding risks in patients with extensive liver metasta-
ses requiring therapeutic anticoagulation for mechanical valves.784,785
Complications include AV block, requiring pacemaker implantation
in 25% of patients.786Frequently, the reduced RV function does
not improve despite tricuspid valve replacement and HF persists.787
Thrombus formation on the tricuspid bioprosthesis can occur, espe-cially during the ﬁrst 3 months post-operatively, and oral anticoagu-
lation with VKA may be considered. Persistent serotonin elevation
can cause recurrent bioprosthesis valve ﬁbrosis. Valve-in-valve trans-
catheter intervention has been reported in bioprosthetic valve failurein metastatic carcinoid heart disease; however, future research is
needed to de ﬁne its role.
783,788,789
In patients with left-sided carcinoid valvular involvement, closure
of interatrial shunts should be considered, although only sparse
data exist for this approach.Recommendation Table 47 —Recommendations for
cardiovascular assessment and monitoring of pregnant
women with cancer
Recommendations ClassaLevelb
Management by an expert MDT (the pregnancy
heart team) in an expert centre is recommended
for pregnant women with cancer who requirecardiotoxic cancer therapy.
741IC
Cardiac assessment prior to cardiotoxic cancer
therapy in pregnant women is recommended and
consists of clinical history, physical examination,ECG, and echocardiography.
741IC
Monthly or bimonthly CV evaluation, including
TTE, should be considered during cardiotoxic
cancer therapycin pregnant women with cancer.IIa C
cTn may be considered at baseline and during
anthracycline chemotherapy in pregnant women
with cancer.IIb C
©ESC 2022
cTn, cardiac troponin; CV, cardiovascular; ECG, electrocardiogram; MDT,
multidisciplinary team; TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cFor patients receiving anthracycline-based chemotherapy.
Recommendation Table 48 —Recommendations for
carcinoid valvular heart diseases
Recommendations ClassaLevelb
Echocardiographycis recommended for the
detection of carcinoid cardiac involvement in all
patients with carcinoid syndrome and elevated NPlevels and/or clinical signs of carcinoid heart
disease, and for surveillance every 3 or 6 months
depending on the severity of cardiac involvementand clinical status.
772,790,791IB
NP should be considered for screening and
surveillance of carcinoid heart disease every 6
months.777–780IIa B
A MDT discussion for optimal medial
management to prevent carcinoid crisis is
recommended before any invasive or surgicalcardiac procedure.IC
Valve replacement surgery is recommended in
symptomatic patients with severe carcinoid
tricuspid or pulmonary VHD and an expected
survival ≥12 months.
d,783,785IC
Valve replacement surgery should be considered
in patients with asymptomatic severe carcinoidtricuspid or pulmonary VHD, progressive RV
dysfunction/dilatation, and an expected survival
≥12 months.
d,772IIa C
ContinuedESC Guidelines 4323Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

9.4. Amyloid light-chain cardiac
amyloidosis
Amyloid light-chain amyloidosis i sap l a s m ac e l ld y s c r a s i a ,w h i c h
is typically treated with therapies very similar to those used inMM, including PI-based therapy.
792It can occur in conjunction
with myeloma or independent ly as a light-chain protein-
producing disorder. Amyloid light- chain amyloidosis is a systemic
disease793,794and it is critical to have a high degree of suspicion for
the diagnosis of cardiac involvement (amyloid light-chain cardiac
amyloidosis [AL-CA]) because a combination of specialized testsis needed to make an accurate diagnosis ( Figure 43 ).
290,793,795,796Valve replacement or repair surgery is
recommended in symptomatic patients withsevere carcinoid mitral or aortic VHD and an
expected survival ≥12 months.
783,785I C
©ESC 2022
MDT, multidisciplinary team; NP, natriuretic peptides; RV, right ventricular; VHD,
valvular heart disease.
aClass of recommendation.
bLevel of evidence.
cIncluding saline contrast infusion at baseline to rule out patent foramen ovale.
dWith controlled serotonin concentrations.
Flushing
Broncho-
constriction
DiarrhoeaAscites
Peripheral
oedemaPleural
effusionCarcinoid heart disease: clinical features/nobreakspaceand diagnostic tests
Clinical features Diagnostic and pronostic tools
TTE
Circulating serotoninNP
Urinary 5HIAACMR
Figure 42 Carcinoid heart disease: clinical features and diagnostic tests. 5HIAA, 5-hydroxyindoleacetic acid; CMR, cardiac magnetic resonance; NP,
natriuretic peptides; TTE, transthoracic echocardiography.4324 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Proteinuria
Renal impairmentKidneyCV
Dyspnoea
Peripheral oedemaAF/flutter
HFpEF or unexplained
right HF
Hypotension or syncope
Nerves
Orthostatic hypotension
Peripheral polyneuropathyPolyneuropathy
GI
Constipation /diarrhoea
MacroglossiaMalabsorption/weight
loss/nauseaBruisingSkin
Laboratorya
ECGb
TTEc
Characteristic echo findingseECHO score ≥8d
CMRfNon-invasive diagnosis of AL-CA
Clinical features Investigations/nobreakspace
Figure 43 Non-invasive diagnosis of amyloid light-chain cardiac amyloidosis. a′, late diastolic velocity of mitral annulus obtained by tissue Doppler im-
aging; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; CV, cardiovascular; E, mitral in ﬂow early
diastolic velocity obtained by pulsed wave; e′, early diastolic velocity of mitral annulus obtained by tissue doppler imaging; ECG, electrocardiogram; echo,
echocardiography; ECV, extracellular volume fraction; GI, gastrointestinal; GLS, global longitudinal strain; HF, heart failure; HFpEF, heart fa ilure with pre-
served ejection fraction; IVS, interventricular septum; LGE, late gadolinium enhancement; LV, left ventricular; LVEDD, left ventricular end dias tolic diam-
eter; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PW, left ventricular posterior wall; s′, systolic velocity of tricuspid annulus obtained by
Doppler tissue imaging; SPEP, serum protein electrophoresis; TAPSE, tricuspid annular plane systolic excursion; TTE, transthoracic echocardiog raphy;
UPEP, urine protein electrophoresis. Individually, the clinical manifestations and ﬁndings on cardiac testing for AL-CA are non-speci ﬁc. Integration of
all clinical and diagnostic ﬁndings is necessary when assessing the likelihood of the diagnosis.aDisproportionately high NT-proBNP; persisting elevated
troponin levels; abnormal free light-chain levels (AL-CA); positive SPEP and/or UPEP (AL-CA).bDisproportionally low QRS voltage; early conduction
system disease; pseudo-infarct pattern.cUnexplained LV thickness ≥12 mm +1 or 2 characteristic echo ﬁndings or ECHO score ≥8; idiopathic peri-
cardial effusion.dECHO score: relative LV wall thickness (IVS +PW/LVEDD) .0.6 (3 points), Doppler E/e′.11 (1 point); TAPSE ≤19 mm (2 points);
GLS≥−13% (1 point); systolic longitudinal strain apex to base ratio .2.9 (3 points).eCharacteristic echocardiography ﬁndings: grade ≥2 diastolic dys-
function; reduced s′,e′, and a′velocities ( ,5 cm/s); decreased GLS to ≥−15%.fDiffuse subendocardial or transmural LGE; elevated native T1 values;
abnormal gadolinium kinetics (myocardial nulling preceding or coinciding with the blood pool); ECV ≥0.40% (strongly supportive).ESC Guidelines 4325Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Cardiac serum biomarkers are an essential step in the diagnostic
and prognostic assessme nts for these patients.797 –799AL-CA has
been extensively reviewed in a recent position paper from theWorking Group on Myocardial and Pericardial Diseases.
290
The classical non-invasive de ﬁnition of AL-CA is based on clinical
suspicion, biomarkers, TTE, CMR, and nuclear scintigraphy criteria(Figure 43 ). Persistent troponin elevation and disproportionately
high NT-proBNP (generally .300 ng/L in the absence of renal fail-
ure or AF) to ventricular function parameters on TTE is a charac-teristic red ﬂag for AL-CA.
800A decrease in GLS with a
distinctive apical sparing pattern (preserved GLS values in the LV
apical region) is considered speci ﬁc for cardiac amyloidosis, al-
though it is not helpful to distinguish between amyloid light-chain
and transthyretin amyloidosis.801Additionally, GLS ≥−15% may
serve as an independent prognostic factor of poor overall survival
in patients with AL-CA.802CMR with LGE and parametric imaging
has emerged as a new non-invasive gold-standard for diagnosis(Figure 43 ).
803,804Nuclear scintigraphy can differentiate transthyre-
tin amyloidosis from AL-CA supported by the presence of mono-
clonal protein.290EMB should be considered in patients with
suspected AL-CA involvement if CMR is not diagnostic.290Ar a r e
condition that may coexist with AL-CA is light-chain deposition dis-
ease, which frequently associates extensive renal involvement andpoor prognosis.
799
Recently, a staging system for AL-CA has demonstrated the prog-
nostic impact of cTnT and NT-proBNP levels.797Heart progression
criteria are de ﬁned by NT-proBNP progression ( .30% and
.300 ng/L increase), cTnT progression ( ≥33% increase) or ejection
fraction decrease ( ≥10% decrease).805–807However, evaluating a
cardiac response to treatment using a decrease in NT-proBNP levels
and New York Heart Association class improvement is still
challenging.
AL-CA frequently results in HF, major cardiac arrhythmias, ortho-
static hypotension, sudden cardiac death, and an increased risk of ar-
terial and venous thrombosis.808–810Beta-blockers, ACE-I, ARB, or
angiotensin receptor-neprilysin inhibitor may not be well tolerated
because of hypotension.290The management of AF is very complex
in this population. Amiodarone is the preferred antiarrhythmic treat-ment and digitalis should be used with caution. Anticoagulation is re-
commended in all AL-CA patients with AF independent of the
CHA
2DS2-VASc score due to the high prothrombotic risk unless
there is a contraindication.290Currently, the guidelines for implanted
devices, including pacemakers and ICDs, do not provide speci ﬁc re-
commendations for AL-CA and decisions should be individualizedafter a MDT discussion.
811
Optimal systemic therapy for AL-CA is rapidly changing, and the
efﬁcacy of certain combination therapies continues to im-
prove.812,813Autologous HSCT for AL-CA is not universally utilized
but is a viable treatment option.814Therapies for AL-CA are evolv-
ing, and daratumumab and PI show promise for improved out-comes.
792,815–817Clinical observations, but no RCT evidence,
suggest the potential role of doxycycline to improve survival in pa-
tients with AL-CA.818,8199.5. Cardiac implantable electronic
devices
RT can cause malfunction of cardiac implantable electronic de-
vices (CIEDs).443,823The risk of RT-induced CIED malfunction
generally increases with the radiation dose,824,825although the
strongest predictor of malfunction is the magnitude of
exposure to neutron emission from high-energy photon RT, conven-tionally de ﬁned as a beam energy .10 megavolts (MV).
824,826,827
Non-neutron-producing treatmen t is therefore preferable in pa-
tients with a CIED.826
RT-induced CIED malfunction can manifest in: (1) transient inter-
ference, with inappropriate triggering during the irradiation only; (2)
a reset, reverting to backup settings, recoverable with device repro-gramming; and, rarely (3) permanent damage to the device due to
direct CIED irradiation.
826,827
The clinical consequences of a CIED malfunction include the inhib-
ition of pacing and inappropriate pacing at maximum sensor rate.826
The clinical effects of device malfunction are greatest when the pa-tient is pacing-dependent. Theoretically, oversensing might lead toinappropriate ICD shocks, although this has not been reported in
the literature.
826
More recent registries have reported minimal or no adverse ef-
fects of RT on CIED malfunction.827,828Nevertheless, as it is not pos-
sible to predict the behaviour of a CIED within or close to an RT
treatment volume, general recommendations should be followedto minimize patient risk ( Figures 44 –46).
188,824,825
Patients with a CIED should be reviewed by their cardiologist/
electrophysiologist to assess the risk of CIED malfunction andRecommendation Table 49 —Recommendations for
amyloid light-chain cardiac amyloidosis diagnosis and
monitoring
Recommendations ClassaLevelb
Echocardiography, NP, and cTn are
recommended for the diagnosis of AL-CA in
patients with plasma cell dyscrasia.290,820–822IB
CMR is recommended in patients with suspected
AL-CA.290,803,804IA
EMB should be considered in patients with
suspected AL-CA involvement if CMR is not
diagnostic.290IIa C
Admission with inpatient ECG monitoring should be
considered for high-risk patients with AL-CA
requiring PI during their ﬁrst cycle of therapy.c,808,811IIa C
©ESC 2022
AL-CA, amyloid light-chain cardiac amyloidosis; CMR, cardiac magnetic resonance; cTn,
cardiac troponin; ECG, electrocardiogram; EMB, endomyocardial biopsy; HFA, Heart
Failure Association; ICOS, International Cardio-Oncology Society; NP, natriuretic
peptides; PI, proteasome inhibitors.
aClass of recommendation.
bLevel of evidence.
cAccording to baseline evaluation using HFA-ICOS PI risk assessment tools (see
Section 4 ).4326 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

patients should be informed of the potential risks of RT.443For pa-
tients with rate-adaptive pacemakers, consideration should be given
to temporary deactivation of the sensor during RT. Although inacti-vation of antitachycardia therapies in patients with ICDs is recom-
mended in several publications, by either reprogramming or
application of a magnet to ICDs, it is infrequently performed in clin-ical practice.
826
CIEDs should not be placed directly in the RT treatment vol-
u m ea n dt h ec u m u l a t i v ed o s es h o u l dn o te x c e e d2G yt oap a c e -m a k e ro r1G yt oa nI C D .
827If the CIED is situated in the path
of the planned radiation beam, it could also interfere withadequate tumour treatment. The photon beam energy should
be kept ,10 MV as the risk of device malfunction/damage in-
creases above this threshold. If higher doses are needed or ifthe CIED cannot be kept out of the beam, consideration should
be given to removing and relocating the CIED away from the
beam, although this will only very rarely be necessary. The mainreason for device relocation is t o allow adequate RT treatment
of the tumour, but consideration should also be given to possible
RT-induced CIED malfunction/damage with consequent need forCIED replacement.
826However, CIED explant and resiting carries
signiﬁcant risks, including the risk of infection, which may be of
Pacing-
dependent or
frequent ICD
therapies 
Pacing-
independent
<5 Gy
≥5 Gy
<10 Gy or
neutrons <10 MV
≥10 Gy or
neutrons ≥10 MV PatientAssessing risk of RT to CIED
Dose region
and risk
category
Low risk High risk Medium riskCIED in the RT
treatment
volume
YES
NO
Risk areas
Figure 44 Risk strati ﬁcation in patients with a cardiac implantable electronic device undergoing radiotherapy. CIED, cardiac implantable electronic de-
vice; Gy, Gray; ICD, implantable cardioverter de ﬁbrillator; MV, megavolt; RT, radiotherapy.ESC Guidelines 4327Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

particular importance in patients receiving chemotherapy or
those who are immunosuppressed. For most patients in whomdeﬁnitive tumour treatment is planned, the risk/bene ﬁt ratio will
usually favour device relocation, whereas for patients receiving
palliative RT or with signi ﬁcant comorbidities, relocation could
be avoided.
826These decisions should be made by a MDT inconjunction with the patient. De vice relocation is not recom-
mended for CIEDs receiving a maximum cumulative incidentdose of ,5 Gy, where the risk is considered negligible.
826,828
There should be continuous visual and voice contact with the pa-
tient during each treatment fraction. CIEDs should be periodicallychecked in patients with ICDs, especially those receiving .10 MV
OR
 Consider moving CIED
CIED evaluation:Leave device in situ
CIED evaluation:
f
o
f
f
r
e/nobreakspace
R
T
R
R
b
ECG and/or pulse 
 o
ximet
r
y monitoring an d externa l pacin g 
a
vailable
a
a
during 
R
T sessions
R
R
W
eek
W
W
 l
y during 
R
T
R
R
Reduce radiation ener
 g
r
y to minimize e xposu
r
e to neut
r
ons
Limit cu
m
ulati
v
e dose
Be
f
o
f
f
r
e/nobreakspace
R
T
R
R
b
 (Class I )
Audio-visual monitorin g
o
w-riskpatient s
 High-risk patients
CIED in the 
 R
T t
R
R
r
eatment
v
olume
MDT
a
 Consider 
 R
T type and dose
R
R
(Figu
r
e 46)
CIED check-up after completing 
 R
T
R
R
(Class I )
Pacing dependent or
f
r
equent I CD ther
 a
pies
Maxi
m
um cu
m
ulati
v
e
incident dose of >5 Gy
(Class I )NNN
Risk stratification of patients with CIED under
 g
r
oing thoracic 
 R
T
R
R
YYY
Figure 45 Management of patients with a cardiac implantable electronic device located in the radiotherapy treatment beam. CIED, cardiac implantable
electronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter de ﬁbrillator; MDT, multidisciplinary team; N, no; RT, radiotherapy; Y,
yes.aMultidisciplinary discussion must consider: (1) whether the CIED is interfering with the RT dose delivered to the tumour; (2) whether the
RT is interfering with CIED function (aim to not exceed 2 Gy to permanent pacemaker and 1 Gy to ICD); (3) risks of moving the CIED: infection (es-pecially in immunocompromised patients), procedural complications (e.g. bleeding with thrombocytopaenia); for younger patients with good progn osis,
consider long-term effects of losing an access site (lead extraction/RT-induced thrombosis).
bIf last CIED check .3 months earlier.4328 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

photon beam energy.827,829For patients receiving electron or kV
photon beam RT, CIED evaluation appears largely unnecessary.827
For patients treated with proton beam RT, special considerationshould be paid to the neutron component of the beam, as the riskof CIED reset is potentially signi ﬁcant.
824,830The CIED should be re-
checked within 2 weeks of completion of RT treatment. Systematic
remote CIED monitoring may be helpful to optimize the patient ’s
surveillance.831
L
o
w-risk patient
 s
 High-risk patient s
 L
o
w-risk patien t
s
 High-risk patient s
 High-risk patient s
R
T type and dose
R
R
Pacing-dependent
CIED evaluation: CIED evaluation: CIED evaluation: CIED evaluation:
Be
f
o
f
f
r
e/nobreakspace
R
T
R
R
a
(Class I )
Audio-visual monitoring
Be
f
o
f
f
r
e/nobreakspace
R
T
R
R
a
W
eek
W
W
 l
y during 
 R
T
R
R
ECG and/or pulse
o
ximet
r
y monitorin g and
externa l pacing 
 a
vailable
a
a
during 
R
T sessions
R
R
Be
f
o
f
f
r
e
R
T
R
R
a
W
eek
W
W
 l
y during 
 R
T
R
R
ECG and/or pulse
o
ximet
r
y monitoring an d
externa l pacing 
 a
vailable
a
a
during 
R
T sessions
R
R
Be
f
o
f
f
r
e
R
T
R
R
a
(Class I )
Audio-visual monitoring
CIED check-up after completing radiother
 a
p
y
p
(Class I )
(Class I )
 (Class I )
Pacing- dependent o r
f
r
equent I CD ther
 a
pies
Neut
r
on-generat ing 
R
T
R
R
or dose
 ≥
2 Gy
<10 MV photons or
2–9 Gy
≥
10 MV photons or
≥
10 Gy
Non-neut
r
on-generat ing 
R
T
R
R
or dose < 2 Gy
Management of patients with CIED located outside the 
 R
T t
R
R
r
eatment
v
olume
N N Y Y
Figure 46 Management of patients with a cardiac implantable electronic device located outside the radiotherapy treatment volume. CIED, cardiac
implantable electronic device; ECG, electrocardiogram; Gy, Gray; ICD, implantable cardioverter de ﬁbrillator; MV, megavolt; N, no; RT, radiotherapy;
Y, yes.aIf last CIED check .3 months earlier.ESC Guidelines 4329Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

10. Patient information,
communication, andself-management
Collaboration between different healthcare professionals and pa-
tients is of paramount importance for the most effective manage-
ment of patients with cancer and CVD. Appropriate language and
communication should be used to allow patients to receive clearand accurate information about their condition, and play an active
role in managing their treatment.
11
The ﬁrst goal of this process is to raise the patient ’s awareness of
the possible presence or development of a CVD, either during can-
cer or after having some oncological therapy. Patients should under-
stand that cancer and CVD share many CVRF and reducing risk isvital for the prevention of cancer, cancer relapse, and the develop-
ment or worsening of a CVD during or after treatment. Patients
should be informed —at the end of chemotherapy —that a persona-
lized follow-up plan and regular CV controls are needed to detect
potential reversible stages of CV toxicities. Education, counselling,
and support to promote healthy lifestyle and to treat modi ﬁableRecommendation Table 50 —Recommendations for
riskstrati ﬁcationandmonitoringforpatientswithcardiac
implantable electronic devices undergoing radiotherapy
Recommendations ClassaLevelb
Risk strati ﬁcation including planned radiation type
and energy, dose to CIED, the patient ’s device
type, and pacing dependence is recommendedprior to starting treatment.
824,825,827,828IC
In patients undergoing RT, a CIED check is
recommended in all patients before and after
completing RT, and during RT according toindividual risk.
824,826IC
In patients with a CIED undergoing RT at high risk
of arrhythmia and/or device dysfunction, ECG
monitoring and/or pulse oximetry are
recommended during every RT session.827,829,831I C
©ESC 2022
CIED, cardiac implantable electronic device; ECG, electrocardiogram; RT, radiotherapy.
aClass of recommendation.
bLevel of evidence.
Interaction between healthcare professionals and patients with cancer
Information
Raise awareness
of possible CVD
with cancer
Understand shared
risk factors for
cancer and CVD
Appropriate lifestyle
modification
Active treatment
of CVRFRecognition and
report of early CV
symptoms and signs
Regular CV follow-up 
(also if asymptomatic)Don’t stop
cardioprotective therapy
without medical advice
Timely EoL and
DNR discussionEducation, counselling, and support
Consider specific psychologic and social conditions
Aid of digital health tools or information leaflets
Appropriate language
and communication
Figure 47 Patient information, communication, and self-management. CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk fac-
tors; DNR, do not resuscitate; EoL, end of life.4330 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

CVRF should be offered to patients with cancer, in order to reduce
the burden of complications during and after anticancer therapy.
Patients should receive guidance to recognize and to report signsand symptoms of CVD, in order to receive prompt and effective treat-
ment, ideally without interfering with their cancer treatment. Patients
should also be advised not to stop cardioprotective therapies withoutmedical guidance, even if they recover their cardiac function. To help
in this complex task, lea ﬂets speci ﬁcally designed for this context may
be used,
832,833eventually with the aid of digital tools ( Figure 47 ).
11. The role of scienti ﬁc societies
in the promotion anddevelopment of cardio-oncologyin modern medicine
Cardio-oncology is a subspecialty that has seen huge development and
growth in recent years with the formation —in almost all national and
international societies —of cardio-oncology working groups.Moreover, cancer and medical associations have also developed an in-
creasing interest in cardio-oncology. Important roles of these scienti ﬁc
societies are clinical research, education, and advocacy. The ESC-CCOstrategic plan and mission include improvement of prevention, diagno-
sis, treatment, and management of CTR-CVT and enhancement of the
standard of care for patients with cancer ( Figure 48 ).
12. Key messages
This is the ﬁrst ESC cardio-oncology Guideline and contains 272 new
recommendations. The key messages from this guideline are:
A guiding principle of cardio-oncology is integration, and
cardio-oncology providers must have knowledge of the broad
scope of cardiology, oncology, and haematology. Communicationbetween different healthcare professionals is critical to optimize
the care of patients with cancer and CVD.
Cardio-oncology programmes facilitate cancer treatment by min-
imizing unnecessary cancer therapy interruptions and CTR-CVT
The role of scientific societies in the promotion and
development of cardio-oncology
Cardio-
oncology
Advocacy
Research
Education
Engagement
Basic and translational
research
Clinical researchLong-term survivorship
programmes
Appropriateresources
CommunicationKnowledge
Organization
Community levelInternational level
National levelRegional levelPolitical strategies
against cancer and CVD
Community
Healthcare authoritiesHealthcare
professionals
PatientsCommunication
strategies
Figure 48 The role of scienti ﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.ESC Guidelines 4331Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

across the entire continuum of cancer care. In patients who de-
velop CTR-CVT, a MDT discussion is required to balance the
risk/bene ﬁt of cancer treatment discontinuation.
There is a new international de ﬁnition of CTR-CVT ( Table 3 ).
CV toxicity risk is a dynamic variable. This guideline is structured to
provide a personalized approach to care based upon the baselineCV toxicity risk. A baseline CV risk assessment is recommended
for all patients with cancer scheduled to receive a potentially car-
diotoxic anticancer therapy. This enables the oncology team toconsider CV risk while making cancer treatment choices, educating
patients regarding their CV risk, and personalizing CV surveillance
and follow-up strategy.
Primary prevention of CV toxicity from cancer therapy aims to
avoid or minimize the development of CTR-CVT in patients with-out CVD.
Secondary prevention refers to interventions in patients with pre-
existing CVD, including prior or new CTR-CVT. A MDT is recom-mended when patients with cancer have complex CVD that may
impact on their cancer treatment.
Deﬁning and delivering an appropriate prevention and surveillance
plan for potential CV complications is recommended. Optimal
management of CVRF and pre-existing CVD is mandatory to facili-
tate cancer therapy and to improve patients ’prognosis.
Detailed monitoring pathways during cancer therapy —including
3D echocardiography, GLS, and cardiac biomarkers —are pro-
vided to detect CV toxicity based upon speci ﬁc cancer therapies
and baseline CV toxicity risk.
Treatment recommendations for CTRCD during and after cancer
therapy depend upon CTRCD severity and symptoms. New guid-ance on continuing trastuzumab in BC patients who develop
asymptomatic moderate CTRCD (LVEF 40 –49%) while starting
cardioprotective medication is provided.
Use of a structured algorithm to guide decisions regarding anticoa-
gulation management in patients with cancer presenting with AF
or VTE encompassing the TBIP assessment is encouraged.
After cancer treatment is completed, the focus of the
cardio-oncology team shifts to coordination of long-term follow-
up. This starts with an ‘end-of-treatment ’assessment in the ﬁrst
year after treatment, reviewing patients with cancer who have re-
ceived cardiotoxic anticancer therapies to reassess their CV tox-
icity risk and guide long-term surveillance planning.
A new algorithm ( Figure 37 ) is provided to guide weaning off of CV
medication in CS.
Patients with cancer, CS, and the patient ’s family/carers should re-
ceive guidance to promote healthy lifestyle and recognize and re-
port signs and symptoms of CVD, to receive prompt and effective
treatment, without interfering with their cancer treatment.
Patients must receive psychological support when needed and
clear and accurate information about their condition to play an ac-
tive role in managing their treatment and increase adherence tocancer and CV treatments.
13. Future needs
There are a low number of dedicated cardio-oncology services and
most patients are reviewed in general cardiology clinics in Europeand worldwide. Strategic investments in cardio-oncology care
networks and cardio-oncology services provision are needed to
meet the projected increased clinical demand in the near fu-ture,
834and to facilitate research, training, and educational activ-
ities. A dedicated training core curriculum for a minimum of
1-year medical training is urgently needed. It may include: (1)knowledge of the broad scope of cardiology, oncology, and
haematology; (2) CV competencies for CTR-CVT prevention,
surveillance, and management of patients with cancer in dedicatedoutpatients ’cardio-oncology clinics; (3) inpatient consultative
services; and (4) dedicated time to achieve competences in CV im-
aging, HF, and vascular cardiology.
Collaboration between healthcare providers, clinical and basic in-
vestigators, healthcare authorities, regulatory bodies, advocacygroups, and patients ’associations is needed to address future needs
(see Section 11 ).
As this Guideline was developed, it became clear that there is a sig-
niﬁcant lack of RCT to guide decision-making, with many recommen-
dations supported by level of evidence C. This is complicated by the
fast-moving pace of new oncology treatment developments against abackground of dynamic CV toxicity likelihood. Therefore, large num-
bers of patients and longer follow-up are required to provide suf ﬁ-
cient statistical power and de ﬁnitive answers. In the future, the
following strategies and areas of research are priorities:
New trial designs focusing upon the ‘at-risk ’cancer patient
populations.
Validating current HFA-ICOS risk assessment tools and surveil-
lance algorithms.
Assessment of new technologies for the detection of early
CTRCD, broadening the biomarker panel and recognizing the spe-ciﬁc patterns in early myocardial damage.
Reﬁning CV risk scores (e.g. EuroSCORE II, SCORE2,
SCORE2-OP, CHA
2DS2-VASc, HAS-BLED, SYNTAX) for appli-
cation in cancer populations.
Optimal treatment of steroid-resistant ICI CV toxicity and long-
term CV effects of ICI therapy.
Selection criteria for modern percutaneous structural (TAVI,
Mitraclip, LAA occluder devices) and electrophysiological (abla-
tion) CV therapies in patients with active cancer.
Patient-speci ﬁc predictive algorithms for QTc prolongation with
cancer drugs.
Assessment of genetic pro ﬁles in more speci ﬁc CTRCD risk
prediction.
Identi ﬁcation of the cancer patient populations with mild or mod-
erate CTRCD during treatment who can safely wean off long-termCV medication.
Optimal modalities for screening long-term survivor populations
for the complications of anthracycline chemotherapy and medias-tinal radiation.
Creation of large cardio-oncology registries to collect ‘big data ’on
large patient populations.
Application of arti ﬁcial intelligence and other new data analytics to
identify new patients with cancer at risk and new parameters that
can predict risk of CTR-CVT, response to speci ﬁc cardioprotec-
tive interventions, and long-term risk and safety to wean off CV
therapies initiated during cancer treatment.4332 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

14. Gaps in evidence
Cancer and CVD are the two major public health problems with great
economic and social impact. In addition, CTR-CVT are associated withan excess of both CV and oncological mortality, especially when they limit
patients ’ability to complete effective treatments. However, the intersec-
tion of cancer and CVD has only recently gained wider interest and manyareas with lack of evidence need to be addressed in future research.
Role of cardio-oncology services and cardio-oncology
care networks
Robust evidence on the impact of dedicated cardio-oncology pro-
grammes and cardio-oncology rehabilitation on the prognosis ofpatients with cancer and survivors.
Speci ﬁcation of roles of different healthcare professionals (includ-
ing nurses and pharmacists) in cardio-oncology teams.
Cardio-oncology care networks to improve the management of
patients with cancer and to discuss dif ﬁcult cases.
Cardio-oncology team support and involvement in oncology trials
design (including patients ’representatives).
Understand how to engage patients with cancer in their own CV
care (inclusion of digital tools).
Research, education, and training in cardio-oncology
Consensus about CV toxicity de ﬁnitions used in oncology trials.
Deﬁne standards for CV toxicity monitoring in oncology trials to
avoid unexpected CV toxicities when new drugs are approved for
clinical use.
Relevant model systems to allow high-throughput screening of
new cancer treatments for CV toxicity.
Improved knowledge on CV toxicity mechanisms of new targeted
cancer therapies and ICI and optimal treatment of CV toxicities.
Improved knowledge on the effects of radiation to speci ﬁc cardiac
substructures and the interactions between cardiotoxic systemic
therapy and RT.
Further research into the underlying mechanisms that connect
CVD and cancer, such as a genetic predisposition to CV toxicity.Personalized medicine and use of big data and arti ﬁcial intelligence
tools.
Cardiovascular toxicity risk strati ﬁcation
Development of CV toxicity risk prediction tools including both
treatment- and patient-related risk factors.
Validated prospective CV toxicity risk scores based on clinical
outcomes.
Further research on the role of genetics in CV toxicity risk
strati ﬁcation.
Validation of CPET parameters for CV outcomes in patients with
cancer.
Prevention, diagnosis, and management of CTR-CVT
Raise awareness of the bene ﬁts of minimizing CV risk in patients
with cancer in order to reduce the risk of CTR-CVT.
More data on new technologies (biomarkers, advanced echocardi-
ography, CMR, etc.) and genetic pro ﬁles for the detection of early
CV toxicity.
Prospective studies showing the impact on outcomes and/or qual-
ity of life (and frailty) of early CTR-CVT diagnosis and treatment.
Further evidence from prospective RCTs to de ﬁne when cardio-
protective medications improve patients ’outcomes.
Further research on the potential for aerobic exercise to reduce
CTR-CVT.
RCTs of (new) CV therapies in patients with different types of
CTR-CVT.
Long-term cancer survivorship programmes
Development of optimal CV follow-up programmes after treat-
ment for cancer (research on risk strati ﬁcation, ef ﬁcacy, and fre-
quency of screening protocols).
Best screening strategies for RT-induced CAD.
Further research on CV preventive strategies for long-term CS.
15.‘What to do ’and ‘what not to do ’messages from the Guidelines
Recommendations ClassaLevelb
Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization
CV toxicity risk strati ﬁcation before starting potential ly cardiotoxic anticancer therapy is recommended in all patients with
cancer.IB
Communicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is
recommended.IC
It is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without
delay.IC
Cardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy. IC
Discussion of the risk/bene ﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary
approach prior to starting treatment is recommended.IC
Cardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk
assessment who require potentially cardiotoxic anticancer therapy.IC
ContinuedESC Guidelines 4333Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Recommendation Table 2 for electrocardiogram baseline assessment
An ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment. IC
In patients with an abnormal baseline ECG, referral to a cardiologist is recommended. IC
Recommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies
Baseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to
be measured during treatment to detect CTRCD.IC
Recommendation Table 4 for cardiac imaging modalities in patients with cancer
General
Echocardiography is recommended as the ﬁrst-line modality for the assessment of cardiac function in patients with cancer. IC
3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF. IB
GLS is recommended in all patients with cancer having echocardiography, if available. IC
Baseline cardiac imaging prior to potentially cardiotoxic therapies
Baseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting
anticancer therapy.IC
Recommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity
Management of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and
after cancer therapy.IC
Recommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity
Management of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy. IC
Recommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months
after therapy
TTE
Baseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy. IB
In all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment. IB
In high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing
treatment.IC
Cardiac serum biomarkers
Baseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy. IB
cTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is
recommended in high- and very high-risk patients.IB
Recommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the ﬁrst 12 months
after therapy
TTE
Baseline echocardiography is recommended before HER2-targeted therapies in all patients. IB
In patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within
12 months after completing treatment.IB
In metastatic HER2 +disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains
asymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment.IC
Cardiac biomarkers
Baseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies. IC
Continued4334 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Recommendation Table 9 for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy
Baseline CV risk assessment and evaluation including BP measurement, ECG, lipid pro ﬁle, HbA1c measurement, and SCORE2/SCORE2-
OP or equivalent is recommended before starting ﬂuoropyrimidines.IC
A baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting ﬂuoropyrimidines. IC
Recommendation Table 10 for baseline risk assessment and monitoring during VEGFi
BP monitoring
BP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit. IC
Daily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2 –3
weeks thereafter is recommended.IC
ECG monitoring
In patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the ﬁrst
3 months and every 3 –6 months thereafter.IC
Echocardiography
Baseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab. IC
Recommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine
kinase inhibitors
Baseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI. IC
In patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the ﬁrst year and every 6 –12
months thereafter.IC
Baseline echocardiography is recommended in patients scheduled to receive dasatinib. IC
Recommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy
BP monitoring and management
BP measurement is recommended for patients treated with BTK inhibitors at every clinical visit. IB
Echocardiography
Baseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors. IC
TTE is recommended in all patients who develop AF during BTK inhibitor therapy. IC
AF
Opportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy. IC
Recommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies
BP monitoring
BP measurement is recommended for patients treated with PI at every clinical visit. IC
Cardiac serum biomarkers
Measurement of NP is recommended prior to PI in high- and very high-risk patients. IC
NP and cTn measurements are recommended at baseline and every 3 –6 months in patients with AL-CA. IB
TTE
Baseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI. IC
ContinuedESC Guidelines 4335Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

VTE prophylaxis
Therapeutic doses of LMWH are recommended in patients with MM with previous VTE. IB
Prophylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least
during the ﬁrst 6 months of therapy.IA
Recommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy
BP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is
recommended.IC
In patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3
months thereafter.IC
Baseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK
inhibitors.IC
Recommendation Table 15 for baseline risk assessment and monitoring during immunotherapy
ECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy. IB
Baseline echocardiography is recommended in high-risk patients before starting ICI therapy. IB
CV assessment is recommended every 6 –12 months in high-risk patients who require long-term ( .12 months) ICI treatment. IC
Recommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in
patients treated with ADT without pre-existing CVD.IB
Baseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy. IB
Annual CV risk assessment is recommended during ADT. IB
Recommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in
BC patients receiving endocrine therapies without pre-existing CVD.IC
Annual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV
events according to SCORE2/SCORE2-OP.IC
Recommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy
QTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib. IA
QTc monitoring is recommended in patients treated with ribociclib with any dose increase. IB
Recommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors
Baseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors. IC
Baseline echocardiography is recommended in all patients with cancer before starting osimertinib. IB
Recommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell
and tumour-in ﬁltrating lymphocytes therapies
Baseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies. IC
A baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies. IC
Measurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2. IC
Continued4336 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Recommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart
Baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended. IB
Recommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients
Baseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is
recommended in HSCT patients.IC
Echocardiography is recommended in all patients before HSCT. IC
Recommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in
patients receiving anticancer treatment
A specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with
new CV toxicity during and after cancer treatment.IC
Recommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline
chemotherapy
Anthracycline chemotherapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy. IB
Discontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD. IC
Temporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and
a multidisciplinary approach regarding the decision to restart is recommended.IC
A multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who
develop mild symptomatic CTRCD.IC
Anthracycline chemotherapy-induced asymptomatic CTRCD
Temporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop
asymptomatic moderate or severe CTRCD.IC
A multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe
asymptomatic CTRCD.IC
Continuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have
developed a signi ﬁcant fall in GLS or a troponin or a NP elevation .ULN.IC
Recommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies
HER2-targeted therapy-induced symptomatic CTRCD
HF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF ,50% during HER2-
targeted treatment.IB
Temporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD
and the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.IC
In patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.
interrupt HER2-targeted therapy are recommended.IC
HER2-targeted therapy-induced asymptomatic CTRCD
Temporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic
severe CTRCD.IC
A multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe
asymptomatic CTRCD.IC
Continuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDcwith
more frequent cardiac monitoring.IC
ACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40 –49%) CTRCDcduring
HER2-targeted treatment.IC
Recommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis
cTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis. IB
In patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is
conﬁrmed or refuted.IC
ContinuedESC Guidelines 4337Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Interruption of ICI treatment is recommended in patients with con ﬁrmed ICI-associated myocarditis. IC
Continuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients
with symptomatic ICI-associated myocarditis.IC
Early high-dose corticosteroids are recommended in patients with cancer and con ﬁrmed ICI-associated myocarditis. IC
Continuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of
symptoms, LV systolic dysfunction, conduction abnormalities, and signi ﬁcant cTn reduction.IC
Admission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when
indicated) is recommended for patients with ICI-associated fulminant myocarditis.IC
A multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-
associated myocarditis.IC
Recommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer
Coronary angiography (invasive or CCTA) is recommended to exclude ACS. IC
CMR is recommended to exclude myocarditis and MI. IB
QT-prolonging drugs are not recommended during the acute TTS phase. III C
Recommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment
An invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6
months.IB
A temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause. IC
In patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL. III C
In patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or
ticagrelor are not recommended if platelets ,50 000/µL.III C
Recommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment
Individualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/
ischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.IC
Recommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment
In patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management
of VHD is recommended, taking into consideration cancer prognosis and patient preferences.IC
In patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the
management of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities.IC
Recommendation Table 31 for the management of atrial ﬁbrillation in patients receiving anticancer treatment
Long-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a
CHA 2DS2-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.IC
Thromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF. IC
Antiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with
cancer.III C
Recommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment
How to manage QTc prolongation in patients with cancer
Discontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular
tachyarrhythmias during treatment.IC
Temporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms
and an ECG should be repeated every 24 h until resolution of the QTcF prolongation.IC
Immediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in
patients with cancer who develop QTcF ≥500 ms.IC
Weekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480 –500 ms who are treated with a QTc-
prolonging cancer therapy.IC
Continued4338 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy. IC
Restarting QTc-prolonging cancer therapy
A multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed signi ﬁcant QTcF
prolongation, to discuss alternative cancer treatments.IC
Weekly ECG monitoring during the ﬁrst 4 –6 weeks and then monthly thereafter is recommended in patients with cancer after
restarting QTc-prolonging cancer therapy.IC
Recommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment
General
Effective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is
recommended.IC
A BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy. IC
The competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any
cancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values
,160 mmHg (systolic) and ,100 mmHg (diastolic).IC
Cancer therapy-induced arterial hypertension treatment
ACE-I or ARB are the ﬁrst-line antihypertensive drugs recommended for BP management in patients with cancer. IB
Dihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP. IC
Combination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic
BP≥160 mmHg and diastolic BP ≥100 mmHg.IC
Diltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug –drug
interactions.III C
Recommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment
Apixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer
without contraindications.IA
LMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL. IA
Catheter-associated VTE
Duration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and
continuing longer if the catheter remains in situ .IC
Recommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment
Extended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or
laparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.IB
Prophylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed
rest or reduced mobility in the absence of bleeding or other contraindications.IB
A discussion with the patient about the relative bene ﬁts and harms, cancer prognosis, drug cost, and duration of treatment is
recommended prior to prophylactic anticoagulation for the primary prevention of VTE.IC
Recommendation Table 36 for management of peripheral artery disease during anticancer treatment
In patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt
culprit cancer therapy is recommended.IC
Recommendation Table 37 for the management of pulmonary hypertension during anticancer treatment
Right-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic
increase in peak TRV .3.4 m/s.IC
In patients with con ﬁrmed dasatinib-induced PAH or new asymptomatic peak TRV .3.4 m/s, an alternative BCR-ABL inhibitor is
recommended after peak TRV recovery to ,2.8 m/s.IC
Recommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment
General
Diagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and
management of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.IC
ContinuedESC Guidelines 4339Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Diagnosis and management of ICI-associated pericarditis
Multimodality CV imaging (echocardiography, CMR +CT), ECG and measurement of cardiac biomarkers are recommended to
conﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.IC
Prednisolone and colchicine are recommended for patients with ICI-associated pericarditis. IC
Interruption of ICI treatment in patients with con ﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is
recommended.IC
A multidisciplinary discussion is recommended before restarting ICI treatment. IC
Recommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment
Educating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended. IC
Education is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD. IC
CVRF assessment is recommended during the ﬁrst year after cancer therapy and thereafter according to the 2021 ESC Guidelines on
CVD prevention in clinical practice.IB
In asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after
completion of cancer therapy.IB
Cardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in
echocardiography and/or cardiac serum biomarkers at the end of therapy assessment.IC
Long-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy. IC
CV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer
therapy.IC
CV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy. IC
ECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy. IC
Recommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer
survivors
Education of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including
the heart and their healthcare providers regarding their increased CV risk is recommended.IB
Annual screening for modi ﬁable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,
mitoxantrone, and/or RT to a volume including the heart.IC
CV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester. IC
Recommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors
Annual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially
cardiotoxic cancer drug or RT.IB
CV toxicity risk restrati ﬁcation is recommended 5 years after therapy to organize long-term follow-up. IC
Recommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic
cancer therapy
ACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD. IC
Recommendation Table 43 for adult cancer survivors with coronary artery disease
Asymptomatic radiation-induced CAD detected during surveillance
Non-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on
CCTA to guide ischaemia-directed management.IC
A MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or
severe left main CAD.IC
Continued4340 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Symptomatic CAD
Pre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-
induced CAD where CABG is considered.IC
Recommendation Table 44 for adult cancer survivors with valvular heart disease
A MDT approach is recommended to discuss and de ﬁne the surgical risk in CS with severe VHD. IC
Recommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy
In high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary
pregnancy heart team is recommended.IC
A baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a
history of CTRCD who are considering pregnancy.IC
A CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who
received potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.IC
Recommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer
Management by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who
require cardiotoxic cancer therapy.IC
Cardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical
examination, ECG, and echocardiography.IC
Recommendation Table 48 for carcinoid valvular heart diseases
Echocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and
elevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of
cardiac involvement and clinical status.IB
A MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac
procedure.IC
Valve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an
expected survival ≥12 months.IC
Valve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an
expected survival ≥12 months.IC
Recommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring
Echocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia. IB
CMR is recommended in patients with suspected AL-CA. IA
Recommendation Table 50 for risk strati ﬁcation and monitoring for patients with cardiac implantable electronic devices undergoing
radiotherapy
Risk strati ﬁcation including planned radiation type and energy, dose to CIED, the patient ’s device type, and pacing dependence is
recommended prior to starting treatment.IC
In patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to
individual risk.IC
In patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are
recommended during every RT session.I C
©ESC 2022
3D, three-dimensional; ACE-I, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndromes; ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain
cardiac amyloidosis; ALK, anaplastic lymphoma kinase; ARB, angiotensin receptor blocker; ASTCT, American Society for Transplantation and Cellul ar; AV, atrioventricular; BC, breast cancer; BCR-
ABL, breakpoint cluster region –Abelson oncogene locus; BP, blood pressure; BTK, Bruton tyrosine kinase; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAR-T, c himeric
antigen receptor T cell; CCB, calcium channel blockers; CCS, chronic coronary syndromes; CCTA, coronary computed tomography angiography; CHA 2DS2-VASc, Congestive heart failure,
Hypertension, Age .75 years (2 points), Diabetes mellitus, Stroke (2 points) —Vascular disease, Age 65 –74 years, Sex category (female); CIED, cardiac implantable electronic device; CMR,
cardiac magnetic resonance; CRS, cytokine release syndrome; CT, computed tomography; cTn, cardiac troponin; CTRCD, cancer therapy-related cardi ac dysfunction; CS, cancer survivors;
CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular r isk factors; DAPT, dual antiplatelet therapy; EACTS, European Associati on for Cardio-Thoracic Surgery; ECG,
electrocardiogram; EGFR, epidermal growth factor receptor; ESC, European Society of Cardiology; GLS, global longitudinal strain; HbA1c, glycate d haemoglobin; HER2, human epidermal
receptor 2; HF, heart failure; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous; LIMA, left internal mammary
artery; LMWH, low-molecular-weight heparins; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multid isciplinary team; MEK, mitogen-activated
extracellular signal-regulated kin ase; MI, myocardial infarction; MM, multiple myeloma; NP, natriuretic peptides; NSTE-ACS, non-ST-segment el evation acute coronary syndromes; PAD,
peripheral artery disease; PAH, pulmonary arterial hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; QTcF, corrected QT inter val using Fridericia correction; RAF, rapidly
accelerated ﬁbrosarcoma; RIMA, right internal mammary artery; RT, radiotherapy; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronar y Risk Estimation 2 —
Older Persons; STEMI, ST-segment elevation myocardial infarction; TdP, torsade de pointes; TIL, tumour-in ﬁltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic
echocardiography; TTS, Takotsubo syndrome; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; VEGFi, vascular endothelial growt h factor inhibitors; VHD, valvular heart
disease; VTE, venous thromboembolism.
aClass of recommendation.
bLevel of evidence.ESC Guidelines 4341Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

16. Quality indicators for
cardio-oncology
Quality indicators (QIs) are tools that may be used to evaluate care
quality, including structural, process, and outcomes of care.835They
may also serve as a mechanism for enhancing adherence to guideline
recommendations, through associated quality improvement initia-
tives and the benchmarking of care providers.836,837As such, the
role of QIs in improving care and outcomes for CVD is increasingly
recognized by healthcare authorities, professional organizations,
payers, and the public.835
The ESC understands the need for measuring and reporting qual-
ity and outcomes of CV care and has established methods for the de-
velopment of the ESC QIs for the quanti ﬁcation of care and
outcomes for CVD.835These methods were used to develop QIs
pertinent to cardio-oncology in parallel with the writing of this
Clinical Practice Guideline document and through the collaborationwith patient representatives and domain experts. The QIs, alongside
their measurement speci ﬁcations and development process will be
published separately.
17. Supplementary data
Supplementary data is available at European Heart Journal online.
18. Data availability statement
No new data were generated or analysed in support of this research.
19. Author information
Author/Task Force Member Af ﬁliations: Liam S. Couch ,
King ’s College London BHF Centre, the Rayne Institute, St
Thomas ’Hospital, King ’s College London, London, United
Kingdom; Riccardo Asteggiano , Cardiology, LARC
(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School ofMedicine, Insubria University, Varese, Italy; Marianne C. Aznar ,
Division of Cancer Sciences, Faculty of Biology, Medicine and
Health, University of Manchester, Manchester, United Kingdom;Jutta Bergler-Klein , Department of Cardiology, Medical
University of Vienna, Vienna, Austria; Giuseppe Boriani ,
Cardiology Division, Department of Biomedical, Metabolic andNeural Sciences, University of Modena and Reggio Emilia,
Policlinico di Modena, Modena, Italy; Daniela Cardinale ,
Cardioncology Unit, European Institute of Oncology —I.R.C.C.S.,
Milan, Italy; Raul Cordoba , Department of Hematology,
Fundacion Jimenez Diaz University Hospital, Madrid, Spain, and
Cancer Research Group, Health Research Institute IIS-FJD, Madrid,Spain; Bernard Cosyns , Cardiology, Centrum voor Hart en
Vaatziekten (CHVZ), Universitair Ziekenhuis Brussel (UZB),
Brussels, Belgium, and In Vivo Molecular and Cellular (ICMI)Center, Vrij Universiteit Brussel, Brussels, Belgium; David
J. Cutter , Nuf ﬁeld Department of Population Health, University
of Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,Oxford University Hospitals NHS Foundation Trust, Oxford,
United Kingdom; Evandro de Azambuja , Medical OncologyDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf
A. de Boer , Cardiology, University Medical Center Groningen,
Groningen, Netherlands; Susan F. Dent , Department of
Medicine, Duke Cancer Institute, Durham, NC, United States of
America; Dimitrios Farmakis , Medical School, University of
Cyprus, Nicosia, Cyprus; Soﬁe A. Gevaert , Cardiology, Ghent
University Hospital, Ghent, Belgium; Diana A. Gorog , Postgraduate
Medicine, University of Hertfordshire, Hat ﬁeld, United Kingdom, and
National Heart and Lung Institute, Imperial College, London, UnitedKingdom, and Cardiology Department, East and North
Hertfordshire NHS Trust, Stevenage, United Kingdom; Joerg
Herrmann , Department of Cardiovascular Diseases, Mayo Clinic,
Rochester, MN, United States of America; Daniel Lenihan ,
Cardio-Oncology, International Cardio-Oncology Society, Tampa, FL,United States of America, and Cardiology, Saint Francis Healthcare,
Cape Girardeau, MO, United States of America; Javid Moslehi ,
Section of Cardio-Oncology & I mmunology, Cardiovascular
Research Institute, University of C alifornia, San Francisco (UCSF),
San Francisco, CA, United States of America; Brenda Moura ,
Cardiology Department, Armed Forces Hospital, Porto, Portugal,and Faculty of Medicine, University of Porto, Porto, Portugal; Sonja
S. Salinger , Clinic for Cardiovascular Disease, University Clinical
Center, Nis, Serbia, and Medical Faculty, University of Nis, Nis,Serbia; Richard Stephens (United Kingdom), ESC Patient Forum,
Sophia Antipolis, France; Thomas M. Suter ,D e p a r t m e n to f
Cardiology, Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland; Sebastian Szmit , Department of Pulmonary
Circulation, Thromboembolic Diseases and Cardiology, Centre of
Postgraduate Medical Education, Otwock, Poland, and Institute ofHematology and Transfusion Medicine, Transfusion Medicine,
Warsaw, Poland; Juan Tamargo , Pharmacology and Toxicology,
Universidad Complutense, Madrid, Spain; Paaladinesh
Thavendiranathan , Department of Medicine, Division of
Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter
Munk Cardiac Center, Toronto General Hospital, University HealthNetwork, University of Toronto, Toronto, Canada; Carlo
G. Tocchetti , Cardio-Oncology Unit, Department of Translational
Medical Sciences, Federico II University, Naples, Italy, and Center forBasic and Clinical Immunology Research (CISI), Federico II
University, Naples, Italy, and Interdepartmental Center for Clinical
and Translational Research (CIRCET), Federico II University, Naples,Italy;Peter van der Meer , Cardiology, University Medical Center
Groningen, Groningen, Netherlands; Helena J.H. van der Pal ,
Princess Máxima Center for Pediatric Oncology, Princess MáximaCenter for Pediatric Oncology, Utrecht, Netherlands.
20. Appendix
ESC Scienti ﬁc Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Patrizio Lancellotti (CPG Review
Coordinator) (Belgium), Franck Thuny (CPG Review Coordinator)
(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),Berthe Aleman (Netherlands), Joachim Alexandre (France), Ana
Barac (United States of America), Michael A. Borger (Germany),4342 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

Ruben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta
Čelutkien ė(Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal
(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy(France), Thor Edvardsen (Norway), Laurent Fauchier (France),
Michael Fradley (United States of America), Julia Grapsa (United
Kingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),Marc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan
(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),Bonnie Ky (United States of America), Ulf Landmesser (Germany),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory
Y. H. Lip (United Kingdom), Maja-Lisa Løchen (Norway),
Katarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra
(Italy), Richard Mindham (United Kingdom), Marie Moonen(Belgium), Tomas G. Neilan (United States of America), Jens
Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva
Prescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien
ten Berg (Netherlands), Rhian M. Touyz (Canada/United
Kingdom), Agnieszka Tycinska (Poland), Matthias Wilhelm(Switzerland), Jose Luis Zamorano (Spain)
ESC National Cardiac Societies actively involved in the review
process of the 2022 ESC Guidelines on cardio-oncology: Algeria:
Algerian Society of Cardiology, Nadia Laredj; Armenia: Armenian
Cardiologists Association, Parounak Zelveian; Austria: Austrian
Society of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan
Society of Cardiology, Fuad Samadov; Belarus: Belorussian
Scienti ﬁc Society of Cardiologists, Uladzimir Andrushchuk;
Belgium: Belgian Society of Cardiology, Bernhard L. Gerber;
Bosnia and Herzegovina: Association of Cardiologists of
Bosnia and Herzegovina, Mirsad Selimovi ć;Bulgaria: Bulgarian
Society of Cardiology, Elena Kinova; Croatia: Croatian Cardiac
Society, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,
Evagoras Economides; Czechia: Czech Society of Cardiology,
Radek Pudil; Denmark: Danish Society of Cardiology, Kirsten
M. Nielsen; Egypt: Egyptian Society of Cardiology, Tarek
A. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;
Finland: Finnish Cardiac Society, Suvi Tuohinen; France: French
Society of Cardiology, Stéphane Ederhy; Georgia: Georgian
Society of Cardiology, Zurab Pagava; Germany: German Cardiac
Society, Tienush Rassaf; Greece: Hellenic Society of Cardiology,
Alexandros Briasoulis; Hungary: Hungarian Society of Cardiology,
Dániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl
K. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;
Israel: Israel Heart Society, Zaza Iakobishvili; Italy: Italian
Federation of Cardiology, Iris Parrini; Kazakhstan: Association of
Cardiologists of Kazakhstan, Amina Rakisheva; Kosovo
(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;
Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;
Latvia: Latvian Society of Cardiology, Oskars Kalejs;
Lebanon:
Lebanese Society of Cardiology, Hadi Skouri; Libya: Libyan
Cardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society
of Cardiology, Diana Žaliaduonyt ė;Luxembourg: Luxembourg
Society of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac
Society, Alice M. Moore; Moldova (Republic of): Moldavian
Society of Cardiology, Daniela Bursacovschi; Morocco: MoroccanSociety of Cardiology, Aatif Benyass; Netherlands : Netherlands
Society of Cardiology, Olivier Manintveld; North Macedonia :
North Macedonian Society of Cardiology, Marijan Bosevski;Norway: Norwegian Society of Cardiology, Geeta Gulati;
Poland: Polish Cardiac Society, Przemys ław Leszek; Portugal:
Portuguese Society of Cardiology, Manuela Fiuza; Romania:
Romanian Society of Cardiology, Ruxandra Jurcut; Russian
Federation: Russian Society of Cardiology, Yury Vasyuk; San
Marino: San Marino Society of Cardiology, Marina Foscoli;
Serbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:
Slovak Society of Cardiology, Miroslav Slanina; Slovenia:
Slovenian Society of Cardiology, Luka Lipar; Spain: Spanish
Society of Cardiology, Ana Martin-Garcia; Sweden: Swedish
Society of Cardiology, Laila Hübbert; Switzerland: Swiss Society
of Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian
Cardiovascular Association, Ahmad Alayed; Tunisia: Tunisian
Society of Cardiology and Cardio-Vascular Surgery, Leila Abid;Turkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:
Ukrainian Association of Cardiology, Elena Nesukay; United
Kingdom of Great Britain and Northern Ireland: British
Cardiovascular Society, Charlotte Manisty, Uzbekistan:
Association of Cardiologists of Uzbekistan, Nigora Srojidinova.
ESC Clinical Practice Guidelines (CPG) Committee: Colin
Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt), Victor Aboyans (France), Sotiris Antoniou (UnitedKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),
Andreas Baumbach (United Kingdom), Michael A. Borger
(Germany), Jelena Čelutkien ė(Lithuania), Maja Cikes (Croatia),
Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent
Fauchier (France), Chris P. Gale (United Kingdom), Sigrun
Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (CzechRepublic), Maja-Lisa Løchen (Norway), Richard Mindham (United
Kingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen
(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United
Kingdom).
21. References
1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning
cardiovascular toxicities of cancer therapies: an International Cardio-Oncology
Society (IC-OS) consensus statement. Eur Heart J 2022; 43:280 –299.
2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation
and management of patients with heart disease and cancer: Cardio-oncology. Mayo
Clin Proc 2014; 89:1287 –1306.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
cancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209 –249.
4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,
Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascu-
lar toxicity developed under the auspices of the ESC Committee for Practice
Guidelines. Eur Heart J 2016; 37:2768 –2801.
5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,
et al. Cardio-oncology services: rationale, organization, and implementation. Eur
Heart J 2019; 40:1756 –1763.
6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.
Evidence-based recommendations for the organization of long-term follow-upESC Guidelines 4343Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

care for childhood and adolescent cancer survivors: a report from the
PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019; 13:759 –772.
7. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al.
Recommendations for cardiomyopathy surveillance for survivors of childhood can-cer: a report from the International Late Effects of Childhood Cancer GuidelineHarmonization Group. Lancet Oncol 2015; 16:e123 –e136.
8. van Kalsbeek RJ, Mulder RLRL, Skinner R, Kremer LCMCM. The concept of cancer
survivorship and models for long-term follow-up. Front Horm Res 2021; 54:1–15.
9. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and ar-
rhythmia. Nat Rev Cardiol 2020; 17:474 –502.
10. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020; 17:
503–522.
11. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.
Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer pa-tients and survivors: a scienti ﬁc statement from the American Heart Association.
Circulation 2019; 139:e997 –e1012.
12. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive car-
diotoxic cancer therapies: a position statement and new risk assessment tools fromthe Cardio-Oncology Study Group of the Heart Failure Association of theEuropean Society. Eur J Heart Fail 2020; 22:1945 –1960.
13. Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al.
Incidence of cardiotoxicity and validation of the Heart Failure Association –
International Cardio-Oncology Society risk strati ﬁcation tool in patients treated
with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat
2021; 188:149 –163.
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J 2021; 42:3599 –3726.
15. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal
muscle: a noncardiac source of increased circulating concentrations of cardiactroponin T. J Am Coll Cardiol 2011; 58:1819 –1824.
16. Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger
B,et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll
Cardiol 2018;
71:1540 –1549.
17. Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al.
Clinical implications of isolated troponinemia following immune checkpoint inhibi-tor therapy. ESMO Open 2021; 6:100216.
18. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U,
et al. Cardiovascular magnetic resonance in nonischemic myocardial in ﬂammation:
expert recommendations. J Am Coll Cardiol 2018; 72:3158 –3176.
19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021
ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J
2021; 42:3227 –3337.
20. Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al.
Which QT correction formulae to use for QT monitoring? J Am Heart Assoc
2016; 5:e003264.
21. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al.
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers:
American Society of Clinical Oncology clinical practice guideline. J Clin Oncol
2017; 35:893 –911.
22. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management
of cardiac disease in cancer patients throughout oncological treatment: ESMO con-sensus recommendations. Ann Oncol 2020; 31:171 –190.
23. Rossello X, Dorresteijn JAN, Janssen A, Lambrinou E, Scherrenberg M,
Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease preven-
tion: a report from the ESC Prevention of CVD Programme led by theEuropean Association of Preventive Cardiology (EAPC) in collaboration with the
Acute Cardiovascular Care Association (ACCA) and the Association of
Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Cardiovasc Nurs
2019; 18:534 –544.
24. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year
follow-up assessment of cardiac function in NSABP B-31, a randomized trial com-paring doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACPplus trastuzumab as adjuvant therapy for patients with node-positive, human epi-
dermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:
3792 –3799.
25. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and car-
diomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart
Assoc 2014; 3:e000472.
26. Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clin-
ical risk score in a real-world cardio-oncology population. Curr Oncol 2017; 24:
176–180.
27. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The de-
velopment of a predictive model to estimate cardiotoxic risk for patients withmetastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;
107:443 –450.
28. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu J V, et al.
Development and validation of a multivariable prediction model for major adversecardiovascular events after early stage breast cancer: a population-based cohortstudy. Eur Heart J 2019; 40:3913 –3920.
29. Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al.
Symptomatic heart failure in acute leukemia patients treated with anthracyclines.JACC CardioOncology 2019; 1:208 –217.
30. Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M,
et al. Strati ﬁcation and management of cardiovascular risk in cancer patients. A con-
sensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC,and AECC. Rev Española Cardiol (English Ed) 2021; 74:438 –448.
31. Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P,
Rodríguez IR, Gómez Prieto P, et al. Cardiovascular risk factors during cancer treat-
ment. Prevalence and prognostic relevance: insights from the CARDIOTOX regis-try.Eur J Prev Cardiol 2022; 29(6):859 –868.
32. Feijen EAM, Leisenring WM, Stratton KL, Ness KK, Van Der Pal HJH, Van Dalen EC,
et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxo-
rubicin for late-onset cardiotoxicity. JAMA Oncol 2019; 5:864 –871.
33. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, et al. Activity and
outcomes of a cardio-oncology service in the United Kingdom —aﬁve-year experi-
ence. Eur J Heart Fail 2018; 20:1721 –1731.
34. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular
disease and cancer. Circulation 2016; 133:1104 –1114.
35. Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, et al. Arterial occlu-
sive events in chronic myeloid leukemia patients treated with ponatinib in the real-
life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE)
chart. Hematol Oncol 2019; 37:296 –302.
36. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis:
crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the
week.
J Am Coll Cardiol 2019; 74:567 –577.
37. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM,
et al. Genetic variants associated with cancer therapy-induced cardiomyopathy.
Circulation 2019; 140:31–41.
38. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC
CardioOncology 2020; 2:539 –552.
39. Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. Cancer J 2015; 21:104 –110.
40. Shari ﬁ-Rad J, Rodrigues CF, Sharopov F, Docea AO, Karaca AC, Shari ﬁ-Rad M, et al.
Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotec-
tive effects of natural bioactive compounds. Int J Environ Res Public Health 2020; 17:
2326.
41. Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, et al.
Outdoor air pollution and cancer: an overview of the current evidence and public
health recommendations. CA Cancer J Clin 2020; 70:460 –479.
42. Lind PM, Lind L. Are persistent organic pollutants linked to lipid abnormalities, ath-
erosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020; 9:
334–348.
43. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The
cancer patient and cardiology. Eur J Heart Fail 2020; 22:2290 –2309.
44. Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card
Electrophysiol Clin 2015; 7:341 –355.
45. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al.
Incidence, diagnosis, and management of QT prolongation induced by cancer ther-apies: a systematic review. J Am Heart Assoc 2017; 6:e007724.
46. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, et al. Drug-induced
QTc interval prolongation: a proposal towards an ef ﬁcient and safe anticancer drug
development. Eur J Cancer 2008; 44:494 –500.
47. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in
cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep 2016; 18:52.
48. Curigliano G, Spitaleri G, De Braud F, Cardinale D, Cipolla C, Civelli M, et al. QTc
prolongation assessment in anticancer drug development: clinical and methodo-logical issues. Ecancermedicalscience 2009; 3:130.
49. Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al.
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health
Organization pharmacovigilance study. Eur Heart J 2021; 42:3915 –3928.
50. Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial ﬁb-
rillation on ibrutinib treatment. Leuk Lymphoma 2019; 60:1447 –1453.
51. Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, et al. Left atrial ab-
normality (LAA) as a predictor of ibrutinib-associated atrial ﬁbrillation in patients
with chronic lymphocytic leukemia. Cancer Biol Ther 2018; 19:1–2.
52. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of
supraventricular arrhythmias during autologous peripheral blood stem cell trans-
plantation. Biol Blood Marrow Transplant 2013; 19:1233 –1237.4344 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

53. Pudil R, Mueller C, Čelutkien ėJ, Henriksen PA, Lenihan D, Dent S, et al. Role of
serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a pos-ition statement from the Cardio-Oncology Study Group of the Heart FailureAssociation and the Cardio-Oncology Council of the European Society ofCardiology. Eur J Heart Fail 2020; 22:1966 –1983.
54. Čelutkien ėJ, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P,
Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving car-
diotoxic therapies: a position statement on behalf of the Heart Failure Association(HFA), the European Association of Cardiovascular Imaging (EACVI) and theCardio-Oncology Council of the European Society of Cardiology (ESC). Eur J
Heart Fail 2020; 22:1504 –1524.
55. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al.
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in can-cer patients: a meta-analysis. Eur J Heart Fail 2020; 22:350 –361.
56. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in
cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographicoutcomes. J Clin Oncol 2012; 30:1042 –1049.
57. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect
of dexrazoxane on myocardial injury in doxorubicin-treated children with acutelymphoblastic leukemia. N Engl J Med 2004; 351:145 –153.
58. Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by
LVEF and troponin T sensitivity following two anthracycline-based regimens inlymphoma: results from a randomized prospective clinical trial. Oncotarget 2016;
7:32519 –32531.
59. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al.
Prognostic value of troponin I in cardiac risk strati ﬁcation of cancer patients under-
going high-dose chemotherapy. Circulation 2004; 109:2749 –2754.
60. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes
in multiple biomarkers are associated with cardiotoxicity in breast cancer patientstreated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015; 61:
1164 –1172.
61. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al.
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of tropo-nin I evaluation. J Clin Oncol 2010; 28:3910 –3916.
62. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of
troponins I and T and N-terminal prohormone of brain natriuretic peptide in mon-itoring cardiac safety of patients with early-stage human epidermal growth factorreceptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant studycardiac marker substudy. J Clin Oncol 2017; 35:878 –884.
63. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.
Heart Failure Association of the European Society of Cardiology practical guidanceon the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21:715 –731.
64. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity
after anthracycline chemotherapy in breast carcinoma: effects on left ventricularejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148:
194–198.
65. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, et al.
Changes in cardiovascular biomarkers with breast cancer therapy and associationswith cardiac dysfunction. J Am Heart Assoc 2020; 9:e014708.
66. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of
cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.J Clin Oncol 2019; 37:1946 –1955.
67. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al.
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 2015; 101:1874 –1880.
68. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR,
Farmakis D, et al. Classi ﬁcation, prevalence, and outcomes of anticancer
therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020; 41:
1720 –1729.
69. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in mul-
tiple biomarkers predict subsequent cardiotoxicity in patients with breast cancertreated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014; 63:
809–816.
70. Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al.
Circulating microRNAs as potential predictors of anthracycline-induced troponinelevation in breast cancer patients: diverging effects of doxorubicin and epirubicin.J Clin Med 2020; 9:1418.
71. Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, et al.
Baseline immunoglobulin e levels as a marker of doxorubicin- andtrastuzumab-associated cardiac dysfunction. Circ Res 2016; 119:1135 –1144.
72. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality im-
aging in the assessment of cardiovascular toxicity in the cancer patient. JACC
Cardiovasc Imaging 2018; 11
:1173 –1186.73. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.
Standardization of adult transthoracic echocardiography reporting in agreementwith recent chamber quanti ﬁcation, diastolic function, and heart valve disease re-
commendations: an expert consensus document of the European Association ofCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18:1301 –1310.
74. De Azambuja E, Procter MJ, Van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O,
Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median
follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014; 32:
2159 –2165.
75. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D
strain for detection of subclinical anthracycline cardiotoxicity in breast cancer pa-tients: A balance with feasibility. Eur Heart J Cardiovasc Imaging 2017; 18:930 –936.
76. Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, et al.
Abnormalities in 3-dimensional left ventricular mechanics with anthracyclinechemotherapy are associated with systolic and diastolic dysfunction. JACC
Cardiovasc Imaging 2018; 11:1059 –1068.
77. Lang RM, Badano LP, Mor-Avi V, A ﬁlalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber quanti ﬁcation by echocardiography in
adults: an update from the American Society of Echocardiography and theEuropean Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging
2015; 16:233 –270.
78. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovi ćZB, Marwick TH.
Reproducibility of echocardiographic techniques for sequential assessment of leftventricular ejection fraction and volumes: application to patients undergoing cancerchemotherapy. J Am Coll Cardiol 2013; 61:77–84.
79. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of
3-dimensional echocardiography in measuring left ventricular volumes and ejectionfraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012; 59:
1799 –1808.
80. Hoffmann R, Barletta G, Von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C,
et al. Analysis of left ventricular volumes and function: a multicenter comparison of
cardiac magnetic resonance imaging, cine ventriculography, and unenhanced andcontrast-enhanced two-dimensional and three-dimensional echocardiography. J
Am Soc Echocardiogr 2014; 27:292 –301.
81. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume
measurement with echocardiography: a comparison of left ventricular opaci ﬁca-
tion, three-dimensional echocardiography, or both with magnetic resonance im-aging. Eur Heart J 2009; 30:98–
106.
82. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical
applications of ultrasonic enhancing agents in echocardiography: 2018 AmericanSociety of Echocardiography Guidelines Update. J Am Soc Echocardiogr 2018; 31:
241–274.
83. Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al.
Serial cardiovascular magnetic resonance strain measurements to identify cardio-
toxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc
Imaging 2021; 14:962 –974.
84. Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, Sourbron S, et al. Cardiotoxicity
and myocardial hypoperfusion associated with anti-vascular endothelial growth fac-
tor therapies: prospective cardiac magnetic resonance imaging in patients with can-
cer.Eur J Heart Fail 2020; 22:1276 –1277.
85. Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M.
Echocardiographic parameters of left ventricular size and function as predictorsof symptomatic heart failure in patients with a left ventricular ejection fraction of
50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015; 16:
977–984.
86. Čelutkien ėJ, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R, et al.
Innovative imaging methods in heart failure: a shifting paradigm in cardiac assess-ment. Position statement on behalf of the Heart Failure Association of the
European Society of Cardiology. Eur J Heart Fail 2018; 20:1615 –1633.
87. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a
systematic review and meta-analysis of global longitudinal strain and ejection frac-tion. Heart 2014; 100:1673 –1680.
88. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test –retest reliability of new and
conventional echocardiographic parameters of left ventricular systolic function. Clin
Res Cardiol 2019; 108:355 –365.
89. Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al.
Variability in echocardiography and MRI for detection of cancer therapy cardiotoxi-city. Heart 2020; 106:817 –823.
90. Thavendiranathan P, Negishi T, Coté MA, Penicka M, Massey R, Cho GY, et al.
Single versus standard multiview assessment of global longitudinal strain for thediagnosis of cardiotoxicity during cancer therapy. JACC Cardiovasc Imaging 2018;
11:1109 –1118.
91. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle
strain to assess left ventricular responses to cardiotoxic chemotherapy and cardi-oprotection. Eur Heart J Cardiovasc Imaging
2014; 15:324 –331.ESC Guidelines 4345Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

92. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myo-
cardial strain imaging by echocardiography for the early detection of cardiotoxicityin patients during and after cancer chemotherapy: a systematic review. J Am Coll
Cardiol 2014; 63:2751 –2768.
93. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D,
et al. Assessment of prognostic value of left ventricular global longitudinal strain for
early prediction of chemotherapy-induced cardiotoxicity: a systematic review andmeta-analysis. JAMA Cardiol 2019; 4:1007 –1018.
94. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert
consensus for multimodality imaging evaluation of adult patients during and aftercancer therapy: a report from the American Society of Echocardiography andthe European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc
Imaging 2014; 15:1063 –1093.
95. Farsalinos KE, Daraban AM, Ünlü S, Thomas JD, Badano LP, Voigt JU. Head-to-head
comparison of global longitudinal strain measurements among nine different ven-dors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr
2015; 28:1171 –1181.e2.
96. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, et al.
Noninvasive measures of ventricular –arterial coupling and circumferential strain
predict cancer therapeutics –related cardiac dysfunction. JACC Cardiovasc Imaging
2016; 9:1131 –1141.
97. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to pre-
dict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis.
Cardiol Rev 2018; 26:29–34.
98. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al.
Comprehensive assessment of changes in left ventricular diastolic function with
contemporary breast cancer therapy. JACC Cardiovasc Imaging 2020; 13:198 –210.
99. Phillips WJ, Johnson C, Law A, Turek M, Small AR, Dent S, et al. Comparison of
Framingham risk score and chest-CT identi ﬁed coronary artery calci ﬁcation in
breast cancer patients to predict cardiovascular events. Int J Cardiol 2019; 289:
138–143.
100. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.
2019 ESC Guidelines for the diagnosis and management of chronic coronary syn-
dromes: The Task Force for the diagnosis and management of chronic coronarysyndromes of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:
407–477.
101. Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac
computed tomography in cardio-oncology: JACC:
CardioOncology primer. Cardio
Oncol 2021; 3:635 –649.
102. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al.
Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll
Cardiol 2021; 77:392 –401.
103. Esmaeilzadeh M, Fresno CMU, Somerset E, Shalmon T, Amir E, Fan CPS, et al. A
combined echocardiography approach for the diagnosis of cancer therapy-relatedcardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 2022; 7:
330–340.
104. Drafts BC, Twomley KM, D ’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to
moderate dose anthracycline-based chemotherapy is associated with early non-invasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc
Imaging 2013; 6:877 –885.
105. Giusca S, Korosoglou G, Montenbruck M, Ger šak B, Schwarz AK, Esch S, et al.
Multiparametric early detection and prediction of cardiotoxicity using myocardialstrain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonanceimaging study during 2 years of follow-up. Circ Cardiovasc Imaging 2021;14:e012459.
106. Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, et al. Assessment
of left ventricular function by CMR versus MUGA scans in breast cancer patientsreceiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging
2019; 35:2085 –2093.
107. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-
dimensional echocardiography in breast cancer: comparison with two-dimensionalechocardiography, multiple-gated acquisition scans, and cardiac magnetic reson-ance imaging. J Clin Oncol 2010; 28:3429 –3436.
108. Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, et al. Accuracy
of left ventricular ejection fraction by contemporary multiple gated acquisitionscanning in patients with cancer: comparison with cardiovascular magnetic reson-ance. J Cardiovasc Magn Reson 2017; 19:34.
109. Hoppeler H, Weibel ER. Limits for oxygen and substrate transport in mammals. J
Exp Biol 1998; 201:1051 –1064.
110. Kaminsky LA, Imboden MT, Arena R, Myers J. Reference standards for cardio-
respiratory ﬁtness measured with cardiopulmonary exercise testing using cycle er-
gometry: data from the Fitness Registry and the Importance of Exercise NationalDatabase (FRIEND) registry. Mayo Clin Proc 2017; 92:228 –233.
111. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Kaminsky LA.
Cardiorespiratory
ﬁtness and mortality in healthy men and women. J Am Coll
Cardiol 2018; 72:2283 –2292.112. Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing,
exercise prescription, and evaluation of functional capacity. Clin Cardiol 1990; 13:
555–565.
113. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, et al. Importance of
assessing cardiorespiratory ﬁtness in clinical practice: a case for ﬁtness as a clinical
vital sign: a scienti ﬁc statement from the American Heart Association. Circulation
2016; 134:e653 –e699.
114. Schmid D, Leitzmann MF. Cardiorespiratory ﬁtness as predictor of cancer mortal-
ity: a systematic review and meta-analysis. Ann Oncol 2015; 26:272 –278.
115. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al.
Cardiorespiratory ﬁtness and classi ﬁcation of risk of cardiovascular disease mortal-
ity.Circulation 2011; 123:1377 –1383.
116. Holtermann A, Marott JL, Gyntelberg F, Søgaard K, Mortensen OS, Prescott E, et al.
Self-reported cardiorespiratory ﬁtness: prediction and classi ﬁcation of risk of car-
diovascular disease mortality and longevity —a prospective investigation in the
Copenhagen City Heart Study. J Am Heart Assoc 2015; 4:e001495.
117. Stamatakis E, Hamer M, O ’Donovan G, Batty GD, Kivimaki M. A non-exercise test-
ing method for estimating cardiorespiratory ﬁtness: associations with all-cause and
cardiovascular mortality in a pooled analysis of eight population-based cohorts. Eur
Heart J 2013; 34:750 –758.
118. Wickramasinghe CD, Ayers CR, Das S, De Lemos JA, Willis BL, Berry JD.
Prediction of 30-year risk for cardiovascular mortality by ﬁtness and risk factor le-
vels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes 2014; 7:
597–602.
119. Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al.
Cardiorespiratory ﬁtness and survival following cancer diagnosis. Eur J Prev
Cardiol 2021;28:1242 –1249.
120. Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of
post-diagnosis cardiorespiratory ﬁtness with cause-speci ﬁc mortality in cancer. Eur
Heart J Qual Care Clin Outcomes 2020; 6:315 –322.
121. Jones LM, Stoner L, Brown C, Baldi JC, McLaren B. Cardiorespiratory ﬁtness pre-
dicts cardiovascular health in breast cancer survivors, independent of body com-
position, age and time post-treatment completion. Breast Cancer 2019; 26:
729–737.
122. Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The utility of exercise testing in
patients with lung cancer. J Thorac Oncol 2016; 11:1397 –1410.
123. West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. Cardiopulmonary
exercise variables are associated with postoperative morbidity after major colonic
surgery: a prospective blinded observational study. Br J Anaesth 2014; 112:665 –671.
124. West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MPW, et al.
Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal
cancer surgery. Br J Surg 2014; 101:1166 –1172.
125. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al.2 0 2 2E S C
guidelines on cardiovascular assessment and management of patients undergoing non-
cardiac surgery. Eur Heart J 2022;43:3826 –3924.
126. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding vari-
ant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in child-hood cancer. Nat Genet 2015; 47:1079 –1084.
127. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al.
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorph-
isms in carbonyl reductase genes —a report from the Children ’s Oncology Group. J
Clin Oncol 2012; 30:1415 –1421.
128. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al.
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are as-
sociated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112:
3754 –3762.
129. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant
myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;
375:1749 –1755.
130. European Society of Cardiology. ESC CardioMed . 3rd ed. Oxford: Oxford
University Press; 2018.
131. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med
2016; 375:1457 –1467.
132. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al.
Cancer diagnosis in patients with heart failure: epidemiology, clinical implications
and gaps in knowledge. Eur J Heart Fail 2018; 20:879 –887.
133. D ’Ascenzi F, Anselmi F, Fiorentini C, Mannucci R, Bonifazi M, Mondillo S. The ben-
eﬁts of exercise in cancer patients and the criteria for exercise prescription in
cardio-oncology. Eur J Prev Cardiol 2021; 28:725 –735.
134. Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, et al.
Association between life ’s simple 7 and noncardiovascular disease: the multi-ethnic
study of atherosclerosis. J Am Heart Assoc 2016; 5:e003954.
135. Michos ED, Marshall CH. Healthy lifestyle bene ﬁts both cancer and cardiovascular
disease: more bang for the buck. JACC CardioOncology 2021; 3:675 –677.4346 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

136. Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of
cancer therapy-related cardiac dysfunction in breast cancer patients undergoingchemotherapy: systematic review. Eur J Prev Cardiol 2022; 29:463 –472.
137. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular tox-
icity in cancer. Circulation 2018; 137:1176 –1191.
138. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/
ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;
39:3021 –3104.
139. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in col-laboration with the EASD. Eur Heart J 2020; 41:255 –323.
140. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019
ESC/EAS Guidelines for the management of dyslipidaemias: lipid modi ﬁcation to re-
duce cardiovascular risk. Eur Heart J 2020; 41:111 –188.
141. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al.
Cardio-oncology drug interactions: a scienti ﬁc statement from the American
Heart Association. Circulation 2022; 145:e811 –e838.
142. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, et al. Deﬁnition of
hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinicalimplications. Eur Heart J 2019; 40:1771 –1777.
143. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardio-
toxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer
2013; 49:2900 –2909.
144. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart
failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.J Am Coll Cardiol 2012; 60:2504 –2512.
145. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, De Caralt TM, et al.
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular sys-tolic dysfunction in patients with malignant hemopathies: the OVERCOME trial
(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients
submitted to intensive ChemOtherapy for the treatment of MalignanthEmopathies). J Am Coll Cardiol 2013; 61:2355 –2362.
146. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F,
Gonçalves Brandão SM, Rigaud VOC,
et al. Carvedilol for prevention of
chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018; 71:
2281 –2290.
147. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al.
Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparingtwo strategies for guiding prevention with enalapril: The International
CardioOncology Society-one trial. Eur J Cancer 2018; 94:126 –137.
148. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of
spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail
2015; 17:81–89.
149. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efﬁciency of ator-
vastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll
Cardiol 2011; 58:988 –989.
150. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al.
Prevention of cardiac dysfunction during adjuvant breast cancer therapy(PRADA): a 2 ×2 factorial, randomized, placebo-controlled, double-blind clinical
trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671 –1680.
151. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, et al. Neurohormonal
blockade and circulating cardiovascular biomarkers during anthracycline therapy inbreast cancer patients: results from the PRADA (Prevention of Cardiac
Dysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc
2017; 6:e006513.
152. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W,
et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardi-
otoxicity in patients with breast cancer. J Am Coll Cardiol 2019; 73:2859 –2868.
153. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al.
Multidisciplinary approach to novel therapies in cardio-oncology research(MANTICORE 101-Breast): a randomized trial for the prevention oftrastuzumab-associated cardiotoxicity. J Clin Oncol 2017; 35:870 –877.
154. Boekhout AH, Gietema JA, Kerklaan BM, VanWerkhoven ED, Altena R, Honkoop
A,et al. Angiotensin II receptor inhibition with candesartan to prevent
trastuzumab-related cardiotoxic effects in patients with early breast cancer a ran-
domized clinical trial. JAMA Oncol 2016; 2:1030 –1037.
155. Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A.
Prevention of anthracycline-induced cardiotoxicity: a systematic review and
meta-analysis. Intern Emerg Med 2021; 16
:477 –486.
156. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-
blockers in chemotherapy-induced cardiotoxicity —a systematic review and
meta-analysis of carvedilol. Heart Fail Rev 2019; 24:325 –333.
157. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. Efﬁcacy of
neurohormonal therapies in preventing cardiotoxicity in patients with cancerundergoing chemotherapy. JACC CardioOncology 2019; 1:54–65.158. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efﬁcacy of
dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC
CardioOncology 2019; 1:68–79.
159. Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on
chemotherapy-induced heart failure: a systematic review and network
meta-analysis of randomized controlled trials. Pharmacol Res 2020; 151:104577.
160. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: ameta-analysis of randomized controlled trials. Heart Fail Rev 2021; 26:101 –109.
161. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by
a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65:
870–873.
162. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,
et al. American Society of Clinical Oncology 2008 clinical practice guideline update:
use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:
127–145.
163. European Medicines Agency. Savene: EPAR —Product Information (Internet) 2008
(updated 2019).
164. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: chal-
lenges and opportunities. J Am Coll Cardiol 2014; 64:938 –945.
165. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of
cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in
breast cancer: a Bayesian network meta-analysis. Eur J Cancer 2015; 51:2314 –2320.
166. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed ad-
ministration of dexrazoxane provides cardioprotection for patients with advanced
breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15:
1333 –1340.
167. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective inter-
ventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev
2011; 2011 :CD003917.
168. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal for-
mulations of doxorubicin with drug administered in free form: changing toxicity
proﬁles.Drug Saf 2001; 24:903 –920.
169. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in
image-guided radiotherapy. Nat Rev Cancer 2007; 7:949 –960.
170. De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.
Radiotherapy toxicity. Nat Rev Dis Prim 2019; 5:13.
171. Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, et al.
Association of breast cancer irradiation with cardiac toxic effects: a narrative re-view. JAMA Oncol 2021; 7:924–932.
172. Ban ﬁll K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac tox-
icity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol
2021; 16:216 –227.
173. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al.
Cardiovascular manifestations from therapeutic radiation: a multidisciplinary ex-
pert consensus statement from the International Cardio-Oncology Society. JACC
CardioOncology 2021; 3:360 –380.
174. Kirwan CC, Coles CE, Bliss J, Kirwan C, Kilburn L, Fox L, et al. It’s PRIMETIME.
Postoperative avoidance of radiotherapy: biomarker selection of women at very
low risk of local recurrence. Clin Oncol 2016; 28:594 –596.
175. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al.
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients
by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474 –2481.
176. Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E,
et al. Statin exposure and risk of heart failure after anthracycline-or trastuzumab-
based chemotherapy for early breast cancer: a propensity score ⍰matched cohort
study.
J Am Heart Assoc 2021; 10:e018393.
177. Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S,
Amir E, et al. Cardioprotective effect of statins in patients with HER2-positive
breast cancer receiving trastuzumab therapy. Can J Cardiol 2019; 35:153 –159.
178. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the
risk for incident heart failure in patients with breast cancer receiving anthracyclinechemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012; 60:
2384 –2390.
179. Chotenimitkhun R, D ’Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S,
et al. Chronic statin administration may attenuate early anthracycline-associated
declines in left ventricular ejection function. Can J Cardiol 2015; 31:302 –307.
180. Obasi M, Abovich A, Vo JB, Gao Y, Papatheodorou SI, Nohria A, et al. Statins to
mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastu-zumab: a systematic review and meta-analysis. Cancer Causes Control 2021; 32:
1395 –1405.
181. Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin use can attenuate the decline in left
ventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic
chemotherapy recipients: a systematic review and meta-analysis. J Clin Med 2021;
10:3731.ESC Guidelines 4347Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

182. San ﬁlippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, et al. Statins are
associated with reduced mortality in multiple myeloma. J Clin Oncol 2016; 34:
4008 –4014.
183. Afzal A, Fiala MA, Gage BF, Wildes TM, San ﬁlippo K. Statins reduce mortality in
multiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk
2020; 20:e937 –e943.
184. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing
chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized,single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019; 24:233 –241.
185. Shahid I, Yamani N, Ali A, Kumar P, Figueredo V, Unzek S, et al. Meta-analysis evalu-
ating the use of statins to attenuate cardiotoxicity in cancer patients receiving an-
thracyclines and trastuzumab-based chemotherapy. Am J Cardiol 2021; 156:
142–145.
186. Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective effects of
carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol
2017; 69:279 –285.
187. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic
systems for patients to report and manage side effects of cancer treatment: system-
atic review. J Med Internet Res 2019; 21:e10875.
188. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García
Sanz R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position
paper and recommendations. Rev Española Cardiol (English Ed) 2017; 70:474 –486.
189. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of
the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast
cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res
Treat 2019; 175:595 –603.
190. Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al.
Comparison of long-term outcome in anthracycline-related versus idiopathic di-
lated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018; 20:898 –906.
191. Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of bio-
markers for the prevention, assessment, and management of heart failure: a scien-tiﬁc statement from the American Heart Association. Circulation 2017;
135:
e1054 –e1091. Erratum in: Circulation 2017;136:e345.
192. De Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in
heart failure. Eur J Heart Fail 2015; 17:559 –569.
193. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we
fail to exploit their potential? Crit Rev Clin Lab Sci 2018; 55:246 –263.
194. Du W, Piek A, Marloes Schouten E, van de Kolk CWA, Mueller C, Mebazaa A, et al.
Plasma levels of heart failure biomarkers are primarily a re ﬂection of extracardiac
production. Theranostics 2018; 8:4155 –4169.
195. Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, et al. Sex-speci ﬁc
associations of cardiovascular risk factors and biomarkers with incident heart fail-
ure. J Am Coll Cardiol 2020; 76:1455 –1465.
196. Bracun V, Aboumsallem JP, van der Meer P, de Boer RA. Cardiac biomarkers in pa-
tients with cancer: considerations, clinical implications, and future avenues. Curr
Oncol Rep 2020; 22:67.
197. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc
Transl Res 2020; 13:431 –450.
198. López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for
the early detection of cardiotoxicity due to anticancer therapies. Rev Española
Cardiol (English Ed) 2017; 70:487 –495.
199. Eschenhagen T, Force T, Ewer MS, De Keulenaer GW, Suter TM, Anker SD, et al.
Cardiovascular side effects of cancer therapies: a position statement from the
Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail
2011; 13:1–10.
200. Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiog-
raphy in cardio-oncology. Echocardiography 2020; 37:1149 –1158.
201. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in
cardio-oncology. JACC CardioOncology 2020; 2:677 –689.
202. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and
incremental value of deformation indices for prediction of trastuzumab-induced
cardiotoxicity. J Am Soc Echocardiogr 2013; 26:493 –498.
203. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Aakhus S, Miyazaki S, et al.
Cardioprotection using strain-guided management of potentially cardiotoxic can-cer therapy: 1 year results of the SUCCOUR trial. Eur Heart J 2020; 41:
ehaa946.3282.
204. Vallabhaneni S, Zhang KW, Alvarez JA, Joshua C, Henning DM, Woodard PK, et al.
Role of cardiovascular magnetic resonance in early detection and treatment of car-diac dysfunction in oncology patients. Int J Cardiovasc Imaging 2021;37:3003 –3017.
205. Lapinskas T, Hireche-Chikaoui H, Zieschang V, Erley J, Stehning C, Gebker R, et al.
Effect of comprehensive initial training on the variability of left ventricular measures
using fast-SENC cardiac magnetic resonance imaging. Sci Rep 2019; 9:12223.
206. Korosoglou G, Giusca S, Montenbruck M, Patel AR, Lapinskas T, Götze C, et al. Fast
strain-encoded cardiac magnetic resonance for diagnostic classi ﬁcation and risk
strati ﬁcation of heart failure patients. JACC Cardiovasc Imaging 2021; 14:1177 –1188.207. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/
AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the managementof heart failure: a report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart Failure
Society of America. Circulation 2017; 136:e137 –e161.
208. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early
detection of anthracycline cardiotoxicity and improvement with heart failure ther-apy. Circulation 2015; 131:1981 –1988.
209. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac
events and the value of echocardiographic evaluation in patients receivinganthracycline-based chemotherapy. Am J Cardiol 2015; 116:442 –446.
210. Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, et al. Examining the
cost-effectiveness of baseline left ventricular function assessment among breast
cancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat
2019; 176:261 –270.
211. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, et al. The utility
of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemo-therapy: a feasibility study. J Card Fail 2016; 22:433 –438.
212. Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, et al.
Circulating biomarkers and cardiac function over 3 years after chemotherapywith anthracyclines: the ICOS-ONE trial. ESC Heart Fail
2020; 7:1452 –1466.
213. Jones M, O ’Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac
troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac
injury. Ann Clin Biochem 2017; 54:149 –157.
214. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al.
Combination therapies for the treatment of HER2-positive breast cancer: current
and future prospects. Expert Rev Anticancer Ther 2018; 18:629 –649.
215. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell
Biol2001; 2:127 –137.
216. Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 over-
expression upregulates antioxidant enzymes, reduces basal levels of reactive oxy-gen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ
Physiol 2015; 309:H1271 –H1280.
217. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer
treatment-induced cardiotoxicity. Expert Opin Drug Saf 2017; 16:1021 –1038.
218. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A
pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast
Cancer Res Treat 2020; 179:161 –171.
219. Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated
in the adjuvant lapatinib and/or trastuzumab treatment optimization trial. Br J
Cancer 2020; 122:1453 –1460.
220. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment
of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophos-phamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy innode-positive, HER2-overexpressing breast cancer. J Clin Oncol 2005; 23:
7811 –7819.
221. Martin M, Press M, Ph D, Mackey J, Glaspy J, Chan A, et al. Adjuvant trastuzumab in
HER2-positive breast cancer. NEJM 2011; 365:1273 –1283.
222. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer: a randomised controlled trial. Lancet
2007; 369:29–36.
223. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,
et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med 2005; 353:1659 –1672.
224. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast can-cer.N Engl J Med 2005; 353:1673 –1684.
225. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de
Azambuja E, et al. 11 years ’follow-up of trastuzumab after adjuvant chemotherapy
in HER2-positive early breast cancer: ﬁnal analysis of the HERceptin Adjuvant
(HERA) trial. Lancet 2017; 389:1195 –1205.
226. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of
left ventricular ejection fraction and myocardial deformation indices in a cohort ofwomen with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J
Am Soc Echocardiogr 2015; 28:509 –514.
227. Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, et al. A
prospective study about trastuzumab-induced cardiotoxicity in HER2-positive
breast cancer. Am J Clin Oncol Cancer Clin Trials 2020; 43:510 –516.
228. Yang ZY, Wang W, Wang X, Qin ZQ. Cardiotoxicity of epidermal growth factor
receptor 2-targeted drugs for breast cancer. Front Pharmacol 2021; 12:741451.
229. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden
C,et al. 2013 ESC guidelines on the management of stable coronary artery disease:
the Task Force on the management of stable coronary artery disease of theEuropean Society of Cardiology. Eur Heart J 2013; 34:2949 –3003.4348 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

230. Padegimas A, Carver JR. How to diagnose and manage patients with
ﬂuoropyrimidine-induced chest pain: a single center approach. JACC
CardioOncology 2020; 2:650 –654.
231. Kwakman JJM, Simkens LHJ, Mol L, Kok WEM, Koopman M, Punt CJA. Incidence of
capecitabine-related cardiotoxicity in different treatment schedules of metastaticcolorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch
Colorectal Cancer Group. Eur J Cancer 2017; 76:93–99.
232. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can
induce acute coronary syndrome similar to 5- ﬂuorouracil. Ann Oncol 2002; 13:
797–801.
233. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the patho-
physiology of 5- ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;
15:47.
234. Edvardsen T, Asch FM, Davidson B, Delgado V, DeMaria A, Dilsizian V, et al.
Non-invasive imaging in coronary syndromes: recommendations of the European
Association of Cardiovascular Imaging and the American Society ofEchocardiography, in collaboration with the American Society of NuclearCardiology, Society of Cardiovascular Comuted Tomography, and Society forCardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022; 23:
e6–e33.
235. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-ﬂuorouracil
and cardiotoxicity: a review. Ther Adv Med Oncol 2018; 10:1758835918780140.
236. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with no-
vel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends
Cardiovasc Med 2013; 23:104 –113.
237. Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thrombo-
embolic events with sunitinib and sorafenib: a systematic review and meta-analysis
of clinical trials. J Clin Oncol 2010; 28:2280 –2285.
238. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibi-
tors: With a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;
36:295 –316.
239. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular tox-
icity of angiogenesis inhibitors in treatment of malignancy: a systematic review andmeta-analysis. Cancer Treat Rev 2017; 53:120 –127.
240. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients.
Cardio-Oncology 2019; 5:7.
241. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the
treatment of cancer on the cardiovascular system: focus on hypertension.Circulation 2011;
124:1687 –1691.
242. Shah CP, Moreb JS. Cardiotoxicity due to targeted anticancer agents: a growing
challenge. Ther Adv Cardiovasc Dis 2019; 13:1753944719843435.
243. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiv-
ing sunitinib. N Engl J Med 2008; 358:95–97.
244. Hamnvik OPR, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical
risk factors for the development of hypertension in patients treated with inhibitorsof the VEGF signaling pathway. Cancer 2015; 121:311 –319.
245. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive
heart failure with vascular endothelial growth factor receptor tyrosine kinase inhi-
bitors. Crit Rev Oncol Hematol 2015; 94:228 –237.
246. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, et al.
Echocardiographic assessment for the detection of cardiotoxicity due to vascular
endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal
cancers. J Am Soc Echocardiogr 2019; 32:267 –276.
247. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib
and sorafenib. N Engl J Med 2011; 365:1649 –1650.
248. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms
of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension andvascular disease. Hypertension 2018; 71:E1–E8.
249. Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval
prolongation among cancer patients treated with vandetanib: a systematic review
and meta-analysis. PLoS One 2012; 7:e30353.
250. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval pro-
longation with vascular endothelial growth factor receptor tyrosine kinase inhibi-tors. Br J Cancer 2015; 112:296 –305.
251. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identi ﬁcation of
anticancer drugs associated with atrial ﬁbrillation: analysis of the WHO pharmacov-
igilance database. Eur Heart J Cardiovasc Pharmacother 2021; 7:312 –320.
252. EMA. Medicines | European Medicines Agency.
Eur Med Agency Sci Med Heal n.d.
253. FDA. Drugs@FDA: FDA-Approved Drugs. FDA US Food Drug Adm n.d.
254. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of
cardiac toxicity in patients receiving vascular endothelial growth factor signalingpathway inhibitors. Am Heart J 2012; 163:156 –163.
255. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial as-
sessment, surveillance, and management of blood pressure in patients receivingvascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst
2010; 102:596 –604.
256. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic mye-
loid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology 2017;
2017:110 –114.
257. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity
in chronic myeloid leukemia. J Clin Oncol 2015; 33:4210 –4218.
258. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular
and metabolic implications of novel targeted cancer therapies: focus on kinase in-hibitors. J Am Coll Cardiol 2015; 66:1160 –1178.
259. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on
chemotherapy and targeted therapies. Circ Arrhythmia Electrophysiol 2017; 10:
e005443.
260. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al.
Vascular toxicities of cancer therapies: the old and the new —an evolving avenue.
Circulation 2016; 133:1272 –1289.
261. Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine
kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse
event reporting system database (FAERS). Cancers (Basel) 2020; 12:826.
262. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, et al. Optimising
outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy:European recommendations for clinical practice. Br J Haematol 2018; 180:666 –679.
263. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, et al.
Atrial ﬁbrillation in patients with chronic lymphocytic leukemia (CLL). Leuk
Lymphoma 2017; 58:1630 –1639.
264. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Blood 2019;
134:1919 –1928.
265. Brown JR, Moslehi J, O ’Brien S, Ghia P, Hillmen P, Cymbalista F, et al.
Characterization of atrial ﬁbrillation adverse events reported in ibrutinib rando-
mized controlled registration trials. Haematologica 2017; 102:1796 –1805.
266. López-Fernández, T, Canales M, Farmakis D, García-Sanz R, Bosch F, Loscertales J,
et al. Ibrutinib-associated atrial ﬁbrillation: a practical approach. Ann Hematol Oncol
2018; 5:1203.
267. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB,
et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 2019; 74:
1667 –1678.
268. Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular
risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-
based cohort study. J Clin Oncol 2021; 39:3453 –3462.
269. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al.
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia:results of the ﬁrst randomized phase III trial. J Clin Oncol 2021; 39:3441 –3452.
270. Common Terminology Criteria for Adverse Events (CTCAE) v6.0 . National Cancer Institute,
2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
271. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiv-
ing acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 2022;
107:1335 –1346.
272. Svennberg E, Tjong F, Goette A, Akoum N, Di Biaise L, Bordachar P, et al. How to use
digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace .
2022;24:979 –1005.
273. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-
oped in collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS). Eur Heart J 2021; 42:373 –498.
274. McMullen JR, Boey EJ, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases
the risk of atrial ﬁbrillation, potentially through inhibition of cardiac PI3K-Akt signal-
ing.Blood 2014; 124:3829 –3830.
275. Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial ﬁbrillation in
patients with mantle cell lymphoma. Leuk Lymphoma 2016; 57:2914 –2916.
276. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-strati ﬁcation and
management. Am J Hematol 2020; 95:548 –567.
277. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued
improvement in survival in multiple myeloma: changes in early mortality and out-
comes in older patients. Leukemia 2014; 28:1122 –1128.
278. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction —Alzheimer ’s dis-
ease of the heart? N Engl J Med 2013; 368:455 –464.
279. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al.
Carﬁlzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N
Engl J Med 2015; 372:142 –152.
280. Chari A, Keith Stewart A, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis
of car ﬁlzomib cardiovascular safety pro ﬁle across relapsed and/or refractory mul-
tiple myeloma clinical trials. Blood Adv 2018; 2:1633 –1644.ESC Guidelines 4349Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

281. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al.
Carﬁlzomib-associated cardiovascular adverse events: a systematic review and
meta-analysis. JAMA Oncol 2018; 4:e174519.
282. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, et al. Causes of late
mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016; 37:
378–385.
283. Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible
proteasome inhibition with car ﬁlzomib as ﬁrst line therapy in patients with newly
diagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol
2018; 838:85–90.
284. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety
proﬁle of single-agent car ﬁlzomib: experience from 526 patients enrolled in 4 phase
II clinical studies. Haematologica 2013; 98:1753 –1761.
285. Ridol ﬁRL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis.
Clinical and pathologic features of 23 patients. Am J Med 1977; 62:677 –686.
286. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary compli-
cations of car ﬁlzomib treatment and associated risk factors using the
SEER-Medicare database. Cancer 2020; 126:808 –813.
287. Feng DL, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al.
Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.
Circulation 2007; 116:2420 –2426.
288. Mancuso S, Carlisi M, Sarocchi M, Napolitano M, Siragusa S. Cardio-oncology in
multiple myeloma: is it time for a speci ﬁc focus? Leuk Lymphoma 2018; 59:
1764 –1766.
289. Danhof S, Schreder M, Rasche L, Stri ﬂer S, Einsele H, Knop S. ‘Real-life ’experience
of preapproval car ﬁlzomib-based therapy in myeloma —analysis of cardiac toxicity
and predisposing factors. Eur J Haematol 2016; 97:25–32.
290. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and
treatment of cardiac amyloidosis. A position statement of the European Society of
Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail
2021; 23:512–526.
291. Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac throm-
bosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119:
2490 –2497.
292. Sonneveld P, Asselbergs E, Zweegman S, Van Der Holt B, Kersten MJ, Vellenga E,
et al. Phase 2 study of car ﬁlzomib, thalidomide, and dexamethasone as induction/
consolidation therapy for newly diagnosed multiple myeloma. Blood 2015; 125:
449–456.
293. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase 2
dose-expansion study (PX-171-006) of car ﬁlzomib, lenalidomide, and low-dose
dexamethasone in relapsed or progressive multiple myeloma. Blood 2013; 122:
3122 –3128.
294. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, et al.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor
and immunomodulatory therapy for the treatment of multiple myeloma. Br J
Haematol 2018; 180:271 –275.
295. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular
and thrombotic complications of novel multiple myeloma therapies: a review. JAMA
Oncol 2017; 3:980 –988.
296. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B,
et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in mye-
loma. Leukemia 2008; 22:414 –423.
297. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC,
et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll
Cardiol 2019; 73:1733 –1734.
298. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American
Society of Hematology 2021 guidelines for management of venous thromboembol-
ism: prevention and treatment in patients with cancer. Blood Adv 2021; 5:927 –974.
299. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous
thromboembolism prophylaxis and treatment in patients with cancer: ASCO clin-
ical practice guideline update. J Clin Oncol 2020; 38:496 –520.
300. Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, et al. Comparison
of venous thromboembolism incidence in newly diagnosed multiple myeloma pa-
tients receiving bortezomib, lenalidomide, dexamethasone (RVD) or car ﬁlzomib,
lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophy-
laxis. Br J Haematol 2022; 196:105 –109.
301. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, et al.
Primary prevention of venous thromboembolism with apixaban for multiple mye-
loma patients receiving immunomodulatory agents. Br J Haematol 2020; 190:
555–561.
302. Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple
myeloma —choice of prophylaxis, role of direct oral anticoagulants and special con-
siderations. Br J Haematol 2018; 183:538 –556.303. Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, et al.
Predictive biomarkers and practical considerations in the management of
carﬁlzomib-associated cardiotoxicity. Leuk Lymphoma 2018; 59:1981 –1985.
304. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin,
warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma
treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol
2011; 29:986 –993.
305. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al.
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed mul-
tiple myeloma treated with lenalidomide. Blood 2012; 119:933 –939.
306. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness ana-
lysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in pa-tients newly diagnosed with multiple myeloma. Thromb Res 2016; 145:119 –
125.
307. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary
thromboembolic prevention in multiple myeloma patients: an exploratory
meta-analysis on aspirin use. Semin Hematol 2018; 55:182 –184.
308. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al.
Cardiovascular adverse events associated with BRAF and MEK inhibitors: a system-
atic review and meta-analysis. JAMA Netw Open 2019; 2:e198890.
309. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and
clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC:
CardioOncology state-of-the-art review. Cardio Oncol 2022; 4:1–18.
310. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved
survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;
367:107 –114.
311. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D,
et al. Improved overall survival in melanoma with combined dabrafenib and trame-
tinib. N Engl J Med 2015; 372:30–39.
312. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600
BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised con-trolled trial. Lancet 2015; 386:444 –451.
313. Bronte E, Bronte G, Novo G, Rinaldi G, Bronte F, Passiglia F, et al. Cardiotoxicity
mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.
Pharmacol Ther 2018; 192:65–73.
314. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, et al.
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS
study: incidence, course and management. Eur J Cancer 2019; 119:97–106.
315. Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK in-
hibitor, trametinib: a case report, literature review, and consideration of mechan-
ism. Cardiovasc Toxicol 2017; 17:487 –493.
316. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular
toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115:
854–
868.
317. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated
with immune checkpoint blockade. N Engl J Med 2018; 378:158 –168.
318. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association
between immune checkpoint inhibitors with cardiovascular events and athero-
sclerotic plaque. Circulation 2020; 142:2299 –2311.
319. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G,
Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor
therapy: a meta-analysis. Eur J Heart Fail 2021; 23:1739 –1747.
320. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al.
Cardiovascular toxicities associated with immune checkpoint inhibitors: an obser-vational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19:1579 –1589.
321. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late car-
diac adverse events in patients with cancer treated with immune checkpoint inhi-
bitors. J Immunother Cancer 2020; 8:e000261.
322. D ’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The
risk of cardiac events in patients receiving immune checkpoint inhibitors: a nation-wide Danish study. Eur Heart J 2021; 42:1621 –1631.
323. Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et al.
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors:
a safety meta-analysis. Eur Heart J 2021; 42:4964 –4977.
324. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al.
Factors associated with immune checkpoint inhibitor –related myocarditis. JAMA
Oncol 2019; 5:1635 –1637.
325. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunother-
apy landscape and the epidemiology, diagnosis, and management of cardiotoxicity:
JACC:CardioOncology primer. JACC CardioOncology 2021; 3:35–47.
326. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors
and cardiovascular toxicity. Lancet Oncol 2018; 19:e447 –e458.
327. Schiffer WB, Deych E, Lenihan DJ, Zhang KW. Coronary and aortic calci ﬁcation are
associated with cardiovascular events on immune checkpoint inhibitor therapy. Int J
Cardiol 2021; 322:177 –182.4350 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

328. Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al. Anti-PD-1 monoclonal
antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J
Immunother Cancer 2019; 7:225.
329. Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O,
Lebrun-Vignes B, et al. Immune checkpoint inhibitor-induced myositis, the earliest
and most lethal complication among rheumatic and musculoskeletal toxicities.
Autoimmun Rev 2020; 19:102586.
330. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al.
Immune checkpoint inhibitor –associated myositis: expanding the spectrum of car-
diac complications of the immunotherapy revolution. Circulation 2018; 138:
743–745.
331. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al.
Myocarditis in the setting of cancer therapeutics: proposed case de ﬁnitions for
emerging clinical syndromes in cardio-oncology. Circulation 2019; 140:80–91.
332. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, et al. Clinical
strategy for the diagnosis and treatment of immune checkpoint inhibitor-associatedmyocarditis: a narrative review. JAMA Cardiol 2021; 6:1329 –1337.
333. Rini B, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et al.
Prospective cardiovascular surveillance of immune checkpoint inhibitor-basedcombination therapy in patients with advanced renal cell cancer: data from the
phase 3 JAVELIN Renal 101 trial. J Clin Oncol 2022; 40:1929 –1938.
334. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al.
Global longitudinal strain and cardiac events in patients with immune checkpoint
inhibitor-related myocarditis. J Am Coll Cardiol 2020; 75:467 –478.
335. Kondapalli L, Bottinor W, Lenneman C. By releasing the brakes with immunother-
apy, are we accelerating atherosclerosis? Circulation 2020; 142:2312 –2315.
336. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-
term implications of toxicity. Nat Rev Clin Oncol 2022;19:254 –267.
337. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy
for prostate cancer is associated with cardiovascular morbidity and mortality: a
meta-analysis of population-based observational studies. PLoS One 2014; 9:
e107516.
338. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al.
Cardiovascular effects of androgen deprivation therapy for the treatment of pros-tate cancer: ABCDE Steps to reduce cardiovascular disease in patients with pros-tate cancer. Circulation
2016; 133:537 –541.
339. Okwuosa TM, Morgans A, Rhee J-W, Reding KW, Maliski S, Plana J-C, et al. Impact
of hormonal therapies for treatment of hormone-dependent cancers (breast andprostate) on the cardiovascular system: effects and modi ﬁcations: a scienti ﬁc state-
ment from the American Heart Association. Circ Genomic Precis Med 2021; 14:
e000082.
340. Barber M, Nguyen L, Wassermann J, Spano J, Funck-Brentano C, Salem J. Cardiac
arrhythmia considerations of hormone cancer therapies. Cardiovasc Res 2019; 115:
878–894.
341. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral
relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J
Med 2020; 382:2187 –2196.
342. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential
impact of gonadotropin-releasing hormone antagonist versus agonist on clinicalsafety and oncologic outcomes on patients with metastatic prostate cancer: ameta-analysis of randomized controlled trials. Eur Urol 2021; 79:44–53.
343. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al.
Cardiovascular safety of degarelix versus leuprolide in patients with prostate can-
cer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;
144:1295 –1307.
344. Wilk M, Wa śko-Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors
may improve outcomes of patients with castration-resistant prostate cancer during
abiraterone acetate treatment —a cardio-oncology study. Front Oncol 2021; 11:
664741.
345. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al.
Hypogonadism as a reversible cause of Torsades de Pointes in men. Circulation
2018; 138:110 –113.
346. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. In ﬂuence of steroid hor-
mones on ventricular repolarization. Pharmacol Ther 2016; 167:38–47.
347. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al.
Androgenic effects on ventricular repolarization a translational study from theinternational pharmacovigilance database to iPSC-cardiomyocytes. Circulation
2019; 140:1070 –1080.
348. Hasegawa K, Ito H, Kaseno K, Miyazaki S, Shiomi Y, Tama N, et al.
Impact of medical
castration on malignant arrhythmias in patients with prostate cancer. J Am Heart
Assoc 2021; 10:e017267.
349. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al.
Recognition, prevention, and management of arrhythmias and autonomic disorders
in cardio-oncology: a scienti ﬁc statement from the American Heart Association.
Circulation 2021; 144:E41 –E55.350. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of degarelix, a
gonadotropin-releasing hormone receptor antagonist for the treatment of pros-tate cancer, on cardiac repolarisation in a randomised, placebo and active compara-
tor controlled thorough QT/QTc trial in healthy men. Clin Drug Investig 2017; 37:
873–879.
351. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM, et al. Anastrozole
alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treat-ment of postmenopausal women with early breast cancer: ﬁrst results of the ATAC
randomised trial. Lancet 2002; 359:2131 –2139.
352. ARIMIDEX® (anastrozole). Highlights of Prescribing Information . Wilmington, DE:
AstraZeneca Pharmaceuticals LP, 2014.
353. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B,
Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole
and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med
2005; 353:2747 –2757.
354. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine
therapy in postmenopausal breast cancer patients: a systematic review and
meta-analysis. J Natl Cancer Inst 2011; 103:1299 –1309.
355. Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al.
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast
cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2018; 110:31–39.
356. Curigliano G, Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM.
Prevention, monitoring, and management of cardiac dysfunction in patients withmetastatic breast cancer. Oncologist 2019; 24:e1034 –e1043.
357. KISQALI (ribociclib). Highlights of Prescribing Information . East Hanover, NJ: Novartis
Pharmaceuticals Corporation, 2018.
358. IBRANCE (palbociclib). Highlights of Prescribing Information . New York, NY: P ﬁzer,
2018.
359. VERZENIO (abemaciclib). Highlights of Prescribing Information . Indianapolis, IN: Eli
Lilly and Company, 2018.
360. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al.
Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expres-
sion and pharmacological data analyses, biological basis, and therapeutic implica-
tions. BioDrugs 2019; 33:613 –620.
361. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S,
et al. Ribociclib as ﬁrst-line therapy for HR-positive, advanced breast cancer. N
Engl J Med 2016; 375:1738 –1748.
362. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus
endocrine therapy for premenopausal women with hormone-receptor-positive,
advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet
Oncol 2018; 19:904 –915.
363. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letro-
zole in advanced breast cancer. N Engl J Med 2016; 375:1925 –1936.
364. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant
plus palbociclib versus fulvestrant plus placebo for treatment of
hormone-receptor-positive, HER2 –negative metastatic breast cancer that pro-
gressed on previous endocrine therapy (PALOMA-3): ﬁnal analysis of the multicen-
tre, double-blind, phas. Lancet Oncol 2016; 17:425 –439.
365. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III
randomized study of ribociclib and fulvestrant in hormone receptor-positive, hu-man epidermal growth factor receptor 2-negative advanced breast cancer:
MONALEESA-3. J Clin Oncol 2018; 36:2465 –2472.
366. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.
Palbociclib has no clinically relevant effect on the QTc interval in patients with ad-
vanced breast cancer. Anticancer Drugs 2018; 29:271 –280.
367. Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival
with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019; 381:
307–316.
368. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall
survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med
2020; 382:514 –524.
369. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias:
a review. Drug Saf 2015; 38:129 –152.
370. Wang L, Wang W. Safety and ef ﬁcacy of anaplastic lymphoma kinase tyrosine ki-
nase inhibitors in non-small cell lung cancer (Review). Oncol Rep 2021; 45:13–28.
371. Rao VU, Reeves DJ, Chugh AR, O ’Quinn R, Fradley MG, Raghavendra M, et al.
Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACCstate-of-the-art review. J Am Coll Cardiol 2021; 77:2693 –2716.
372. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or
crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020; 383:
2018 –2029.
373. Thein KZ, Swarup S, Ball S, Quirch M, Vorakunthada Y, Htwe KK, et al. Incidence of
cardiac toxicities in patients with advanced non-small cell lung cancer treated with
osimertinib: a combined analysis of two phase III randomized controlled trials. Ann
Oncol 2018; 29:viii500.ESC Guidelines 4351Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

374. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxi-
city: a retrospective review of the FDA Adverse Events Reporting System (FAERS).
JACC CardioOncology 2019; 1:172 –178.
375. Kunimasa K, Kamada R, Oka T, Oboshi M, Kimura M, Inoue T, et al. Cardiac adverse
events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC
CardioOncology 2020; 2:1–10.
376. Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a re-
view of data. J Clin Oncol 2021; 39:328 –337.
377. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell
therapy. Biol Blood Marrow Transplant 2019; 25:e123 –e127.
378. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al.
Cardiovascular events among adults treated with chimeric antigen receptor
T-cells (CAR-T). J Am Coll Cardiol 2019; 74:3099 –3108.
379. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovas-
cular and pulmonary events associated with chimeric antigen receptor T-cell ther-
apy. J Am Coll Cardiol 2021; 78:1800 –1813.
380. Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik
AA. Cardiovascular toxicity and mortality associated with adoptive cell therapy
and tumor-in ﬁltrating lymphocytes for advanced stage melanoma. J Immunother
2021; 44:86–89.
381. Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell
therapy-related cardiovascular outcomes and management: systemic disease ordirect cardiotoxicity? JACC CardioOncology 2020; 2:97–109.
382. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M.
Cardiovascular effects of CAR T cell therapy: a restrospective study. JACC
CardioOncology 2020; 2:193 –203.
383. Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ. Cardiac events associated with chi-
meric antigen receptor T-cells (CAR-T): a VigiBase perspective. J Am Coll Cardiol
2020; 75:2521 –2523.
384. Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen
receptor T-cell therapy-associated cardiomyopathy in patients with refractory or
relapsed non-Hodgkin lymphoma. Circulation 2020; 142:1687
–1690.
385. Lee JB, Vasic D, Kang H, Fang KKL, Zhang L. State-of-art of cellular therapy for acute
leukemia. Int J Mol Sci 2021; 22:4590.
386. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune
checkpoint inhibitor-related adverse events. J Immunother Cancer 2021; 9:e002435.
387. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al.
Diagnosis, grading and management of toxicities from immunotherapies in children,
adolescents and young adults with cancer. Nat Rev Clin Oncol 2021; 18:435 –453.
388. Maus M V, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society
for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector
cell-related adverse events. J Immunother Cancer 2020; 8:e001511.
389. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al.
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N
Engl J Med 2013; 368:987 –998.
390. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann
M,et al. Radiation dose-response relationship for risk of coronary heart disease in
survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34:235 –243.
391. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol ADG,
et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl
Cancer Inst 2015; 107:djv008.
392. Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past,
present, and future of radiation-induced cardiotoxicity: re ﬁnements in targeting,
surveillance, and risk strati ﬁcation. JACC CardioOncology 2021; 3:343 –359.
393. Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of
an underrecognized pathology. J Am Heart Assoc 2021; 10:e021686.
394. Carlson LE, Watt GP, Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. Coronary
artery disease in young women after radiation therapy for breast cancer. JACC
CardioOncology 2021; 3:381 –392.
395. Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, et al. Is mean
heart dose a relevant surrogate parameter of left ventricle and coronary arteries
exposure during breast cancer radiotherapy: a dosimetric evaluation based on
individually-determined radiation dose (BACCARAT study). Radiat Oncol 2019;
14:29.
396. Hoppe BS, Bates JE, Mendenhall NP, Morris CG, Louis D, Ho MW, et al. The mean-
ingless meaning of mean heart dose in mediastinal lymphoma in the modern radi-
ation therapy era. Pract Radiat Oncol 2020; 10:e147 –e154.
397. Maraldo M V, Giusti F, Vogelius IR, Lundemann M, Van der Kaaij MAE, Ramadan S,
et al. Cardiovascular disease after treatment for Hodgkin ’s lymphoma: an analysis of
nine collaborative EORTC-LYSA trials. Lancet Haematol 2015; 2:e492 –e502.
398. Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, et al.
Mean heart dose is an inadequate surrogate for left anterior descending coronary
artery dose and the risk of major adverse cardiac events in lung cancer radiation
therapy. Int J Radiat Oncol 2021;110:1473 –1479.399. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al.
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent can-
cer: retrospective analysis of the childhood cancer survivor study cohort. BMJ2009;
339:b4606.
400. Van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers
JMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year dis-
ease risk. JAMA Intern Med 2015; 175:1007 –1017.
401. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, et al.
Radiation dose-response for risk of myocardial infarction in breast cancer survi-
vors. Int J Radiat Oncol Biol Phys 2019; 103:595 –604.
402. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission
tomography-guided treatment in early-stage favorable Hodgkin lymphoma: ﬁnal re-
sults of the international, randomized phase III HD16 trial by the German Hodgkin
Study Group. J Clin Oncol 2019; 37:2835 –2845.
403. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of
a trial of PET-directed therapy for early-stage Hodgkin ’s lymphoma. N Engl J Med
2015; 372:1598 –1607.
404. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving sur-
gery with or without irradiation in women aged 65 years or older with early breast
cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16:266 –273.
405. Song AJ, Manukian G, Taylor AK, Anne PR, Simone NL. Concerns for active breath-
ing control (ABC) with breast cancer in the era of COVID-19: maximizing infection
control while minimizing heart dose. Adv Radiat Oncol 2020; 5:573 –574.
406. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al.
Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma:bene ﬁt of deep inspiration breath-hold. Acta Oncol (Madr) 2015; 54:60–66.
407. Persson GF, Scherman Rydhög J, Josipovic M, Maraldo M V, Nygård L, Costa J, et al.
Deep inspiration breath-hold volumetric modulated arc radiotherapy decreasesdose to mediastinal structures in locally advanced lung cancer. Acta Oncol (Madr)
2016; 55:1053 –1056.
408. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al.
Proton therapy for adults with mediastinal lymphomas: the InternationalLymphoma Radiation Oncology Group guidelines. Blood 2018; 132:1635 –1646.
Erratum in: Blood 2019;133:1384 –1385.
409. Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children
and adults undergoing hematopoietic stem cell transplantation. J Thromb
Thrombolysis 2021; 51:854 –869.
410. Oliveira GH, Al-Kindi SG, Guha A, Dey AK, Rhea IB, DeLima MJ. Cardiovascular risk
assessment and management of patients undergoing hematopoietic cell transplant-ation. Bone Marrow Transplant 2021; 56:544 –551.
411. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al.
Hematopoietic cell transplantation (HCT)-speci ﬁc comorbidity index: a new tool
for risk assessment before allogeneic HCT. Blood 2005; 106:2912 –2919.
412. Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M, et al. Premature car-
diovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood
2007; 110:3463 –3471.
413. Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, et al. Clinical preva-
lence and outcome of cardiovascular events in the ﬁrst 100 days postallogeneic
hematopoietic stem cell transplant. Eur J Haematol 2021; 106:32–39.
414. Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac tox-
icity associated with post-transplant cyclophosphamide in allogeneic stem cell
transplantation. JACC CardioOncology
2021; 3:250 –259.
415. López-Fernández T, Vadillo IS, de la Guía AL, Barbier KH. Cardiovascular issues in
hematopoietic stem cell transplantation (HSCT). Curr Treat Options Oncol 2021; 22:
51.
416. Ohmoto A, Fuji S. Cardiac complications associated with hematopoietic stem-cell
transplantation. Bone Marrow Transplant 2021; 56:2637 –2643.
417. Takatsuka H, Nakajima T, Nomura K, Okikawa Y, Wakae T, Toda A, et al. Prognosis
value of atrial natriuretic peptide and brain natriuretic peptide for heart failure inpatients undergoing allogeneic bone marrow transplantation. Hematology 2006;
11:351 –354.
418. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al.
Assessment of cardiotoxicity during haemopoietic stem cell transplantation withplasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26:309 –313.
419. Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ.
Cardiac biomarkers during cancer therapy: practical applications forcardio-oncology. JACC CardioOncology 2020; 2:791 –794.
420. Mohammed J, Smith SR, Burns L, Basak G, Aljurf M, Savani BN, et al. Role of physical
therapy before and after hematopoietic stem cell transplantation: white paper re-
port. Biol Blood Marrow Transplant 2019; 25:e191 –e198.
421. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al.
Cardiovascular risk factors and morbidity in long-term survivors of testicular can-
cer: a 20-year follow-up study. J Clin Oncol 2010; 28:4649 –4657.4352 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

422. Herrmann J. Cardiovascular toxicity with cisplatin in patients with testicular cancer:
looking for something heavier than heavy metal. JACC CardioOncology 2020; 2:
456–459.
423. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao
Pérez L, Marconi G, et al. Safety of FLT3 inhibitors in patients with acute myeloid
leukemia. Expert Rev Hematol 2021; 14:851 –865.
424. Dong H, Yao L, Wang M, Wang M, Li X, Sun X, et al. Can ACEI/ARB prevent the
cardiotoxicity caused by chemotherapy in early-stage breast cancer? —A
meta-analysis of randomized controlled trials. Transl Cancer Res 2020; 11:
7034 –7043.
425. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al.
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharma-cologic therapy. J Am Coll Cardiol 2010; 55:213 –220.
426. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab der-
uxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382:
610–621.
427. Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of tras-
tuzumab therapy in patients with HER2-positive breast cancer and reduced left
ventricular ejection fraction. Breast Cancer Res Treat 2019; 175:239 –246.
428. Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC,
et al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.
JACC CardioOncology 2019; 1:1–10.
429. Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy car-
diotoxicity: JACC:CardioOncology state-of-the-art review. Cardio Oncol 2022; 4:
19–37.
430. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al.
Independent adjudication of symptomatic heart failure with the use of doxorubicin
and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined re-
view of cardiac data from the National Surgical Adjuvant Breast and Bowel ProjectB-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin
Oncol 2010; 28:3416 –3421.
431. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al.
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical
course and response to medical treatment.
J Clin Oncol 2005; 23:7820 –7826.
432. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term
cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson
Cancer Center experience. J Clin Oncol 2006; 24:4107 –4115.
433. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, et al. Long-term follow-up
assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of
HER2-targeted therapies in patients with breast cancer and compromised heartfunction. Breast Cancer Res Treat 2021; 185:863 –868.
434. Mahmood SS, Fradley MG, Cohen J V, Nohria A, Reynolds KL, Heinzerling LM, et al.
Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol
2018; 71:1755 –1764.
435. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al.
Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis.
Circulation 2021; 144:1521 –1523. Erratum in: Circulation 2021;144:e490.
436. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al.
Major adverse cardiovascular events and the timing and dose of corticosteroids
in immune checkpoint inhibitor-associated myocarditis. Circulation 2020; 141:
2031 –2034.
437. Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suf ﬁotti M, Moslehi JJ, et al.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myo-carditis. J Immunother Cancer 2021; 9:e003594.
438. Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early
detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT.
Front Cardiovasc Med 2021; 8:614997.
439. Chen Y, Jia Y, Liu Q, Shen Y, Zhu H, Dong X, et al. Myocarditis related to immune
checkpoint inhibitors treatment: two case reports and literature review. Ann Palliat
Med 2021; 10:8512 –8517.
440. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al.
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of diseasethrough endomyocardial biopsy. Eur J Heart Fail 2021; 23:1725 –1735.
441. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al.
2019 ESC Guidelines for the management of patients with supraventricular tachy-cardia. Eur Heart J 2020;
41:655 –720.
442. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022
ESC Guidelines for the management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death. Eur Heart J 2022; 43:3997 –4126.
443. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur
Heart J 2021; 42:3427 –3520.
444. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015
ESC Guidelines for the diagnosis and management of pericardial diseases: the TaskForce for the Diagnosis and Management of Pericardial Diseases of the EuropeanSociety of Cardiology (ESC) Endorsed by: The European Association for
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921 –2964.
445. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.
Management of acute myocarditis and chronic in ﬂammatory cardiomyopathy: an
expert consensus document. Circ Heart Fail 2020; 13:e007405.
446. Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al.
Management of immune checkpoint inhibitor –induced myocarditis: the French
Working Group ’s Plea for a pragmatic approach. JACC CardioOncology 2021; 3:
157–161.
447. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-
blind, placebo-controlled, pilot trial of in ﬂiximab, a chimeric monoclonal antibody
to tumor necrosis factor- α, in patients with moderate-to-severe heart failure:
Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH)trial. Circulation 2003; 107:3133 –3140.
448. Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensi ﬁed im-
munosuppressive therapy in patients with immune checkpoint inhibitor-inducedmyocarditis. J Immunother Cancer 2020; 8:e001887.
449. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune
checkpoint inhibitor rechallenge after immune-related adverse events in patientswith cancer. JAMA Oncol 2020; 6:865 –871.
450. Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunc-
tion after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016; 23
:
e1925 –e1928.
451. Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. U.S. Food and
Drug Administration approval summary: atezolizumab for metastatic non –small
cell lung cancer. Clin Cancer Res 2017; 23:4534 –4539.
452. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS,
et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic
of the week. J Am Coll Cardiol 2019; 74:1714 –1727.
453. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al.
Myocardial T1 and T2 mapping by magnetic resonance in patients with immunecheckpoint inhibitor –associated myocarditis. J Am Coll Cardiol 2021; 77:1503 –1516.
454. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al.
Management of immune-related adverse events in patients treated with immunecheckpoint inhibitor therapy: American Society of Clinical Oncology clinical prac-tice guideline. J Clin Oncol 2018; 36:1714 –1768.
455. Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular
events associated with chimeric antigen receptor T cell therapy: cross-sectionalFDA adverse events reporting system analysis: cardiovascular events with CAR-T
therapy. Biol Blood Marrow Transplant 2020; 26:2211 –2216.
456. Kupari M, Volin L, Suokas A, Hekali P, Ruutu T. Cardiac involvement in bone mar-
row transplantation: serial changes in left ventricular size, mass and performance. J
Intern Med 1990; 227:259 –266.
457. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al.
Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow
Transplant 2015; 50:1212 –1216.
458. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020
ESC Guidelines for the management of acute coronary syndromes in patients pre-senting without persistent ST-segment elevation. Eur Heart J 2021; 42:1289 –1367.
459. Abo S, Ritchie D, Denehy L, Panek-Hudson Y, Irving L, Granger CL. A hospital and
home-based exercise program to address functional decline in people followingallogeneic stem cell transplantation. Support Care Cancer 2018; 26:1727 –1736.
460. Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in
cancer patients. Curr Oncol Rep 2018; 20:27.
461. Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, et al. Is it feasible to conduct a
randomised controlled trial of pretransplant exercise (prehabilitation) for patientswith multiple myeloma awaiting autologous haematopoietic stem cell transplant-ation? Protocol for the PREeMPT study. BMJ Open 2018; 8:e021333.
462. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National
prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with
prior history of mediastinal/intrathoracic cancer and radiation therapy. Int J
Cardiol 2020; 309:14–18.
463. Sattler K, El-Battrawy I, Lang S, Zhou X, Schramm K, Tülümen E, et al. Prevalence of
cancer in Takotsubo cardiomyopathy: short and long-term outcome. Int J Cardiol
2017; 238:159 –165.
464. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology
of Takotsubo syndrome —a joint scienti ﬁc statement from the HFA TTS and
Myocardial Function Working Group of the ESC —Part 2: vascular pathophysi-
ology, gender and sex hormones, genetics, chronic cardiovascular problems andclinical implications. Eur J Heart Fail 2022; 24:274 –286.
465. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology
of Takotsubo syndrome —a joint scienti ﬁc statement from the HFA TTS Study
Group and Myocardial Function Working Group of the ESC —Part 1: overview
and the central role for catecholamines and sympathetic nervous system. Eur J
Heart Fail 2022; 24:257 –273.ESC Guidelines 4353Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

466. Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating
microRNAs predispose to Takotsubo syndrome following high-dose adrenalineexposure. Cardiovasc Res 2022; 118:1758 –1770.
467. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International
expert consensus document on Takotsubo syndrome (part II): diagnostic workup,outcome, and management. Eur Heart J 2018; 39:2047 –2062.
468. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International
expert consensus document on Takotsubo syndrome (part I): clinical characteris-tics, diagnostic criteria, and pathophysiology. Eur Heart J 2018; 39:2032 –2046.
469. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al.
Current state of knowledge on Takotsubo syndrome: a Position Statement fromthe Taskforce on Takotsubo Syndrome of the Heart Failure Association of theEuropean Society of Cardiology. Eur J Heart Fail 2016; 18:8–27.
470. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al.
Cancers predispose neutrophils to release extracellular DNA traps that contributeto cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012; 109:13076 –13081.
471. Mrotzek SM, Lena A, Hadzibegovic S, Ludwig R, Al-Rashid F, Mahabadi AA, et al.
Assessment of coronary artery disease during hospitalization for cancer treatment.Clin Res Cardiol 2021; 110:200 –210.
472. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm
causing temporary ST elevation myocardial infarction (inferior STEMI) —systemic
inﬂammatory response syndrome after use of pembrolizumab. Arch Med Sci
Atheroscler Dis 2017; 2:100 –102.
473. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al.
Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case reportand review of the literature and international registries. Target Oncol 2018; 13:
509–515.
474. Iannaccone M, D ’Ascenzo F, Vadalà P, Wilton SB, Noussan P, Colombo F, et al.
Prevalence and outcome of patients with cancer and acute coronary syndromeundergoing percutaneous coronary intervention: a BleeMACS substudy. Eur
Heart Journal Acute Cardiovasc Care 2018; 7:631 –638.
475. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al.
Acute myocardial infarction treatments and outcomes in 6.5 million patientswith a current or historical diagnosis of cancer in the USA. Eur Heart J 2020; 41:
2183 –
2193.
476. Velders MA, Boden H, Hofma SH, Osanto S, Van Der Hoeven BL, Heestermans
AACM, et al. Outcome after ST elevation myocardial infarction in patients with
cancer treated with primary percutaneous coronary intervention. Am J Cardiol
2013; 112:1867 –1872.
477. Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, et al. Ischemia and
bleeding in cancer patients undergoing percutaneous coronary intervention. JACC
CardioOncology 2019; 1:145 –155.
478. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al.
Percutaneous coronary intervention in cancer patients: a report of the prevalenceand outcomes in the United States. Eur Heart J 2019; 40:1790 –1800.
479. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary
intervention in metastatic cancer patients with acute coronary syndrome over a10-year period. J Cancer Res Clin Oncol 2016; 142:471 –479.
480. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al.
Temporal trends and outcomes of acute myocardial infarction in patients with can-
cer.Ann Transl Med 2017; 5:482.
481. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and out-
comes of acute coronary syndrome in the cancer population. Clin Cardiol 2012; 35:
443–450.
482. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al.
Evaluation and management of cancer patients presenting with acute cardiovascu-lar disease: a Consensus Document of the Acute CardioVascular Care (ACVC) as-
sociation and the ESC council of Cardio-Oncology —Part 1: acute coronary
syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;
10:947 –959.
483. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY,
et al. Effect of primary percutaneous coronary intervention on in-hospital out-
comes among active cancer patients presenting with ST-elevation myocardial in-farction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care
2021; 10:829 –839.
484. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI
Expert consensus statement: Evaluation, management, and special considerationsof cardio-oncology patients in the cardiac catheterization laboratory (endorsedby the Cardiological Society of India, and Sociedad Latino Americana deCardiolog ıa Intervencionista). Catheter Cardiovasc Interv 2016; 87:E202 –E223.
485. Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, et al.
‘Bringing on the light ’in a complex clinical scenario: optical coherence tomog-
raphy –guided discontinuation of antiplatelet therapy in cancer patients with coron-
ary artery disease (PROTECT-OCT registry). Am Heart J 2017; 194:83–91.486. Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M,
et al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients
with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018;
122:1465 –1470.
487. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al.
Prophylactic options in patients with 5- ﬂuorouracil-associated cardiotoxicity. Br J
Cancer 2003; 88:1507 –1509.
488. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain
relieved by diltiazem. Am J Cardiol 2012; 110:1623 –1626.
489. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy
to prevent 5- ﬂuorouracil-related myocardial ischemia: a case report. Cancer
Chemother Pharmacol 1999; 43:157 –161.
490. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular com-
plications of cancer therapy: best practices in diagnosis, prevention, and manage-
ment: part 2. J Am Coll Cardiol 2017; 70:2552 –2565.
491. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al.
Cardio-oncology: vascular and metabolic perspectives: a scienti ﬁc statement from
the American Heart Association. Circulation 2019; 139:e579 –e602.
492. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence,
pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231 –2247.
493. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of
cancer-related treatment. Circ Res 2016; 118:1008 –1020.
494. Novo G, Di Lisi D, Bronte E, MacAione F, Accurso V, Badalamenti G, et al.
Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors:
a real-world single-center experience. Oncology 2020; 98:445 –451.
495. Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary inter-
ventions in cancer patients. Expert Rev Cardiovasc Ther 2020; 18:25–32.
496. Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al.
Percutaneous coronary intervention in patients with cancer and readmissions with-in 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;
42:1019 –1034.
497. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ,
et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis
Registry. J Am Coll Cardiol 2009; 53:1399 –1409.
498. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al.
Deﬁning high bleeding risk in patients undergoing percutaneous coronary interven-
tion. Circulation 2019; 140:240 –261.
499. Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: eti-
ology, diagnosis, and management. Curr Treat Options Cardiovasc Med 2017; 19:53.
500. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid,
subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treatedwith radiation therapy. J Am Med Assoc 2003; 290:2831 –2837.
501. Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, Matasar MJ, et al.
Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin
lymphoma survivors. J Clin Oncol 2017; 35:3837 –3843.
502. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al.
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk fac-
tors. Ann Oncol 2012; 23:897 –902.
503. Sato A, Yoshihisa A, Miyata-Tatsumi M, Oikawa M, Kobayashi A, Ishida T, et al.
Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxi-city in patients with breast cancer. Mol Clin Oncol 2019; 10:37–42.
504. Watanabe Y, Kozuma K, Hioki H, Kawashima H, Nara Y, Kataoka A, et al.
Comparison of results of transcatheter aortic valve implantation in patients withversus without active cancer. Am J Cardiol 2016; 118:572 –577.
505. Nagata H, Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, et al. Two cases of lob-
ectomy for lung cancer after transcatheter aortic valve implantation. Surg Case
Reports 2018; 4:139.
506. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al.
Transcatheter aortic valve replacement in oncology patients with severe aorticstenosis. JACC Cardiovasc Interv 2019; 12:78
–86.
507. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021
ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2022; 43:561 –632.
508. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P,
Díez-Villanueva P, et al. Atrial ﬁbrillation in active cancer patients: expert position
paper and recommendations. Rev Española Cardiol (English Ed) 2019; 72:749 –759.
509. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial ﬁbrillation in
cancer. J Am Coll Cardiol 2014; 63:945 –953.
510. Yun JP, Choi EK, Do Han K, Park SH, Jung JH, Park SH, et al. Risk of atrial ﬁbrillation
according to cancer type: a nationwide population-based study. JACC
CardioOncology 2021; 3:221 –232.
511. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al.
Incidence, risk factors, and mortality of atrial ﬁbrillation in breast cancer: a
SEER-Medicare analysis. Eur Heart J 2021; 43:300 –312.4354 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

512. Hu YF, Liu CJ, Chang PMH, Tsao HM, Lin YJ, Chang SL, et al. Incident thrombo-
embolism and heart failure associated with new-onset atrial ﬁbrillation in cancer pa-
tients. Int J Cardiol 2013; 165:355 –357.
513. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP.
Anticoagulation strategies in patients with cancer: JACC review topic of the
week. J Am Coll Cardiol 2019; 73:1336 –1349.
514. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, et al. Atrial ﬁb-
rillation in patients with active malignancy and use of anticoagulants: under-
prescription but no adverse impact on all-cause mortality. Eur J Intern Med 2019;
59:27–33.
515. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in pa-
tients with different types of cancer the unmet need for onco-cardiology. Mayo
Clin Proc 2016; 91:81–83.
516. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE.
Anticancer drug-induced cardiac rhythm disorders: current knowledge and basicunderlying mechanisms. Pharmacol Ther 2018; 189:89–103.
517. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, et al. Practical man-
agement of ibrutinib in the real life: focus on atrial ﬁbrillation and bleeding. Hematol
Oncol 2018; 36:624 –632.
518. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al.
Management of cardiovascular complications of Bruton tyrosine kinase inhibitors.Br J Haematol 2022; 196:70–78.
519. Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al.
Thromboembolism, mortality, and bleeding in 2,435,541 atrial ﬁbrillation patients
with and without cancer: a nationwide cohort study. Cancer 2021; 127:2122 –2129.
520. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC,
Heidbuchel H, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of
Burden; Substrate): a novel approach to in-depth characterization (rather than clas-
siﬁcation) of atrial ﬁbrillation. Thromb Haemost 2021; 121:270 –278.
521. Boriani G, Bonini N, Albini A, Venturelli A, Imberti JF, Vitolo M. Cardioversion of
recent-onset atrial ﬁbrillation: current evidence, practical considerations, and con-
troversies in a complex clinical scenario. Kardiol Pol 2020; 78:1088 –1098.
522. Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, Di Biase L, Mansour M,
et al. Pulmonary vein isolation for atrial ﬁbrillation in the postpneumonectomy
population: a feasibility, safety, and outcomes study. J Cardiovasc Electrophysiol
2015; 26:385 –389.
523. Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargo R, Freedman B, et al.
Antithrombotic therapy for atrial ﬁbrillation: CHEST guideline and expert panel re-
port. Chest 2018; 154:1121 –1201.
524. Proietti M, Lane DA, Boriani G, Lip GYH. Stroke prevention, evaluation of bleeding
risk, and anticoagulant treatment management in atrial ﬁbrillation contemporary
international guidelines. Can J Cardiol 2019; 35:619 –633.
525. Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al.
Anticoagulation in patients with atrial ﬁbrillation and active cancer: an international
survey on patient management. Eur J Prev Cardiol 2021; 28:611 –621.
526. D ’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al.
CHA 2DS2-VASC score and risk of thromboembolism and bleeding in patients
with atrial ﬁbrillation and recent cancer. Eur J Prev Cardiol 2018; 25:651 –658.
527. Farmakis D. Anticoagulation for atrial ﬁbrillation in active cancer: what the cardiol-
ogists think. Eur J Prev Cardiol 2021; 28:608 –610.
528. Cohen A, Donal E, Delgado V, Pepi M, Tsang T, Gerber B, et al. EACVI recommen-
dations on cardiovascular imaging for the detection of embolic sources: endorsedby the Canadian Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2021;
22:E24 –E57.
529. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. De ﬁnition of
major bleeding in clinical investigations of antihemostatic medicinal products in sur-gical patients. J Thromb Haemost 2010; 8:202 –204.
530. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European
Heart Rhythm Association practical guide on the use of non-vitamin K antagonist
oral anticoagulants in patients with atrial ﬁbrillation. Europace 2021; 23:1612 –1676.
531. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al.
Efﬁcacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial ﬁb-
rillation and a history of cancer: Observations from ROCKET AF. Eur Heart J Qual
Care Clin Outcomes 2019; 5:145 –152.
532. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efﬁcacy
and safety of apixaban versus warfarin in patients with atrial ﬁbrillation and a history
of cancer: insights from the ARISTOTLE trial. Am J Med 2017; 130:1440 –1448.e1.
533. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efﬁcacy and
safety of edoxaban in patients with active malignancy and atrial ﬁbrillation: analysis
of the engage AF-TIMI 48 trial. J Am Heart Assoc 2018; 7:e008987.
534. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior
safety of direct oral anticoagulants compared to warfarin in patients with atrial ﬁ
b-
rillation and underlying cancer: a national Veterans Affairs database study. J Geriatr
Cardiol 2019; 16:706 –709.535. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative
effectiveness of direct oral anticoagulants and warfarin in patients with cancer andatrial ﬁbrillation. Blood Adv 2018; 2:200 –209.
536. Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, et al. Direct
oral anticoagulants versus vitamin K antagonists in patients with atrial ﬁbrillation
and cancer a meta-analysis. J Thromb Thrombolysis 2021; 51:419 –429.
537. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al.
Effectiveness and safety of oral anticoagulants among nonvalvular atrial ﬁbrillation
patients with active cancer. JACC CardioOncology 2021; 3:411 –424.
538. Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated
with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: da-bigatran versus rivaroxaban. Cancer Med 2021; 10:7079 –7088.
539. Isogai T, Saad AM, Abushouk AI, Shekhar S, Kuroda S, Gad MM, et al. Procedural
and short-term outcomes of percutaneous left atrial appendage closure in patients
with cancer. Am J Cardiol 2021; 141:154 –157.
540. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A,
et al. European Heart Rhythm Association (EHRA) consensus document on man-
agement of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Paci ﬁc Heart
Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa
(CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;
21:7–8.
541. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH,
et al. Risk of thromboembolism associated with atrial ﬁbrillation following noncar-
diac surgery. J Am Coll Cardiol 2018; 72:2027 –2036.
542. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence
of ventricular arrhythmias in patients with advanced cancer and implantable
cardioverter-de ﬁbrillators. JACC Clin Electrophysiol
2017; 3:50–56.
543. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J
Physiol 2016; 594:2459 –2468.
544. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.
2017 AHA/ACC/HRS guideline for management of patients with ventricular ar-rhythmias and the prevention of sudden cardiac death: Executive summary: a re-
port of the American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart
Rhythm 2018; 15:e190 –e252.
545. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long
QT syndrome. An update. Circulation 1993; 88:782 –784.
546. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al.
Drug-induced arrhythmias: a scienti ﬁc statement from the American Heart
Association. Circulation 2020; 142:E214 –E233.
547. AZCERT. CredibleMeds.org n.d.
548. Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of
QT prolongation induced by anti-cancer drugs: target therapy and old agents.
Different algorithms for different drugs. Cancer Treat Rev 2018; 63:135 –143.
549. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical
evaluation of QT/QTc interval prolongation and proarrhythmic potential —ques-
tions & answers. Sci Med Heal 2020:EMA/CHMP/ICH/415588/2020.
550. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune check-
point inhibitor therapy and myocarditis: a systematic review of reported cases. J
Cancer Res Clin Oncol 2019; 145:1527 –1557.
551. Cirne F, Zhou S, Kappel C, El-Kadi A, Barron CC, Ellis PM, et al. ALK inhibitor-
induced bradycardia: a systematic review and meta-analysis. Lung Cancer 2021;
161:9–17.
552. Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart
Fail Clin 2019; 15:487 –495.
553. Szmit S, Jurczak W, Zaucha JM, Drozd-Soko łowska J, Spycha łowicz W, Joks M, et al.
Pre-existing arterial hypertension as a risk factor for early left ventricular systolicdysfunction following (R)-CHOP chemotherapy in patients with lymphoma. JA m
Soc Hypertens 2014; 8:791
–799.
554. Di Lorenzo G, Autorino R, Bruni G, Cartentì G, Ricevuto E, Tudini M, et al.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcin-
oma: a multicenter analysis. Ann Oncol 2009; 20:1535 –1542.
555. Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treat-
ment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcin-oma. Clin Genitourin Cancer 2017; 15:384 –390.e3.
556. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angioten-
sin system inhibitors: impact on outcome in sunitinib-treated patients for metastat-ic renal cell carcinoma. Ann Oncol 2015; 26:1128 –1133.
557. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OPR, Sabbisetti VS,
et al. Angiotensin system inhibitors and survival outcomes in patients with meta-
static renal cell carcinoma. Clin Cancer Res 2015; 21:2471 –2479.
558. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH.
Thromboembolism is a leading cause of death in cancer patients receiving out-patient chemotherapy. J Thromb Haemost 2007; 5:632 –634.ESC Guidelines 4355Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

559. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O ’Donnell CJ.
Epidemiology of venous thromboembolism in the Framingham Heart Study.Thromb Res 2016; 145:27–33.
560. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thrombo-
embolism in patients with cancer —a cohort study using linked United Kingdom da-
tabases. Eur J Cancer 2013; 49:1404 –1413.
561. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden
of disease and bene ﬁts of thromboprophylaxis. Cancer 2011; 117:1334 –1349.
562. Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A
meta-analysis of case fatality rates of recurrent venous thromboembolism and ma-
jor bleeding in patients with cancer. Thromb Haemost 2020; 120:702 –713.
563. Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Risk
scores for occult cancer in patients with unprovoked venous thromboembolism:results from an individual patient data meta-analysis. J Thromb Haemost 2020; 18:
2622 –2628.
564. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the pa-
tient with cancer. J Clin Oncol 2009; 27:4839 –4847.
565. Li X, Hu Y, Lin P, Zhang J, Tang Y, Yi Q, et al. Comparison of different clinical prog-
nostic scores in patients with pulmonary embolism and active cancer. Thromb
Haemost 2021; 121:834 –844.
566. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019
ESC Guidelines for the diagnosis and management of acute pulmonary embolism
developed in collaboration with the European Respiratory Society (ERS). Eur
Heart J 2020; 41:543 –603.
567. Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M, et al. Second
consensus document on diagnosis and management of acute deep vein thrombosis:updated document elaborated by the ESC Working Group on aorta and peripheral
vascular diseases and the ESC Working Group on pulmonary circulation and right
ventricular function. Eur J Prev Cardiol 2022; 29:1248 –1263
568. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MS V, et al. Risk of arterial
thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70:926
–938.
569. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J
Cardiol 2018; 72:89–93.
570. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al.
Screening adult survivors of childhood cancer for cardiomyopathy: comparisonof echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;
30:2876 –2884.
571. Hooks M, Okasha O, Velangi PS, Nijjar PS, Farzaneh-Far A, Shenoy C. Left ventricu-
lar thrombus on cardiovascular magnetic resonance imaging in non-ischaemic car-diomyopathy. Eur Heart J Cardiovasc Imaging 2020. doi:10.1093/ehjci/jeaa244.
Online ahead of print 7 October 2020.
572. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent
venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146 –153.
573. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term
low-molecular-weight heparin versus usual care in proximal-vein thrombosis pa-tients with cancer. Am J Med 2006; 119:1062 –1072.
574. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary preven-
tion of venous thromboembolic events in patients with active cancer: enoxaparinalone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl
Thromb 2006; 12:389 –396.
575. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al.
Comparison of low-molecular-weight heparin and warfarin for the secondary pre-
vention of venous thromboembolism in patients with cancer: a randomized con-trolled study. Arch Intern Med 2002; 162:1729 –1735.
576. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al.
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patientswith active cancer: a randomized clinical trial. JAMA J Am Med Assoc 2015; 314:
677–686.
577. Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Bleeding risk and major ad-
verse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol
2016; 203:372 –378.
578. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.
Edoxaban for the treatment of cancer-associated venous thromboembolism. N
Engl J Med 2018; 378:615 –624.
579. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison
of an oral factor Xa inhibitor with low molecular weight heparin in patients withcancer with venous thromboembolism: results of a randomized trial
(SELECT-D). J Clin Oncol 2018; 36
:2017 –2023.
580. McBane II RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,
et al. Apixaban and dalteparin in active malignancy-associated venous thrombo-
embolism: the ADAM VTE trial. J Thromb Haemost 2020; 18:411 –421.
581. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman M V, Connors JM, et al.
Apixaban for the treatment of venous thromboembolism associated with cancer.N Engl J Med 2020; 382:1599 –1607.582. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous
thromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019; 30:
897–907.
583. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al.
Bleeding with apixaban and dalteparin in patients with cancer-associated venous
thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;
121:616 –624.
584. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al.
Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin
among venous thromboembolism patients with active cancer: a US claims data ana-
lysis. Thromb Haemost 2021; 121:383 –395.
585. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al.
Direct oral anticoagulants for the treatment of acute venous thromboembolism as-
sociated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020;
120:1128 –1136.
586. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indol ﬁC. Direct oral anticoagulants
in patients with active cancer: a systematic review and meta-analysis. JACC
CardioOncology 2020; 2:428 –440.
587. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism.
Blood 2019; 133:291 –298.
588. Den Exter PL, Hooijer J, Dekkers OM, Huisman M V. Risk of recurrent venous
thromboembolism and mortality in patients with cancer incidentally diagnosed
with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol
2011; 29:2405 –2409.
589. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz M,
Blasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated throm-
bosis beyond 6 months: TiCAT study. Thromb Res 2017; 157:90–96.
590. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman M V, et al.
Treatment of venous thromboembolism in cancer patients with dalteparin for up
to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13:1028 –1035.
591. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020
ACC/AHA guideline for the management of patients with valvular heart disease: a
report of the American College of Cardiology/American Heart Association JointCommittee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:e25 –e197.
592. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous
thromboembolism in cancer patients on simultaneous and palliative care. Cancers
(Basel) 2020; 12:1167.
593. Xin Z, Liu F, Du Y, Mao F, Wang X, Xu P, et al. Primary prophylaxis for venous
thromboembolism in ambulatory cancer patients: a systematic review and networkmeta-analysis. Ann Cardiothorac Surg 2020; 9:2970 –2981.
594. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 internation-
al clinical practice guidelines for the treatment and prophylaxis of venous thrombo-
embolism in patients with cancer. Lancet Oncol 2019; 20:e566 –e581.
595. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al.
Duration of prophylaxis against venous thromboembolism with enoxaparin after
surgery for cancer. N Engl J Med 2002; 346:975 –980.
596. Khorana A, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and
validation of a predictive model for chemotherapy-associated thrombosis. Blood
2008; 111:4902 –4907.
597. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El
Shemmari S, et al. A predictive score for thrombosis associated with breast, colo-
rectal, lung, or ovarian cancer: the prospective COMPASS –cancer-associated
thrombosis study. Oncologist 2017; 22:1222 –1231.
598. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.
Nadroparin for the prevention of thromboembolic events in ambulatory patients
with metastatic or locally advanced solid cancer receiving chemotherapy: a rando-
mised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10:943 –949.
599. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for can-
cer.N Engl J Med 2012; 366:601 –609.
600. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AWSS. Primary
prophylaxis for venous thromboembolism in ambulatory cancer patients receiving
chemotherapy. Cochrane Database Syst Rev 2016; 12:CD008500.
601. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al.
Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J
Med 2019; 380:711 –719.
602. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban
for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med
2019; 380:720 –728.
603. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk
factors among cancer patients treated with anticoagulation. Am J Hematol 2019; 94:
780–785.
604. Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thrombo-
embolism and bleeding on anticoagulation. Thromb Res 2016; 140:S93 –S98.4356 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

605. Roule V, Verdier L, Blanchart K, Ardouin P, Lemaitre A, Bignon M, et al. Systematic
review and meta-analysis of the prognostic impact of cancer among patients withacute coronary syndrome and/or percutaneous coronary intervention. BMC
Cardiovasc Disord 2020; 20:38.
606. Freedberg DE, Kim LS, Yang YX. The risks and bene ﬁts of long-term use of proton
pump inhibitors: expert review and best practice advice from the AmericanGastroenterological Association. Gastroenterology 2017; 152:706 –715.
607. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC
focused update on dual antiplatelet therapy in coronary artery disease developedin collaboration with EACTS. Eur Heart J 2018; 39:213 –260.
608. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical
expert consensus statement on the classi ﬁcation of cardiogenic shock: This docu-
ment was endorsed by the American College of Cardiology (ACC), the American
Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and theSociety of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv
2019; 94:29–37.
609. Schiffer CA, Bohlke K, Anderson KC. Platelet transfusion for patients with cancer:
American Society of Clinical Oncology Clinical Practice Guideline Update
Summary. J Oncol Pract 2018; 14:129 –133.
610. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding,
and anticoagulation in patients with malignancy. Blood Adv 2019; 3:3770 –3779.
611. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer
therapy-related increases in arterial stiffness: a systematic review and meta-analysis.J Am Heart Assoc 2020; 9:e015598.
612. Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular
syndrome in a patient with metastatic melanoma under immune checkpoint block-
ade. BMC Cancer 2017; 17:327.
613. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M,
Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlu-
sive disease and other vascular events during nilotinib therapy in CML. Am J Hematol
2011; 86:533 –539.
614. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al.
Impact of dose intensity of ponatinib on selected adverse events: multivariate ana-
lyses from a pooled population of clinical trial patients. Leuk Res 2016; 48:84–91.
615. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, Le Coutre P. Vascular
safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;
125:901 –906.
616. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary
arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:
2128 –2137.
617. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, et al.
Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J
Pathol 2015; 185:356 –371.
618. Jevnikar M, Montani D, Savale L, Seferian A, Jutant EM, Boucly A, et al. Chronic
thromboembolic pulmonary hypertension and totally implantable central venous
access systems. Eur Respir J 2021; 57:2002208.
619. Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Tumoral pulmonary hypertension. Eur
Respir Rev 2019; 28:180065.
620. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur Heart J 2022; 43:3618 –3731.
621. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib ver-
sus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J
Med 2010; 362:2260 –2270.
622. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer:
Contemporary prevalence, management and outcomes. Heart 2020; 106:569 –574.
623. Kim SR, Kim EK, Cho J, Chang SA, Park SJ, Lee SC, et al. Effect of anti-in ﬂammatory
drugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll
Cardiol 2020; 76:1551 –1561.
624. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial
disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer
2021; 9:e002771.
625. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint
inhibitors-associated pericardial disease: a systematic review of case reports.
Cancer Immunol Immunother 2021; 70:3041 –3053.
626. Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D,
Palacios-Rubio J, et al. Cause and long-term outcome of cardiac tamponade. Am J
Cardiol 2016; 117
:664 –669.
627. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of
cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419
specimens. Cancer Cytopathol 2017; 125:128 –137.
628. Patel N, Ra ﬁque AM, Eshaghian S, Mendoza F, Biner S, Cercek B, et al. Retrospective
comparison of outcomes, diagnostic value, and complications of percutaneous pro-
longed drainage versus surgical pericardiotomy of pericardial effusion associatedwith malignancy. Am J Cardiol 2013; 112:1235 –1239.629. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, et al. Targeted cancer
therapies with pericardial effusions requiring pericardiocentesis focusing on im-
mune checkpoint inhibitors. Am J Cardiol 2019; 123:1351 –1357.
630. Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of
nivolumab-induced pericardial effusion: a case report and review of literature.
Exp Hematol Oncol 2018; 7:11.
631. Dixon SB, Howell CR, Lu L, Plana JC, Joshi VM, Luepker R V, et al. Cardiac biomar-
kers and association with subsequent cardiomyopathy and mortality among adultsurvivors of childhood cancer: a report from the St. Jude Lifetime Cohort.
Cancer 2021; 127:458 –466.
632. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association
of cardiovascular risk factors with cardiac events and survival outcomes among pa-
tients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018; 36:
2710 –2717.
633. Nolan MT, Marwick TH, Plana JC, Li Z, Ness KK, Joshi VM, et al. Effect of traditional
heart failure risk factors on myocardial dysfunction in adult survivors of childhood
cancer. JACC Cardiovasc Imaging 2018; 11:1202 –1203.
634. Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of
chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast
cancer patients. Breast Cancer Res Treat 2020; 182:333 –343.
635. Smarz K, Jaxa-Chamiec T, Chwyczko T, G łówczy ńska R, Jegier A, Niedoszytko P,
et al. Cardiopulmonary exercise testing in adult cardiology: expert opinion of the
Working Group of Cardiac Rehabilitation and Exercise Physiology of the Polish
Cardiac Society. Kardiol Pol 2019; 77:730
–756.
636. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efﬁcacy of
exercise therapy on cardiorespiratory ﬁtness in patients with cancer: a systematic
review and meta-analysis. J Clin Oncol 2018; 36:2297 –2304.
637. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for
prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015; 6:
115–124.
638. Wallen MP, Hennessy D, Brown S, Evans L, Rawstorn JC, Wong Shee A, et al.
High-intensity interval training improves cardiorespiratory ﬁtness in cancer patients
and survivors: a meta-analysis. Eur J Cancer Care (Engl) 2020; 29:e13267.
639. Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L,
et al. Effect of aerobic and resistance exercise intervention on cardiovascular dis-
ease risk in women with early-stage breast cancer: a randomized clinical trial.
JAMA Oncol 2019; 5:710 –714.
640. Adams SC, Delorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects
of high-intensity interval training on fatigue and quality of life in testicular cancersurvivors. Br J Cancer 2018; 118:1313 –1321.
641. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al.
High-intensity exercise during chemotherapy induces bene ﬁcial effects 12 months
into breast cancer survivorship. J Cancer Surviv 2019; 13:244 –256.
642. Marriott CFS, Petrella AFM, Marriott ECS, Boa Sorte Silva NC, Petrella RJ.
High-intensity interval training in older adults: a scoping review. Sport Med - Open
2021; 7:49.
643. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al.
Cardiovascular health of patients with cancer and cancer survivors: a roadmap
to the next level. J Am Coll Cardiol 2015; 65:2739 –2746.
644. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al.
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;
370:2011 –2019.
645. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart
failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase in-
hibitor. Cancer 2008; 112:2500 –
2508.
646. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to diagnose
and manage QT prolongation in cancer patients. JACC CardioOncology 2021; 3:
145–149.
647. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood
cancer survival in Europe 1999 –2007: results of EUROCARE-5 —a population-
based study. Lancet Oncol 2014; 15:35–47.
648. Geenen MM, Cardous-Ubbink MC, Kremer LCM, Van Den Bos C, Van Der Pal
HJH, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term
survivors of childhood cancer. J Am Med Assoc 2007; 297:2705 –2715.
649. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al.
Cardiovascular disease in survivors of childhood cancer: insights into epidemiology,pathophysiology, and prevention. J Clin Oncol 2018; 36:2135 –2144.
650. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al.
Population-based long-term cardiac-speci ﬁc mortality among 34 489 ﬁve-year sur-
vivors of childhood cancer in Great Britain. Circulation 2017; 135:951 –963.
651. Kremer LCM, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of
anthracycline-induced clinical heart failure in children: a systematic review. Ann
Oncol 2002; 13:503 –512.ESC Guidelines 4357Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

652. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al.
Therapy-related cardiac risk in childhood cancer survivors: an analysis of the child-
hood cancer survivor study. J Clin Oncol 2019; 37:1090 –1101.
653. van Dalen EC, Mulder RL, Suh E, Ehrhardt MJ, Aune GJ, Bardi E, et al. Coronary ar-
tery disease surveillance among childhood, adolescent and young adult cancer sur-
vivors: a systematic review and recommendations from the International Late
Effects of Childhood Cancer Guideline Harmonization Group. Eur J Cancer 2021;
156:127 –137.
654. Leerink JM, van der Pal HJH, Kremer LCM, Feijen EAM, Meregalli PG, Pourier MS,
et al. Reﬁning the 10-year prediction of left ventricular systolic dysfunction in long-
term survivors of childhood cancer. JACC CardioOncology 2021; 3:62–72.
655. Armstrong GT, Oef ﬁnger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al.
Modi ﬁable risk factors and major cardiac events among adult survivors of childhood
cancer. J Clin Oncol 2013; 31:3673 –3680.
656. Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular
risk factors in hematopoietic cell transplantation survivors: role in development of
subsequent cardiovascular disease. Blood 2012; 120:4505 –4512.
657. Carpenter K, Scavotto M, McGovern A, Ma C, Kenney LB, Mack JW, et al. Early par-
ental knowledge of late effect risks in children with cancer. Pediatr Blood Cancer
2022; 69:e29473.
658. Herrmann J. From trends to transformation: where cardio-oncology is to make a
difference. Eur Heart J 2019; 40:3898 –3900.
659. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Tri ﬁletti DM, Jiang C, et al. A
population-based study of cardiovascular disease mortality risk in US cancer pa-
tients. Eur Heart J 2019; 40:3889 –3897.
660. Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Tri ﬁletti DM, Chinchilli VM, et al.
Fatal heart disease among cancer patients. Nat Commun 2020; 11:2011.
661. Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M, et al.
Long-term effect of epirubicin on incidence of heart failure in women with breast
cancer: insight from a randomized clinical trial. Eur J Heart Fail 2018; 20:1447 –1453.
662. Jacobse JN, Steggink LC, Sonke GS, Schaapveld M, Hummel YM, Steenbruggen TG,
et al. Myocardial dysfunction in long-term breast cancer survivors treated at ages
40–50 years. Eur J Heart Fail 2020; 22:338 –346.
663. Boyne DJ, Mickle AT, Brenner DR, Friedenreich CM, Cheung WY, Tang KL, et al.
Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic re-
view and meta-analysis. Cancer Med 2018; 7:4801 –4813.
664. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease
and lung cancer after radiotherapy for early breast cancer: prospective cohortstudy of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005;
6:557 –565.
665. de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen
RWM, et al. Long-term cause-speci ﬁc mortality in Hodgkin lymphoma patients. J
Natl Cancer Inst 2021; 113:760 –769.
666. Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, et al. Prediction
of cardiovascular disease among hematopoietic cell transplantation survivors. Blood
Adv2018; 2:1756 –1764.
667. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter
TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast
cancer (HERA): An open-label, randomised controlled trial. Lancet 2013; 382:
1021 –1028.
668. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac
safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol
2016; 34:581 –587.
669. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart
failure in older women treated with adjuvant anthracycline chemotherapy for
breast cancer. J Clin Oncol 2007; 25:3808 –3815.
670. Lancellotti P, Nkomo VT, Badano LP, Bergler J, Bogaert J, Davin L, et al. Expert
Consensus for multi-modality imaging evaluation of cardiovascular complications
of radiotherapy in adults: a report from the European Association of
Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc
Echocardiogr 2013; 26:1013 –
1032.
671. Tromp J, Boerman LM, Sama IE, Maass SWMC, Maduro JH, Hummel YM, et al.
Long-term survivors of early breast cancer treated with chemotherapy are charac-
terized by a pro-in ﬂammatory biomarker pro ﬁle compared to matched controls.
Eur J Heart Fail 2020; 22:1239 –1246.
672. Cao Z, Xu C, Yang H, Li S, Wang Y. The role of healthy lifestyle in cancer incidence
and temporal transitions to cardiometabolic disease. JACC CardioOncology 2021; 3:
663–674.
673. Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-
factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressivenon-Hodgkin ’s lymphoma. J Clin Pharm Ther 2014; 39:168 –174.
674. Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS.
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse
B-cell non-Hodgkin ’s lymphoma. J Clin Oncol 2008; 26:3159 –3165.675. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of
enalapril on mortality and the development of heart failure in asymptomatic pa-
tients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:
685–691.
676. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of
captopril on mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med 1992; 327:669 –677.
677. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients
with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet
2001; 357:1385 –1390.
678. Abdel-Qadir H, Tai F, Croxford R, Austin PC, Amir E, Calvillo-Argüelles O, et al.
Characteristics and outcomes of women developing heart failure after early stage
breast cancer chemotherapy: a population-based matched cohort study. Circ Heart
Fail2021; 14:e008110.
679. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al.
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiother-
apy: ESMO clinical practice guidelines. Ann Oncol 2012; 23:vii155 –66.
680. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated car-
diovascular disease. Crit Rev Oncol Hematol 2003; 45:55
–75.
681. Taylor C, Duane FK, Dodwell D, Gray R, Wang Z, Wang Y, et al. Estimating the
risks of breast cancer radiotherapy: evidence from modern radiation doses tothe lungs and heart and from previous randomized trials. J Clin Oncol 2017; 35:
1641 –1649.
682. Reed GW, Masri A, Grif ﬁn BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality
in patients with radiation-associated coronary artery disease treated with percu-
taneous coronary intervention. Circ Cardiovasc Interv 2016; 9:e003483.
683. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, et al. Outcomes after
percutaneous coronary intervention with stents in patients treated with thoracic
external beam radiation for cancer. JACC Cardiovasc Interv 2014; 7:1412 –1420.
684. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to
prevent and manage radiation-induced coronary artery disease. Heart 2018; 104:
1647 –1653.
685. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following
chemotherapy for germ cell tumors. JNCCN J Natl Compr Cancer Netw 2012; 10:
537–544.
686. Sudhakar R. Response to treatment and outcomes of acute coronary syndrome in
the cancer population. Clin Cardiol 2012; 35:646.
687. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related
mortality. N Engl J Med 2013; 368:574 –577.
688. Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery dis-
ease in cancer patients. Chronic Dis Transl Med 2019; 5:221 –233.
689. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.
(2018 ESC/EACTS Guidelines on myocardial revascularization). Kardiol Pol 2018;
76:1585 –1664.
690. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term
survival of patients with radiation heart disease undergoing cardiac surgery: a co-hort study. Circulation 2013; 127:1476 –1484.
691. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease.
Heart 2016; 102:269 –276.
692. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al.
2017 ESC/
EACTS Guidelines for the management of valvular heart disease. Eur Heart J
2017; 38:2739 –2791.
693. Lind A, Totzeck M, Mahabadi AA, Jánosi RA, El Gabry M, Ruhparwar A, et al. Impact
of cancer in patients undergoing transcatheter aortic valve replacement: a single-
center study. JACC CardioOncology 2020; 2:735 –743.
694. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter
compared with surgical aortic valve replacement in patients with previous chest-
directed radiation therapy. JACC CardioOncology 2021; 3:397 –407.
695. Guha A, Dey AK, Omer S, Abraham WT, Attizzani G, Jneid H, et al. Contemporary
trends and outcomes of percutaneous and surgical mitral valve replacement or re-
pair in patients with cancer. Am J Cardiol 2020; 125:1355 –1360.
696. Elbadawi A, Albaeni A, Elgendy IY, Ogunbayo GO, Jimenez E, Cornwell L, et al.
Transcatheter versus surgical aortic valve replacement in patients with prior medi-
astinal radiation. JACC Cardiovasc Interv 2020; 13:2658 –2666.
697. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after trans-
catheter aortic valve replacement in cancer survivors with prior chest radiation
therapy: a systematic review and meta-analysis. Cardio-Oncology 2020; 6:8.
698. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F,
Eisenwort G, et al. Nilotinib-induced vasculopathy: identi ﬁcation of vascular endo-
thelial cells as a primary target site. Leukemia 2017; 31:2388 –2397.
699. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary
Raynaud ’s phenomenon and other late vascular complications following chemo-
therapy for testicular cancer. Eur J Cancer 1995; 31A :2229 –2238.
700. Stelwagen J, Lubberts S, Steggink LC, Steursma G, Kruyt LM, Donkerbroek JW,
et al. Vascular aging in long-term survivors of testicular cancer more than 20 years4358 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

after treatment with cisplatin-based chemotherapy. Br J Cancer 2020; 123:
1599 –1607.
701. Andreassi MG, Piccaluga E, Gargani L, Sabatino L, Borghini A, Faita F, et al.
Subclinical carotid atherosclerosis and early vascular aging from long-term low-
dose ionizing radiation exposure: a genetic, telomere, and vascular ultrasound studyin cardiac catheterization laboratory staff. JACC Cardiovasc Interv 2015; 8:616 –627.
702. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al. Accelerated
carotid artery disease after high-dose head and neck radiotherapy: is there a rolefor routine carotid duplex surveillance? J Vasc Surg 1999; 30:1045 –1051.
703. Carpenter DJ, Mowery YM, Broadwater G, Rodrigues A, Wisdom AJ, Dorth JA,
et al. The risk of carotid stenosis in head and neck cancer patients after radiation
therapy. Oral Oncol 2018; 80:9–15.
704. Szpakowski N, Desai MY. Radiation-associated pericardial disease. Curr Cardiol Rep
2019; 21:97.
705. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epide-
miologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys
2007; 67:10–18.
706. Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, et al. Incidence and predictors of
pericardial effusion after chemoradiation therapy for locally advanced non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2017; 99:70–79.
707. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for peri-
cardial effusion in inoperable esophageal cancer patients treated with de ﬁnitive
chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008; 70:707 –714.
708. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, et al.
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76:
S77–S85.
709. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH,
et al. Management of acute and recurrent pericarditis: JACC state-of-the-art re-
view. J Am Coll Cardiol 2020; 75:76–92.
710. Donnellan E, Phelan D, Mccarthy CP, Collier P, Desai M, Grif ﬁnB .
Radiation-induced heart disease: a practical guide to diagnosis and management.Cleve Clin J Med 2016; 83:914
–922.
711. Crestanello JA, McGregor CGA, Danielson GK, Daly RC, Dearani JA, Orszulak TA,
et al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation
therapy. Ann Thorac Surg 2004; 78:826 –831.
712. Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart 2009; 95:
252–258.
713. Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer.
Support Care Cancer 2002; 10:523 –528.
714. Noor B, Akhavan S, Leuchter M, Yang EH, Ajijola OA. Quantitative assessment of
cardiovascular autonomic impairment in cancer survivors: a single center case ser-
ies.Cardio-Oncology 2020; 6:11.
715. Gibson TM, Li Z, Green DM, Armstrong GT, Mulrooney DA, Srivastava DK, et al.
Blood pressure status in adult survivors of childhood cancer: a report from theSt. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017; 26:
1705 –1713.
716. Friedman DN, Tonorezos ES, Cohen P. Diabetes and metabolic syndrome in sur-
vivors of childhood cancer. Horm Res Paediatr 2019; 91:118 –127.
717. Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and
exercise interventions in cancer survivors. Acta Oncol (Madr) 2011; 50:167 –178.
718. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient man-
agement. J Clin Oncol 2002; 20:1128 –1143.
719. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast
cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123:
627–635.
720. Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J
Clin Oncol 2010; 28:4066 –4073.
721. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective
study of adiposity and weight change in relation to prostate cancer incidence and
mortality. Cancer 2007; 109:675 –684.
722. Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of
obesity and obesity-related conditions on colorectal cancer prognosis. Cancer
Control 2010;
17:52–57.
723. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival
after breast cancer diagnosis. J Clin Oncol 2005; 23:1370 –1378.
724. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact
of body mass index and weight change after treatment on cancer recurrence andsurvival in patients with stage III colon cancer: Findings from Cancer and LeukemiaGroup B 89803. J Clin Oncol 2008; 26:4109 –4115.
725. Kroenke CH, Fung TT, Hu FB, Holmes MD. Dietary patterns and survival after
breast cancer diagnosis. J Clin Oncol 2005; 23:9295 –9303.
726. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns
and breast cancer recurrence and survival among women with early-stage breastcancer. J Clin Oncol 2009; 27:919 –926.727. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association
of dietary patterns with cancer recurrence and survival in patients with stage III co-lon cancer. J Am Med Assoc 2007; 298:754 –764.
728. Yang J, Li C, Shen Y, Zhou H, Shao Y, Zhu W, et al. Impact of statin use on cancer-
speci ﬁc mortality and recurrence: a meta-analysis of 60 observational studies.
Medicine 2020; 99:e19596.
729. Kim J, Choi EA, Han YE, Woo Lee J, Seul Kim Y, Kim Y, et al. Association between
statin use and all-cause mortality in cancer survivors, based on the Korean healthinsurance service between 2002 and 2015. Nutr Metab Cardiovasc Dis 2020; 30:
434–440.
730. Ren QW, Yu SY, Teng THK, Li X, Cheung KS, Wu MZ, et al. Statin associated lower
cancer risk and related mortality in patients with heart failure. Eur Heart J 2021; 42:
3049 –3059.
731. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and
aerobic exercise program reverses muscle loss in men undergoing androgen sup-
pression therapy for prostate cancer without bone metastases: a randomized con-trolled trial. J Clin Oncol 2010; 28:340 –347.
732. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled
physical activity trials in cancer survivors: a systematic review and meta-analysis. J
Cancer Surviv 2010; 4:87–100.
733. Campia U, Barac A. Exercise and aerobic ﬁtness to reduce cancer-related cardio-
vascular toxicity. Curr Treat Options Cardiovasc Med 2016; 18:44.
734. Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and
risk of major cardiovascular events in adult survivors of childhood Hodgkin lymph-oma: a report from the childhood cancer survivor study. J Clin Oncol 2014; 32:
3643 –3650.
735. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of exercise
with mortality in adult survivors of childhood cancer. JAMA Oncol 2018;4:1352 –1358.
736. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz
AL,et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J
Clin2012; 62:242 –274.
737. CDC. Cancer Data and Statistics | Survival Information from the National Cancer
Institute and Centers for Disease Control and Prevention. 2013.
738. Thompson KA, Hildebrandt MAT, Ater JL. Cardiac outcomes with pregnancy
after cardiotoxic therapy for childhood cancer. JA mC o l lC a r d i o l 2017; 69:
594–595.
739. Nolan M, Oikonomou EK, Silversides CK, Hines MR, Thompson KA, Campbell BA,
et al. Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in
pregnancy. JACC CardioOncology 2020; 2:153 –162.
740. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK,
et al. A retrospective evaluation of risk of peripartum cardiac dysfunction in survi-
vors of childhood, adolescent and young adult malignancies. Cancers (Basel) 2019;
11:1046.
741. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardio-
vascular diseases during pregnancy. Eur Heart J 2018; 39:3165 –3241.
742. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al.
Cardiovascular considerations in caring for pregnant patients: a scienti ﬁc statement
from the American Heart Association. Circulation 2020; 141:e884 –e903.
743. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classi ﬁcation of
Tumours of the Lung, Pleura, Thymus and Heart , 4th ed. 2015. ISBN 978-92-832-2436-5
744. Burke A, Tavora F. The 2015 WHO Classi ﬁcation of tumors of the heart and peri-
cardium. J Thorac Oncol 2016;
11:441 –452.
745. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, et al.
Incidence rate of primary cardiac tumors: a 14-year population study. J
Cardiovasc Med 2016; 17:37–43.
746. Maleszewski JJ, Bois MC, Bois JP, Young PM, Stulak JM, Klarich KW. Neoplasia and
the heart: pathological review of effects with clinical and radiological correlation. J
Am Coll Cardiol 2018; 72:202 –227.
747. Tyebally S, Chen S, Bhattacharyya S, Mughrabi S, Hussain Z, Manisty C, et al. Cardiac
tumors: JACC CardioOncology state-of-the-art review. JACC CardioOncology 2020;2:
293–311.
748. Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, et al.
Differential diagnosis of cardiac masses using contrast echocardiographic perfusionimaging. J Am Coll Cardiol 2004; 43:1412 –1419.
749. Thiene G, Rizzo S, Marra MP, Valente M, Basso C. Masses and cardiac tumours: clas-
siﬁcation and diagnosis. ESC CardioMED, 2018. DOI:10.1093/med/9780198784906.
003.0386
750. Zaragosa-Macias E, Chen MA, Gill EA. Real time three-dimensional echocardiog-
raphy evaluation of intracardiac masses. Echocardiography 2012; 29:207 –219.
751. Beroukhim RS, Prakash A, Valsangiacomo Buechel ER, Cava JR, Dorfman AL, Festa
P,et al. Characterization of cardiac tumors in children by cardiovascular magnetic
resonance imaging: a multicenter experience. J Am Coll Cardiol 2011; 58:1044 –1054.ESC Guidelines 4359Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

752. Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al.
Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J
Nucl Med 2012; 53:856 –863.
753. Kassop D, Donovan MS, Cheezum MK, Nguyen BT, Gambill NB, Blankstein R, et al.
Cardiac masses on cardiac CT: a review. Curr Cardiovasc Imaging Rep 2014; 7:9281.
754. D ’Angelo EC, Paolisso P, Vitale G, Foà A, Bergamaschi L, Magnani I, et al. Diagnostic
accuracy of cardiac computed tomography and 18F- ﬂuorodeoxyglucose with posi-
tron emission tomography in cardiac masses. JACC Cardiovasc Imaging 2020; 13:
2400 –2411.
755. Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours:
diagnosis and management. Lancet Oncol 2005; 6:219 –228.
756. Szmit S, Zagrodzka M, Kurzyna M, Opolski G, Szczylik C. Sunitinib malate, a recep-
tor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure
due to heart metastases from renal cell carcinoma. Cardiology 2009; 114:67–71.
757. Peccatori FA, Azim JA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer,
pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol 2013; 24:vi160 –70.
758. Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al.
Multidisciplinary consensus on cancer management during pregnancy. Clin Transl
Oncol 2021; 23:1054 –1066.
759. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary man-
agement of cancer during pregnancy. JCO Oncol Pract 2020; 16:545 –557.
760. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al.
Gynecologic cancers in pregnancy: guidelines based on a third international consen-
sus meeting. Ann Oncol 2019; 30:1601 –1612.
761. Dunleavy K, McLintock C. How I treat lymphoma in pregnancy. Blood 2020; 136:
2118 –2124.
762. Ducas RA, Elliott JE, Melnyk SF, Premecz S, Dasilva M, Cleverley K, et al.
Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac
Hemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study. J Cardiovasc
Magn Reson 2014; 16:1.
763. Savu O, Jurcu ţR, Giu şca ̌S, Van Mieghem T, Gussi I, Popescu BA, et al.
Morphological and functional adaptation of the maternal heart during pregnancy.
Circ Cardiovasc Imaging 2012; 5:289 –297.
764. Narayanan M, Elkayam U, Naqvi TZ. Echocardiography in pregnancy: part 2. Curr
Cardiol Rep 2016; 18:90.
765. Furenäs E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy popu-
lation: dynamics of NTproBNP and hs-cTroponin T. Open Heart 2020; 7:e001293.
766. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natri-
uretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:
1247 –1253.
767. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in
the incidence of venous thromboembolism during pregnancy or postpartum: a
30-year population-based study. Ann Intern Med 2005; 143:697 –706.
768. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst
venous thromboembolism in pregnant women in hospital: population based cohort
study from England. BMJ2013; 347:f6099.
769. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst
venous thromboembolism in and around pregnancy: a population-based cohort
study. Br J Haematol 2012; 156:366 –373.
770. Hase EA, de Barros VIPVL, Igai AMK, Francisco RPV, Zugaib M. Risk assessment of
venous thromboembolism and thromboprophylaxis in pregnant women hospita-
lized with cancer: preliminary results from a risk score. Clinics (Sao Paulo) 2018;
73:e368.
771. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and manage-
ment. Heart 2004; 90:1224 –1228.
772. Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al.
Diagnosing and managing carcinoid heart disease in patients with neuroendocrine
tumors: an expert statement. J Am Coll Cardiol 2017; 69:1288 –1304.
773. Dobson R, Burgess MI, Pritchard DM, Cuthbertson DJ. The clinical presentation
and management of carcinoid heart disease. Int J Cardiol 2014; 173:29–32.
774. Lichtenauer M, Pichler T, Eder S, Mirna M, Magnes T, Wernly B, et al. Carcinoid
heart disease involving the left heart: a case report and biomarker analysis. ESC
Heart Fail 2019; 6:222 –227.
775. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid
syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet
Oncol 2017; 18:525 –534.
776. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation
2007; 116:2860 –2865.
777. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG. Role of natriuretic
peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J
Cancer 2004; 90:2073 –2079.
778. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, et al. The associ-
ation of a panel of biomarkers with the presence and severity of carcinoid heart
disease: a cross-sectional study. PLoS One 2013; 8:e73679.779. Korse CM, Taal BG, De Groot CA, Bakker RH, Bonfrer JMG. Chromogranin-A and
N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diag-
nostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293 –4299.
780. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal
pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart dis-ease. Am J Cardiol 2008; 102:938 –942.
781. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al.
Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid
syndrome. J Clin Oncol 2017; 35:14–23.
782. Dumoulein M, Verslype C, Van Cutsem E, Meuris B, Herijgers P, Flameng W, et al.
Carcinoid heart disease: case and literature review. Acta Cardiol 2010; 65:261 –264.
783. Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, et al. Improving
outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg
2019; 158:99–107.e2.
784. Mabvuure N, Cumberworth A, Hindocha S. In patients with carcinoid syndrome
undergoing valve replacement: will a biological valve have acceptable durability?
Interact Cardiovasc Thorac Surg 2012; 15:467 –471.
785. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late
outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;
66:2189 –2196.
786. Sunjic I, Shin D, Sunjic KM, Popat JV, Tran T, Chae SH, et al. Incidence of atrioven-
tricular block after valve replacement in carcinoid heart disease. Cardiol Res 2020;
11:56–60.
787. Kuntze T, Owais T, Secknus MA, Kaemmerer D, Baum R, Girdauskas E. Results of
contemporary valve surgery in patients with carcinoid heart disease. J Heart Valve
Dis2016; 25:356 –363.
788. Luthra S, Olevano C, Richens T, Tsang GM. Percutaneous transcatheter
valve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease.
JACC Case Reports 2020; 2:533 –536.
789. Zacks JS, Lavine R. Avoiding a repeat sternotomy in recurrent carcinoid heart dis-
ease. JACC Case Reports 2020; 2:537 –538.
790. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features
of carcinoid heart disease identi ﬁed by 2- and 3-dimensional echocardiography and
cardiac MRI. Circ Cardiovasc Imaging 2010; 3:103 –111.
791. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al.
Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients.
Circulation 1993; 87:1188 –1196.
792. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood 2020;
136:2620 –2627.
793. Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epi-
demiology, diagnosis, and management. JACC CardioOncology 2019; 1:117 –130.
794. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update
for treating physicians. Blood 2013; 121:5124 –5130.
795. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common
questions encountered in the diagnosis and management of cardiac amyloidosis.
Circulation 2017; 135:1357 –1377.
796. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice
Guidelines in Oncology. Systemic Light Chain Amyloidosis Version 1. Natl Compr
Cancer Netw 2021. https://www.nccn.org/.
797. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised
prognostic staging system for light chain amyloidosis incorporating cardiac biomar-
kers and serum free light chain measurements. J Clin Oncol 2012; 30:989 –995.
798. Zhang KW, Miao J, Mitchell JD, Alvarez-Cardona J, Tomasek K, Su YR, et al. Plasma
hepatocyte growth factor for diagnosis and prognosis in light chain and transthyr-
etin cardiac amyloidosis. JACC CardioOncology 2020; 2:56–66.
799. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical char-
acteristics and prognostic factors in multiple myeloma patients with light chain de-
position disease. Am J Hematol 2017; 92:739 –745.
800. Grogan M, DIspenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to
promote early diagnosis and cardiac response. Heart 2017; 103:1065 –1072.
801. Jurcu ţR, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, et al. Multimodality imaging
in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging
2020; 21:833 –844.
802. Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, et al. Incremental
value of global longitudinal strain for predicting survival in patients with advanced
AL amyloidosis. JACC CardioOncology 2020; 2:223 –231.
803. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging
investigations in detecting and differentiating cardiac amyloidosis: a systematic re-
view and meta-analysis. ESC Heart Fail 2019; 6:1041 –1051.
804. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al.
Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC
Cardiovasc Imaging 2020; 13:69–80.
805. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al.
Consensus guidelines for the conduct and reporting of clinical trials in systemic
light-chain amyloidosis. Leukemia 2012; 26:2317 –2325.4360 ESC GuidelinesDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

806. Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, et al. Grading car-
diac response in AL amyloidosis: implications for relapse and survival. Br J Haematol
2019; 186:144 –146.
807. Vaxman I, Gertz M. Recent advances in the diagnosis, risk strati ﬁcation, and man-
agement of systemic light-chain amyloidosis. Acta Haematol 2019; 141:93–106.
808. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac
amyloidosis. JACC Clin Electrophysiol 2020; 6:351 –361.
809. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al.
Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloid-osis. J Am Coll Cardiol 2019; 73:589 –597.
810. Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality
in light chain cardiac amyloidosis with heart failure. Sci Rep 2019; 9:8552.
811. Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: a
review of current literature. Clin Med Insights Cardiol 2020; 14:1179546820963055.
812. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib,
melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020; 38:
3252 –3260.
813. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis:
safety run-in results of ANDROMEDA. Blood 2020; 136:71–80.
814. Huang X, Ren G, Chen W, Guo J, Zhao L, Zeng C, et al. The role of induction ther-
apy before autologous stem cell transplantation in low disease burden AL amyloid-
osis patients. Amyloid 2021;28:75 –83.
815. Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, et al. A chan-
ging landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail
2019; 7:958 –966.
816. Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the
treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci 2019;
4:438 –448.
817. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al.
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N
Engl J Med 2021; 385:46–58.
818. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality
in cardiac light chain (AL) amyloidosis. Blood Cancer J 2017; 7:e546.
819. Shen K, Fu W, Wu Y, Dong Y, Huang Z, Wei Y, et al. Doxycycline combined with
bortezomib –cyclophosphamide –dexamethasone chemotherapy for newly diag-
nosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial.Circulation 2021;145:8 –17.
820. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, et al.
Longitudinal systolic strain, cardiac function improvement, and survival followingtreatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging
2017; 18:1057 –1064.
821. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac
biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87:
465–471.
822. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum
cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for
primary systemic amyloidosis. J Clin Oncol 2004; 22:3751 –3757.
823. Zaremba T, Jakobsen AR, SØgaard M, ThØgersen AM, Johansen MB, Madsen LæB,
et al. Risk of device malfunction in cancer patients with implantable cardiac deviceundergoing radiotherapy: a population-based cohort study. Pacing Clin
Electrophysiol 2015; 38:343 –356.
824. Miften M, Mihailidis D, Kry SF, Reft C, Esquivel C, Farr J, et al. Management of radio-
therapy patients with implanted cardiac pacemakers and de ﬁbrillators: a report of
the AAPM TG-203. Med Phys 2019; 46:e757 –e788.
825. Hurkmans CW, Knegjens JL, Oei BS, Maas AJJ, Uiterwaal GJ, van der Borden AJ,
et al. Management of radiation oncology patients with a pacemaker or ICD: a
new comprehensive practical guideline in The Netherlands. Radiat Oncol 2012; 7:
198.
826. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke GD,
et al. 2017 HRS expert consensus statement on magnetic resonance imaging and
radiation exposure in patients with cardiovascular implantable electronic devices.Heart Rhythm 2017; 14:e97 –e153.
827. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Riahi S. Radiotherapy in pa-
tients with pacemakers and implantable cardioverter de ﬁbrillators: a literature re-
view. Europace 2016; 18:479 –491.
828. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, et al.
Radiotherapy-induced malfunction in contemporary cardiovascular implantableelectronic devices: clinical incidence and predictors. JAMA Oncol 2015; 1:624 –632.
829. Zecchin M, Severgnini M, Fiorentino A, Malavasi VL, Menegotti L, Alongi F, et al.
Management of patients with cardiac implantable electronic devices (CIED) under-
going radiotherapy: a consensus document from Associazione Italiana Aritmologiae Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica
(AIRO), Associazione Italiana Fisica Medica (AIFM). Int J Cardiol 2018; 255:175 –183.
830. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, et al. Malfunctions
of implantable cardiac devices in patients receiving proton beam therapy: incidence
and predictors. Int J Radiat Oncol Biol Phys 2013; 87:570 –575.
831. Sharifzadehgan A, Laurans M, Thuillot M, Huertas A, Baudinaud P, Narayanan K,
et al. Radiotherapy in patients with a cardiac implantable electronic device. Am J
Cardiol 2020; 128:196 –201.
832. Stienen JJC, Ottevanger PB, Wennekes L, Dekker HM, van der Maazen RWM,
Mandigers CMPW, et al. Development and evaluation of an educational E-tool
to help patients with non-Hodgkin ’s lymphoma manage their personal care path-
way. JMIR Res Protoc 2015; 4:e6.
833. Murphy P, Levine A, Lerma T, Young S, Hwang J, Goldsby R. A portable survivor-
ship care plan: a tool that helps educate and improve knowledge in childhood can-
cer survivors. Support Care Cancer 2021; 29:169 –177.
834. Asteggiano R, Aboyans V, Lee G, Salinger S, Richter D. Cardiology care delivered to
cancer patients. Eur Heart J 2020; 41:205 –206.
835. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society
of Cardiology methodology for the development of quality indicators for the quan-
tiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes
2022; 8:4–13.
836. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the
United Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018; 379:
948–957.
837. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality
8 years into global payment. N Engl J Med 2019; 381:252 –263.ESC Guidelines 4361Downloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by MUSC Library user on 12 November 2025

